Asia Pacific Academy of Ophthalmology (APAO)

Eye Diseases Clinical Trials Summary

Searched by Topics

(<u>http://www.clinicaltrials.gov</u>)

Sorted Out by Xiaoxin Li and Yujing Bai

On Behalf of APAO Standing Committee Meetings & Reports

Table of Contents

1_Amblyopia 2_Anisometropia 3_Aphakia 4_Astigmatism 5 Behcet Syndrome 6_Blepharitis 7_Blepharoptosis 8_Blepharospasm 9 Blindness 10_Capsule Opacification 11_Cataract 12_Central Serous Chorioretinopathy 13 Choroid Diseases 14 Choroidal Neovascularization 15_Choroideremia 16_Choroiditis 17_Conjunctival Diseases 18_Corneal Diseases 19 Dacryocystitis 20_Diabetic Retinopathy 21_Diplopia 22_Dry Eye Syndromes 23_Enophthalmos 24 Epiretinal Membrane 25_Esotropia 26_Exfoliation Syndrome 27_Exophthalmos 28 Exotropia 29 Eye Abnormalities 30_Eye Diseases, Hereditary **31_Eye Infections** 32_Eye Injuries 33 Eye Neoplasms 34_Eye Pain 35 Eyelid Diseases 36_Geographic Atrophy 37_Glaucoma 38_Graves Disease 39 Hordeolum

40_Hydrophthalmos

41_Hyperopia 42 Iridocyclitis 43_Keratitis 44 Keratoconjunctivitis 45_Keratoconjunctivitis Sicca 46_Keratoconus 47 Lacrimal Apparatus Diseases 48 Lens Diseases 49_Low Tension Glaucoma 50 Macular Degeneration 51 Macular Edema 52_Mydriasis 53_Myopia 54_Neuromyelitis Optica 55 Night Blindness 56_Nystagmus, Pathologic 57 Ocular Hypertension 58_Ocular Motility Disorders 59_Ophthalmoplegia 60_Opsoclonus-Myoclonus Syndrome 61 Optic Atrophies 62_Optic Nerve Diseases 63 Optic Neuritis 64_Optic Neuropathy, Ischemic 65_Orbital Diseases 66_Panuveitis 67_Pars Planitis 68_Presbyopia 69 Pterygium 70 Refractive Errors 71_Retinal Artery Occlusion 72_Retinal Degeneration 73_Retinal Detachment 74 Retinal Drusen 75_Retinal Dystrophies 76 Retinal Hemorrhage 77_Retinal Neoplasms 78_Retinal Neovascularization **79** Retinal Perforations 80 Retinal Vein Occlusion

81 Retinitis 82 Retinitis Pigmentosa 83_Retinoblastoma 84_Retinopathy of Prematurity 85_Retinoschisis 86 Scotoma 87_Sjogren's Syndrome 88_Strabismus 89_Supranuclear Palsy, Progressive 90 Usher Syndromes 91 Uveal Diseases 92 Uveitis 93_Vision Disorders 94 Vitreous Detachment 95_Vitreous Hemorrhage 96 Xerophthalmia

1. Amblyopia

Rank	Status	Study	
1	Completed	Thickness of Retinal Layers in Amblyopia	
	no results	Condition: Amblyopia	
	published yet	Intervention:	Other: Optical coherence tomography

2. Anisometropia

Rank	Status	Study	
1	Unknown †	Ocular Response Analyzer Assessment of Intraocular	
		Pressure and Corneal Biomechanical Properties in Myopic and	
		Anisometropic Patients Under Atropine Treatment	
		Conditions: Myopia; Anisometropia	
		Intervention:	

3. Aphakia

Rank	Status	Study	
1	Completed	Aphakia Versus Pseudophakia in Children Under 2 Years	
	no results	Undergoing Bilateral Congeni	tal Cataract Surgery
	published	Condition:	Congenital Cataract
	yet	Interventions:	Device: Intraocular Lens (Acrysof
			IOL); Device: No IOL
2	Recruiting	Evaluate Capsular Apposition	to Intraocular Lens
		Conditions:	Capsule Opacification; Tissue Ad
		hesions;	
		Aphakia - Lens Capsule Present;	
			Opacification of Intraocular Lens
		Intervention:	
3	Active, not	Visual Quality Following Asph	neric Intraocular Lens (IOL)
	recruiting	Implantation - a Comparative	Clinical Study
		Conditions:	Aphakia; Cataract
		Interventions:	Device: Study IOL; Device: Hoya
			iSert 751; Device: Negatively as
			pheric IOL

4. Astigmatism

Rank	Status	Study		
1	Completed	Product Performance of a Tor	ic Contact Lens	
	Has Results	Conditions:	Myopia; Astigmatism	
	Published on	Interventions:	Device: SofLens DD Toric; Devic	
	website		e: Ciba Vision Focus Dailies Toric	
			Contact Lens	
2	Completed	Prospective Comparative Stud	dy of Refractive Outcome of	
	no results	STAAR and Alcon Toric Intrac	ocular Lenses	
	published	Condition:	Astigamtism	
	yet	Intervention:	Procedure: Phacoemulsification	
			with implantation of toric IOL	
3	Completed	Evaluation of Effectiveness of	Correcting Refractive Error With	
	no results	Ready-made Spectacles		
	published	Conditions:	Myopia; Hyperopia; Astigmati	
	yet		sm	
		Interventions:	Device: Ready-made spectacles;	
			Device: Spectacles	
4	Completed	Evaluation of Effectiveness of	Correcting Refractive Error With	
	no results	Ready-made Spectacles		
	published	Conditions:	Myopia; Hyperopia; Astigmat	
	yet		ism	
		Interventions:	Device: Ready-made spectacles;	
			Device: Spectacles	
5	Completed		construction of Computerized Intraoperative Keratometer and	
	no results	Experimental Study		
	published	Conditions:	Corneal Astigmatism; Orientation	
	yet	Intervention:	Device: computerized intraoperativ	
			e keratomer	
6	Completed	Clinical Trial of Contact Lense	es in Extended Wear	
	no results	Condition:	Astigmatism	
	published	Interventions:	Device: senofilcon A toric contact le	
	yet		ns; Device: balafilcon A toric cont	
			act lens	
7	Terminated		nses on Low Astigmatism in Japan	
	no results	Conditions:	Refractive Error; Myopia; Ast	
	published		igmatism	
	yet	Interventions:	Device: senofilcon A toric soft co	
			ntact lens; Device: senofilcon A	

		sphere soft contact lens	
8	Recruiting	Clinical Evaluation of Toric Int	traocular Lens Made by Aurolab
		Condition:	Astigmatism
		Intervention:	Procedure: intra ocular lens
9	Recruiting	Effect of Posterior Corneal To	ricity on Refractive Outcome of
		Pseudophakia	
		Conditions:	Astigmatism; Cataract
		Interventions:	Procedure: phacoemulsification; D
10	Recruiting	Randomized, Non-inferiority T	rial Comparing SMILE and LASIK
		Conditions:	Myopia; Astigmatism; Hyperm
			etropia
		Interventions:	Procedure: Femtosecond LASIK;
			Procedure: Small incision
44	A other mot	Taria Ortholografalamy, Claudi	Ienticule extraction (SMILE)
11	Active, not recruiting	Toric Orthokeratology - Slowin Conditions:	Myopia; Astigmatism
	recruing	Interventions:	
		interventions.	ses; Device: Single-vision spec
			tacles
12	Unknown [†]	Randomized, Prospective Comparison of the Outcome of Toric	
		Implantable Contact Lens (TICL) and Q-LASIK for the Correction	
		of Myopia With Astigmatism	
		Conditions: Myopia; Astigmatism	
		Interventions:	Procedure: the implantation of toric
			implantable collamer
			lens; Procedure: customized laser-assisted in situ
			keratomileusis
13	Unknown [†]	Effect of Pterygium Excision of	on Intraocular Lens Power
		Calculation for Subsequent Ca	ataract Operation
		Conditions:	Pterygium; Cataract; Astigm
			atism
		Intervention:	Procedure: pterygium excision
14	Unknown †		Relaxing Incision (LRI) in Conjunction
			for Astigmatic Correction in Chinese
		Eyes Condition:	Corneal Actigmaticm
			Corneal Astigmatism
		Intervention:	Procedure: Limbal relaxing incision

15	Unknown †	Compare Anterior Chamber Biometry in Healthy and Post-LASIK Patients	
		Conditions: Myopia; Astigmatism	
		Intervention:	

5. Behcet Syndrome

Rank	Status	Study	
1	Completed	Phase III Study in Refractory E	Behcet's Disease
	no results	Condition:	Behcet Disease
	published	Interventions:	Drug: AIN457; Drug: Place
	yet		bo
2	Terminated	Safety and Efficacy of AIN457	in Behçet's Patients With
		Posterior or Panuveitis	
		Condition:	Uveitis
		Interventions:	Biological: AIN457; Drug:
			Placebo
3	Unknown [†]	Flucinolone Acetonide Implan	t for Treating Refractory Ocular
		Behcet's Disease	
		Conditions:	Ocular Behcet's Disease,;
			Non-Infectious Uveitis; Refr
			actory Uveitis
		Intervention:	Drug: flucinolone acetonide

6. Blepharitis

Rank	Status	Study	
1	Completed	Trial to Compare the Efficacy of Systane Ultra and Refresh	
	Has Results	Drop in the Treatment of Dry Eye in Asian Eyes	
	Published	Conditions:	Xerophthalmia; Blepharitis
	on website	Interventions:	Drug: Systane Ultra eyedrops;
		Drug: Refresh eye drops	
2	Completed	Loteprednol and Tobramycin Versus Tobramycin and	
	Has Results	Dexamethasone, in the Treatn	nent of
	published	Blepharokeratoconjunctivitis	
	in journal	Conditions: Conjunctivitis; Keratitis; Bl	
		Interventions: Drug: Loteprednol and tobramy cin; Drug: Tobramycin and de	
			xamethasone

7. Blepharoptosis

Rank	Status	Study	
1	Completed	Efficacy of Aurosling in Front	alis Sling Suspension
	no results published	Surgery	
	yet	Condition:	Ptosis, Eyelid
		Intervention:	Procedure: Aurosling

8. Blepharospasm

Rank	Status	Study	
1	Completed	Movement Disorder Survey in	East China
	no results	Conditions: Primary Dystonia; Hemifacial Spasm	
	published	Intervention:	
	yet		
2	Completed	Efficacy and Safety Study of M	Ieditoxin® to Treat Essential
	no results	Blepharospasm	
	published	Condition:	Essential Blepharospasm
	yet	Intervention:	Drug: Botulinum Toxin Type A
3	Completed	Comparison of Korean Botulinum Toxin Type A Versus	
	no results	Botox in the Treatment of Ess	ential Blepharospasm
	published	Condition:	Blepharospasm
	yet	Intervention:	Drug: Korean Botulinum toxin
			type A (KbtxA) and Botox
			injection
4	Completed	Efficacy of Aurosling in Fronta	alis Sling Suspension Surgery
	no results	Condition:	Ptosis, Eyelid
	published	Intervention:	Procedure: Aurosling
	yet		-

9. Blindness

Rank	Status	Study	
1	Completed	Vascular Endothelial Growth I	Factor (VEGF) Trap-Eye:
	Has Results	Investigation of Efficacy and Safety in Wet Age-Related	
	Published	Macular Degeneration (AMD)	
	on website	Condition:	Macular Degeneration
		Interventions:	Drug: Ranibizumab; Biologic al: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
2	Completed	Impact of Maternal Vitamin A	or Beta-Carotene
	Has Results	Supplementation on Maternal	and Infant Mortality in
	published	Bangladesh	-
	in journals	Conditions:	Vitamin A Deficiency; Materna
			I Mortality; Infant Mortality
		Intervention:	Dietary Supplement: Vitamin A
			or Beta-Carotene Supplements
3	Completed	Dietary Vitamin A Requiremen	nt in Chinese Children and the
	no results	New Technology of Dietary As	
	published	Condition:	Vitamin A Deficiency
	yet	Intervention:	
4	Completed	Vitamin A Bioavailability in Lactating Women With Marginal	
	no results	Vitamin A Status	
	published	Condition:	Vitamin A Deficiency
	yet	Interventions:	Other: 0 mg retinol activity equiv
	_		alents; Other: 12 mg of BC;
			Other: 6 mg of CX; Other: 1.0
			mg RAE
5	Completed	The Extract of Green Tea on C	
	no results	Double Blindness Clinical Tria	al
	published	Condition:	Obesity
	yet	Intervention:	Drug: the extract of green tea
6	Completed	Newborn Vitamin A (VA) Supp	
	no results	Pakistan	
	published	Condition:	Vitamin A Deficiency
	yet	Interventions:	Dietary Supplement: Vitamin A;
			Dietary Supplement: Placebo
7	Completed	An Efficacy Trial of Iron, Zinc	and Vitamin A Fortified Rice in
	no results	Children in Satun, Thailand	
	published	Conditions:	Vitamin A Deficiency; Iron D
		001101101	

	yet		eficiency; Zinc Deficiency
		Intervention:	Dietary Supplement: fortified ex
			truded rice
8	Completed	Efficacy of Vitamin A in Fortif	ed Extruded Rice in School
	no results	Children	
	published	Condition:	Vitamin A Deficiency
	yet	Intervention:	Dietary Supplement: Triple
			fortified extruded tice (Fe, Zn and vitamin A)
9	Terminated	Community Trial of Newborn	Vitamin A Supplementation to
		Reduce Infant Mortality in Run	al Bangladesh
		Conditions:	Infant Mortality; Vitamin A Defi ciency
		Intervention:	Drug: vitamin A supplementation (50,000 IU)
10	Recruiting	Safety & Efficacy of Subretina	I Implants for Partial
		Restoration of Vision in Blind	Patients
		Conditions: Retinal D	egeneration,; Retinitis Pigment
		osa	
			e: surgical implantation of
		subretina	
11	Recruiting	PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)	
		Condition:	Anterior Ischemic Optic Neuropa
		Intervention:	Drug: Diagnostic procedures
12	Recruiting	Efficacy of Newborn Vitamin /	
12	Recruiting	Improving Immune Function	
		Condition:	Vitamin A Deficiency
		Interventions:	Dietary Supplement: retinyl palm
			itate; Dietary Supplement: Pla cebo
13	Active, not	VEGF Trap-Eye in Choroidal Neov	vascularization Secondary to
	recruiting	Pathologic Myopia (mCNV)	
		Condition:	Myopia, Pathological
		Interventions:	Biological: VEGF Trap-Eye (BA
			Y86-5321); Procedure: No D
			rug

10. Capsule Opacification

Rank	Status	Study		
1	Completed	Posterior Capsule Opacification (PCO) With Single Piece		
	no results	Hydrophobic Versus Hydrophillic Intraocular Lens (IOL)		
	published	Condition:	Posterior Capsule Opacification	
	yet	Intervention:	Procedure: Phacoemulsification	
2	Completed	Posterior Capsule Opacification	on (PCO) With AcrySof	
	no results	Single-Piece IOL		
	published	Condition:	Posterior Capsule Opacification	
	yet	Intervention:	Procedure: Phaco	
3	Completed	Posterior Capsule Opacification	on Study	
	no results	Condition:	Cataract	
	published	Interventions:	Device: Square edge PMMA IOL	
	yet		; Device: Round edge PMMA I	
			OL; Device: Acrysof IOL; De	
			vice: square Edge PMMA IOL;	
			Device: Square Edge PMMA IOL	
4	Completed	AquaLase Capsule Wash for F	Pediatric Eyes	
	no results	Conditions:	Cataract; Pediatric Cataract	
	published yet	Intervention:		
5	Recruiting	Evaluate Capsular Apposition to In	traocular Lens	
	_	Conditions:	Capsule Opacification; Tissue	
			Adhesions; Aphakia - Lens Ca	
			psule Present; Opacification of	
			Intraocular Lens	
		Intervention:		

Rank	Status	Study		
1	Completed		abeculectomy Historical Control Study	
	Has Results	in India		
	published	Conditions:	Glaucoma; Cataract	
	in journals	Intervention:	Device: OculusGen	
			Biodegradable Collagen Matrix	
			Implant	
2	Completed	ReSTOR Natural +3.0D Study	In Japan	
	Has Results	Condition:	Cataract	
	published	Intervention:	Device: ACRYSOF Multifocal	
	on website		Single-piece Intraocular Lens	
			(IOL) Model SN6AD1	
3	Completed	Guangdong Uptake of Surger	y Trial	
	Has Results	Condition:	Cataract	
	published	Intervention:	Behavioral: Video and counseling	
	in journals		for cataract patients	
4	Completed	Study of Phacodepth Require	d for Safe and Effective Chop During	
	Has Results	Phacoemulsification for Catar	act.	
	published	Condition:	Cataract	
	on website	Intervention:		
5	Completed	Study of Intracameral Adrenaline for Pupil Dilation Without Topical		
	no results	Mydriatics in Refractive Catar	act Surgery	
	published	Condition:	Cataract	
	yet	Intervention:	Drug: adrenalin	
6	Completed	Combined Intracameral Lidoc	aine for Manual Small Incision Cataract	
	no results	Surgery Under Topical Anesth	nesia	
	published	Condition:	Cataract	
	yet	Interventions:	Procedure: MSICS under topical	
			anesthesia with intracameral	
			lidocaine; Procedure: MSICS	
			under topical anesthesia with	
			intracameral balanced salt	
-	Completed	Effect of Makila Occurrents of	solution.	
7	Completed no results	Adherence	on on Childhood Cataract Follow-up	
	no results published		Cotoroct	
	yet	Condition:	Cataract	
	900	Intervention:	Other: Mobile short message servi	
			Ce	

11. Cataract

8	Completed	Outcomes of 3 Incision-size-dependent Phacoemulsification			
o	Completed no results	Systems			
	published	Condition:	Cataract		
	yet				
	-	Intervention:			
9	Completed	Evaluation of the Rotational Stability of The AcrySof Toric			
	no results		ular Bag in High Myopic Subjects		
	published	Condition:	Cataract		
	yet	Intervention:	Procedure: Cataract Surgery		
10	Completed	Nepafenac Compared to Place	ebo for Ocular Pain and Inflammation		
	no results	Condition:	Cataract		
	published	Interventions:	Drug: Nepafenac; Other: Nepafe		
	yet		nac Vehicle		
11	Completed	Effect of Phacoemulsification	n on Ocular Blood Flow in Human		
	no results	Conditions:	Cataract; Hypertension; Diabe		
	published		tes		
	yet	Intervention:			
12	Completed	Evaluation of Anatomic and	Visual Outcomes of Initially Closed		
	no results	Macular Holes			
	published	Condition:	Macular Holes		
	yet	Intervention:			
13	Completed	Effect on Wound Healing of Vigamox Versus Cravit			
	no results	Condition: Catarac	t Extraction		
	published	Interventions: Drug: M	oxifloxacin 0.5% ophthalmic		
	yet	solution	(Vigamox); Drug: Levofloxacin		
		0.5% ophthalmic solution (Cravit)			
14	Completed	The Effect of a Blue Light Fil	tering IOL		
	no results	Conditions:	to Compare the Effect of Two Types		
	published		of IOLs; on the Incidence of Cystoi		
	yet		d Macular Edema;		
			After Cataract Surgery		
		Intervention:	Procedure: intraocular lens implanta		
			tion		
15	Completed	A Single Centre Study to Cor	npare the Efficacy and Safety of		
	no results	Femtosecond Laser-Assisted	d Versus Manual Cataract Surgery		
	published	Condition:	Cataract		
	yet	Interventions:	Procedure: Lens Fragmentation by		
			means of a		
			femtosecondlaser; Procedure: Ma		

			nual Phacoemulsification	
16	Completed	Aphakia Versus Pseudophaki	a in Children Under 2 Years	
	no results	Undergoing Bilateral Congenital Cataract Surgery		
	published	Condition:	Congenital Cataract	
	yet	Interventions:	Device: Intraocular Lens (Acrysof I OL); Device: No IOL	
17	Completed	AquaLase Capsule Wash for F	Pediatric Eyes	
	no results	Conditions:	Cataract; Pediatric Cataract	
	published	Intervention:		
	yet			
18	Completed	-	ess of DYME as an Agent for Selective	
	no results	Staining of the Anterior Capsu		
	published	Condition:	Mature Cataracts	
	yet	Intervention:	Drug: DYME	
19	Completed	Outcomes of Phacoemulsifica	ation With Torsional Ultrasound	
	no results	Condition:	Cataract	
	published	Interventions:	Procedure: Torsional ultrasound	
	yet		(INFINITI, Alcon,	
			USA); Procedure:	
			Longitudinal U/S (Infiniti system,	
			Alcon, USA); Procedure:	
			Longitudinal U/S (LEGACY	
- 20	Completed	The Dele of Conculor Tension	20000, Alcon, USA)	
20	Completed no results	Contraction	Ring (CTR) in Anterior Capsular	
	published	Conditions:	Retinitis Pigmentosa; Cataract	
	yet	Intervention:	Procedure: IOL surgery	
21		Aurolab Hydrophobic Foldabl		
21	Completed no results	Condition:	Cataract	
	published			
	yet	Intervention:	Device: Intraocular Lens	
22	Completed	Posterior Capsule Opacification	on Study	
	no results	Condition:	Cataract	
	published	Interventions:	Device: Square edge PMMA IOL;	
	yet		Device: Round edge PMMA IOL;	
			Device: Acrysof IOL; Device: squa	
			re Edge PMMA IOL; Device: Squa	
			re Edge PMMA IOL	
23	Completed	Outcome Following Phacoem	ulsification Versus Small Incision	

	no results	Cataract Surgery (SICS)
	published	Conditions: Visual Outcomes; Quality of Life
	yet	Interventions: Procedure: phacoemulsification an
		d SICS; Procedure: manual smal
		l incision surgery; Procedure: ph
		acoemulsification
24	Completed	Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight
	no results	Heparin in Pediatric Cataract Surgery
	published	Condition: Inflammation
	yet	Interventions: Drug: Enoxaparin; Drug: Balan
		ced Salt Solution
25	Completed	CME With Different Fluidic Parameters
	no results	Condition: Cystoid Macular Edema Following
	published	Cataract Surgery
	yet	Intervention: Procedure: microcoaxial phacoemul
		sification
26	Completed	Intraoperative and Postoperative Outcomes of Three Ophthalmic
	no results	Viscosurgical Devices During Phacoemulsification
	published	Condition: Intraoperative Performance and
	yet	Postoperative Outcomes
		Following Cataract Surgery
		Intervention: Procedure: Microcoaxial Phacoem
		ulsification
27	Completed	Posterior Capsule Opacification (PCO) With Single Piece
	no results	Hydrophobic Versus Hydrophillic Intraocular Lens (IOL)
	published	Condition: Posterior Capsule Opacification
	yet	Intervention: Procedure: Phacoemulsification
28	Completed	Posterior Capsule Opacification (PCO) With AcrySof Single-Piece
	no results	IOL
	published	Condition: Posterior Capsule Opacification
	yet	Intervention: Procedure: Phaco
29	Completed	Posterior Assisted Levitation of Dropped Nucleus
	no results	Condition: Cataract
	published	Intervention:
	yet	
30	Completed	Comparison of the Quality of Vision Provided by AMO Tecnis Z9000
	no results	and Alcon Laboratories MA60 Acrysof Posterior Chamber Intraocular
	published	Lenses
	yet	

		Condition:	Cataract	
		Interventions:	Device: Tecnis Z9000 intraocula	
		interventions:	r lens; Device: MA60 intraocul	
			ar lens	
31	Completed	Comparative Study of Three I		
31	Completed no results	Comparative Study of Three IOL Power Calculation Formulae for Asian Eyes Shorter Than 22mm or Longer Than 25mm		
	published	Condition:	Cataract	
	yet			
	yci	Intervention:	Procedure: IOL calculation formul	
			a	
32	Completed	Three Intraocular Lenses Des		
	no results	Intermediate and Near Vision	-	
	published	Condition:	Cataract	
	yet	Interventions:	y	
			: ReSTOR 3.0; Device: AMO T	
			ecnis Multifocal	
33	Completed		ntraocular Pressure Reduction Before	
	no results	Phacoemulsification		
	published	Condition:	Cataract	
	yet	Intervention:	Procedure: Honan balloon applic	
			ation	
34	Terminated	Visual Function After Implanta	ation of AcrySof® Toric Lens	
		Condition:	Cataract	
		Intervention:	Device: AcrySof Toric Intraocular Lens	
35	Terminated	DY002: Safety and Effectivene	ess of DYME as an Agent for Selective	
		Staining of the Anterior Capsu	Ile During Cataract Surgery	
		Condition:	Mature Cataracts	
		Intervention:	Drug: DYME	
36	Recruiting	A Study to Evaluate New or W	orsening Lens Opacifications in	
		Subjects With Non-metastatic	Prostate Cancer Receiving	
		Denosumab for Bone Loss Du	e to Androgen-Deprivation Therapy	
		Conditions:	Cancer; Cataract; Low Bone	
			Mineral Density; Osteopenia;	
			Osteoporosis; Prostate Cancer	
		Interventions:	Biological: Denosumab; Biologi	
			cal: Placebo	
37	Recruiting	Clinical Evaluation of a New C	artridge for the Implantation of	
		Foldable Intraocular Lenses		

		Condition:	Cataract
		Intervention:	Procedure: cartridge
38	Recruiting	Clinical and Genetic Studies of	
		Hereditary Cataracts	C C
		Condition:	Cataract
		Intervention:	
39	Recruiting	Outcomes Following Phacoen	nulsification With 1.8 & 2.2mm Incision:
		Randomized Clinical Trial	
		Condition:	Cataract
		Intervention:	Procedure: Microcoaxial Phaco
			emulsification
40	Recruiting	Effect of Posterior Corneal To	ricity on Refractive Outcome of
		Pseudophakia	
		Conditions:	Astigmatism; Cataract
		Interventions:	Procedure: phacoemulsification;
			Device: Pentacam (Oculus,G
			ermany)examination
41	Recruiting	Clinical and Genetic Studies of	of Families With Congenital or
		Hereditary Cataracts	
		Condition:	Cataract
	D 111	Intervention:	
42	Recruiting	Evaluate Capsular Apposition	
		Conditions:	Capsule Opacification; Tissue
			Adhesions; Aphakia - Lens C apsule Present; Opacification
			of Intraocular Lens
		Intervention:	
43	Recruiting	A Study to Evaluate New or W	orsening Lens Opacifications in
_	J	Subjects With Non-metastatic	•
		Denosumab for Bone Loss Du	e to Androgen-Deprivation Therapy
		Conditions:	Cancer; Cataract; Low Bone
			Mineral Density; Osteopenia;
			Osteoporosis; Prostate Cancer
		Interventions:	Biological: Denosumab; Biologi
			cal: Placebo
44	Recruiting	-	Vorsening Lens Opacifications in
		Subjects With Non-metastatic	Prostate Cancer Receiving

		Denosumab for Bone Loss Due to Androgen-Deprivation Therapy			
		Conditions:	Cancer; Cataract; Low Bone Mineral Density; Osteopenia;		
			Osteoporosis; Prostate Cancer		
		Interventions:	Biological: Denosumab; Biologic al: Placebo		
45	Recruiting	Intraoperative Dexamethason	e Implant Improves Outcome of		
		Cataract Surgery With Diabeti	c Macular Edema		
		Conditions:	Macular Edema, Cystoid; Vision Di sorders; Diabetic Macular Edema;		
			Cystoid Macular Edema Following Ca taract Surgery; Cataract		
		Interventions:	Drug: Dexamethasone Drug delivery system		
			(Ozurdex); Procedure: Cataract sur gery		
47	Recruiting	Effect of Minimising Ultrasour	nd Power to 1% During Cataract		
		Surgery on Corneal Endotheli	um.		
		Condition:	Cataract		
		Interventions:	Procedure: one percent ultrasound pow		
			er in CMICS; Procedure: 40 percent		
			ultrasound power in CMICS		
48	Recruiting	Clinical and Genetic Studies of	of Families With Congenital or		
		Hereditary Cataracts			
		Condition:	Cataract		
		Intervention:			
49	Recruiting		cularity and Diameter of Femtosecond		
			Capsulotomy in Singapore National		
		Eye Centre	Drivery Discourse October 1		
		Condition:	Primary Disease: Cataract		
		Interventions:	Device: Femtosecond Laser		
			(VICTUS™ Femtosecond Laser		
			Platform); Device: Manual (CCC technique with Utrata forcepes)		
50	Enrolling	Antioxidants for Prevention o	,		
50	by	Condition:	Effect of Antioxidants on Occurr		
	invitation		ence of Cataracts		
		Intervention:			
L	1				

51	Enrolling	The Effect of Cataract Extraction on the Contractility of Ciliary		
	by	Muscle		
	invitation	Conditions:	Presbyopia; Cataract	
		Intervention:	Other: UBM with pilocarpine in presbyo	
			pia	
52	Active, not	LENS - Long-term Eltrombopa	ag Observational Study	
	recruiting	Conditions:	Ocular Safety; Purpura, Thrombocyto	
			penic, Idiopathic	
		Intervention:	Drug: Observational Study	
53	Active, not	LENS - Long-term Eltrombopa	ag Observational Study	
	recruiting	Conditions:	Ocular Safety; Purpura, Thrombocyto	
			penic, Idiopathic	
		Intervention:	Drug: Observational Study	
54	Active, not		n Ring in Preventing Anterior Capsule	
	recruiting	Shrinkage After Cataract Surg		
		Condition:	Cataract With Exfoliation Syndrome	
		Intervention:		
55	Active, not	Visual Quality Following Asph		
	recruiting	Implantation - a Comparative	-	
		Conditions:	Aphakia; Cataract	
		Interventions:	Device: Study IOL; Device: Hoya iSe rt 751; Device: Negatively aspheric I	
			OL	
56	Active, not	LENS - Long-term Eltrombopa		
	recruiting	Conditions:	Ocular Safety; Purpura, Thromboc	
			ytopenic, Idiopathic	
		Intervention:	Drug: Observational Study	
57	Not yet	Effects of Vitamin C and Lyciu	Im Barbarum Supplements on the	
	recruiting	Progression of Senile Catarac	t in Hong Kong Chinese Population	
		Condition:	Lens Opacity	
		Interventions:	Dietary Supplement: Starch; Diet	
			ary Supplement: Vitamin C; Diet	
			ary Supplement: Lycium Barbarum	
58	Unknown [†]	Surgical Treatment of Concur	rent Cataract and Primary Pterygium	
		Conditions:	Pterygium; Cataract; Lenses, Intraoc	
		Interventions:	Procedure: combined pterygium and cata	
			by cataract operation	
59	Unknown [†]	Effect of Pterygium Excision of	on Intraocular Lens Power Calculation	

		for Subsequent Cataract Operation		
		Conditions:	Pterygium; Cataract; Astig	
			matism	
		Intervention:	Procedure: pterygium excision	
60	Unknown [†]	Comparison of Manual Super	Small Incision Cataract Surgery and	
		Phacoemulsification		
		Conditions:	Cataract; Phacoemulsification	
		Interventions:	Procedure: MSSICS; Procedure: P	
			hacoemulsification	
61	Unknown †	Dose-Ranging Study of an Ophthal	amic Solution in Patients With Loss of Visual	
		Function Due to Age-Related Nucle	ear Cataract	
		Condition:	Nuclear Cataract	
		Interventions:	Drug: LiquiTears; Drug: C-KAD	
			Ophthalmic Solution	
62	Unknown †	Comparison of Functional Vision P	rovided by AMO Tecnis Z9000 and Alcon	
		SA60AT Acrysof		
		Condition:	Cataract	
		Interventions:	Device: AMO Tecnis Z9000; D	
			evice: Alcon SA60AT Acrysof	
63	Unknown †	Combined Phacotube vs Phacotrabe	eculectomy: A Randomized Controlled Trial	
		Conditions:	Glaucoma; Cataract	
		Interventions:	Procedure: Glaucoma Implant Surger	
			y; Procedure: trabeculectomy; Pr	
			ocedure: phacoemulsification	
64	Unknown †	Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in		
		Primary Glaucoma: A Case-Control Study		
		Conditions:	Cataract; Glaucoma	
		Intervention:	Device: ologen™ Collagen Matrix	
			Implant as an aid in	
			phacotrabeculectomy surgery	

12. Central Serous Chorioretinopathy

Rank	Status	Study				
1	Completed	Comparison of Multifocal Elec	ctroretinogram Assessment in			
	Has Results	Chronic Central Serous Chori	Chronic Central Serous Chorioretinopathy (CSC) Between			
	published on	Laser Treatment Group and Photodynamic Therapy Group in				
	website	Chronic Central Serous Chorioretinopathy				
		Condition: Central Serous Chorioretinopathy				
		Intervention:				
2	Completed	Central Serous Chorioretinopathy Treated by Modified				
	no results	Photodynamic Therapy				
	published	Condition:	Central Serous Chorioretinopat			
	yet		hy			
		Interventions:	Drug: Verteporfin PDT, half-dos			
			e; Drug: verteporfin PDT, half			
			-fluence			
3	Completed	Microperimetric Evaluation Af	ter Half-dose Photodynamic			
	no results	Therapy for Chronic Central S	erous Chorioretinopathy			
	published	Condition:	Chronic Central Serous Chorioretine			
	yet		pathy			
		Intervention:	Procedure: half-dose photodynamic			
			therapy			
4	Completed	High-dose Antioxidants for Ce	entral Serous Chorioretinopathy			
	no results	Condition:	Central Serous Chorioretinopathy			
	published yet	Intervention:	Drug: antioxidants tablets			
5	Recruiting	Study of Photodynamic Thera	py (PDT) in Patients With Central			
		Serous Chorioretinopathy (CS	SC)			
		Condition:	Central Serous Chorioretinopathy			
		Intervention:	Procedure: PDT			
6	Recruiting	The Safe Effective Light Dose	of Photodynamic Therapy for			
		Chronic Central Serous Chori	oretinopathy			
		Condition:	Central Serous Chorioretinopathy			
		Intervention:	Procedure: Photodynamic therapy			
7	Recruiting	Ranibizumab Versus Low-flue	ence Photodynamic Therapy in			
		the Treatment of Chronic Cen	tral Serous Chorioretinopathy			
		Condition:	Chronic Central Serous Chorior etinopathy			
		Interventions:	Drug: Verteporfin; Drug: rani			
			bizumab			
8	Recruiting	Central Serous Chorioretinop	athy: Etiology, Course and			

	Prognosis		
		Condition:	Central Serous Chorioretinopathy
		Intervention:	

13. Choroid Diseases

Rank	Status	Study		
1	Completed	Safety and Efficacy of a New 1	Freatment as Adjunctive Therapy	
	Has Results	to Anti-vascular Endothelial Growth Factor (Anti-VEGF)		
	published	Treatment in Patients With Ag	e-Related Macular Degeneration	
	on website	(AMD)		
		Conditions:	Choroidal Neovascularization;	
			Age-Related Maculopathy	
		Interventions:	Drug: dexamethasone; Biologi	
			cal: ranibizumab; Other: sham	
2	Completed	A Study of the Safety and Effic	cacy of a New Treatment for	
	Has Results	Non-Infectious Intermediate o	r Posterior Uveitis	
	published	Conditions:	Intermediate Uveitis; Posterior U	
	in journals		veitis	
		Interventions:	Drug: Dexamethasone; Drug: de	
			xamethasone; Drug: Sham inject	
			ion	
3	Completed	Clinical Study Of Pegaptanib	Sodium (EYE001) For Wet-Type	
	Has Results	Age-Related Macular Degeneration		
	published	Condition:	Macular Degeneration	
	on website	Intervention:	Drug: pegaptanib sodium	
4	Completed	Safety and Efficacy of Ranibizumab in Japanese Patients With		
	Has Results	Subfoveal Choroidal Neovascularization Secondary to		
	published	Age-related Macular Degeneration		
	in journals	Condition:	Subfoveal Choroidal	
			Neovascularization(CNV)	
			Secondary to Age-related Macular	
			Degeneration (AMD)	
		Intervention:	Drug: Ranibizumab	
5	Terminated	A Study Using Intravitreal Injections of a Small Interfering RNA		
	Has Results	in Patients With Age-Related I	-	
	published	Conditions:	Choroid Neovascularization; Ag	
	on website		e-Related Macular Degeneration	
		Interventions:	Drug: AGN 211745; Drug: Ranib	
			izumab 500µg	
6	Completed	Evaluation of Safety and Efficience		
	no results	Ranibizumab Injections in Chinese Patients With Wet Age		
	published	Related Macular Degeneration		
	yet	Condition:	Age Related Macular Degeneration	
		Intervention:	Drug: ranibizumab 0.5 mg	

-	0			
7	Completed	A Study Assessing the Safety and Efficacy of Multiple		
	no results	Intravitreal KH902 in Patients With CNV Due to AMD		
	published	Condition:	Neovascular Age-related Macula	
	yet		r Degeneration	
		Intervention:	Biological: Intravitreal injection of KH902	
8	Completed	Population-based Study of Mac	ular Choroidal	
	no results	vascularization in a Chinese Po	pulation	
	published	Conditions:	Geographic Atrophy; Wet Mac	
	yet		ular Degeneration; Retinal Dru sen	
		Intervention:	Other: Follow-up observation	
9	Completed	Phase II Open Label Multicent	er Study For Age Related Macular	
	no results	Degeneration Comparing PF-0	04523655 Versus Lucentis In The	
	published	Treatment Of Subjects With C	NV (MONET Study).	
	yet	Condition:	Age Related Macular Degeneratio	
			n	
		Interventions:	Drug: 0.5 mg ranibizumab; Drug:	
			3 mg PF-04523655; Drug: 1 mg	
			PF-04523655	
10	Completed	Efficacy and Safety of Ranibizumab in Patients With Visual		
	no results	Impairment Due to Choroidal Neovascularization Secondary to		
	published	Pathologic Myopia		
	yet	Condition:	Pathological Myopia	
		Interventions:	Drug: 0.5 mg ranibizumab driven by	
			disease activity; Drug: 0.5 mg	
			ranibizumab driven by stabilization	
			criteria; Drug: verteporfin PDT	
11	Completed	EXTEND III - Efficacy and Safety of Ranibizumab in Patients		
	no results	With Subfoveal Choroidal Neovascularization (CNV) Secondary		
	published	to Age-related Macular Degeneration (AMD)		
	yet	Conditions:	Choroidal Neovascularization; A	
			ge-Related Macular Degeneration	
		Intervention:	Drug: ranibizumab	
12	Completed	Clinical Study Of EYE001 For		
	no results	Macular Degeneration)		
	published	Condition:	Macular Degeneration	
	yet	Intervention:	Drug: pegaptanib sodium	
⊢			51.01	

no results Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) yet Condition: Wet Age-Related Macular Degeneration 14 Completed no results published Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes 14 Completed no results published Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes 15 Completed no results Other Than Age Related Macular Degeneration 15 Completed no results Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration yet Conditions: Subfoveal Choroidal Neovascularization Montal Neovascular arization (CNV); Secondary to Age-related Macular Degeneration (AMD) 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration Condition: Age-Related Macular Degeneration Age-Related Macular Degeneration 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD Condition:		no results	Charaidal Neovacoularization	Secondary to Age Polated
yet Condition: Wet Age-Related Macular Degeneration 14 Completed no results Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes 14 Completed no results Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes 14 Completed no results Other Than Age Related Macular Degeneration 15 Completed no results Conditions: 15 Completed no results Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD				
14 Completed no results published Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration 14 Completed no results Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration 15 Completed no results Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration 15 Completed no results Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD				Wat Are Delated Meauler Degree
Interventions: Drug: PTK787; Drug: Placebo 14 Completed no results published Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration yet Conditions: Choroidal Neovascularization; Retinal Pigment Epithelial Detachment 15 Completed no results published Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration yet Conditions: Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration yet Conditions: Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) Intervention: Drug: ranibizumab Intervention: Drug: ranibizumab 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) Mopia, Pathological Interventions: 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD		yet	Condition:	•
14 Completed no results published yet Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration 15 Completed no results published Conditions: Choroidal Neovascularization; Retinal Pigment Epithelial Detachment 15 Completed no results published yet Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD				
no results published yetPatients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular DegenerationyetConditions:Choroidal Neovascularization; Retinal Pigment Epithelial Detachment15Completed no results published yetSafety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration16TerminatedA Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration16TerminatedA Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration17Active, not recruitingVEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)18RecruitingA Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD				
published yetOther Than Age Related Macular DegenerationyetConditions:Choroidal Neovascularization; Retinal Pigment Epithelial Detachment15Completed no results published yetSafety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular DegenerationyetConditions:Subfoveal Choroidal Neovascularization Secondary to Age-related Macular DegenerationyetConditions:Subfoveal Choroidal Neovascul arization (CNV); Secondary to Age-related Macular Degeneration (AMD)16TerminatedA Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration17Active, not recruitingVEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)18RecruitingA Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD	14			· · · · · ·
yet Conditions: Choroidal Neovascularization; Retinal Pigment Epithelial Detachment 15 Completed no results Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration yet Conditions: Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration yet Conditions: Subfoveal Choroidal Neovascul arization (CNV); Secondary to Age-related Macular Degeneration (AMD) Intervention: Drug: ranibizumab 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD				
Retinal Pigment Epithelial Detachment 15 Completed no results published yet Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration yet Conditions: Subfoveal Choroidal Neovascul arization (CNV); Secondary to Age-related Macular Degeneration (AMD) 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD		-	_	-
Detachment Intervention: Drug: Ranibizumab 15 Completed no results published yet Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration yet Conditions: Subfoveal Choroidal Neovascul arization (CNV); Secondary to Age-related Macular Degeneration (AMD) 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD		yet	Conditions:	
Intervention: Drug: Ranibizumab 15 Completed no results published yet Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration yet Conditions: Subfoveal Choroidal Neovascul arization (CNV); Secondary to Age-related Macular Degeneration (AMD) 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 16 Terminated VEGF Trap-Eye in Choroidal Neovascularization Secondary to Intervention: 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD				•
15 Completed no results published yet Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD				Detachment
no results published yetSubfoveal Choroidal Neovascularization Secondary to Age-related Macular DegenerationyetConditions:Subfoveal Choroidal Neovascul arization (CNV);Secondary to Age-related Macular Degeneration (AMD)Age-related Macular Degeneration (AMD)16TerminatedA Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration Condition:16TerminatedA Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration Intervention:17Active, not recruitingVEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)18RecruitingA Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD			Intervention:	Drug: Ranibizumab
published yet Age-related Macular Degeneration Conditions: Subfoveal Choroidal Neovascul arization (CNV); Secondary to Age-related Macular Degeneration (AMD) 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) 18 Recruiting A Randomized, Double-masked, Multicenter, Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD	15	Completed	Safety and Tolerability of Ran	ibizumab in Patients With
yet Conditions: Subfoveal Choroidal Neovascul arization (CNV); Secondary to Age-related Macular Degeneration (AMD) 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD		no results	Subfoveal Choroidal Neovasc	ularization Secondary to
arization (CNV); Secondary to Age-related Macular Degeneration (AMD) 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration Condition: 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD		published	Age-related Macular Degenera	ation
to Age-related Macular Degeneration (AMD) Intervention: Drug: ranibizumab 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD		yet	Conditions:	Subfoveal Choroidal Neovascul
Image: Degeneration (AMD) Intervention: Drug: ranibizumab 16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration Condition: Age-Related Macular Degeneration Intervention: Drug: AG-013,958 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) Intervention: Myopia, Pathological Interventions: Biological: VEGF Trap-Eye (BAY8 6-5321); 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD				arization (CNV); Secondary
Intervention:Drug: ranibizumab16TerminatedA Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration Condition:Age-Related With Age-Related Macular Degeneration17Active, not recruitingVEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)17Active, not recruitingVEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)18RecruitingA Randomized, Double-masked, Multicenter, Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD				to Age-related Macular
16 Terminated A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration Condition: Age-Related Macular Degeneration Intervention: Drug: AG-013,958 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) Condition: Myopia, Pathological Interventions: Biological: VEGF Trap-Eye (BAY8 6-5321); 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD				Degeneration (AMD)
With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration Condition: Age-Related Macular Degeneration Intervention: Drug: AG-013,958 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) Condition: Myopia, Pathological Interventions: Biological: VEGF Trap-Eye (BAY8 6-5321); Procedure: No Drug A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD			Intervention:	Drug: ranibizumab
Age-Related Macular Degeneration Condition: Age-Related Macular Degeneration Intervention: Drug: AG-013,958 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) Condition: Myopia, Pathological Interventions: Biological: VEGF Trap-Eye (BAY8 6-5321); Procedure: No Drug 18 Recruiting Age-Related Macular Degeneration Safty and Efficacy Study of KH902 in Patients With Wet AMD	16	Terminated	A Study Of The Safety And Ef	ficacy Of AG-013,958 In Subjects
Condition: Age-Related Macular Degeneration Intervention: Drug: AG-013,958 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) Condition: Myopia, Pathological Interventions: Biological: VEGF Trap-Eye (BAY8 6-5321); 18 Recruiting A Randomized, Double-masked, Multicenter, Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD			With Subfoveal Choroidal Nec	ovascularization Associated With
Intervention: Drug: AG-013,958 17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) Condition: Myopia, Pathological Interventions: Biological: VEGF Trap-Eye (BAY8 6-5321); 18 Recruiting A Randomized, Double-masked, Multicenter, Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD				
17 Active, not recruiting VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) Condition: Myopia, Pathological Interventions: Biological: VEGF Trap-Eye (BAY8 6-5321); 18 Recruiting A Randomized, Double-masked, Multicenter, Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD			Condition:	Age-Related Macular Degeneration
recruiting Pathologic Myopia (mCNV) Condition: Myopia, Pathological Interventions: Biological: VEGF Trap-Eye (BAY8 6-5321); Procedure: No Drug 18 Recruiting A Randomized, Double-masked, Multicenter, Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD			Intervention:	Drug: AG-013,958
Condition: Myopia, Pathological Interventions: Biological: VEGF Trap-Eye (BAY8 6-5321); Procedure: No Drug 18 Recruiting A Randomized, Double-masked, Multicenter,Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD	17	Active, not	VEGF Trap-Eye in Choroidal Neovascularization Secondary to	
Interventions: Biological: VEGF Trap-Eye (BAY8 6-5321); Procedure: No Drug 18 Recruiting A Randomized, Double-masked, Multicenter, Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD		recruiting	Pathologic Myopia (mCNV)	
18 Recruiting A Randomized, Double-masked, Multicenter, Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD			Condition:	Myopia, Pathological
18 Recruiting A Randomized, Double-masked, Multicenter, Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD			Interventions:	Biological: VEGF Trap-Eye (BAY8
Safty and Efficacy Study of KH902 in Patients With Wet AMD				6-5321); Procedure: No Drug
	18	Recruiting	A Randomized, Double-maske	ed, Multicenter,Sham-controlled,
Condition: Neovascular Age-related Macul			Safty and Efficacy Study of KH902 in Patients With Wet AMD	
			Condition:	Neovascular Age-related Macul
ar Degeneration				· ·
Intervention: Biological: Recombinant			Intervention:	-
Human VEGF Receptor-Fc				•
Fusion Protein				•
19 Recruiting Pilot Study of a Suprachoroidal Retinal Prosthesis				

		Conditions:	Retinitis Pigmentosa; Choroid eremia	
		Intervention:	Device: Prototype wide view suprachoroidal retinal prosthesis	
20	Unknown [†]	Intravitreal Pegaptanib in Treatment of Choroidal		
		Neovascularisation Secondary to Pathologic Myopia		
		Condition:	Myopic Choroidal Neovasc	
			ular Membrane	
		Intervention:	Drug: Intravitreal Pegaptan	
			ib	

14. Choroidal Neovascularization

Rank	Status	Study	
1	Completed	Changes in Retinal Function A	After Intravitreal Ranibizumab for
	Has Results	Age-related Macular Degeneration	
	published on	Condition:	Age-related Macular Degeneration
	website	Intervention:	Drug: ranibizumab
2	Terminated	A Study Using Intravitreal Injections of a Small Interfering RNA in	
	Has Results	Patients With Age-Related Macular Degeneration	
	published on	Conditions:	Choroid Neovascularization; Ag
	website		e-Related Macular Degeneration
		Interventions:	Drug: AGN 211745; Drug: Rani
			bizumab 500µg
3	Completed	Safety and Efficacy of Ranibiz	umab in Japanese Patients With
	Has Results	Subfoveal Choroidal Neovasc	ularization Secondary to
	published in	Age-related Macular Degenera	ation
	journals	Condition:	Subfoveal Choroidal
			Neovascularization(CNV)
			Secondary to Age-related Macular
			Degeneration (AMD)
		Intervention:	Drug: Ranibizumab
4	Completed	Safety and Efficacy of a New Therapy as Adjunctive Therapy to	
	Has Results	Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects	
	published on	With Wet Age-Related Macular Degeneration (AMD)	
	website	Conditions:	Choroidal Neovascularization; Age
			-Related Maculopathy
		Interventions:	Drug: dexamethasone; Biological: r
			anibizumab
5	Completed	Clinical Study Of Pegaptanib	Sodium (EYE001) For Wet-Type
	Has Results	Age-Related Macular Degener	ation
	published on	Condition:	Macular Degeneration
	website	Intervention:	Drug: pegaptanib sodium
6	Completed	Safety and Efficacy of a New 1	Freatment as Adjunctive Therapy to
	Has Results	Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in	
	published on	Patients With Age-Related Ma	cular Degeneration (AMD)
	website	Conditions:	Choroidal Neovascularization; Age
			-Related Maculopathy
		Interventions:	Drug: dexamethasone; Biological: r
			anibizumab; Other: sham
7	Completed	A Population-based Study of I	
	no results	Neovascularization in a Chine	se Population

	a literation		
	published yet	Conditions:	Geographic Atrophy; Wet Macula r Degeneration; Retinal Drusen
		Intervention:	Other: Follow-up observation
8	Completed	A Study Assessing the Safety	and Efficacy of Multiple Intravitreal
	no results	KH902 in Patients With CNV D	
	published yet	Condition:	Neovascular Age-related Macular De
			generation
		Intervention:	Biological: Intravitreal injection of KH
			902
9	Completed	Evaluation of Safety and Effic	acy of Once Monthly Ranibizumab
	no results		With Wet Age Related Macular
	published yet	Degeneration (AMD) Patients	C C
		Condition:	Age Related Macular Degeneration
		Intervention:	Drug: ranibizumab 0.5 mg
10	Completed	Efficacy and Safety of Ranibiz	<u> </u>
	no results		Neovascularization Secondary to
	published	Pathologic Myopia	·····, ···
	yet	Condition:	Pathological Myopia
		Interventions:	Drug: 0.5 mg ranibizumab driven by
			disease activity; Drug: 0.5 mg
			ranibizumab driven by stabilization
			criteria; Drug: verteporfin PDT
11	Completed	Phase II Open Label Multicent	er Study For Age Related Macular
	no results	Degeneration Comparing PF-04523655 Versus Lucentis In The	
	published	Treatment Of Subjects With CNV (MONET Study).	
	yet	Condition:	Age Related Macular Degeneration
		Interventions:	Drug: 0.5 mg ranibizumab; Drug: 3
			mg PF-04523655; Drug: 1 mg PF-0
			4523655
12	Completed	EXTEND III - Efficacy and Safe	ety of Ranibizumab in Patients With
	no results	Subfoveal Choroidal Neovasc	ularization (CNV) Secondary to
	published	Age-related Macular Degenera	ation (AMD)
	yet	Conditions:	Choroidal Neovascularization; Ag
			e-Related Macular Degeneration
		Intervention:	Drug: ranibizumab
13	Completed	Clinical Study Of EYE001 For	Wet-Type AMD (Age-Related
	no results	Macular Degeneration)	
	published	Condition:	Macular Degeneration
	yet		-

		Intervention:	Drug: pegaptanib sodium
14	Completed		ibizumab in Patients With Subfoveal
	no results		Secondary to Age-related Macular
	published	Degeneration	
	yet	Conditions:	Subfoveal Choroidal Neovasculariz ation (CNV); Secondary to Age-related Macular Degeneration (AMD)
		Intervention:	Drug: ranibizumab
15	Completed	Study to Investigate the Safety	y and Efficacy of Ranibizumab in
_	no results		ascularisation Due to Causes Other
	published	Than Age Related Macular De	
	yet	Conditions:	Choroidal Neovascularization; Re
			tinal Pigment Epithelial Detachment
		Intervention:	Drug: Ranibizumab
16	Completed		K787 in Patients With Subfoveal
10	no results		Secondary to Age-Related Macular
	published	Degeneration (AMD)	
	yet	Condition:	Wet Age-Related Macular Degener
			ation
		Interventions:	Drug: PTK787; Drug: Placebo
17	Completed	An Extension to Study MD710	8240
	no results	Condition:	Macular Degeneration
	published	Intervention:	Drug: Pazopanib
	yet		
18	Completed	To Evaluate the Pharmacodyn	namics, Safety, and
	no results	-	ib Drops in Adult Subjects With
	published	Neovascular AMD	
	yet	Condition:	Macular Degeneration
		Intervention:	Drug: Pazopanib
19	Completed	Myopic Macular Haemorrhage	25
	no results	Condition:	Myopic Macular Haemorrhages
	published	Intervention:	
	yet		
20	Terminated		ficacy Of AG-013,958 In Subjects
		With Subfoveal Choroidal Neovascularization Associated With	
		Age-Related Macular Degener	ation
		Condition:	Age-Related Macular Degeneration
		Intervention:	Drug: AG-013,958

21	Active, not	A Randomized, Double-masked, Multicenter, Controlled Study of		
	recruiting	Intravitreal KH902 in Patients With Neovascular AMD		
		Condition:	Neovascular Age-related Macular	
			Degeneration	
		Intervention:	Biological: intravitreal injection of K	
			H902	
22	Active, not	VEGF Trap-Eye in Choroidal N	leovascularization Secondary to	
	recruiting	Pathologic Myopia (mCNV)		
		Condition:	Myopia, Pathological	
		Interventions:	Biological: VEGF Trap-Eye (BAY86-	
			5321); Procedure: No Drug	
23	Recruiting	A Randomized, Double-maske	d, Double-masked, Multicenter,Sham-controlled,	
		Safty and Efficacy Study of KH902 in Patients With Wet AMD		
		Condition:	Neovascular Age-related Macular	
			Degeneration	
		Intervention:	Biological: Recombinant Human	
			VEGF Receptor-Fc Fusion Protein	
24	Unknown †	Intravitreal Pegaptanib in Trea	ravitreal Pegaptanib in Treatment of Choroidal	
		Neovascularisation Secondary to Pathologic Myopia		
		Condition:	Myopic Choroidal Neovascular Me	
			mbrane	
		Intervention:	Drug: Intravitreal Pegaptanib	

15. Choroideremia

Rank	Status	Study		
1	Recruiting	Pilot Study of a Suprachoroidal Retinal Prosthesis		
		Conditions:	Retinitis Pigmentosa;	Choroideremia
		Intervention:	Device: Prototype wide	e view
			suprachoroidal retinal	prosthesis

16. Choroiditis

Rank	Status	Study	
1	Completed	A Study of the Safety and Efficacy of a New Treatment for	
	Has Results	Non-Infectious Intermediate or Posterior Uveitis	
	published	Conditions:	Intermediate Uveitis; Posterior Uv
	in journal		eitis
		Interventions:	Drug: Dexamethasone; Drug: dex
			amethasone; Drug: Sham injectio
			n

17. Conjunctival	Diseases
------------------	----------

Rank	Status	Study	
1	Completed	Acupuncture for Dry Eye Syndrome	
	Has Results	Condition:	Dry Eye Syndromes
	published in	Interventions:	Device: Standardized Acupuncture;
	journals		Device: Non-acupuncture point
			shallow penetration acupuncture
2	Completed	The Effect of Oral Azithromyc	in in the Treatment of Chlamydial
	Has Results	Conjunctivitis	
	published on	Condition:	Chlamydial Conjunctivitis
	website	Intervention:	Drug: Azithromycin
3	Completed	A Study of the Safety and Eff	icacy of Gatifloxacin in Patients
	Has Results	With Bacterial Conjunctivitis	
	published on	Condition: Bacterial Conju	nctivitis
	website	Interventio Drug: Gatifloxad	cin 0.5% eye drops; Drug: placebo
		ns: eye drops	
4	Completed	Alrex® Versus Patanol in the	Treatment of Seasonal Allergic
	Has Results	Conjunctivitis(SAC)	
	published on	Condition:	Seasonal Allergic Conjunctivitis
	website	Interventions:	Drug: Loteprednol etabonate 0.2%;
			Drug: Olopatadine 0.1%
5	Completed	Trial to Compare the Efficacy	of Systane Ultra and Refresh Drop
	Has Results	in the Treatment of Dry Eye in	n Asian Eyes
	published on	Conditions:	Xerophthalmia; Blepharitis
	website	Interventions:	Drug: Systane Ultra eyedrops; Dru
			ye drops
6	Completed	Loteprednol and Tobramycin	Versus Tobramycin and
	Has Results	Dexamethasone, in the Treat	
	published in	Blepharokeratoconjunctivitis	
	journals	Conditions:	Conjunctivitis; Keratitis; Blephari
		Interventions:	Drug: Loteprednol and tobramycin;
			rug: Tobramycin and dexamethasone
7	Completed	Efficacy, Tolerability, and Cor	
	Has Results	Eyedrops in Patients Undergo	
	published on	Condition:	Dry Eye Syndromes
	website	Interventions:	Drug: Pre-LASIK 0.3% hypromel
			lose; Drug: Post-LASIK 0.3%
			hypromellose
8	Completed	Safety and Efficacy of Cyclos	porine Ophthalmic Emulsion in

	Has Results	Patients With Primary Pterygin	Im
	published on	Condition:	Pterygium
	website	Interventions:	Drug: cyclosporine ophthalmic emuls
		interventions.	on 0.05%; Drug: Vehicle
9	Completed	Ketotifen Ophthalmic Solution	With Emedastine in Patients With
•	No results	Seasonal Allergic Conjunctivit	
	published	Condition:	Seasonal Allergic Conjunctivitis
	yet	Intervention:	Drug: Ketotifen
10	Completed		a and Pterygium Historical Control
	No results	Study in Beijing Remin Hospit	
	published	Conditions:	Glaucoma; Pterygium
	yet	Intervention:	Device: OculusGen
			Biodegradable Collagen Matrix
11	Completed	Ologen (OculusGen)-Glaucom	a and Pterygium Historical Control
	No results	Study in China Zhong-Shan H	
	published	Conditions:	Glaucomas; Pterygium
	yet	Intervention:	Device: OculusGen Biodegradable
			Collagen Matrix Implant
12	Completed	Ologen (OculusGen)-Glaucom	a and Pterygium Historical Control
	No results	Study in China Beijing Hospita	al
	published	Conditions:	Glaucoma; Pterygium
	yet	Intervention:	Device: OculusGen Biodegradable
			Collagen Matrix Implant
13	Completed	Polyglactin Sutures Versus Ny	lon Sutures for Suturing of
	No results		ygium Surgery: a Randomised
	published	Controlled Trial	
	yet	Condition:	Pterygium
		Interventions:	Procedure: Polyglactin sutures for
			suturing of conjunctival autograft in
			pterygium surgery; Procedure:
			Nylon sutures for suturing of
			conjunctival autograft in pterygium surgery
14	Completed	A Phase II, Dose Ranging Stur	dy Of CP-690,550 Eye Drops In
	No results	Patients With Dry Eye Disease	
	published	Condition:	Dry Eye Syndromes
	yet	Interventions:	Drug: CP-690,550 Eye drops; Dr
	1		

	1		
			ug: CP-690,550 Eye drops-vehicle;
			Drug: Sodium Hyaluronate
15	Completed	Acupuncture for Dry Eye	
	No results	Condition:	Dry Eye
	published yet	Interventions:	Device: Acupuncture; Drug: Refr esh Plus
4.0			
16	Completed No results	Evaluation of the Effect and T	
			Component and Symptoms of Dry
	published	Eye Syndrome in Allergic Con	-
	yet	Condition:	Allergic Conjunctivitis
		Interventions:	Drug: NAABAK eyedrops; Drug: Saline eyedrops
17	Completed	Efficacy and Safety Study of A	ATs in Patients With Dry Eye
	No results	Syndrome	
	published	Conditions:	Dry Eye Syndromes; Keratoconj
	yet		unctivitis Sicca
		Interventions:	
		interventions.	Drug: AT01; Drug: AT02; Drug : AT03; Drug: AT04
18	Completed	A Study to Evaluate the Tolera	ability of Eye Drop DA-6034 in
	No results	Healthy Volunteers	
	published	Condition:	Dry Eye Syndrome
	yet	Interventions:	Drug: DA-6034; Drug: Placebo
19	Completed	Comparison of Autologous Se	erum and Umbilical Cord Serum
	No results	Eyedrops for Dry Eye Syndroi	
	published		Dry Eye Syndrome
	yet	Interventions:	Drug: Umbilical cord serum eyedr
		Interventions.	с ,
			ops; Drug: Autologous serum e yedrops
20	Completed		
20	Completed No results		d CXCR3 in Dry Eye Syndrome
		Condition:	Dry Eye Syndrome
	published	Intervention:	
04	yet	Dhase 2 Study of KLC 0011 in	Detiente With Dry Eve Sundremes
21	Completed		Patients With Dry Eye Syndromes
	No results	Condition:	Dry Eye Syndromes
	published	Interventions:	Drug: Placebo; Drug: KLS-0611
	yet		
22	yet Completed	A Study of KCT-0809 in Patier	nts With Dry Eye Syndromes
22		A Study of KCT-0809 in Patier Condition:	nts With Dry Eye Syndromes Dry Eye Syndromes

	yet	Interventions:	Drug: KCT-0809; Drug: Placebo
23	Completed	· · · · ·	abel, Extension Study of 0.1%
	No results		ic Suspension in Patients With
	published	Vernal Keratoconjunctivitis	
	yet	Conditions:	Keratoconjunctivitis; Conjunctivitis
		Intervention:	Drug: FK506
24	Completed	Late Phase 2 Study of OPC-12	2759 Ophthalmic Suspension
	No results	Condition:	Dry Eye Syndromes
	published	Intervention:	Drug: OPC-12759
	yet		
25	Completed No results	-	udy of OPC-12759 Ophthalmic
	published	Suspension	
	yet	Condition:	Dry Eye Syndromes
	yct	Intervention:	Drug: OPC-12759 Ophthalmic suspe nsion
26	Completed	Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic	
	No results	Suspension in Patients With V	/ernal Keratoconjunctivitis
	published	Conditions:	Keratoconjunctivitis; Conjunctivitis
	yet	Interventions:	Drug: FK506; Drug: placebo
27	Completed	Confirmatory Study of OPC-12	2759 Ophthalmic Suspension
	No results	Condition:	Dry Eye Syndromes
	published	Interventions:	Drug: OPC-12759 Ophthalmic suspe
	yet		nsion; Drug: Hyalein Mini Ophthal mic solution
28	Completed	Study of DE-114 Ophthalmic S	Solution in Patients With Allergic
	No results	Conjunctivitis	
	published	Condition:	Allergic Conjunctivitis
	yet	Interventions:	Drug: DE-114 ophthalmic solution;
			Drug: Placebo ophthalmic solution;
			Drug: Olopatadine Hydrochloride
			0.1% Ophthalmic Solution
29	Completed	•	Ophthalmic Solution in Patients
	No results	With Allergic Conjunctivitis	
	published	Condition:	Allergic Conjunctivitis
	yet	Intervention:	Drug: DE-114 ophthalmic solu
			tion
30	Terminated		duced Allergic Symptoms by Orally
		Taken Superfine Beta-1,3-Glue	can

r			
		Condition:	Allergic Conjunctivitis
		Intervention:	Drug: beta-1,3-glucan
31	Completed	Dose-Response Study of OPC	C-12759 Ophthalmic Suspension
	No results	Condition:	Dry Eye Syndromes
	published yet	Intervention:	Drug: OPC-12759
32	Completed	An Open-label, Long-term Stu	udy, With AL-4943A Ophthalmic
	No results	Solution, 0.2% in Patients Wit	th Allergic Conjunctivitis
	published	Condition:	Allergic Conjunctivitis
	yet	Intervention:	Drug: AL-4943A (olopatidine 0.2%)
33	Completed	Phase III Confirmatory Study	of DE-089 Ophthalmic Solution in
	No results	Patients With Dry Eye	
	published	Condition:	Dry Eye
	yet	Interventions:	Drug: 3% DE-089 ophthalmic solut
			ion; Drug: 0.1% sodium hyaluro
			nate ophthalmic solution
34	Completed	Clinical Evaluation of 0.1% Old	patadine Hydrochloride
	No results	Ophthalmic Solution in Pediatr	ric Patients
	published	Condition:	Allergic Conjunctivitis
	yet	Intervention:	Drug: Olopatadine hydrochloride
			ophthalmic solution 0.1%
35	Completed	Safety Study of OPC-12759 Op	hthalmic Solution
	No results	Condition:	Dry Eye Syndromes
	published	Interventions:	Drug: OPC-12759 Ophthalmic soluti
	yet		on; Drug: OPC-12759 Ophthalmic
			suspension
36	Completed		stine in Children From 2 to < 12
	No results	Years of Age With Either Allerg	gic Rhinoconjunctivitis (AR) or
	published	Chronic Urticaria (CU)	
	yet	Conditions:	Allergic Rhinoconjunctivitis; Chron ic Urticaria
		Intervention:	Drug: Bilastine
37	Completed	The Effect of Punctal Plugs on	Tear Volume and Osmolality
	No results	Condition:	Dry Eye Syndromes
	published	Intervention:	Device: Temporary Collagen
	yet		Inserts
38	Completed	Safety and Efficacy Study of N	ew Eye Drop Formulations With

	No results	Refresh Tears® in Patients Wi	ith Dry Eye Disease
	published	Condition:	Dry Eye Syndromes
	yet	Interventions:	Drug: Formulation 1: Eye Drops New Platform (EDNP) -
			1; Drug: Formulation 2: EDNP - 2; carboxymethylcellulose sodium based artificial tear
39	Completed	Efficacy and Safety Study of C	Cyclosporine 0.010% to Treat Atopic
	No results	Keratoconjunctivitis	
	published	Condition:	Atopic Conjunctivitis
	yet	Interventions:	Drug: Cyclosporine Vehicle; Dr
			ug: Cyclosporine 0.010%; Drug
			: Open-labeled Cyclosporine 0.01
			0%
40	Completed		adine Hydrochloride/Ketorolac
	No results		lution Compared With Olopatadine
	published		Iution in Patients With Seasonal
	yet	Allergic Conjunctivitis	Dhinitia Allergia Casaanalu Caniung
		Conditions:	Rhinitis, Allergic, Seasonal; Conjund
		Interventions:	Drug: olopatadine hydrochloride /ketor tromethamine fixed dose combination solution; Drug: olopatadine hydrochl ophthalmic solution
41	Completed	To Evaluate the Physical Effect	cts of Systane(R) Lubricant Eye
	No results	Drops Compared to Refresh T	
	published	Condition:	Dry Eye
	yet	Interventions:	Other: Systane; Other: Refres h Tears
42	Completed	A Study of Patient Perception	and Quality of Life Associated With
	No results	the Use of Olopatadine 0.2% in	n Subjects With Allergic
	published	Conjunctivitis	
	yet	Condition:	Allergic Conjunctivitis
		Intervention:	Drug: Olopatadine Hydrochloride
			Ophthalmic Solution, 0.2%
43	Completed	Rotational Narrow Strip Versu	is Full Conjunctival Graft in
	No results	Pterygium Excision	
	published	Condition:	Pterygium
	yet	Interventions:	Procedure: Rotational Narrow
			Strip Conjunctival

			Graft; Procedure: Full Conjunc
	Operation	Majatura Ohamhar Olaasaa (a	tival Graft
44	Completed No results		or Dry Eye in Asian Population
	published	Condition:	Dry Eye
	yet	Intervention:	Device: 7eye(Panoptx)™ moistu re chamber glasses
45	Completed	Assessment of Fibrin Glue in	Pterygium Surgery and Other Forms
	No results	of External Eye Surgery	
	published	Conditions:	Pterygium; Ocular Surface Cicat
	yet		rizing Diseases
		Intervention:	Device: Tisseel fibrin adhesive
46	Completed	Autologous ex Vivo Conjunct	ival Epithelial Cell Expansion for
	No results	Ocular Surface Transplantation	on
	published	Conditions:	Pterygium; Ocular Surface Diseas
	yet		e; Stevens Johnson Syndrome;
			Chemical Injury
		Intervention:	Procedure: Cultivated conjunctival
			transplantation
47	Completed	Use of Autologous Serum Eye	e-drops as Tears in Patients With
	No results	Recalcitrant Dry Eye	
	published	Condition:	Xerophthalmia
	yet	Intervention:	Drug: Autologous serum eyedro
			ps
48	Completed	Randomized Controlled Trial	of Subconjunctival Bevacizumab
	No results	Injection in Impending Recurr	rent Pterygium
	published	Condition:	Pterygium of the Conjunctiva and Corr
	yet	Interventions:	Drug: Fluorometholone; Drug: Beva
49	Completed	Treatment of Epidemic Kerato	oconjunctivitis With 2%
	No results	Povidone-iodine	
	published	Condition:	Viral Conjunctivitis
	yet	Intervention:	Drug: 2% povidone-iodine
50	Completed	Sodium Hyaluronate and Wav	refront Aberrations in Dry Eyes
	No results	Condition:	Dry Eye
	published	Interventions:	Drug: 0.18% sodium hyaluronate;
	yet		Drug: 0.9% sodium chloride solution
51	Completed	To Compare Fibrin Glue and Suture in Primary Pterygium	
	No results	Excision With Amniotic Memb	prane Transplantation
	published	Condition:	Pterygium

	yet	Intervention:	Procedure: Amniotic membrane
			transplantation using fibrin glue
52	Completed		arboxymethylcellulose With 0.005%
	No results	Stabilized Oxychlorocomplex	
	published	Carboxymethylcellulose in the	e Treatment of Dry Eye
	yet	Condition:	Dry Eye Syndromes
		Intervention:	Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
53	Completed	Efficacy Study of FK-506 and	Cyclosporine in Vernal
	No results	Keratoconjunctivits (VKC)	
	published	Condition:	Keratoconjunctivitis, Vernal
	yet	Interventions:	Drug: tacrolimus; Drug: cyclospori
			ns
54	Enrolling by	TearLab Core Validation Study	/
	invitation	Condition:	Dry Eye Disease
		Intervention:	
55	Active, not	A Phase II Study of KCT-0809	in Patients With Dry Eye Syndrome
	recruiting	Condition:	Dry Eye Syndromes
		Interventions:	Drug: KCT-0809; Drug: Placebo
56	Recruiting	Topical Bevacizumab for Prev	enting Recurrent Pterygium
	_	Conditions:	Pterygium; Bevacizumab; VEGF;
		Interventions:	Drug: bevacizumab eye drop 0.05%;
			ine 0.9%
57	Recruiting	Phase II Study of DA-6034 Eye	Drops in Dry Eye Syndrome
		Condition:	Dry Eye Syndrome
		Interventions:	Drug: DA-6034 3%; Drug: DA-603
			4 5%; Drug: DA-6034 Placebo
58	Recruiting	Confirmatory Study of OPC-12	2759 Ophthalmic Solution
		Condition:	Dry Eye
		Interventions:	Drug: OPC-12759; Drug: Placebo
59	Recruiting	Intralesional Bevacizumab Inje	ection on Primary Pterygium
		Conditions:	Pterygium; Inflammation
		Interventions:	Drug: Intralesional injection of bevac
			izumab; Drug: Topical antihistami
			ne and vasoconstrictor
60	Recruiting	The Effect of Hinge Location on Co	orneal Sensation and Dry Eye After
		LASIK: A Systematic Review and M	Meta-analysis

		• ••••	
		Condition:	Dry Eye
		Intervention:	
61	Recruiting		g Insertion in Patients With Dry Eye
		Condition:	Dry Eye
		Intervention:	Device: Punctal Plug
62	Recruiting	Study of DE-089 Ophthalmic Solut	ion in Patients With Dry Eye
		Condition:	Dry Eye
		Interventions:	Drug: diquafosol ophthalmic solution
			; Drug: 0.1% sodium hyaluronate
			ophthalmic solution.
63	Recruiting	Study of DE-089 Ophthalmic Solut	ion in Patients With Dry Eye
		Condition:	Dry Eye
		Interventions:	Drug: diquafosol ophthalmic solution
			; Drug: 0.1% sodium hyaluronate
			ophthalmic solution.
64	Recruiting	Repeatability and Agreement of An	
		Tomography (AS-OCT) and Therm	
		Condition:	Dry Eye Syndromes
		Intervention:	Device: EyeGiene
65	Recruiting	-	inflammatory Drugs in Treatment of
		Moderate and Severe Dry Eye Condition:	
		Condition:	Moderate to Severe Dry Eye Diseas
		Interventions:	C Drug: nonsteroid anti-inflammatory
			drops plus artificial tear
			substitute; Drug: corticosteroids
			plus artificial tear
			substitute; Drug: artificial tear sub
			stitute
66	Recruiting	Risk Factors and Biomarkers	Associated With Recurrence After
		Excision of Primary Pterygium	
		Condition:	Pterygium
		Intervention:	
67	Recruiting	A Parallel Group Phase II Stuc	dy of KCT-0809 in Patients With Dry
		Eye Syndromes	
		Condition:	Dry Eye Syndromes
		Interventions:	Drug: KCT-0809; Drug: Placebo
68	Recruiting	Hydroxychloroquine Treatmen	nt of Dry Eyes in Patients With

		Primary Sjögren's Syndrome	
			Autoimmune Diseases; Sjogren'
			s Syndrome; Dry Eye
		Interventions:	Drug: Hydroxychloroquine; Drug:
			Placebo
69	Recruiting		Observe the Cytological Changes
		of Ocular Surface Cells in Vario	
		Conditions:	
			r
70	Deenviting	Intervention:	and Efficiency of Laternay
70	Recruiting	A Study to Evaluate the Safety Ophthalmic Suspension 0.5%	and Efficacy of Lotemax
			vitis, Seasonal Allergic; Con
			, Giant Papillary; Inflammati
		on	, , , ,
		Intervention: Drug: Lot	eprednol Etabonate
71	Unknown [†]	Effect of Pterygium Excision or	n Intraocular Lens Power
		Calculation for Subsequent Ca	taract Operation
		Conditions:	Pterygium; Cataract; Astigm
			atism
			Procedure: pterygium excision
72	Unknown [†]	The Pathogenesis of Superior I	-
			Superior Limbic Keratoconjunctivitis
		Intervention:	
73	Unknown [†]	-	ent Cataract and Primary Pterygium
			Pterygium; Cataract; Lenses, In traocular
			Procedure: combined pterygium and
		linterventions.	cataract operation; Procedure:
			pterygium excision followed by
			cataract operation
74	Unknown †	Comparison of Efficacy, Safety and	Anti-Inflammatory Effect Between
			sion and REFRESH® in Patients With
		Moderate to Severe Dry Eyes	
			Dry Eye
			Drug: 0.05% cyclosporin eye drop
75	Unknown †	Corneal Epitheliotropic Factors in A	
		Nonautoimmune and Stevens-Johnso	on Syndrome With Dry Eye

		Condition:	Stevens-Johnson Syndrome
		Intervention:	,
76	Unknown †	Ologen(Oculusgen)-Glaucoma and	Pterygium Historical Control Study in
		China Shanghai Sixth People's Hosp	<u>pital</u>
		Conditions:	Glaucomas; Pterygium
		Intervention:	Device: ologen™ Collagen
			matrix implantation in glaucoma
			filtering surgery
77	Unknown †	Comparison of Glue With Sutures for	
		Condition:	Pterygium
		Intervention:	Procedure: Pterygium excision and
			conjunctival autograft
78	Unknown †		us in Conjunctiva of Dry Eye Patients
		Condition:	Dry Eye Disease
		Intervention:	
79	Not yet	FST-100 in the Treatment of A	cute Adenoviral Conjunctivitis
	recruiting	Condition: Act	ute Adenoviral Conjunctivitis
			ug: FST-100; Drug: FST-100 (Com
		por	nent #1); Drug: FST-100 Vehicle
80	Not yet		Efficacy of A New Eye Drop Formulation
	recruiting	With OPTIVE [™] in Subjects With I	
		Condition:	Dry Eye Disease
		Interventions:	Drug: Carboxymethycellulose Based
			Eye Drop Formulation A; Drug:
			Carboxymethylcellulose Based Preservative-Free Lubricant Eye
			Drops
81	Withdrawn	The Application of Fibrin Glue	
		Conditions:	Pterygium; Corneal Ulcer
		Intervention:	Drug: tissue fibrin glue appl
		Intervention:	

18. Corneal Diseases

Rank	Status	Study	
1	Completed	Loteprednol and Tobramycin	Versus Tobramycin and Dexamethasone,
	Has Results	in the Treatment of Blepharok	eratoconjunctivitis
	Published in	Conditions:	Conjunctivitis; Keratitis; Blepharitis
	journals	Interventions:	Drug: Loteprednol and tobramycin; Drug:
	1		Tobramycin and dexamethasone
2	Completed	Acupuncture for Dry Eye Synd	drome
	Has Results	Condition:	Dry Eye Syndromes
	Published in	Interventions:	Device: Standardized Acupuncture; D
	journals		evice: Non-acupuncture point shallow
			penetration acupuncture
3	Completed		nfort of 0.3% Hypromellose Eyedrops in
	Has Results	Patients Undergoing LASIK S	• •
	Published on	Condition:	Dry Eye Syndromes
	website	Interventions:	Drug: Pre-LASIK 0.3% hypromellose; Dru
			g: Post-LASIK 0.3% hypromellose
4	Completed		dy Of CP-690,550 Eye Drops In Patients
	No results	With Dry Eye Disease	
	published yet	Condition:	Dry Eye Syndromes
		Interventions:	Drug: CP-690,550 Eye drops; Dr
			ug: CP-690,550 Eye drops-vehicle;
5	Completed	Acupuncture for Dry Eye	Drug: Sodium Hyaluronate
5	No results	Condition:	Dry Eye
	published yet		
<u> </u>		Interventions:	Device: Acupuncture; Drug: Refresh Plus olerance of Preservative Free NAAGA on
6	Completed No results		and Symptoms of Dry Eye Syndrome in
	published yet	Allergic Conjunctivitis Patient	
	, , , , , , , , , , , , , , , , , , ,	Condition:	Allergic Conjunctivitis
		Interventions:	Drug: NAABAK eyedrops; Drug: Sali
			ne eyedrops
7	Completed	Efficacy and Safety Study of A	ATs in Patients With Dry Eye Syndrome
	No results	Conditions:	Dry Eye Syndromes; Keratoconjunctiviti
	published yet		s Sicca
		Interventions:	Drug: AT01; Drug: AT02; Drug: AT03; Drug: AT04
8	Completed	A Study to Evaluate the Tolera	ability of Eye Drop DA-6034 in Healthy
	No results	Volunteers	· · · ·

	published yet	Condition:	Dry Eye Syndrome
		Interventions:	Drug: DA-6034; Drug: Placebo
9	Completed		erum and Umbilical Cord Serum Eyedrops
	No results	for Dry Eye Syndrome	
	published yet	Condition:	Dry Eye Syndrome
		Interventions:	Drug: Umbilical cord serum eyedrops; Dr
			ug: Autologous serum eyedrops
10	Completed	CXCL9, CXCL10, CXCL11, and	d CXCR3 in Dry Eye Syndrome
	No results	Condition:	Dry Eye Syndrome
	published yet	Intervention:	
11	Completed	Effect on Wound Healing of Vi	igamox Versus Cravit
	No results	Condition:	Cataract Extraction
	published yet	Interventions:	Drug: Moxifloxacin 0.5% ophthalmic solution
			(Vigamox); Drug: Levofloxacin 0.5%
			ophthalmic solution (Cravit)
12	Completed	-	scope to Evaluate the Corneal Wound
	No results	Healing After Various Ocular S	•
	published yet	Condition:	Corneal Diseases
		Intervention:	
13	Completed		Patients With Dry Eye Syndromes
	No results published yet	Condition:	Dry Eye Syndromes
		Interventions:	Drug: Placebo; Drug: KLS-0611
14	Completed	A Study of KCT-0809 in Patien	
	No results published yet	Condition:	Dry Eye Syndromes
		Interventions:	Drug: KCT-0809; Drug: Placebo
15	Completed No results	Phase III, Long-Term, Open-La	
	published yet	Keratoconjunctivitis	ic Suspension in Patients With Vernal
		Conditions:	Keratoconjunctivitis; Conjunctivitis
		Intervention:	Drug: FK506
16	Completed	Late Phase 2 Study of OPC-12	.
	No results	Condition:	Dry Eye Syndromes
	published yet	Intervention:	Drug: OPC-12759
17	Completed		udy of OPC-12759 Ophthalmic Suspension
	No results	Condition:	Dry Eye Syndromes
	published yet	Intervention:	Drug: OPC-12759 Ophthal
			mic suspension
L	1	I	•

18	Completed	Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in	
	No results	Patients With Vernal Keratoconjunctivitis	
	published yet	Conditions:	Keratoconjunctivitis; Conjunctivitis
		Interventions:	Drug: FK506; Drug: placebo
19	Completed	Confirmatory Study of OPC-12	2759 Ophthalmic Suspension
	No results	Condition:	Dry Eye Syndromes
	published yet	Interventions:	Drug: OPC-12759 Ophthalmic suspension;
20	Completed	Late Phase II Confirmatory St	udy of DE-089 Ophthalmic Solution in
	No results	Patients With Dry Eye	
	published yet	Condition:	Dry Eye
		Interventions:	Drug: DE-089 ophthalmic soluti
			on; Drug: Placebo ophthalmic
			solution
21	Completed		-12759 Ophthalmic Suspension
	No results published yet	Condition:	Dry Eye Syndromes
		Intervention:	Drug: OPC-12759
22	Completed		of DE-089 Ophthalmic Solution in Patients
	No results	With Dry Eye	
	published yet	Condition:	Dry Eye
		Interventions:	Drug: 3% DE-089 ophthalmi c solution; Drug: 0.1% so
			dium hyaluronate ophthalmi
			c solution
23	Completed	Safety Study of OPC-12759 Op	ohthalmic Solution
	No results	Condition:	Dry Eye Syndromes
	published yet	Interventions:	Drug: OPC-12759 Ophthalmic
			solution; Drug: OPC-12759
			Ophthalmic suspension
24	Active, not	Steroids for Corneal Ulcers Tr	ial
	recruiting	Conditions:	Corneal Ulcer; Eye Infections, Ba cterial
		Interventions:	
		interventions:	Drug: Antibiotics; Drug: Topical co rticosteroid; Drug: Placebo
25	Completed	Mycotic Ulcer Treatment Trial	I
	No results	Conditions:	Corneal Ulcer; Eye Infections, Fu
	published yet		ngal
		Interventions:	Drug: Natamycin; Drug: Voriconaz
			ole

26	Completed	Therapeutic Exploratory Study of Comparing Natamycin and	
20	Completed No results	Voriconazole to Treat Fungal Corneal Ulcer	
	published yet		
	published yet	Condition: Fungal Keratitis	
		Interventio Drug: Natamycin 5%; Drug: Voriconaz	
		ns: ole; Procedure: Corneal de-epithelializ	
		ation	
27	Completed	To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops	
	No results	Compared to Refresh Tears(R) Lubricant Eye Drops	
	published yet	Condition: Dry Eye	
		Interventions: Other: Systane; Other: Refresh Te ars	
28	Completed	Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic	
	No results	Keratoconjunctivitis	
	published yet	Condition: Atopic Conjunctivitis	
		Interventions: Drug: Cyclosporine Vehicle; Drug: Cyclospori	
		ne 0.010%; Drug: Open-labeled Cyclosporine	
		0.010%	
29	Completed	Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin	
	No results	in Patients With Acute Bacterial Corneal Ulcers	
	published yet	Conditions: Acute Bacterial Corneal Ulcers; Bac	
		terial Keratitis	
		Interventions: Drug: Gatifloxacin 0.3% ophthalmic s	
		olution; Drug: Ciprofloxacin 0.3% o	
		phthalmic solution	
30	Completed	Moisture Chamber Glasses for Dry Eye in Asian Population	
	No results	Condition: Dry Eye	
	published yet	Intervention: Device: 7eye(Panoptx)™ moisture cha	
		mber glasses	
31	Completed	A Clinical Study of Keratoconus in Asian Patients and Assessment of	
	No results	Different Topographic Patterns of Keratoconus in Asian Patients	
	published yet	Condition: Keratoconus	
		Intervention:	
32	Completed	Randomized Controlled Trial of Subconjunctival Bevacizumab Injection	
	No results	in Impending Recurrent Pterygium	
	published yet	Condition: Pterygium of the Conjunctiva and	
	_	Cornea	
		Interventions: Drug: Fluorometholone; Drug:	
		Bevacizumab	
L			

33	Completed	Treatment of Epidemic Kerato	conjunctivitis With 2% Povidone-iodine
	No results	Condition:	Viral Conjunctivitis
	published yet	Intervention:	Drug: 2% povidone-iodine
34	Completed	Sodium Hyaluronate and Wav	efront Aberrations in Dry Eyes
	No results	Condition:	Dry Eye
	published yet	Interventions:	Drug: 0.18% sodium hyaluronate;
			Drug: 0.9% sodium chloride solutio
			n
35	Completed		arboxymethylcellulose With 0.005%
	No results	Stabilized Oxychlorocomplex	
	published yet	Carboxymethylcellulose in the	
		Condition:	Dry Eye Syndromes
		Intervention:	Drug: 0.5% carboxymethylcellulose
			(CMC) with purite and CMC alone
36	Completed	Efficacy Study of FK-506 and	Cyclosporine in Vernal
	No results	Keratoconjunctivits (VKC)	
	published yet	Condition:	Keratoconjunctivitis, Vernal
		Interventions:	Drug: tacrolimus; Drug: cyclospori
37	Terminated	The Application of Cultured Corpo	ns a Stem Cells in Patients Suffering From Corneal
57	Terminateu	Stem Cell Insufficiency	a Stem Cens in Fatients Suffering From Comean
		Condition:	Unilateral Limbal Stem Cell Insuffici
			ency
		Intervention:	Procedure: Transplant of cultured
			limbal stem cells on cornea
38	Terminated	The Application of Oral Mucosal E	pithelial Cell Sheets Cultivated on Amino
		Membrane in Patients Suffering From	om Corneal Stem Cell Insufficiency or
		Symblepharon.	
		Conditions:	Limbal Insufficiency; Symblephar
			on
		Intervention:	Procedure: Cultured oral mucosa
			cell sheet transplantation
39	Active, not	<u>A Phase II Study of KCT-0809 in P</u>	atients With Dry Eye Syndrome
	recruiting	Condition:	Dry Eye Syndromes
•	1	Interventions:	Drug: KCT-0809; Drug: Placebo
		interventions.	Drug. NOT 0000, Drug. Hacebo
40	Withdrawn	The Application of Fibrin Glue in C	· · ·

		Intervention:	Drug: tissue fibrin glue application (Tisseel)
41	Enrolling by	TearLab Core Validation Study	165001
	invitation	Condition:	Dry Eye Disease
		Intervention:	
42	Recruiting	Studies in Families With Corn Diseases	eal Dystrophy or Other Inherited Corneal
		Conditions:	Corneal Dystrophies, Hereditary; Corn eal Disease
		Intervention:	
43	Recruiting	Influence of Cosmetic Color T Surface	inted Contact Lenses on the Ocular
		Conditions:	Conjunctival Infections, Irritations and Inflammations; Hypertrophy; Conjunc tiva; Corneal Pannus; Corneal Epit helial Wound
		Intervention:	Other: contact lens wear
44	Recruiting	The Asia Cornea Society Infe	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
45	Recruiting	Xenogenic Keratoplasty From	Porcine Cornea
		Condition:	Corneal Transplantation
		Interventions:	Genetic: Xenogenic cornea;
			Genetic: homogenic cornea
46	Recruiting	LASIK: A Systematic Review	on Corneal Sensation and Dry Eye After
		Condition:	Dry Eye
		Intervention:	
47	Recruiting		Corneal Matrix to Treat Corneal Ulcer
	g	Condition:	Corneal Ulcer
		Intervention:	Device: acellular corneal matrix
48	Recruiting	Study of DE-089 Ophthalmic S	Solution in Patients With Dry Eye
	_	Condition:	Dry Eye
		Interventions:	Drug: diquafosol ophthalmic solut
			ion; Drug: 0.1% sodium
			hyaluronate ophthalmic solution.
49	Recruiting	Efficacy of Nonsteroidal Anti-	inflammatory Drugs in Treatment of

		Moderate and Severe Dry Eye	Disease
		Condition:	Moderate to Severe Dry Eye Dis ease
		Interventions:	Drug: nonsteroid
			anti-inflammatory drops plus
			artificial tear substitute; Drug:
			corticosteroids plus artificial tear
			substitute; Drug: artificial tear s
50	Pocruiting	The Asia Corner Society Infectious	ubstitute
50	Recruiting	The Asia Cornea Society Infectious Condition:	Corneal Ulcer
		Intervention:	Comear Olcer
54	Deenviting		- Incontion in Definite With Day Free
51	Recruiting	Condition:	g Insertion in Patients With Dry Eye Dry Eye
		Intervention:	Device: Punctal Plug
52	Recruiting		Solution in Patients With Dry Eye
JZ	Recluting	Condition:	Dry Eye
		Interventions:	Drug: diquafosol ophthalmic solu
		interventions.	tion; Drug: 0.1% sodium
			hyaluronate ophthalmic solution.
53	Recruiting	The Asia Cornea Society Infec	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
54	Recruiting	Repeatability and Agreement	of Anterior Segment Optical Coherence
		Tomography (AS-OCT) and Th	nermography
		Condition:	Dry Eye Syndromes
		Intervention:	Device: EyeGiene
55	Recruiting	The Asia Cornea Society Infec	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
56	Recruiting	The Asia Cornea Society Infec	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
57	Recruiting	Phase II Study of DA-6034 Eye Dre	ops in Dry Eye Syndrome
		Condition:	Dry Eye Syndrome
		Interventions:	Drug: DA-6034 3%; Dru
			g: DA-6034 5%; Drug: D
			A-6034 Placebo

58	Recruiting	Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary	
	-	Sjögren's Syndrome	
		Conditions: Autoimmune Diseases;	
		Sjogren's Syndrome; Dr	
		y Eye	
		Interventions: Drug: Hydroxychloroquine;	
		Drug: Placebo	
59	Recruiting	The Asia Cornea Society Infectious Keratitis Study	
		Condition: Corneal Ulcer	
		Intervention:	
60	Recruiting	Safety and Efficacy Study of Artificial Cornea	
		Condition: Corneal Transplantation	
		Intervention: Device: Auro KPro (Keratopros thesis)	
61	Recruiting	Mycotic Ulcer Treatment Trial II	
		Conditions: Corneal Ulcer; Eye Infection	
		s, Fungal	
		Interventions: Drug: Voriconazole; Drug: Pl acebo	
62	Recruiting	Confirmatory Study of OPC-12759 Ophthalmic Solution	
		Condition: Dry Eye	
		Interventions: Drug: OPC-12759; Drug: Placebo	
63	Recruiting	The Asia Cornea Society Infectious Keratitis Study	
	5	Condition: Corneal Ulcer	
		Intervention:	
64	Recruiting	The Asia Cornea Society Infectious Keratitis Study	
		Condition: Corneal Ulcer	
		Intervention:	
65	Unknown †	Riboflavin-UVA Induced Collagen Crosslinking Treatment for Corneal	
		Ectasia	
		Conditi Corneal Ectasia	
		on:	
		Interve Procedure: riboflavin-induced collagen cross-linking	
		ntions: treatment; Device: Riboflavin-UVA induced	
	Deemiting	collagen cross-linking treatment for corneal ectasia	
66	Recruiting	A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes	
		Eye Synulonies	

		Condition:	Dry Eye Syndromes
		Interventions:	Drug: KCT-0809; Drug: Placebo
67	Unknown [†]	Reliability of Pachymetry Mea	
07	Olikilowii	Confoscan 4 and Ultrasound	
		Condition:	Keratitis
		Intervention:	
68	Unknown †		nt of Corneal Neovascularization
		Condition:	Corneal Neovascularization
		Intervention:	Drug: Bevacizumab
69	Unknown [†]	The Pathogenesis of Superior	•
		Condition:	Superior Limbic Kerato
			conjunctivitis
		Intervention:	-
70	Unknown †	Corneal Epitheliotropic Factors in A	Autologous Serum Eye Drops in
	-	Nonautoimmune and Stevens-John	son Syndrome With Dry Eye
		Condition:	Stevens-Johnson Syndrome
		Intervention:	
71	Unknown †	Comparison of Efficacy, Safety and	Anti-Inflammatory Effect Between
		Topical 0.05%Cyclosporine A Emu	lsion and REFRESH® in Patients With
		Moderate to Severe Dry Eyes	
		Condition:	Dry Eye
		Intervention:	Drug: 0.05% cyclospor
			in eye drop
725	Unknown †	Intacs for Keratoconus	
		Condition:	Keratoconus
		Intervention:	Device: Intacs intracorneal ring insertion
73	Unknown †	The SNEC DSAEK EndoGlide Clin	nical Trial
		Condition:	Bullous Keratopathy
		Intervention:	Device: Endoglide
74	Unknown †	The Evaluation of Thiol Redox Sta	tus in Conjunctiva of Dry Eye Patients
		Condition:	Dry Eye Disease
		Intervention:	
75	Unknown †	Antibiotic Susceptibility of Conjun	ctival Bacterial Isolates From Refractive
		Surgery Patients	
		Condition:	Bacterial Keratitis
		Intervention:	

76	Unknown †	Corneal Thinning During Topical Bevacizumab Therapy	
		Condition:	Corneal Neovascularization
		Intervention:	Drug: bevacizumab (Avastin)

19. Dacryocystitis

Rank	Status	Study
1	Completed	The Microbiological Spectrum in Acute Dacryocystitis
	No results	Condition: Dacryocystitis
	published yet	Intervention:

20. Diabetic Retinopathy

Rank	Status	Study	
1	Complete	Diabetic Retinopathy Candesa	artan Trials
	Has Results	Condition:	Type 1 Diabetes
	published in	Intervention:	Drug: candesartan cilexetil
	journals		
2	Completed		oplication for the Treatment of
	Has Results	Corneal Epithelium Defect Aft	-
	published in	Conditions:	Corneal Epithelial Defect; Dia
	journals		betic Retinopathy; Penetratin
			g Keratoplasty
		Interventions:	Other: autologous serum; Ot
			her: Non-autologous serum
3	Completed	The Cost-effectiveness of Scr	eening for Diabetic Retinopathy in
	no results	Hong Kong	
	published	Condition:	Diabetic Retinopathy
	yet	Interventions:	Other: charging a co-payment for Dia
			Retinopathy screening; Other: free
			without charging a co-payment
4	Completed	A Study on Traditional Chines	se Medicine (TCM) Comprehensive
	no results	Protocol of Prevention and Co	ontrol in Diabetic Retinopathy
	published	Condition:	Diabetic Retinopathy
	yet	Interventions:	Drug: Qi ming granula; Drug: Plac
			ebo Comparator
5	Completed	Intravitreal Bevacizumab for F	Proliferative Diabetic Retinopathy
	no results	Condition:	Diabetic Retinopathy
	published	Intervention:	Drug: bevacizumab
	yet	-	
6	Completed	-	ritreal Bevacizumab Injection in
	no results	Diabetic Vitrectomy	
	published	Conditions:	Proliferative Diabetic Retinopathy;
	yet		Vitrectomy
		Intervention:	Drug: Bevacizumab
7	Completed		/itrectomy and Grid/Focal Laser for
	no results	Diabetic Macular Edema (DME	
	published	Conditions:	Diabetic Retinopathy; Macular
	yet		Edema
		Intervention:	Procedure: Triple therapy of
			vitrectomy, IVTA and grid/focal
			laser photocoagulation

8	Completed	Macular Hole in Diabetic Retir	nopathy	
	no results	Conditions:	Macular Hole; Proliferative Diabeti	
	published		Retinopathy	
	yet	Intervention:		
9	Completed	Fractalkine, a CX3C Chemokin	ne, Act as a Mediator of Ocular	
	no results	Angiogenesis		
	published	Conditions:	Proliferative Diabetic Retinopathy;	
	yet	Intervention:		
10	Completed	Intravitreal Bevacizumab Pret	reatment for Reducing Preretinal	
	no results	Hemorrhage in Diabetic Vitreo	ctomy	
	published	Condition:	Proliferative Diabetic Retinopathy	
	yet	Intervention:		
11	Completed	Bevacizumab and Long Acting	g Gas in Diabetic Vitrectomy	
	no results	Condition:	Proliferative Diabetic Retinopathy	
	published	Intervention:	Drug: Bevacizumab	
	yet		<u> </u>	
12	Completed	Reduction in the Occurrence	of Center-Involved Diabetic	
	no results	Macular Edema		
	published	Condition:	Diabetic Retinopathy	
	yet	Interventions:	Drug: ruboxistaurin; Drug: placebo	
13	Completed	Macular Appearance After Dia	abetic Vitrectomy	
	no results	Conditions:	Proliferative Diabetic Retinopathy;	
	published	Intervention:		
	yet			
14	Completed	Topical Autologous Insulin Application for the Treatment of		
	no results	Corneal Epithelium Defect Aft		
	published	Condition:	Corneal Epithelial Defects Aft	
	yet		er Ocular Surgeries	
		Interventions:	Drug: Topical insulin eye drop	
			s; Drug: Conventional posto	
_			perative eye drops	
15	Completed		Ilow-up Examinations and Surgical	
	no results	Outcome for Proliferative Diak		
	published	Condition:	Proliferative Diabetic Retinopathy	
	yet	Intervention:	Procedure: Vitrectomy	
16	Completed		/itrase for Clearance of Severe	
	no results	Vitreous Hemorrhage		
	published	Conditions:	Vitreous Hemorrhage; Diabetic Ref	
	yet			

			opathy	
		Intervention:	Drug: Vitrase (ovine hyaluronidase)	
17	Completed no results published yet	Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy		
	you	Condition:	Diabetic Macular Edema	
		Interventions:	Drug: 2304 Eye Drops High Dose;	
			g,ggg.	
			Drug: 2304 Eye Drops Low Dose; Drug: Placebo Eye Drops	
18	Completed	Green Laser Photocoagulation	n Study in Proliferative Diabetic	
	no results	Retinopathy		
	published	Condition:	Diabetic Retinopathy	
	yet	Interventions:	Device: Green Laser (Aurolas, A	
			urolab); Device: Green Laser (I ridex)	
19	Completed	Diabetic Retinopathy and Diab	petic Macular Edema Screening by	
	no results	Non-Physicians With Limited	Training	
	published	Condition:	Diabetic Retinopathy	
	yet	Interventions:	Device: Digital retina image; Dev	
			ice: direct ophthalmoscopy; Proc	
			edure: comprehensive eye exam	
20	Terminated		ascularization of Diabetic Retinopathy	
		Conditions:	The Mechanism of Retinal	
			Neovascularization of Diabetic; Retinopathy.	
		Intervention:	Genetic: genetic analyzer	
21	Terminated		f Vitreosolve® for Non-Proliferative	
	lonnatod	Diabetic Retinopathy Subjects		
		Condition:	Diabetic Retinopathy	
		Intervention:	Drug: Vitreosolve	
22	Terminated	Study Evaluating Efficacy and	Safety of PF-04523655 Versus	
		Laser in Subjects With Diabet	ic Macular Edema	
		Conditions:	Diabetic Retinopathy; Diabetes Complications	
		Interventions:	Procedure: Laser Treatment; Dr ug: PF-04523655 high; Drug: PF	

			-04523655 middle; Drug: PF-04 523655 low	
23	Active, not	Multicentre Randomized Cor		
25	recruiting	Multicentre, Randomized, Controlled Trial of Qideng Mingmu Capsule in The Treatment of Diabetic Retinopathy		
		Conditions:	Diabetic Retinopathy; Diabetic Eye Problems; Retinal Disorder	
			s	
		Interventions:	Drug: Qideng Mingmu capsule;	
			Drug: Placebo Comparator	
24	Recruiting	Autologous Plasmin and Fibri Retinopathy	inolytic System in Diabetic	
		Condition:	Macular Edema	
		Intervention:	Procedure: Intravitreal injection	
25	Recruiting	Effect of Intravitreal Bevacizu	mab on Focal Edema With Hard	
		Exudates Secondary to Diabe	tic Retinopathy	
		Condition:	Diabetes Complications	
		Intervention:	Drug: Avastin (bevacizumab)	
26	Recruiting	Genetic Association of Diabetic Retinopathy-1		
		Conditions:	Diabetes; Diabetic Retinopathy	
		Intervention:		
27	Recruiting	Intravitreal Bevacizumab (Avasting	B) Versus Intravitreal Dexamethasone	
		(Ozurdex TM) for Persistent Diabetic	<u>e Macular Oedema</u>	
		Conditions:	Diabetic Retinopathy; Macular Edema	
		Interventions:	Drug: bevacizumab; Drug: dex amethasone	
28	Recruiting	Thiazolidinedione (TZD) on the Di	abetic Retinopathy and Nephropathy	
		Condition:	Diabetes	
		Interventions:	Drug: Actos (Pioglitazone); Dru	
			g: Acarbose	
29	Recruiting	A Phase 2 Clinical Study to Investi	gate Effects of Darapladib in Subjects	
		With Diabetic Macular Edema		
		Condition:	Retinopathy, Diabetic	
		Interventions:	Drug: darapladib; Drug: plac	
	D. III		ebo	
30	Recruiting	Effect of the Adjunctive IVB B		
		Condition:	Diabetic Retinopathy	
		Intervention:	Drug: bevacizumab	

31	Recruiting	Macular Tractional Retinoschisis in Proliferative Diabetic		
		Retinopathy		
		Condition:	Proliferative Diabetic Retinopathy	
		Intervention:		
32	Not yet	Biomarkers of Diabetic Retinopath		
	recruiting	Conditions:	Type 2 Diabetes Mellitus; Mild Nor Retinopathy	
		Intervention:		
33	Unknown [†]	Shiga Progression of Diabeter	s, Nephropathy and Retinopathy	
		Condition:	Type 2 Diabetes Mellitus	
		Interventions:	Drug: Pioglitazone add on to SU o	
			r biguanide; Drug: SU or Biguan	
34	Unknown †		reosolve® for Non-Proliferative Diabetic	
		Retinopathy Subjects Condition:	Diabetic Retinopathy	
		Intervention:	Drug: Vitreosolve	
35	Unknown †		ent in Conventional Double Frequency	
		Nd: YAG Panretinal Photocoagulat Photocoagulation	ion with PASCAL Panietinar	
		Conditions: Macular Edema; Diabetic Retino		
		athy; Visual Field Loss		
		Interventions:	Procedure: PASCAL laser; Proce dure: Conventional laser	
36	Unknown †	Intravitreal Bevacizumab for Retina	al Disorders	
		Conditions:	Wet AMD; Macular Oedema; P	
			roliferative Diabetic Retinopathy	
		Intervention:	Drug: Bevacizumab (Avastin)	
37	Unknown †	Study on Tear Proteins in Diabetic	Retinopathy of Type 2 Diabetics	
		Condition:	Diabetes Mellitus	
		Intervention:		
38	Unknown †	Diabetic Retinopathy Sulodexide Study		
		Condition:	Diabetic Retinopathy	
		Intervention:	Drug: sulodexide	
39	Unknown †	Intravitreal Long Acting Gas in the	•	
		Vitreous Hemorrhage in Diabetic V		
		Conditions:	Diabetes Mellitus; Diabetic	
			Retinopathy; Vitreous Hem	

			orrhage
		Intervention:	Procedure: Intravitreal long a
			cting gas
40	Unknown †	Intravitreal Injection of Bevacizum	ab and Gas for Diabetic Premacular
		Hemorrhage With Active Fibrovasc	cular Proliferation
		Condition:	Diabetic Retinopathy With Premacula
		Intervention:	Drug: Intravitreal Bevacizumab
412	Unknown †	Pars Plana Vitrectomy for Diabetic	Fibrovascular Proliferation With and
		Without Internal Limiting Membran	ne Peeling
		Condition:	Patients With Proliferative Diabetic
			Retinopathy Who Have Active
			Fibrovascular Proliferation
		Intervention:	Procedure: ILM peeling

21. Diplopia

Rank	Status	Study		
1	Recruiting	Polycaprolactone / Tricalcium	Phosphate (PCL/TCP) v Titanium	
		Orbital Implant : Randomised Trial		
		Conditions:	Fractures; Enophthalmos; Diplo	
			pia	
		Interventions:	Device: Polycaprolactone / Tri-Calci	
			um Phosphate; Device: Titanium	
			Mesh	

22. Dry Eye Syndromes

Rank	Status	Study		
1	Completed	Acupuncture for Dry Eye Syndrome		
	Has Results	Condition:	Dry Eye Syndromes	
	published in	Interventions:	Device: Standardized Acupuncture;	
	journals		Device: Non-acupuncture point	
			shallow penetration acupuncture	
2	Completed	Trial to Compare the Efficacy	of Systane Ultra and Refresh Drop in	
	Has Results	the Treatment of Dry Eye in As	sian Eyes	
	published on	Conditions:	Xerophthalmia; Blepharitis	
	website	Interventions:	Drug: Systane Ultra eyedrops; Drug : Refresh eye drops	
3	Completed	Efficacy, Tolerability, and Con	nfort of 0.3% Hypromellose Eyedrops	
	Has Results	in Patients Undergoing LASIK	Surgery	
	published on	Condition:	Dry Eye Syndromes	
	website	Interventions:	Drug: Pre-LASIK 0.3% hypromellose;	
			Drug: Post-LASIK 0.3% hypromello	
			Se	
4	Completed	Efficacy and Safety Study of A	ATs in Patients With Dry Eye	
	no results	Syndrome		
	published yet	Conditions:	Dry Eye Syndromes; Keratoconjunc tivitis Sicca	
		Interventions:	Drug: AT01; Drug: AT02; Drug: A T03; Drug: AT04	
5	Completed	A Phase II, Dose Ranging Stu	dy Of CP-690,550 Eye Drops In	
	no results	Patients With Dry Eye Disease	9	
	published	Condition:	Dry Eye Syndromes	
	yet	Interventions:	Drug: CP-690,550 Eye drops; Drug: C	
6	Completed	CXCL9, CXCL10, CXCL11, and	d CXCR3 in Dry Eye Syndrome	
	no results	Condition:	Dry Eye Syndrome	
	published yet	Intervention:		
7	Completed	Acupuncture for Dry Eye		
	no results	Condition:	Dry Eye	
	published	Interventions:	Device: Acupuncture; Drug: Refres	
	yet		h Plus	
8	Completed	Comparison of Autologous Serum and Umbilical Cord Serum		
	no results	Eyedrops for Dry Eye Syndron	me	
	published	Condition:	Dry Eye Syndrome	
	yet			

		Interventions:	Drug: Umbilical cord serum eyedrops;	
			Drug: Autologous serum eyedrops	
9	Completed	A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy		
	no results	Volunteers		
	published	Condition:	Dry Eye Syndrome	
	yet	Interventions:	Drug: DA-6034; Drug: Placebo	
10	Completed	Evaluation of the Effect and T	olerance of Preservative Free NAAGA	
	no results	on the Inflammatory Compone	ent and Symptoms of Dry Eye	
	published	Syndrome in Allergic Conjunc	tivitis Patients	
	yet	Condition:	Allergic Conjunctivitis	
		Interventions:	Drug: NAABAK eyedrops; Drug: Sal	
			ine eyedrops	
11	Completed	Phase 2 Study of KLS-0611 in	Patients With Dry Eye Syndromes	
	no results	Condition:	Dry Eye Syndromes	
	published	Interventions:	Drug: Placebo; Drug: KLS-0611	
	yet			
12	Completed	A Study of KCT-0809 in Patier		
	no results	Condition:	Dry Eye Syndromes	
	published yet	Interventions:	Drug: KCT-0809; Drug: Placebo	
13	Completed	Confirmatory Study of OPC-12	2759 Ophthalmic Suspension	
	no results	Condition:	Dry Eye Syndromes	
	published	Interventions:	Drug: OPC-12759 Ophthalmic suspensi	
	yet		ug: Hyalein Mini Ophthalmic solution	
14	Completed	Long Term Administration Study of OPC-12759 Ophthalmic		
	no results	Suspension		
	published	Condition:	Dry Eye Syndromes	
	yet	Intervention:	Drug: OPC-12759 Ophthalmic suspensi	
			on	
15	Completed	Late Phase 2 Study of OPC-12	2759 Ophthalmic Suspension	
	no results	Condition:	Dry Eye Syndromes	
	published yet	Intervention:	Drug: OPC-12759	
16	Completed	Late Phase II Confirmatory St	udy of DE-089 Ophthalmic Solution in	
	no results	Patients With Dry Eye		
	published	Condition:	Dry Eye	
	yet	Interventions:	Drug: DE-089 ophthalmic solution;	
			Drug: Placebo ophthalmic solution	
17	Completed	Phase III Confirmatory Study	of DE-089 Ophthalmic Solution in	

	no results	Patients With Dry Eye	
	published		
	yet	Condition:	Dry Eye
	yet	Interventions:	Drug: 3% DE-089 ophthalmic solution;
			ug: 0.1% sodium hyaluronate ophthalm
			ution
18	Completed	Dose-Response Study of OPC	-12759 Ophthalmic Suspension
	no results	Condition:	Dry Eye Syndromes
	published yet	Intervention:	Drug: OPC-12759
19	Completed	Safety Study of OPC-12759 Op	phthalmic Solution
	no results	Condition:	Dry Eye Syndromes
	published	Interventions:	Drug: OPC-12759 Ophthalmic solution;
	yet		g: OPC-12759 Ophthalmic suspension
20	Completed	Clinical Pharmacological Stud	dy of AL-43546 Ophthalmic Product in
	no results	Subjects With Shortened Tear	Film Break Up Time
	published	Condition:	Dry Eye Disease
	yet	Interventions:	Drug: Hydroxypropyl Guar Galactomani
			an; Drug: 0.1% sodium hyaluronate o
			hthalmic solution
21	Completed	Exploratory Study for Dry Mou	uth in Patients With Sjögren's
	no results	Syndrome	
	published	Conditions:	Xerostomia; Sjogren's Syndrome
	yet	Intervention:	Drug: Rebamipide
22	Completed	Safety and Efficacy Study of N	New Eye Drop Formulations With
	no results	Refresh Tears® in Patients Wi	ith Dry Eye Disease
	published	Condition:	Dry Eye Syndromes
	yet	Interventions:	Drug: Formulation 1: Eye Drops New
			Platform (EDNP) -
			1; Drug: Formulation 2: EDNP - 2;
			Drug: carboxymethylcellulose
			sodium based artificial tear
23	Completed	The Effect of Punctal Plugs or	n Tear Volume and Osmolality
	no results	Condition:	Dry Eye Syndromes
	published	Intervention:	Device: Temporary Collagen Inserts
	yet		
24	Completed	To Evaluate the Physical Effect	cts of Systane(R) Lubricant Eye Drops
	e e inpiere a		
	no results	Compared to Refresh Tears(R) Lubricant Eye Drops
		Compared to Refresh Tears(R Condition:	Dry Eye

		I
25	Completed	Moisture Chamber Glasses for Dry Eye in Asian Population
	no results	Condition: Dry Eye
	published	Intervention: Device: 7eye(Panoptx)™ moisture cha
	yet	er glasses
26	Completed	Use of Autologous Serum Eye-drops as Tears in Patients With
	no results	Recalcitrant Dry Eye
	published	Condition: Xerophthalmia
	yet	Intervention: Drug: Autologous serum eyedrops
27	Completed	Comparative Study of 0.5% Carboxymethylcellulose With 0.005%
	no results	Stabilized Oxychlorocomplex (PURITE™) Versus 0.5%
	published	Carboxymethylcellulose in the Treatment of Dry Eye
	yet	Condition: Dry Eye Syndromes
		Intervention: Drug: 0.5% carboxymethylcellulose
		(CMC) with purite and CMC alone
28	Completed	Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes
	no results	Condition: Dry Eye
	published	Interventions: Drug: 0.18% sodium hyaluronate;
	yet	Drug: 0.9% sodium chloride solution
29	Completed	Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson
	no results	Syndrome Patient With Chronic Dry Eye
	published	Condition: Stevens-Johnson Syndrome
	yet	Intervention: Drug: 0.05%cyclosporin eye drop
30	Enrolling by	TearLab Core Validation Study
	invitation	Condition: Dry Eye Disease
		Intervention:
31	Enrolling by	Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome
	invitation	Condition: Primary Sjogren's Syndrome
		Intervention:
32	Active, not	A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome
	recruiting	Condition: Dry Eye Syndromes
		Interventions: Drug: KCT-0809; Drug: Placebo
33	Recruiting	The Effect of Hinge Location on Corneal Sensation and Dry Eye
		After LASIK: A Systematic Review and Meta-analysis
		Condition: Dry Eye
		Intervention:
34	Recruiting	Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
		Condition: Dry Eye
L		

		3 .	osol ophthalmic soluti	
		•	0.1% sodium	
25	De em itin e	hyaluronate ophthalmic solution.		
35	Recruiting	Repeatability and Agreement of Coherence Tomography (AS-O		
		Condition:		
			Dry Eye Syndromes	
		Intervention:	Device: EyeGiene	
36	Recruiting	Hydroxychloroquine Treatmen	t of Dry Eyes in Patients with	
		Primary Sjögren's Syndrome		
		Conditions:	Autoimmune Diseases; Sjogren' s Syndrome; Dry Eye	
		Interventions:	Drug: Hydroxychloroquine; Drug: Placebo	
37	Recruiting	Using Impression Cytology to	Observe the Cytological Changes of	
		Ocular Surface Cells in Various	s Ocular Surface Disorders	
		Conditions:	Pterygium; Dry Eye; Tumor	
		Intervention:		
38	Recruiting	A Parallel Group Phase II Study of KCT-0809 in Patients With Dry		
		Eye Syndromes		
		Condition:	Dry Eye Syndromes	
		Interventions:	Drug: KCT-0809; Drug: Placebo	
39	Recruiting	Safety and Efficacy of Punctal Eye	Plug Insertion in Patients With Dry	
		Condition:	Dry Eye	
		Intervention:	Device: Punctal Plug	
40	Recruiting	Phase II Study of DA-6034 Eye	Drops in Dry Eye Syndrome	
		Condition:	Dry Eye Syndrome	
		Interventions:	Drug: DA-6034 3%; Drug: DA-6034 5	
41	Recruiting	Efficacy of Nonsteroidal Anti-in	nflammatory Drugs in Treatment of	
		Moderate and Severe Dry Eye Disease		
		Condition: Moderate to Severe Dry Eye Disease		
		Interventio Drug: nonsteroid	anti-inflammatory drops plus	
		ns: artificial tear subs	stitute; Drug: corticosteroids plus	
		artificial tear		
		substitute; Drug	g: artificial tear substitute	
42	Not yet	A Study to Compare the Safety	and Efficacy of A New Eye Drop	
	recruiting	Formulation With OPTIVE™ in	Subjects With Dry Eye Disease	

	1			
		Condition:		Dry Eye Disease
		Interventions:		Drug: Carboxymethycellulose Based Ey
				Drop Formulation A; Drug:
				Carboxymethylcellulose Based
				Preservative-Free Lubricant Eye Drops
43	Unknown [†]	Allogeneic Mesenc	hymal Sten	n Cells Transplantation for Primary
		Sjögren's Syndrom	e (pSS)	
		Conditions:	Sjogren's	Syndrome; Mesenchymal Stem Cells
		Intervention:	Biological:	Allogeneic Mesenchymal Stem Cells
			(AlloMSC)	
44	Unknown [†]	Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in		
		Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye		
		C	ondition:	Stevens-Johnson Syndrome
		Inte	ervention:	
45	Unknown †	Comparison of Efficac	y, Safety and	Anti-Inflammatory Effect Between Topical
		0.05%Cyclosporine A	Emulsion and	d REFRESH® in Patients With Moderate to
		Severe Dry Eyes		
		C	ondition:	Dry Eye
		Inte	ervention:	Drug: 0.05% cyclosporin eye drop
46	Unknown †	The Evaluation of Thic	ol Redox Stat	us in Conjunctiva of Dry Eye Patients
		c	ondition:	Dry Eye Disease
		Inte	ervention:	

23. Enophthalmos

Rank	Status	Study	
1	Recruiti	Polycaprolactone / Tricalcium Phosphate (PCL/TCP) v Titanium Orbital	
	ng	Implant : Randomised Trial	
		Conditions:	Fractures; Enophthalmos; Diplopia
		Interventions:	Device: Polycaprolactone / Tri-Calcium Ph
			osphate; Device: Titanium Mesh

24. Epiretinal Membrane

Rank	Status	Study	
1	Completed	Macular Appearance After Dia	betic Vitrectomy
	no results	Conditions:	Proliferative Diabetic Retinopathy; V
	published		trectomy
	yet	Intervention:	
2	Completed	Evaluation of the Cone Outer	Segment Tips Line After Epiretinal
	no results	Membrane Surgery	
	published	Condition:	Epiretinal Membrane
	yet	Intervention:	Device: optical coherence tomography
3	Recruiting	Outcomes of Vitrectomy Com	bined With Subtenon Triamcinolone
		Injection for the Idiopathic Ep	iretinal Membrane
		Condition:	Epiretinal Membrane
		Interventions:	Procedure: Vitrectomy only group; P
			ocedure: Combined therapy group

25. Esotropia

Rank	Status	Study
1	Completed	Under-correction in Refractive Accommodative Esotropia
	no results	Condition: Accommodative Esotropia
	published	Intervention: Device: Glasses prescription
	yet	
1	Completed	Long-Term Outcomes in the Treatment of Infantile and
	no results	Acquired Esotropia With Botulinum Toxin
	published	Condition: Esotropia
	yet	Intervention:

26. Exfoliation Syndrome

Rank	Status	Study
1	Active, not	Efficacy of a Capsular Tension Ring in Preventing Anterior
	recruiting	Capsule Shrinkage After Cataract Surgery in Exfoliation
		<u>Syndrome</u>
		Condition: Cataract With Exfoliation Syndrome
		Intervention:
2	Recruiting	LOXL1 Polymorphism in Pseudoexfoliation Syndrome
		Condition: Pseudoexfoliation Syndrome
		Intervention:

27. Exophthalmos

Rank	Status	Study	
1	Completed	Function of Regulatory T Cells	s Improved by Dexamethasone in Graves'
	no results	Patients	
	published	Condition:	Graves' Disease
	yet	Intervention:	Drug: Dexamethasone
2	Completed	Pilot Study to Determine Safe	ty and Efficacy of Orbital Injections of
	no results	LIPO-102 in Patients With Syn	nptomatic Exophthalmos Associated With
	published	Thyroid-related Eye Disease (TED)
	yet	Condition:	Thyroid-Related Eye Disease
		Interventions:	Drug: LIPO-102; Drug: Placebo
3	Completed	Thyroid-Associated Ophthalm	opathy Subtypes and Orbital Antibodies
	no results	Condition:	Graves' Ophthalmopathy
	published yet	Intervention:	Drug: Carbimazole, radio-active iodi
	yet		ne (I131)
4	Completed	Pilot Study to Determine Safe	ty and Efficacy of Orbital Injections of
	no results		nptomatic Exophthalmos Associated With
	published	Thyroid-related Eye Disease (TED)
	yet	Condition:	Thyroid-Related Eye Disease
		Interventions:	Drug: LIPO-102; Drug: Placebo
5	Completed	Thyroid Treatment Trial	
	no results published	Condition:	Graves Ophthalmopathy
	yet	Intervention:	Drug: Intravenous
			Methylprednisolone + Oral
			Methotrexate vs Intravenous
			Methylprednisolone + Placebo
6	Completed		ing After Thyroidectomy Necessary?
	no results published	Conditions:	Thyroid Neoplasms; Thyroid Nodul
	yet		es; Graves Disease; Goiter
		Interventions:	Procedure: Pressure dressing; Proc
7	Boorviting	The Proceeding Study of Stor	edure: Normal dressing
1	Recruiting	131 and Prevention of Advers	ndard Treatment of Graves Disease Iodine
		Conditions:	Hypothyroidism; Exophthalmos
		Intervention:	Radiation: lodine 131
8	Recruiting		rmal Imaging (DITI) in Graves' Disease
0	Recruiting	Condition:	Graves' Disease
		Intervention:	

9	Recruiting	Doxycycline Treatment in Graves' Orbitopathy		
		Conditions:	Graves Ophthalmopathy; Graves Disea se; Eye Diseases; Thyroid Diseases; Endocrine System Diseases; Eye Dis eases, Hereditary; Hyperthyroidism; Autoimmune Diseases; Immune System Diseases	
		Intervention:	Drug: Doxycycline	
10	Recruiting	Differential Diagnosis Value of PS	V of Thyroid Superior Artery Using Color Flow	
		Doppler Sonography in Transient T	<u>'hyrotoxicosis</u>	
		Conditions:	Thyrotoxicosis; Peak Systolic Velocity o	
			f Superior Thyroid Artery; Thyroiditis;	
		Intervention:	Graves Disease	
11	Recruiting	Treatment of Upper Eyelid Retracti	on Related to Thyroid-associated	
		Ophthalmopathy Using Subconjund	ctival Triamcinolone Injections	
		Condition:	Thyroid-associated Ophthalmopathy	
		Intervention:	Drug: subconjunctival triamcinolone injecti	
			on	
12	Unknown [†]	The Role of TSH Receptor, PP	AR-r, IGF-1R, IGF and Cytokines in	
		Different Stages of Graves'Ophthalmopathy		
		Condition:	Graves' Ophthalmopathy	
		Intervention:		

28. Exotropia

Rank	Status	Study		
1	Completed	completed Surgery and Convergence Insufficiency Intermittent Exotropia		
	no results	Condition:	Complications	5
	published	Interventions:	Procedure: Po	ost exercise Surgery; Procedure: Ortho
	yet		ptics; Proce	dure: Postop orthoptics; Procedure: P
			ost exercises	surgery
1	Recruiting	Study of Non-surgical Treatment Versus Observation in Asian		
		Children With Intermittent Exotropia		
			Condition:	Intermittent Exotropia
			Intervention:	Procedure: Non surgical therapy

29. Eye Abnormalities

Rank	Status	Study
1	Unknown †	The Genetic Characteristics in South Korean Patients With
		Primary Congenital Glaucoma
		Condition: Primary Congenital Glaucoma
		Intervention:

30. Eye Diseases, Hereditary

Rank	Status	Study	
1	Completed	Study of the Correlation Between Macular Thickness Analyzed by Optical	
	no results	Coherence Tomography and the Visual Functions in Retinitis	
	published	Pigmemtosa	
	yet	Condition: Retinitis Pigmentosa	
		Intervention:	
2	Completed	Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies	
	no results	Condition: Graves' Ophthalmopathy	
	published	Intervention: Drug: Carbimazole, radio-active iodin	
	yet	e (I131)	
3	Completed	The Role of Capsular Tension Ring (CTR) in Anterior Capsular	
	no results	Contraction	
	published	Conditions: Retinitis Pigmentosa; Cataract	
	yet	Intervention: Procedure: IOL surgery	
4	Completed	Thyroid Treatment Trial	
	no results	Condition: Graves Ophthalmopathy	
	published	Intervention: Drug: Intravenous	
	yet	Methylprednisolone + Oral	
		Methotrexate vs Intravenous	
		Methylprednisolone + Placebo	
5	Recruiting	Doxycycline Treatment in Graves' Orbitopathy	
		Conditions: Graves Ophthalmopathy; Graves Disease; Eye	
		Diseases; Thyroid Diseases; Endocrine Syste	
		m Diseases; Eye Diseases, Hereditary; Hypert	
		hyroidism; Autoimmune Diseases; Immune Sy	
		stem Diseases	
		Intervention: Drug: Doxycycline	
6	Recruiting	Molecular Genetics of Retinal Degenerations	
		Conditions: Retinal Degeneration; Retinitis Pig	
		mentosa	
		Intervention:	
7	Recruiting	Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary	
		Optic Neuropathy (LHON)	
		Condition: Leber Hereditary Optic Neuropathy	
		Intervention: Drug: rAAV2-ND4	
8	Recruiting	Studies in Families With Corneal Dystrophy or Other Inherited Corneal	
		Diseases	
		Conditions: Corneal Dystrophies, Hereditary;	

			Corneal Disease	
		Intervention:		
9	Recruiting	Difference Between Rehabilita	tion Therapy and Stem Cells	
		Transplantation in Patients Wi	ith Spinal Cord Injury in China	
		Condition:	Spinal Cord Injuries	
		Interventions:	Procedure: rehabilitation of limb function; Pr	
10	Recruiting	Safety & Efficacy of Subretina	I Implants for Partial Restoration of Vision	
		in Blind Patients		
		Conditions:	Retinal Degeneration,; Retinitis Pigmentosa	
		Intervention:	Procedure: surgical implantation of subretinal device	
11	Recruiting	Treatment of Upper Eyelid Ret	traction Related to Thyroid-associated	
		Ophthalmopathy Using Subco	njunctival Triamcinolone Injections	
		Condition:	Thyroid-associated Ophthalmopathy	
		Intervention:	Drug: subconjunctival triamcinolone injecti	
			on	
12	Recruiting	SCIPA (Spinal Cord Injury and Physical Activity) Hands-On: Early		
		Intensive Hand Rehabilitation		
		Condition:	Spinal Cord Injury	
		Interventions:	Device: ReJoyce Workstation; Other:	
42	Deemiting	Bilet Chudu ef e Cumrechereid	Standard Care	
13	Recruiting	Pilot Study of a Suprachoroida		
		Conditions:	Retinitis Pigmentosa; Choroideremia	
		Intervention:	Device: Prototype wide view suprachoroidal retinal prosthesis	
14	Recruiting	SCIPA (Spinal Cord Injury and	Physical Activity) Hands-On: Early	
••	reorating	Intensive Hand Rehabilitation		
		Condition:	Spinal Cord Injury	
		Interventions:	Device: ReJoyce Workstation; Other: Stand	
			ard Care	
15	Recruiting	Molecular Genetics of Retinal	Degenerations	
		Conditions:	Retinal Degeneration; Retinitis Pigmentos	
			а	
		Intervention:		
16	Recruiting	Molecular Genetics of Retinal Degenerations		
		Conditions:	Retinal Degeneration; Retinitis Pigmentos	
			а	
		Intervention:		

17	Active, not	Umbilical Cord	d Blood Mononu	Iclear Cell Transplant to Treat Chronic
	recruiting	Spinal Cord Injury		
		Condition:	Spinal Cord Inj	uries
		Intervention	Biological: Umb	pilical Cord Blood Mononuclear Cell;
		s:	Biological: Ur	nbilical Cord Blood Mononuclear
			Cell, Methylpre	dnisolone; Biological: Umbilical
			Cord Blood Mo	nonuclear Cell, Methylprednisolone,
			Lithium Carbon	ate
18	Active, not	Safety and Fea	asibility of Umb	ilical Cord Blood Cell Transplant Into
	recruiting	Injured Spinal	Cord	
			Condition:	Spinal Cord Injuries
			Interventions:	Biological: Umbilical Cord Blood Monon
				uclear Cell; Drug: Methylprednisolon
				e; Drug: Lithium
19	Active,not	Lithium, Cord	Blood Cells and	I the Combination in the Treatment of
	recruiting	Acute & Sub-a	cute Spinal Cor	<u>d Injury</u>
		Condition:	Spinal Cord Inju	iry
		Interventio	Procedure: Con	ventional Treatment; Drug: Lit
		ns:	hium Carbonate	e; Biological: Cord Blood Cell;
			Other: Place	bo
20	Enrolling by	Efficacy and S	afety of Oral Va	Iproic Acid for Retinitis Pigmentosa
	invitation		Conditions:	Retinitis Pigmentosa; Retinal Disea
				ses; Eye Diseases; Eye Disease,
				Hereditary; Retinal Degeneration
			Intervention:	Drug: Valproic Acid
21	Enrolling by	Feasibility and	Safety of Adult	Human Bone Marrow-derived
	invitation			ntravitreal Injection in Patients With
		Retinitis Pigm		
			Condition:	Retinitis Pigmentosa
			Intervention:	Other: Intravitreal injection
				of bone marrow-derived
				mesenchymal stem cells
22	Unknown [†]			Placebo-Controlled Trial of Curcumin in
		Leber's Hered	itary Optic Neur	
			Condition:	Optic Atrophy, Hereditary, Leber
			Intervention:	Drug: curcumin
23	Unknown †	Expression of Op	ptic Atrophy Type	1 (OPA1) Protein in Lung Adenocarcinoma
			Condition:	Lung Adenocarcinoma

		Intervention:		
24	Unknown †	The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages		
		of Graves'Ophthalmopathy		
		Condition: Graves' Ophthalmopathy		
		Intervention:		

David			
Rank	Status	Study	
1	Completed Has Results	The Effect of Oral Azithromycin in the Treatment of Chlamydial	
		<u>Conjunctivitis</u>	
	published on website	Condition: Chlamydial Conjunctivitis	
	on website	Intervention: Drug: Azithromycin	
2	Completed	A Study of the Safety and Efficacy of Gatifloxacin in Patients With	
	Has Results	Bacterial Conjunctivitis	
	published	Condition: Bacterial Conjunctivitis	
	on website	Interventions: Drug: Gatifloxacin 0.5% eye drops;	
		Drug: placebo eye drops	
3	Completed	Mycotic Ulcer Treatment Trial I	
	no results	Conditions: Corneal Ulcer; Eye Infections, Fungal	
	published	Interventions: Drug: Natamycin; Drug: Voriconazole	
	yet		
4	Completed	Safety and Efficacy Study of Gatifloxacin Compared With	
	no results	Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers	
	published	Conditions: Acute Bacterial Corneal Ulcers; B	
	yet	acterial Keratitis	
		Interventions: Drug: Gatifloxacin 0.3% ophthalmic	
		solution; Drug: Ciprofloxacin 0.3%	
		ophthalmic solution	
5	Completed	Therapeutic Exploratory Study of Comparing Natamycin and	
	no results	Voriconazole to Treat Fungal Corneal Ulcer	
	published	Condition: Fungal Keratitis	
	yet	Interventions: Drug: Natamycin 5%; Drug: Voriconaz	
		Corneal de-epithelialization	
6	Completed	Treatment of Epidemic Keratoconjunctivitis With 2%	
	no results	Povidone-iodine	
	published	Condition: Viral Conjunctivitis	
	yet	Intervention: Drug: 2% povidone-iodine	
7	Recruiting	The Asia Cornea Society Infectious Keratitis Study	
	J	Condition: Corneal Ulcer	
		Intervention:	
8	Recruiting	Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer	
	Recruiting	Condition: Corneal Ulcer	
		Intervention: Device: acellular corneal matrix	
9	Recruiting	The Asia Cornea Society Infectious Keratitis Study	
		Condition: Corneal Ulcer	

31. Eye Infections

		Intervention:	
10	Recruiting	The Asia Cornea Society Infe	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
11	Recruiting	The Asia Cornea Society Infec	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
12	Recruiting	The Asia Cornea Society Infec	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
13	Recruiting	Mycotic Ulcer Treatment Trial	<u>II</u>
		Conditions:	Corneal Ulcer; Eye Infections, Fungal
		Interventions:	Drug: Voriconazole; Drug: Placebo
14	Not yet	FST-100 in the Treatment of A	cute Adenoviral Conjunctivitis
	recruiting	Condition:	Acute Adenoviral Conjunctivitis
		Interventions:	Drug: FST-100; Drug: FST-100 (Com ug: FST-100 Vehicle
15	Recruiting	The Asia Cornea Society Infe	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
16	Recruiting	The Asia Cornea Society Infec	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
17	Recruiting	The Asia Cornea Society Infec	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
18	Active, not	Steroids for Corneal Ulcers T	rial
	recruiting	Conditions:	Corneal Ulcer; Eye Infections, Bacteri
		Interventions:	Drug: Antibiotics; Drug: Topical cortico eroid; Drug: Placebo
19	Withdrawn	The Application of Fibrin Glue	e in Ocular Surface Diseases
		Conditions:	Pterygium; Corneal Ulcer
		Intervention:	Drug: tissue fibrin glue application (T isseel)
20	Unknown [†]	Comparison of Combination 4	Antibiotics Eyedrop to Artificial Tear in
		Hordeolum After Incision and	
		Condition:	Hordeolum

Interventions:	Drug: neomycin sulfate,
	polymyxin B sulfate and
	gramicidin; Drug: Artificial tear

32. Eye Injuries

Rank	Status	Study				
1	Completed	Comparison of the Effects on Promoting Corneal Epithelial Wound				
	no results	Healing Between	Human Auto	-Serum and	Cord Blood Serur	<u>n</u>
	published		Condition:	Eye Injuries		
	yet	Int	terventions:	Procedure:	venous puncture;	Other:
				obtain serur	n from perripheral	blood or
				cord blood		
1	Unknown †	Transplantation of Cultivated Corneal Epithelial Sheet in Patients With				
		Ocular Surface Disease				
		Condition:	Eye Injury			
		Interventions:	Biological: c	onservative;	Procedure: Medio	cal Therapy

Rank	Status	Study		
1	Completed	Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy		
	no results	and Autologous Hematopoieti	c Stem Cell Transplantation	
	published	Conditions:	Neuroblastoma; Brain Tumor;	
	yet		Retinoblastoma; Wilms Tum	
			or; Mycoses	
		Intervention:	Drug: itraconazole	
2	Completed	Rebeccamycin Analogue in Tr	reating Children With Solid Tumors	
	no results	or Non-Hodgkin's Lymphoma		
	published	Conditions:	Brain and Central Nervous System Tu	
	yet		s; Lymphoma; Neuroblastoma;	
			inoblastoma; Sarcoma; Unspecifie	
			Childhood Solid Tumor, Protocol Spec	
		Intervention:	Drug: becatecarin	
3	Completed	Vincristine, Carboplatin, and E	Etoposide or Observation Only in	
	no results	Treating Patients Who Have U	ndergone Surgery for Newly	
	published	Diagnosed Retinoblastoma		
	yet	Condition:	Retinoblastoma	
		Interventions:	Drug: carboplatin; Drug: etoposide;	
			Drug: vincristine sulfate; Other: clinic	
			l observation	
4	Completed	Vincristine, Carboplatin, and Etoposide or Observation Only in		
	no results	Treating Patients Who Have U	ndergone Surgery for Newly	
	published	Diagnosed Retinoblastoma		
	yet	Condition:	Retinoblastoma	
		Interventions:	5 1 / 5 1 /	
			ulfate; Other: clinical observation	
5	Completed		reating Children With Solid Tumors	
	no results	or Non-Hodgkin's Lymphoma		
	published	Conditions:	Brain and Central Nervous System Tu	
	yet		Neuroblastoma; Retinoblastoma;	
			d Childhood Solid Tumor, Protocol Spe	
		Intervention:	Drug: becatecarin	
6	Completed		Etoposide or Observation Only in	
	no results			
	published	Diagnosed Retinoblastoma		
	yet	Condition:	Retinoblastoma	
		Interventions:	Drug: carboplatin; Drug: etoposide;	
			Drug: vincristine sulfate; Other:	

33. Eye Neoplasms

7 Active, not recruiting Trial Comparing Two Carboplatin Doses in Groups Intraocular Retinoblastoma	C and D		
	Intraocular Retinoblastoma		
Condition: Intraocular Retinobla	stoma		
Intervention: Drug: carboplatin			
8 Active, not Cixutumumab in Treating Patients With Relapsed of	or Refractory		
recruiting Solid Tumors			
Conditions: Adrenocortical Carcin	noma; Kidney C		
cer; Liver Cancer;			
Retinoblastoma;	Sarcoma		
Interventions: Biological: cixutumun			
tory biomarker analys			
9 Active, not Systemic Vincristine, Carboplatin, and Etoposide, S			
recruiting Carboplatin, and Local Ophthalmic Therapy in Trea With Intraocular Retinoblastoma	ating Children		
Condition: Retinoblastoma			
Interventions: Biological: filgrastim;	Drug: carboola		
in; Drug: etoposide	•		
ne sulfate; Procedu	•		
Procedure: laser su	rgery		
10 Recruiting Combination Chemotherapy and Cyclosporine Foll	owed By		
Cryotherapy and/or Laser Therapy in Treating Patie	ents With Newly		
Diagnosed Retinoblastoma in Both Eyes			
Condition: Retinoblastoma			
Interventions: Biological: filgrastim;	•		
	g: vincristine sulfa erapy; Procedu		
Procedure: laser th 11 Recruiting Combination Chemotherapy, Autologous Stem Cel			
and/or Radiation Therapy in Treating Young Patien			
Extraocular Retinoblastoma			
Condition: Retinoblastoma			
Interventions: Biological: filgrastim;	Drug: carbopl		
atin; Drug: cisplatir	n; Drug: cyclop		
	: etoposide; Dr		
	vincristine sulfat		
	logous bone mar Procedure:		
row transplantation; autologous hematopo			
	ocedure:		

			peripheral blood stem cell transplantation; Radiation: radiation	
			therapy	
12	Recruiting	Combination Chemotherapy and Cyclosporine Followed By		
		Cryotherapy and/or Laser The	erapy in Treating Patients With Newly	
		Diagnosed Retinoblastoma in	Both Eyes	
		Condition:	Retinoblastoma	
		Interventions:	Biological: filgrastim; Drug: carbopla	
			n; Drug: cyclosporine; Drug: etopo	
			ide; Drug: vincristine sulfate; Proc	
			dure: cryosurgery; Procedure: laser	
			erapy; Procedure: neoadjuvant thera	
			у	
13	Unknown [†]	Flavopiridol in Treating Children With Relapsed or Refractory		
		Solid Tumors or Lymphomas		
		Conditions:	Brain and Central Nervous System Tu	
			d Germ Cell Tumor; Kidney Cancer;	
			Lymphoma; Neuroblastoma; Retir	
			coma; Unspecified Childhood Solid	
			Specific	
		Intervention:	Drug: alvocidib	

34. Eye Pain

Rank	Status	Study		
1	Completed	Nepafenac Compared to Placebo for Ocular Pain and		
	no results	Inflammation		
	published	Condition:	Cataract	
	yet	Interventions:	Drug: Nepafenac;	Other: Nepafenac Vehicle

35. Eyelid Diseases

Rank	Status	Study		
1	Completed	Trial to Compare the Efficacy	of Systane Ultra and Refresh	
	Has Results	Drop in the Treatment of Dry I	<u>Eye in Asian Eyes</u>	
	published	Conditions:	Xerophthalmia; Blepharitis	
	on website	Interventions:	Drug: Systane Ultra eyedrops;	
			Drug: Refresh eye drops	
2	Completed	Loteprednol and Tobramycin Versus Tobramycin and		
	Has Results	Dexamethasone, in the Treatn	nent of	
	published	Blepharokeratoconjunctivitis		
	in journals	Conditions:	Conjunctivitis; Keratitis; Ble	
			pharitis	
		Interventions:	Drug: Loteprednol and tobramy	
			cin; Drug: Tobramycin and de	
			xamethasone	
3	Completed	Efficacy and Safety Study of M	Ieditoxin® to Treat Essential	
	no results	<u>Blepharospasm</u>		
	published	Condition:	Essential Blepharospasm	
	yet	Intervention:	Drug: Botulinum Toxin Typ	
			e A	
4	Completed	Comparison of Korean Botuli	num Toxin Type A Versus	
	no results	Botox in the Treatment of Ess	ential Blepharospasm	
	published	Condition:	Blepharospasm	
	yet	Intervention:	Drug: Korean Botulinum	
			toxin type A (KbtxA) and	
			Botox injection	
5	Completed	Efficacy of Aurosling in Front	alis Sling Suspension Surgery	
	no results	Condition:	Ptosis, Eyelid	
	published	Intervention:	Procedure: Aurosling	
6	yet Unknown [†]	Comparison of Combination A	Antibiotics Eyedrop to Artificial	
Ū		Tear in Hordeolum After Incision and Curettage		
		Condition:	Hordeolum	
		Interventions:	Drug: neomycin sulfate,	
			polymyxin B sulfate and	
			gramicidin; Drug: Artifici	
			al tear	

36. Geographic Atrophy

Rank	Status	Study		
1	Completed	Safety and Efficacy of Brimon	idine Intravitreal Implant in Patients	
	no results	With Geographic Atrophy Due to Age-related Macular		
	published	Degeneration (AMD)		
	yet	Condition:	Macular Degeneration	
		Interventions:	Drug: Brimonidine Tartrate Implant;	
2	Completed	A Population-based Study of	Macular Choroidal	
	no results	Neovascularization in a Chine	se Population	
	published	Conditions:	Geographic Atrophy; Wet Macular	
	yet		Degeneration; Retinal Drusen	
		Intervention:	Other: Follow-up observation	
3	Completed	Safety and Efficacy of Brimonidine Intravitreal Implant in Patients		
	no results	With Geographic Atrophy Due to Age-related Macular		
	published	Degeneration (AMD)		
	yet	Condition:	Macular Degeneration	
		Interventions:	Drug: Brimonidine Tartrate Implant;	
			rug: Sham	
4	Completed	Safety and Efficacy of Brimonidine Intravitreal Implant in Patients		
	no results	With Geographic Atrophy Due to Age-related Macular		
	published	Degeneration (AMD)		
	yet	Condition:	Macular Degeneration	
		Interventions:	Drug: Brimonidine Tartrate Implant;	

37. Glaucoma

Rank	Status	Study		
1	Completed		cy of Bimato	prost Timolol Ophthalmic
	Has Results	Solution in Patien	ts With Ope	n Angle Glaucoma or Ocular
	published on	Hypertension		
	website	Conditions:	Open-angle	Glaucoma; Ocular Hypertension
		Interventions:	Drug: 0.03%	Bimatoprost/0.5% Timolol
			Ophthalmic S	Solution; Drug: 0.03%
			Bimatoprost	Ophthalmic Solution and 0.5%
			Timolol Oph	thalmic Solution
2	Completed	Safety and Efficat	cy of Brimon	idine Tartrate/Timolol Fixed
	Has Results	Combination in P	atients With	Glaucoma or Ocular
	published on	Hypertension		
	website	Conditions:	Glaucoma;	Ocular Hypertension
		Interventions:	Drug: brime	onidine tartrate/timolol fixed
			combinatio	n ophthalmic
			solution;	Drug: brimonidine tartrate opht
			halmic solu	tion; Drug: timolol ophthalmic
			solution;	Other: fixed combination vehicl
			е	
3	Completed	Systemic Glutath	ione Level in	Normal Tension Glaucoma
	Has Results		Condition:	Normal Tension Glaucoma
	published on	In	tervention:	
	website			
4	Completed	A Phase 3 Prospective, Randomized, Double-Masked, 12-Week,		
	Has Results published on	Parallel Group Study In Pediatric Subjects With Glaucoma.		
	website		Condition:	Glaucoma
	website	Int	erventions:	Drug: Timolol; Drug: latan
	Completed	Olegen (Osuku 2		oprost
5	Completed Has Results		enj-Phacotra	abeculectomy Historical Control
	published in	Study in India	Conditioner	
	journals		Conditions:	Glaucoma; Cataract
	-		tervention:	Device: OculusGen Biodegradable
6	Completed			And Xalatan In Patients With
	Has Results		gle Glaucom	a (POAG) Or Ocular Hypertension
	published on	<u>(OH).</u>		
	website		Conditions:	Glaucoma, Primary Open
				Angle (POAG); Ocular
				Hypertension
		Int	erventions:	Drug: Xalacom (KP2035)

		; Drug: Xalatan		
7	Completed	Xalacom And Combination Of Unfixed Latanoprost And Timolol		
	no results	In Subjects With Open-Angle Glaucoma Or Ocular		
	published	<u>Hypertension</u>		
	yet	Conditions: Glaucoma, Open Angle; Ocular H		
		Interventions: Drug: Xalacom; Drug: unfixed Lat		
8	Completed	Ologen (OculusGen)-Glaucoma and Pterygium Historical		
	no results	Control Study in Beijing Remin Hospital		
	published	Conditions: Glaucoma; Pterygium		
	yet	Intervention: Device: OculusGen Biodegradable		
9	Completed	Ologen (OculusGen)-Glaucoma and Pterygium Historical		
	no results	Control Study in China Beijing Hospital		
	published	Conditions: Glaucoma; Pterygium		
	yet	Intervention: Device: OculusGen Biodegradable		
10	Completed	Ologen (OculusGen)-Glaucoma and Pterygium Historical		
	no results	Control Study in China Zhong-Shan Hospital		
	published	Conditions: Glaucomas; Pterygium		
	yet	Intervention: Device: OculusGen Biodegradable		
11	Completed	Optical Coherence Tomography Imaging of the Posterior		
	no results	Segment in High Myopia.		
	published	Conditions: Myopia; Maculopathy; Glaucon		
	yet	Intervention:		
12	Completed	5FU vs 5FU With Viscoelastic Formulation for the Prevention of		
	no results	Scarring Post-trabeculectomy		
	published	Conditions: Glaucoma; Trabeculectomy; W		
	yet	Interventions: Drug: 5 Fluorouracil with hyaluronic		
13	Completed	The Performances of Spectral Domain Optical Coherence		
	no results	Tomography (OCT) for Distinguishing Glaucomatous Eyes		
	published	Conditions: Glaucoma Patient; Glaucoma Su:		
	yet	Intervention:		
14	Completed	A Study Comparing The Efficacy, Safety And Tolerability Of		
	no results	Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment		
	published	Of Primary Open-Angle Glaucoma And Ocular Hypertension		
	yet	Conditions: Primary Open Angle Glaucoma; (
		Interventions: Drug: latanoprost 75 ug; Drug: lat		
15	Completed	Safety and Efficacy of Brinzolamide Dosed TID With		
	no results	Dorzolamide Dosed TID in Reducing Intraocular Pressure in		
	published	Patients With Open Angle Glaucoma or Ocular Hypertension		

	yet	Conditions: Glaucoma; Ocular Hypertension		
		Interventions: Drug: Azopt; Drug: Cosopt		
16	Completed	Study of PGA Suture in Ophthalmology		
	no results	Condition: Glaucoma		
	published	Intervention: Device: Polyglycolic acid suture		
	yet			
17	Completed	Safety and Efficacy of Triple Combination Therapy in Patients		
	no results	With Glaucoma or Ocular Hypertension		
	published	Conditions: Glaucoma; Ocular Hypertension		
	yet	Intervention: Drug: bimatoprost/brimonidine tartra		
18	Completed	DuoTrav® Eye Drops As Replacement Therapy Program		
	no results	Conditions: Open-angle Glaucoma; Ocular H		
	published	Intervention: Drug: DuoTrav		
	yet			
19	Completed	Investigation of Genetic Disease Marker Associated With		
	no results	Korean Glaucoma Patients		
	published	Condition: Single-nucleotide Polymorphism (S		
	yet	Intervention: Genetic: SNP analysis of the DNA		
20	Completed	Diurnal Intraocular Pressure and Peripapillary Retinal Blood		
	no results	Flow in Medically Controlled Open-Angle Glaucoma		
	published	Condition: Open-Angle Glaucoma		
	yet	Intervention:		
21	Completed	Screening for Glaucoma in Namil Area, South Korea		
	no results	Conditions: Glaucoma; Intraocular Pressure;		
	published	Intervention:		
	yet			
22	Completed	Long-Term IOP Fluctuation and VF Progression After Triple		
	no results	Procedure		
	published	Conditions: Glaucoma; Filtering Surgery; Ir		
	yet	Intervention:		
23	Completed	ELAZOP Switching Study in Korea		
	no results	Condition: Open Angle Glaucoma		
	published	Intervention: Drug: Elazop (Azarga)		
	yet			
24	Completed	Comparison of Anterior Chamber Paracentesis and		
	no results	Conventional Mannitol Infusion in Patients With Primary Acute		
	published	Angle-closure Glaucoma		
	yet	Conditions: Glaucoma; Acute Primary		
		Angle-closure Glaucoma		

		Intervention:		
25	Completed	A Study to Evaluate Efficacy and Safety Effects Using Mikelan®		
	no results	LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE		
	published	Ophthalmic Solution (OS) 0.5%	<u>% in Ocular Hypertension Patients</u>	
	yet	Condition:	Glaucoma	
		Intervention:	Drug: carteolol (Mikelan), timolol	
			(Timoptol), latanoprost (Xalatan)	
26	Completed	A Phase 2, Dose Finding Stud	y of PF-03187207 in Patients With	
	no results	Primary Open Angle Glaucom	a or Ocular Hypertension.	
	published	Conditions:	Primary Open Angle Gla	
	yet		ucoma; Ocular Hypert	
			ension	
		Interventions:	Drug: PF-03187207;	
			Drug: Latanoprost	
27	Completed	To Investigate the Safety and	Efficacy of DE-104 Ophthalmic	
	no results	Solution to Treat Open-Angle	Glaucoma or Ocular	
	published	<u>Hypertension</u>		
	yet	Conditions:	Open-Angle Glaucoma;	
			Ocular Hypertension	
		Interventions:	Drug: DE-104 ophthalmi	
			c solution; Drug: DE-1	
			04 vehicle	
28	Completed		DE-104 Ophthalmic Solution to	
	no results	Treat Open-Angle Glaucoma o		
	published yet	Conditions:	Open-Angle Glaucoma; Ocular H ertension	
		Interventions:	Drug: DE-104 ophthalmic solution, I	
			concentration; Drug: DE-104	
			ophthalmic solution, medium	
			concentration; Drug: DE-104	
			ophthalmic solution, high	
			concentration; Drug: DE-104 veh	
29	Completed	DE-111 Against Timolol Ophth	nalmic Solution 0.5%	
	no results	Conditions:	Open Angle Glaucoma;	
	published		Ocular Hypertension	
	yet	Interventions:	Drug: DE-111 ophthalmic	
			solution; Drug: Timolol	
			ophthalmic solution 0.5%	
30	Completed	DE-111 Against Tafluprost Op	hthalmic Solution 0.0015% Alone	

	no results	and Concomita	nt Use of Taflu	prost Ophthalmic Solution
	published	<u>0.0015% Plus T</u>	imolol Ophthal	mic Solution 0.5%
	yet	Conditions:	Open Angle G	ilaucoma; Ocular Hypert
			ension	
		Interventions	Drug: DE-111	ophthalmic solution; Dru
		:	g: Tafluprost o	ophthalmic solution 0.0015
			%; Drug: Co	oncomitant use of tafluprost
			ophthalmic so	lution 0.0015% plus timolol
			ophthalmic so	lution 0.5%
31	Completed	Safety and Efficacy of Travoprost/Timolol BAC-free		
	no results	Conditions:	Open-angle G	laucoma; Ocular Hyper
	published		tension	
	yet	Interventions	Drug: Travopr	ost 0.004%/Timolol 0.5%
		:	•	thalmic Solution; Drug:
			-	004%/Timolol 0.5%
			Ophthalmic So	olution (DuoTrav®)
32	Completed	A Study Comparing The Efficacy, Safety And Tolerability Of		
	no results	Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment		
	published	Of Primary Ope	n-Angle Glauc	oma And Ocular Hypertension
	yet		Conditions:	Primary Open Angle Glaucoma;
		.	nterventions:	Drug: latanoprost 75 ug; Drug: lat
				ug: latanoprost 50 ug
33	Completed	A 5-Year Postm	arketing Safet	y Study Of Xalcom In Patients
	no results	With Open Ang	<u>le Glaucoma O</u>	r Ocular Hypertension
	published		Conditions:	Glaucoma, Open-Angle; Ocular H
	yet		Intervention:	Drug: Xalacom
34	Completed	A Safety and Ef	ficacy Study o	f Travoprost 0.004% Compared to
	no results	Latanoprost 0.0	005% in Patient	s With Chronic Angle-Closure
	published	<u>Glaucoma</u>		
	yet		Conditions:	Glaucoma, Angle-Closure; Ocula
		1	nterventions:	Drug: Travoprost (0.004%); Drug
35	Completed	Safety and Effic	cacy of a New F	Formulation of
	no results	Bimatoprost/Ti	molol Ophthalr	nic Solution Compared With
	published	Bimatoprost/Ti	molol Ophthalr	nic Solution in Patients With
	yet	Glaucoma or O	cular Hyperten	<u>sion</u>
			Conditions:	Glaucoma; Ocular Hypertension
		1	nterventions:	Drug: bimatoprost /timolol formulation
				solution; Drug: Ganfort® (bimator
				ophthalmic solution)

36	Completed	IOP-Lowering Efficacy of Brin	zolamide 1.0% Added to	
	no results	Travoprost 0.004%/Timolol 0.5% Fixed Combination as		
	published	Adjunctive Therapy		
	yet	Condition:	Glaucoma	
		Intervention:	Drug: Azopt	
37	Completed	Optic Nerve Compliance Stud	<u>v</u>	
	no results	Condition:	Glaucoma	
	published	Intervention:	Procedure: Brief Elevation of IOP	
	yet			
38	Completed		cacy of Travacom in Patients With	
	no results	Uncontrolled Intraocular Pres		
	published	Condition:	Uncontrolled Intraocular Pressure	
	yet	Intervention:	Drug: Travacom	
39	Completed		acy, Safety And Tolerability Of	
	no results		ug/ml To Xalatan In The Treatment	
	published		oma And Ocular Hypertension	
	yet	Conditions:	Primary Open Angle Glaucoma;	
		Interventions:	Drug: latanoprost 75 ug; Drug: lat	
			prost 50 ug	
40	Completed	Ologen (OculusGen)-Glaucom	na MMC Control in Pakistan	
	no results	Conditions:	Glaucoma; Trabeculectomy	
	published	Interventions:	Device: ologen collagen matrix in gl	
	yet		surgery; Drug: MMC in glaucoma	
41	Completed	A Study of Ganfort Versus Du	otrav in Patients With Primary	
	no results	Open Angle Glaucoma or Ocu	lar Hypertension	
	published	Conditions:	Ocular Hypertension; Primary Op	
	yet	Interventions:	Drug: Ganfort; Drug: Duotrav	
42	Completed	Sequential Laser Iridotomy Us	sing Argon and Q-Switched 532	
	no results	nm Frequency Doubled Neody	ymium Yag Laser: A Pilot Study	
	published	Conditions:	Chronic Angle Closure Glaucoma;	
	yet	Intervention:	Procedure: Q-switched fd Nd:yag in	
43	Completed	Results of Mass Switch From	Latanoprost to Travoprost	
	no results	Condition:	Glaucoma	
	published	Intervention:		
	yet			
44	Completed	Role of Polymorphisms in the	IL-1 Gene Cluster	
	no results	Condition:	Glaucoma	
	published	Intervention:		
	yet			

45	Completed	Laser Iridotomy Versus Phace	pemulsification in Acute Angle	
	no results	Closure		
	published	Condition:	Angle Closure Glaucoma	
	yet	Intervention:	Procedure: Laser Preipheral Iridoto	
46	Terminated	Study of Brimonidine and Tim	nolol Ophthalmic Solution With	
		Latanoprost Compared With L	_atanoprost in Glaucoma Patients	
		Condition:	Glaucoma, Angle-Closure	
		Interventions:	Drug: brimonidine 0.2%/timolol 0.5%	
47	Terminated	OculusGen-Glaucoma Histori	cal Control Study in Taiwan	
		Condition:	Glaucoma	
		Intervention:	Device: OculusGen Biodegradable	
			Collagen Matrix Implant	
48	Enrolling by	The High Cup/Disc Ratio in Cl	hildren	
	invitation	Condition:	Glauco	
			ma	
		Intervention:		
49	Active, not recruiting	SOLX Gold Shunt Versus Con Refractory Glaucoma	trol Implant: Randomized Trial for	
	recruiting	Conditions:	Glaucoma; Glaucoma, Open Ang	
		Interventions:	Device: SOLX Gold Shunt GMS-plu	
50	Enrolling by	Impact of Health Literacy and		
	invitation	Patient Adherence in South India		
		Conditions:	Patient Noncompliance; Health Li	
		Intervention:		
51	Active, not	Clinical Evaluation of Safety a	and Efficacy of Refrigeration Free	
	recruiting	Latanoprost		
		Conditions:	Glaucoma, Open-Angle; Ocular H	
		Interventions:	Drug: refrigeration free latanoprost;	
52	Active, not	A Safety and Efficacy Study of Bimatoprost 0.01% in Primary		
	recruiting		6) or Ocular Hypertension (OH)	
		Conditions:	Glaucoma, Open-Angle; Ocular H	
		Intervention:	Drug: Bimatoprost 0.01%	
53	Recruiting		erative Bevacizumab Injection on	
		Trabeculectomy Outcome	Clauseme	
		Condition:	Glaucoma	
	David Itt	Interventions:	Drug: Bevacizumab; Drug: Mitom	
54	Recruiting	The Effect of "Eye Drop Guide	e" on the Success Rate of Eye	

		Drops Self-instillation in Glaucoma Patients		
		Condition:	Eye Drops Self-instillation	
		Interventions:	Device: Eye Drop Guide technique;	
55	Recruiting	Clinical and Molecular Studies	s in Families With Glaucoma and	
		Related Diseases		
		Condition:	Glaucoma	
		Intervention:		
56	Recruiting	Hydroxypropylmethylcellulose	e 0.3% and Sodium Hyaluronate	
		0.18% for Ocular Surface Dise	ase in Glaucoma	
		Conditions:	Ocular Surface Disease; Glaucon	
		Interventions:	Drug: hydroxypropylmethylcellulose	
57	Recruiting	Clinical Evaluation of Efficacy	of SLT to Topical Medication in	
		Lowering IOP		
		Condition:	Glaucoma	
		Interventions:	Drug: Latanoprost; Procedure: Sl	
58	Recruiting		f Chinese Patients With Normal	
		Tension Glaucoma		
		Condition:	Glaucoma	
		Intervention:		
59	Recruiting		and Ocular Hypotensive Efficacy	
		of AR-12286 in Patients With Elevated Intraocular Pressure for <u>3 Months</u>		
		Conditions:	Ocular Hypertension; Open-angle	
		Interventions:	Drug: AR-12286 Ophthalmic Solution	
			maleate ophthalmic solution 0.5%	
60	Recruiting	Ologen (OculusGen)-Glaucom	a Case Control Trial in India	
		Condition:	Glaucoma	
		Intervention:	Device: OculusGen Biodegradable	
61	Recruiting	A Study of the Safety and Effic	cacy of Bimatoprost Ophthalmic	
		Solution in Paediatric Patients	With Glaucoma	
		Condition:	Glaucoma	
		Interventions:	Drug: bimatoprost ophthalmic soluti	
			formulation A, bimatoprost	
			vehicle; Drug: timolol ophthalmic	
			lution	
52	Recruiting	DE-111 Ophthalmic Solution in		
		Glaucoma or Ocular Hyperten		
		Condition:	Open Angle Glaucoma	

				or Ocular Hypertension
		Inte	rvention:	Drug: DE-111 ophthalmi
				c solution
62	Recruiting	Evaluation of Safety	and Effic	acy of Glaucoma Shunt (Aurolab
		Artificial Drainage In	nplant) in	Refractory Glaucoma
		C	ondition:	Glaucoma
		Inte	rvention:	Device: Artificial drainage implant
63	Recruiting	Preservative-Free Ta	afluprost ((MK-2452) for the Treatment of
		Open-Angle Glauco AM1)	<u>ma or Οcι</u>	Ilar Hypertension (MK-2452-002
		Co	nditions:	Glaucoma; Ocular Hypertension
		Interv	ventions:	Drug: Preservative-Free Tafluprost
64	Recruiting	Ologen (OculusGen)-Glaucom	na MMC Control Trial in India
		C	ondition:	Glaucoma
		Interv	ventions:	Device: OculusGen Biodegradable
				Implant; Drug: Trabeculectomy w
65	Recruiting	Efficacy and Safety Study of Combigan and 0.5% Timoptic in		
		Normal Tension Gla		Normal Tanaian Olayaama
		_	ondition:	Normal Tension Glaucoma
66	Deerwiting		ventions:	Drug: Brimonidine/Timolol mixed cd
66	Recruiting			Ophthalmic Formulation of Open Angle Glaucoma and Ocular
		Hypertension		
		Conditions:	Open-An	gle Glaucoma; Ocular Hyperte
			nsion	
		Interventions:	Drug: bin	natoprost ophthalmic formulation
			A; Dru	g: bimatoprost ophthalmic formula
			-	Drug: bimatoprost ophthalmic for
				C; Drug: bimatoprost ophthalmi
				ation D; Drug: bimatoprost opht
				rmulation E; Drug: bimatoprost nic formulation F; Drug: Sham;
			opininalin	
			Drug: tim	olol 0.5%; Drug: bimatoprost o
			phthalmic	c solution 0.03%; Drug: latanop
			rost 0.00	5%; Drug: timolol vehicle (place
			bo)	
67	Recruiting			cacy of Bimatoprost Ophthalmic
		Solution in Paediatr	ic Patients	s With Glaucoma

		Condition:	Glaucoma	
		Interventions:	Drug: bimatoprost ophthalmic solut	
68	Recruiting	A Study of the Safety and Efficiency	cacy of Bimatoprost Ophthalmic	
	-	Solution in Paediatric Patients With Glaucoma		
		Condition:	Glaucoma	
		Interventions:	Drug: bimatoprost ophthalmic	
			solution formulation A, bimatoprost	
			vehicle; Drug: timolol ophthalmic	
			olution	
69	Unknown [†]	Psychopathology of Normal-te	ension Glaucoma in Hong Kong	
		Chinese Out-patient		
		Condition:	Glaucoma	
		Intervention:		
70	Unknown [†]	Ologen(Oculusgen)-Glaucoma	a and Pterygium Historical	
		Control Study in China Shang	<u>hai Sixth People's Hospital</u>	
		Conditions:	Glaucomas; Pterygium	
		Intervention:	Device: ologen™ Collagen matrix i	
71	Unknown †	Prospective Evaluation of the	Efficacy of Pascal Laser	
		Iridotomy and Pascal Laser Peripheral Iridoplasty: A Pilot		
		<u>Study</u>		
		Condition:	Glaucoma	
		Intervention:	Procedure: pattern scanning laser	
72	Unknown [†]	Efficacy of Retinal Nerve Fibe	r Layer (RNFL) / Retinal	
		Thickness Ratio by Cirrus OC		
		Technology as a Diagnostic P		
		Conditions:	Glaucoma; Myopia	
		Intervention:		
73	Unknown †		ar Perfusion Pressure of Cosopt	
		in Normal Tension Glaucoma		
		Condition:	Normal Tension Glaucoma	
		Interventions:	Drug: dorzolamide/timolol fixed cor	
74	Unknown [†]	Relationship Between Topiran	nate Use and Ocular Angle Status	
		Condition:	Glaucoma, Angle-Closure	
		Intervention:	Drug: Topiramate	
75	Unknown [†]	Comparison of Retinal Nerve	Fiber Layer (RNFL) Thickness	
		Measurements by Time-Doma	in and Spectral-Domain OCT In	
		Glaucoma Patients		
		Condition:	Primary Open Angle Glaucoma	

		Intervention:		
76	Unknown [†]	Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell		
		Layer Thickness Ratio by RT-View Utilizing Spectral -Domain		
		Technology as a Diagnostic Predictor of Glaucoma.		
		Condition: Primary Open Angle Glaucoma		
		Intervention:		
77	Unknown [†]	Corneal Endothelium After Glaucoma Surgery		
		Conditions: Glaucoma; Corneal Damage; I		
		Intervention:		
78	Unknown [†]	Safety Study of Conventional Versus Micropulse Transscleral		
		Cyclophotocoagulation in Treating End-Stage Glaucoma		
		Conditions: Advanced Glaucoma; Refractory		
		Interventions: Procedure: Micropulse Transscleral		
79	Unknown [†]	Intraocular Pressure (IOP) Lowering Effect of Selective Laser		
		Trabeculoplasty Versus Prostaglandin Analogues in Angle		
		Closure Glaucoma		
		Condition: Glaucoma		
		Interventions: Procedure: Selective Laser Trabecu		
80	Unknown [†]	External Micropulse Diode Laser Transscleral Trabeculoplasty		
		(EMDLT) for Severe Open Angle Glaucoma		
		Condition: Primary Open Angle Glaucoma		
		Intervention: Device: EXTERNAL MICROPULSE		
81	Unknown [†]	Comparison of Bimatoprost and Latanoprost in Patients With		
		Chronic Angle-Closure Glaucoma: A Randomized Cross-Over		
		<u>Study</u>		
		Condition: Glaucoma, Angle-Closure		
		Interventions: Drug: Latanoprost-Bimatoprost; [
82	Unknown [†]	Oculusgen (Ologen) Collagen Matrix Implant for		
		Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control		
		Study		
		Conditions: Cataract; Glaucoma		
		Intervention: Device: ologen™ Collagen Matrix Ir		
83	Unknown [†]	Imaging Ahmed Glaucoma Tubes With a Pericardial Graft and		
		Tissue Glue or Partial-Thickness Scleral Flap and Sutures		
		Conditions: Advanced Glaucoma; Failed Trat		
	+	Interventions: Procedure: Pericardial graft & tissue		
84	Unknown [†]	Argon Laser Peripheral Iridoplasty for Primary Angle Closure		
		Glaucoma		

		Condition:	Glaucoma	
		Interventions:	Procedure: Argon Laser Iridoplasty;	
85	Unknown [†]		cotrabeculectomy:A Randomized	
00	Chikhowh	Controlled Trial	Strabeculectomy.A Randomized	
		Conditions:	Glaucoma; Cataract	
		Interventions:	Procedure: Glaucoma Implant Surg	
86	Unknown [†]	The Genetic Study of Primary		
		Condition:	Glaucoma	
		Intervention:		
87	Unknown [†]		on(Brimonidine 0.2% and Timolol	
		0.5%)With Latanoprost Compa		
		<u>Monotherapy</u>		
		Condition:	Glaucoma	
		Intervention:	Drug: Combigan Ophthalmic	
			Solutiom	
88	Unknown [†]	The Genetic Characteristics in	South Korean Patients With	
		Primary Congenital Glaucoma		
		Condition:	Primary Congenital Glaucoma	
		Intervention:		
89	Unknown [†]		Cirrus High Definition (HD) Optical	
		Coherence Tomography (OCT Condition:		
			Glaucoma	
90	Unknown [†]	Intervention:	to Drovent Diels Feilure After	
90	Unknown	Subconjunctival Bevacizumak Glaucoma Filtration Surgery	To Prevent bleb Failure Alter	
		Condition:	Glaucoma	
		Intervention:	Drug: Subconjunctival Bevacizumat	
91	Unknown [†]		cts on Optic Nerve Structure &	
		Function		
		Condition:	Glaucoma	
		Interventions:	Procedure: Argon laser Iridoplasty;	
92	Unknown [†]	Normative Database of the Re	tinal Nerve Fiber Layer Thickness	
		Measured by the Cirrus HD OCT in Asians		
		Condition:	Glaucoma	
		Intervention:		
93	Unknown [†]	Retinal Nerve Fiber Layer Thic	ckness Analysis With Cirrus HD	
		OCT Versus Stratus Optical C	oherence Tomography (OCT)	

-			
		Condition:	Glaucoma
		Intervention:	
94	Unknown [†]	Personality Characteristics an	nd Compliance With
		Antiglaucoma Medication	
		Condition:	Glaucoma
		Intervention:	
95	Unknown [†]	Retinal Nerve Fiber Layer Thic	kness Measurement on
		Parapapillary Atrophy With the	e Cirrus High-Definition (HD)
		Optical Coherence Tomograp	hy (OCT)
		Condition:	Glaucoma
		Intervention:	
96	Unknown [†]	Corrected Measurement of the Retinal Nerve Fiber Layer	
		Thickness by Optic Disc Conf	iguration With the Cirrus HD OCT
		Conditions:	Glaucoma; Myopia
		Intervention:	
97	Unknown [†]	The Effect of Bevacizumab on	the Trabeculectomy
		Condition:	Glaucoma
		Intervention:	Drug: intraocular injections
			of bevacizumab
98	Not yet	Post-operative Satisfaction W	ith Glaucoma Surgery Trial
	recruiting	Condition:	Glaucoma
		Interventions:	Behavioral: film and trained counse
99	Not yet	Safety and Efficacy of Triple C	Combination Therapy With
	recruiting	Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol	
		Ophthalmic Solution in Patients With Glaucoma or Ocular	
		Hypertension	
		Conditions:	Glaucoma; Ocular Hypertension
		Intervention:	Drug: dorzolamide hydrochloride 2.
			ophthalmic solution (Triple Combina

38. Graves Disease

Rank	Status	Study		
1	Completed	Thyroid-Associated Ophthalm	opathy Subtypes and Orbital	
	no results	Antibodies		
	published	Condition:	Graves' Ophthalmopathy	
	yet	Intervention:	Drug: Carbimazole, radio-active io	
			dine (I131)	
2	Completed	Thyroid Treatment Trial		
	no results	Condition:	Graves Ophthalmopathy	
	published	Intervention:	Drug: Intravenous	
	yet		Methylprednisolone + Oral	
			Methotrexate vs Intravenous	
			Methylprednisolone + Placebo	
3	Recruiting	Doxycycline Treatment in Gra	ves' Orbitopathy	
		Conditions:	Graves Ophthalmopathy; Grav	
			es Disease; Eye Diseases; T	
			hyroid Diseases; Endocrine Sy	
			stem Diseases; Eye Diseases,	
			Hereditary; Hyperthyroidism;	
			Autoimmune Diseases; Immun	
			e System Diseases	
		Intervention:	Drug: Doxycycline	
4	Recruiting	Treatment of Upper Eyelid Ret	traction Related to	
		Thyroid-associated Ophthalm	opathy Using Subconjunctival	
		Triamcinolone Injections		
		Condition:	Thyroid-associated Ophthalmopa	
			thy	
		Intervention:	Drug: subconjunctival triamcinolo	
			ne injection	
5	Unknown [†]	The Role of TSH Receptor, PP	AR-r, IGF-1R, IGF and Cytokines	
		in Different Stages of Graves'Ophthalmopathy		
		Condition:	Graves' Ophthalmopathy	
		Intervention:		

39. Hordeolum

Rank	Status	Study		
1	Unknown [†]	Comparison of Combination Antibiotics Eyedrop to Artificial		
		Tear in Hordeolum After Incision and Curettage		
		Condition:	Hordeolum	
		Interventions:	Drug: neomycin sulfate,	
			polymyxin B sulfate and	
			gramicidin; Drug: Artificial tear	

40. Hydrophthalmos

Rank	Status	Study
1	Recruiting	Clinical and Molecular Studies in Families With Glaucoma and
		Related Diseases
		Condition: Glaucoma
		Intervention:
2	Unknown †	The Genetic Characteristics in South Korean Patients With
		Primary Congenital Glaucoma
		Condition: Primary Congenital Glaucoma
		Intervention:

41. Hyperopia

Rank	Status	Study	
1	Completed	Evaluation of Effectiveness of Correcting Refractive Error With	
	no results	Ready-made Spectacles	
	published	Conditions: Myo	pia; Hyperopia; Astigmati
	yet	sm	
			ce: Ready-made spectacles; <i>v</i> ice: Spectacles
2	Completed	Time Course Comparison of Contac	t Lens Maintenance Systems
	no results	for Hydrogel Lenses	
	published	Conditions: Myo	pia; Hyperopia
	yet	Interventions: Devi	ce: Silicone Hydrogel Contact L
		ense	es; Device: 1x PMBH preserv
		ed N	IPS; Device: 1x Polyquad/Ald
		ox M	IPS
3	Completed	Comparison of Contact Lens Mainte	enance Systems for Silicone
	no results	Hydrogel Lenses	
	published	Conditions: Myo	pia; Hyperopia
	yet	Intervention: Devi	ce: Silicone hydrogel contact lens
4	Recruiting	Presbyopic Supracor Treatment for	Near Myopic/Hyperopic
		Pseudophakic Eyes	
		Conditions: Myo	pia; Hyperopia; Presbyopia
		Intervention: Devi	ce: Supracor
5	Recruiting	Randomized, Non-inferiority Trial Co	omparing SMILE and LASIK
		Conditions: Myo	pia; Astigmatism; Hypermetro
		pia	
		Interventions: Proc	edure: Femtosecond LASIK; Pr
		ocec	lure: Small incision lenticule
		extra	action (SMILE)
6	Unknown [†]	Ocular Imaging With Spectral Doma	in Optical Coherence
		<u>Tomography</u>	
		Conditions: Heal	thy; Myopia; Hypermetropia
		Intervention: Devi	ce: Spectral domain-OCT
			us™ HD-OCT, Carl Zeiss
		Med	itec AG)

42. Iridocyclitis

Rank	Status	Study		
1	Completed	A Multi-center Study to Assess the Efficacy and Safety of LX211 in		
	no results	Active Non-infectious Anterio	r Uveitis	
	published	Conditions:	Uveitis, Anterior; Panuveitis	
	yet	Interventions:	Drug: Placebo; Drug: LX211	
2	Completed	Safety and Efficacy Study of I	ontophoresis and Dexamethasone	
	no results	Phosphate to Treat Anterior U	veitis	
	published	Condition:	Uveitis, Anterior	
	yet	Interventions:	Drug: EGP-437 1.6 mA-min at 0.4 with	
			EyeGate® II System; Drug: EGP-43	
			4.8 mA-min at 1.2 mA with EyeGate® I	
			System; Drug: EGP-437 10.0	
			mA-min at 2.5 mA with EyeGate® II	
			System; Drug: EGP-437 14.0	
			mA-min at 3.5 mA with EyeGate $^{ m I\!R}$ II	
			System	
3	Recruiting	Topical Administration of 0.15	% Ganciclovir Gel for CMV Anterior	
		<u>Uveitis / Endotheliitis</u>		
		Conditions:	Cytomegalovirus Anterior Segment Infe	
			tion; Anterior Uveitis; Endotheliitis	
		Intervention:	Drug: Ganciclovir	

43. Keratitis

Rank	Status	Study	
1	Completed	Efficacy and Safety Study of C	Cyclosporine 0.010% to Treat
	Has Results	Atopic Keratoconjunctivitis	
	published on	Condition:	Atopic Conjunctivitis
	website	Interventions:	Drug: Cyclosporine Vehicle;
			Drug: Cyclosporine 0.010%
2	Completed	Acupuncture for Dry Eye Synd	drome
	Has Results	Condition:	Dry Eye Syndromes
	Published in	Interventions:	Device: Standardized Acupun
	journals		cture; Device:
			Non-acupuncture point
			shallow penetration
			acupuncture
3	Completed	Efficacy, Tolerability, and Con	nfort of 0.3% Hypromellose
	Has Results	Evedrops in Patients Undergo	bing LASIK Surgery
	published on	Condition:	Dry Eye Syndromes
	website	Interventions:	Drug: Pre-LASIK 0.3% hypro
			mellose; Drug: Post-LASIK
			0.3% hypromellose
4	Completed	Loteprednol and Tobramycin	Versus Tobramycin and
	Has Results	Dexamethasone, in the Treatm	nent of
	published in	Blepharokeratoconjunctivitis	
	journals	Conditions:	Conjunctivitis; Keratitis; Bl epharitis
		Interventions:	Drug: Loteprednol and tobram ycin; Drug: Tobramycin and dexamethasone
5	Completed	To Evaluate the Physical Effect	
5	no results	Eye Drops Compared to Refre	
	published yet	Drops	
		Condition:	Dry Eye
		Interventions:	Other: Systane; Other: Refr
			esh Tears
6	Completed	A Phase II, Dose Ranging Stu	dy Of CP-690,550 Eye Drops In
	no results	Patients With Dry Eye Disease	
	published yet	Condition:	Dry Eye Syndromes
		Interventions:	Drug: CP-690,550 Eye drops;
			Drug: CP-690,550 Eye dro
			ps-vehicle; Drug: Sodium H

7 Completed no results published yet Phase III, Long-Term, Open-Label, Extension Study of 0.1%. Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis 8 Completed no results published yet Conditions: Keratoconjunctivitis; Conjun ctivitis 9 Completed no results published yet Late Phase 2 Study of OPC-12759 Ophthalmic Suspension Condition: Dry; EyS Syndromes 9 Completed no results published yet Long Term Administration Study of OPC-12759 Ophthalmic Suspension Drug; OPC-12759 Ophthalmic Suspension 10 Completed no results published yet Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes Drug; OPC-12759 Ophthalmic Suspension 11 Completed no results published yet Phase 2 Study of 0.1% Tacrolimus(FK506) Ophthalmic. Suspension in Patients With Vernal Keratoconjunctivitis; Conditions: Drug; FK506; Drug; PL2060; 12 Completed no results published yet Acupuncture for Dry Eye Interventions: Drug; FK506; Drug; placebo 13 Completed no results published yet Acupuncture for Dry Eye Interventions: Drug; NAABAK eyedrops; Drug; Refresh Plus 13 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis Interventions: Drug; NAABAK eyedrops; Drug; Saline eyedrops 14 Completed no results published yet Treatment of Epidem				yaluronate
published yetVernal KeratoconjunctivitisCompleted no results published yetLate Phase 2 Study of OPC-12759 Ophthalmic Suspension Condition: Dry Eye Syndromes Intervention: Drug: CPC-127599Completed no results published yetLong Term Administration Study of OPC-12759 Ophthalmic Suspension10Completed no results published yetCondition: Dry Eye Syndromes Intervention: Suspension10Completed no results published yetPhase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes Intervention: Dry Eye Syndromes Drug: OPC-12759 Ophthalmic suspension11Completed no results published yetPhase 2 Study of LS-0611 in Patients With Dry Eye Syndromes Interventions: Dry Eye Syndromes Drug: KLS-06111Completed no results published yetPhase III Study of 0.1% Tacrolimus(FK506) Ophthalmic. Suspension in Patients With Vernal Keratoconjunctivitis; Conjun ctivitis12Completed no results published yetAcupuncture for Dry Eye Interventions: Drug: FK506; Drug: placebo13Completed no results published yetEvaluation of the Effect and Tolerance of Preservative Free NAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Povidone-iodine14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis Povidone-iodine Condition:14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis Povidone-iodine Condition:14Completed no results published yetTreatment of Epidemic Keratoconjunctivit	7	Completed	Phase III, Long-Term, Open-La	abel, Extension Study of 0.1%
Conditions: Keratoconjunctivitis; Conjun ctivitis Intervention: Drug: FK506 8 Completed no results published yet Late Phase 2 Study of OPC-12759 Ophthalmic Suspension 9 Completed no results published yet Long Term Administration Study of OPC-12759 Ophthalmic. Suspension 10 Completed no results published yet Long Term Administration Study of OPC-12759 Ophthalmic. Suspension 10 Completed no results published yet Phase 2 Study of KLS-0611 in Patients With Dry Eve Syndromes 11 Completed no results published yet Phase 2 Study of 0.1% Tacrolimus(FK506) Ophthalmic. Suspension in Patients With Vernal Keratoconjunctivitis Condition: Dry Eye Syndromes 11 Completed no results published yet Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic. Suspension in Patients With Vernal Keratoconjunctivitis; Conjun ctivitis Suspension in Patients With Vernal Keratoconjunctivitis; Conjun ctivitis 12 Completed no results published yet Acupuncture for Dry Eye Interventions: Dry Eye Interventions: 13 Completed no results published yet Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of, Dry Eye Syndrome in Allergic Conjunctivitis 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis Treatment of Epidemic				ic Suspension in Patients With
a ctivitis Intervention: Drug: FK506 8 Completed no results published yet Late Phase 2 Study of OPC-12759 Ophthalmic Suspension 9 Completed no results Long Term Administration Study of OPC-12759 Ophthalmic. Suspension 9 Completed no results Long Term Administration Study of OPC-12759 Ophthalmic. Suspension 10 Completed no results Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes published yet Condition: Dry Eye Syndromes no results Phase 2 Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension Syndromes 11 Completed no results Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis; Dublished yet Condition: Dry Eye Syndromes 12 Completed no results Acupuncture for Dry Eye Interventions: Dry Eye Interventions: Dry Eye Interventions: 13 Completed no results NAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients 14 Completed no results Treatment of Epidemic Keratoconjunctivitis Treatment of Epidemic Keratoconjunctivitis 14 Completed no results Treatment of Epidemic Keratoconjunctivitis Viral Conjunctivitis		published yet		
8 Completed no results published yet Late Phase 2 Study of OPC-12759 Opthalmic Suspension 9 Completed no results published yet Long Term Administration Study of OPC-12759 Opthalmic Suspension 9 Completed no results published yet Long Term Administration Study of OPC-12759 Opthalmic Suspension 10 Completed no results published yet Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes 11 Completed no results published yet Phase 2 Study of 0.1% Tacrolimus(FKS06) Opthalmic Suspension in Patients With Vernal Keratoconjunctivitis Suspension in Patients With Vernal Keratoconjunctivitis Conditions: Conjunctivitis Conditions: 12 Completed no results published yet Acupuncture for Dry Eye Interventions: Drug: FK506; Drug: placebo 13 Completed no results published yet Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Dr ug: Saline eyedrops 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis Viral Conjunctivitis			Conditions:	
no results published yetCondition: Intervention:Dry Eye Syndromes Intervention:9Completed no results published yetLong Term Administration Study of OPC-127599Completed no results published yetLong Term Administration Study of OPC-12759 Ophthalmic. Suspension10Completed no results published yetDrug: OPC-12759 Ophthalmic suspension10Completed no results published yetPhase 2 Study of KLS-0611 in Patients With Dry Eye. Syndromes11Completed no results published yetPhase 1 Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis Conditions:12Completed no results published yetPhase III Study of 0.1% Tacrolimus(FK506) Drug: placebo12Completed no results published yetAcupuncture for Dry Eye Interventions:13Completed no results published yetEvaluation of the Effect and Tolerance of Preservative Free NAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Interventions:14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis Drug: Viral Conjunctivitis			Intervention:	Drug: FK506
published yet Intervention: Drug: OPC-12759 9 Completed no results published yet Long Term Administration Study of OPC-12759 Ophthalmic. Suspension 10 Completed no results published yet Phase 2 Study of KLS-0611 in Patients With Dry Eye. Syndromes 10 Completed no results published yet Phase 2 Study of KLS-0611 in Patients With Dry Eye. Syndromes 11 Completed no results published yet Phase 1II Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis; Conditions: Drug: FLS-061 11 Completed no results published yet Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic. Suspension in Patients With Vernal Keratoconjunctivitis; Conditions: Neratoconjunctivitis; Conjun ctivitis 12 Completed no results published yet Acupuncture for Dry Eye Interventions: Drug: FK506; Drug: placebo 13 Completed no results published yet Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Dr ug: Saline eyedrops 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis Viral Conjunctivitis	8	Completed	Late Phase 2 Study of OPC-12	2759 Ophthalmic Suspension
9 Completed no results published yet Long Term Administration Study of OPC-12759 Ophthalmic. Suspension 10 Completed no results published yet Condition: Suspension Dry Eye Syndromes Intervention: Suspension 10 Completed no results published yet Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes 11 Completed no results published yet Phase 1II Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis published yet 12 Completed no results published yet Acupuncture for Dry Eye Interventions: Drug: FK506; Drug: placebo 13 Completed no results published yet Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Dr ug: Saline eyedrops 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis Intervention: Viral Conjunctivitis			Condition:	Dry Eye Syndromes
no results published yet Suspension 10 Completed no results published yet Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes 10 Completed no results published yet Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes 11 Completed no results published yet Phase 10 Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis Suspension in Patients With Vernal Keratoconjunctivitis published yet 11 Completed no results published yet Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis Condition: Drug: FK506; Drug: placebo 12 Completed no results published yet Acupuncture for Dry Eye Interventions: Drug: FK506; Drug: placebo 13 Completed no results published yet Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Dr ug: Saline eyedrops 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Viral Conjunctivitis		published yet	Intervention:	Drug: OPC-12759
published yet Condition: Dry Eye Syndromes 10 Completed no results published yet Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes 11 Completed no results published yet Phase 11 Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis 11 Completed no results published yet Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis 12 Completed no results published yet Acupuncture for Dry Eye Interventions: Dry Eye Dry Eye 13 Completed no results published yet Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis With 2%, Povidone-iodine	9	Completed	Long Term Administration Stu	udy of OPC-12759 Ophthalmic
10 Completed no results published yet Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes 11 Completed no results published yet Phase 11 Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis published yet 11 Completed no results published yet Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis published yet 12 Completed no results published yet Acupuncture for Dry Eye Interventions: 13 Completed no results published yet Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Interventions: 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis Interventions: 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis				
10 Completed no results published yet Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes 11 Completed no results Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes 11 Completed no results Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic. Suspension in Patients With Vernal Keratoconjunctivitis published yet 12 Completed no results published yet Phase III Study of Dry Eye Conditions: Drug: FK506; Drug: placebo 12 Completed no results published yet Acupuncture for Dry Eye Interventions: Dry Eye Interventions: 13 Completed no results published yet Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Dr ug: Saline eyedrops 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis Povidone-iodine		published yet	Condition:	Dry Eye Syndromes
no results published yet Syndromes 11 Completed no results published yet Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic. Suspension in Patients With Vernal Keratoconjunctivitis; Dublished yet 12 Completed no results published yet Phase III Study of D.1% Tacrolimus(FK506) Ophthalmic. Suspension in Patients With Vernal Keratoconjunctivitis; Conditions: 12 Completed no results published yet Acupuncture for Dry Eye Interventions: Drug: FK506; Drug: placebo 13 Completed no results published yet Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Dr ug: Saline eyedrops 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine			Intervention:	°
published yet Condition: Dry Eye Syndromes 11 Completed no results Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic. Suspension in Patients With Vernal Keratoconjunctivitis 11 Completed no results Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic. Suspension in Patients With Vernal Keratoconjunctivitis; Dublished yet 12 Completed no results Conditions: Keratoconjunctivitis; Condition: Conjun ctivitis 12 Completed no results Acupuncture for Dry Eye Interventions: Dry Eye published yet Interventions: Device: Acupuncture; Drug: Refresh Plus 13 Completed no results Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients 14 Completed no results Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine	10	Completed	Phase 2 Study of KLS-0611 in	Patients With Dry Eye
Interventions:Drug: Placebo;Drug: KLS-06111Completed no results published yetPhase III Study of 0.1% Tacrolimus(FK506) Ophthalmic, Suspension in Patients With Vernal Keratoconjunctivitis Conditions:Keratoconjunctivitis Keratoconjunctivitis;12Completed no results published yetAcupuncture for Dry Eye Interventions:Dry Eye Dry Eye Interventions:13Completed no results published yetEvaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Interventions:Drug: NAABAK eyedrops; Dr ug: Saline eyedrops14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis Povidone-iodineTreat Conjunctivitis Povidone-iodine			<u>Syndromes</u>	
11 Completed no results published yet Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic. Suspension in Patients With Vernal Keratoconjunctivitis Conditions: Keratoconjunctivitis; Conjun ctivitis 12 Completed no results published yet Acupuncture for Dry Eye Interventions: Drug: FK506; Drug: placebo 13 Completed no results published yet Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Dr ug: Saline eyedrops 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis Povidone-iodine		published yet	Condition:	Dry Eye Syndromes
no results published yetSuspension in Patients With Vernal Keratoconjunctivitis Conditions: Keratoconjunctivitis; Conjun ctivitis12Completed no results published yetAcupuncture for Dry Eye Condition: Dry Eye Interventions: Device: Acupuncture; Drug: Refresh Plus13Completed no results published yetEvaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Dr ug: Saline eyedrops14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis Condition: Viral Conjunctivitis			Interventions:	Drug: Placebo; Drug: KLS-061
published yetConditions:Keratoconjunctivitis;Conjun ctivitis12Completed no results published yetAcupuncture for Dry Eye Condition:Dry Eye Dry Eye13Completed no results published yetEvaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis	11	_		
ctivitis12Completed no results published yetAcupuncture for Dry Eye Condition: Dry Eye Interventions: Device: Acupuncture; Drug: Refresh Plus13Completed no results published yetEvaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Condition: Drug: NAABAK eyedrops; Dr ug: Saline eyedrops14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis				
12 Completed no results published yet Acupuncture for Dry Eye Condition: Dry Eye Interventions: Device: Acupuncture; Drug: Refresh Plus 13 Completed no results published yet Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Condition: Allergic Conjunctivitis 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis Condition: Viral Conjunctivitis		published yet	Conditions:	
no results published yetCondition:Dry Eye Interventions:13Completed no results published yetEvaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Condition:14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis Condition:14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis Condition:14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis Condition:			Interventions:	Drug: FK506; Drug: placebo
published yet Intervention: Dry Eyc 13 Completed no results published yet Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis	12		Acupuncture for Dry Eye	
13 Completed no results published yet Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis Condition:			Condition:	Dry Eye
no results published yetNAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Condition: Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Dr ug: Saline eyedrops14Completed no results published yetTreatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine14Completed no results published yetCondition: Viral Conjunctivitis		published yet	Interventions:	
published yet Dry Eye Syndrome in Allergic Conjunctivitis Patients Condition: Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Dr ug: Saline eyedrops Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine published yet Condition: Viral Conjunctivitis	13	Completed	Evaluation of the Effect and T	olerance of Preservative Free
Condition: Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Drug: Saline eyedrops 14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Condition: Viral Conjunctivitis		no results	NAAGA on the Inflammatory (Component and Symptoms of
14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Viral Conjunctivitis		published yet	Dry Eye Syndrome in Allergic	Conjunctivitis Patients
14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Condition: Viral Conjunctivitis			Condition:	Allergic Conjunctivitis
14 Completed no results published yet Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Condition:			Interventions:	0
no results published yetPovidone-iodine Condition:Condition:Viral Conjunctivitis	14	Completed	Treatment of Epidemic Kerato	
published yet Condition: Viral Conjunctivitis				
Intervention: Drug: 2% povidone-iodine		published yet		Viral Conjunctivitis
			Intervention:	Drug: 2% povidone-iodine

15	Completed	Sodium Hyaluronate and Wav	efront Aberrations in Dry Eyes
	no results	Condition:	Dry Eye
	published yet	Interventions:	Drug: 0.18% sodium hyaluronat
			e; Drug: 0.9% sodium chlorid
			e solution
16	Completed	Comparative Study of 0.5% Ca	arboxymethylcellulose With
	no results	0.005% Stabilized Oxychloroc	
	published yet	0.5% Carboxymethylcellulose	
		Condition:	Dry Eye Syndromes
		Intervention:	Drug: 0.5%
			carboxymethylcellulose (CMC)
			with purite and CMC alone
17	Completed	Efficacy Study of FK-506 and	Cyclosporine in Vernal
	no results published yet	Keratoconjunctivits (VKC)	
	published yet	Condition:	Keratoconjunctivitis, Vernal
		Interventions:	Drug: tacrolimus; Drug: cyclo
			sporins
18	Completed no results	Late Phase II Confirmatory St	
	published yet	Solution in Patients With Dry Condition:	Dry Eye
	published yet		
		Interventions:	Drug: DE-089 ophthalmic solu tion; Drug: Placebo ophthal
			mic solution
19	Completed	Confirmatory Study of OPC-12	
	no results		Dry Eye Syndromes
	published yet	Interventions:	Drug: OPC-12759 Ophthalmic s
			uspension; Drug: Hyalein Min
			i Ophthalmic solution
20	Completed	A Study of KCT-0809 in Patier	nts With Dry Eye Syndromes
	no results	Condition:	Dry Eye Syndromes
	published yet	Interventions:	Drug: KCT-0809; Drug: Place
			bo
21	Completed	Dose-Response Study of OPC	-12759 Ophthalmic
	no results	<u>Suspension</u>	
	published yet	Condition:	Dry Eye Syndromes
		Intervention:	Drug: OPC-12759
22	Completed	Phase III Confirmatory Study	of DE-089 Ophthalmic Solution
	no results	in Patients With Dry Eye	

	published yet	Condition:	Dry Eye
		Interventions:	Drug: 3% DE-089 ophthalmic s
			olution; Drug: 0.1% sodium h
			yaluronate ophthalmic solution
23	Completed	Safety Study of OPC-12759 Op	ohthalmic Solution
	no results	Condition:	Dry Eye Syndromes
	published yet	Interventions:	Drug: OPC-12759 Ophthalmic s
			olution; Drug: OPC-12759 Op
			hthalmic suspension
24	Completed	Study of DE-089 Ophthalmic S	Solution in Patients With Dry
	no results	<u>Eye</u>	
	published yet	Condition:	Dry Eye
		Interventions:	Drug: diquafosol ophthalmic s
			olution; Drug: 0.1% sodium
			hyaluronate ophthalmic
			solution.
25	Completed	Efficacy and Safety Study of A	ATs in Patients With Dry Eye
	no results published yet	<u>Syndrome</u>	
	published yet	Conditions:	Dry Eye Syndromes; Kerato conjunctivitis Sicca
		Interventions:	Drug: AT01; Drug: AT02;
			Drug: AT03; Drug: AT04
26	Completed	A Study to Evaluate the Tolera	ability of Eye Drop DA-6034 in
	no results	Healthy Volunteers	
	published yet	Condition:	Dry Eye Syndrome
		Interventions:	Drug: DA-6034; Drug: Placeb
			0
27	Completed	Comparison of Autologous Se	erum and Umbilical Cord
	no results	Serum Eyedrops for Dry Eye S	<u>Syndrome</u>
	published yet	Condition:	Dry Eye Syndrome
		Interventions:	Drug: Umbilical cord serum ey
			edrops; Drug: Autologous s
			erum eyedrops
28	Completed		d CXCR3 in Dry Eye Syndrome
	no results	Condition:	Dry Eye Syndrome
	published yet	Intervention:	
29	Withdrawn	The Application of Fibrin Glue	
		Conditions:	Pterygium; Corneal Ulcer

		Intervention:	Drug: tissue fibrin glue applica tion (Tisseel)
30	Completed	The Effect of Punctal Plugs or	n Tear Volume and Osmolality
	no results	Condition:	Dry Eye Syndromes
	published yet	Intervention:	Device: Temporary Co Ilagen Inserts
31	Completed	Safety and Efficacy Study of N	lew Eye Drop Formulations
	no results	With Refresh Tears® in Patien	ts With Dry Eye Disease
	published yet	Condition:	Dry Eye Syndromes
		Interventions:	Drug: Formulation 1: Eye
			Drops New Platform (EDNP) -
			1; Drug: Formulation 2: ED
			NP - 2; Drug:
			carboxymethylcellulose sodium based artificial tear
32	Completed	Therapeutic Exploratory Study	y of Comparing Natamycin and
52	no results	Voriconazole to Treat Fungal	
	published yet	Condition:	Fungal Keratitis
		Interventions:	Drug: Natamycin 5%; Drug:
			Voriconazole; Procedure: C
			orneal de-epithelialization
33	Completed	Safety and Efficacy Study of G	Batifloxacin Compared With
	no results	Ciprofloxacin in Patients With	Acute Bacterial Corneal
	published yet	<u>Ulcers</u>	
		Conditions:	Acute Bacterial Corneal Ulcer s; Bacterial Keratitis
		Interventions:	Drug: Gatifloxacin 0.3% ophth
			almic solution; Drug: Ciprofl
			oxacin 0.3% ophthalmic soluti
	Completed	Museule Illees Tractment Triat	on
34	Completed no results	Mycotic Ulcer Treatment Trial	
	published yet	Conditions:	Corneal Ulcer; Eye Infection s, Fungal
		Interventions:	S, Fungai Drug: Natamycin; Drug: Vori
			conazole
35	Completed	Moisture Chamber Glasses fo	r Dry Eye in Asian Population
	no results	Condition:	Dry Eye
	published yet	Intervention:	Device: 7eye(Panoptx)™ moi

			sture chamber glasses
36	Completed	Study of DE-089 Ophthalmic S	Solution in Patients With Dry
	no results	<u>Eye</u>	
	published yet	Condition:	Dry Eye
		Interventions:	Drug: diquafosol ophthalmic s
			olution; Drug: 0.1% sodium
			hyaluronate ophthalmic
			solution.
37	Active, not	A Phase II Study of KCT-0809	in Patients With Dry Eye
	recruiting	<u>Syndrome</u>	
		Condition:	Dry Eye Syndromes
		Interventions:	Drug: KCT-0809; Drug: Plac ebo
38	Active, not	Steroids for Corneal Ulcers T	rial
	recruiting	Conditions:	Corneal Ulcer; Eye Infection
			s, Bacterial
		Interventions:	Drug: Antibiotics; Drug: Topi
			cal corticosteroid; Drug: Pla
			cebo
39	Enrolling by	TearLab Core Validation Stud	_
	invitation	Condition:	Dry Eye Disease
		Intervention:	
40	Recruiting	Repeatability and Agreement	
		Coherence Tomography (AS-	
		Condition:	Dry Eye Syndromes
		Intervention:	Device: EyeGiene
41	Recruiting	The Asia Cornea Society Infec	
		Condition:	Corneal Ulcer
		Intervention:	
42	Recruiting	The Asia Cornea Society Infec	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
43	Recruiting	The Asia Cornea Society Infec	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
44	Recruiting	The Asia Cornea Society Infec	ctious Keratitis Study
		Condition:	Corneal Ulcer

		Intervention:	
45	Recruiting	Confirmatory Study of OPC-12	2759 Ophthalmic Solution
		Condition:	Dry Eye
		Interventions:	Drug: OPC-12759; Drug: Plac
46	Recruiting	Efficacy of Nonsteroidal Anti-	inflammatory Drugs in
		Treatment of Moderate and Se	evere Dry Eye Disease
		Condition: Moderate	to Severe Dry Eye Disease
		•	steroid anti-inflammatory drops
			ial tear substitute; Drug:
			oids plus artificial tear
47	Deemviting	substitute;	<u> </u>
47	Recruiting	Primary Sjögren's Syndrome	nt of Dry Eyes in Patients With
		Conditions:	Autoimmune Diseases; Sjo
			gren's Syndrome; Dry Eye
		Interventions:	Drug: Hydroxychloroquine;
			Drug: Placebo
48	Recruiting	The Asia Cornea Society Infec	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
49	Recruiting	A Parallel Group Phase II Stud	ly of KCT-0809 in Patients With
		Dry Eye Syndromes	
		Condition:	Dry Eye Syndromes
		Interventions:	Drug: KCT-0809; Drug: Plac ebo
50	Recruiting	The Asia Cornea Society Infec	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
51	Recruiting	The Asia Cornea Society Infec	ctious Keratitis Study
		Condition:	Corneal Ulcer
		Intervention:	
52	Recruiting	Mycotic Ulcer Treatment Trial	<u>II</u>
		Conditions:	Corneal Ulcer; Eye Infection s, Fungal
		Interventions:	Drug: Voriconazole; Drug: P lacebo
53	Recruiting	The Asia Cornea Society Infec	ctious Keratitis Study

State Condition: Corneal Ulcer 54 Recruiting The Effect of Hinge Location on Corneal Sensation and Dry. Eve After LASIK: A Systematic Review and Meta-analysis 55 Recruiting Transplantation of Aceilular Corneal Matrix to Treat Corneal Ulcer 55 Recruiting Transplantation of Aceilular Corneal Matrix to Treat Corneal Ulcer 56 Recruiting Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome Condition: 56 Recruiting Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome Interventions: 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients. With Dry Eye 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 59 Unknown [†] Comparison of Efficacy. Safety and Anti-Inflammatory Effect Between Topical 0.05%/Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: 59 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye. Drops in Nonautoimmune and Stevens-Johnson Syndrome				
54 Recruiting The Effect of Hinge Location on Corneal Sensation and Dry Eve After LASIK: A Systematic Review and Meta-analysis Condition: Dry Eye Intervention: 55 Recruiting Transplantation of Acellular Corneal Matrix to Treat Corneal. Uicer 56 Recruiting Transplantation of Acellular Corneal Matrix to Treat Corneal ma trix 56 Recruiting Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome Condition: Dry Eye Syndrome Interventions: Drug: DA-6034 3%; Drug: D A-6034 5%; Drug: DA-6034 Placebo 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 59 Unknown [†] Comparison of Efficacy, Safety and Ant-Inflammatory Effect Between Topical 0.05% Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye 59 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye Intervention: Dry Eye			Condition:	Corneal Ulcer
Statustics Eye After LASIK: A Systematic Review and Meta-analysis Condition: Dry Eye Intervention: 55 Recruiting Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer 56 Recruiting Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer 56 Recruiting Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome Condition: Dry Eye Syndrome Interventions: Drug: DA-6034 3%; Drug: D A-6034 5%; Drug: DA-6034 Placebo 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Intervention: Dry Eye Intervention: Device: Punctal Plug 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 59 Unknown [†] Comparison of Efficacy. Safety and Anti-Inflammatory Effect Between Topical 0.05%/Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye 59 Unknown [†] Comparison of Efficacy. Safety and Anti-Inflammatory Effect Between Topical 0.05%/Cyclosporine e dr op 60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye.			Intervention:	
S5 Recruiting Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer S5 Recruiting Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer S6 Recruiting Phase II Study of DA-6034 Eve Drops in Dry Eve Syndrome Condition: Dry Eye Syndrome S6 Recruiting Phase II Study of DA-6034 Eve Drops in Dry Eve Syndrome Condition: Dry Eye Syndrome Interventions: Drug: DA-6034 3%; Drug: D A-6034 5%; Drug: DA-6034 Placebo S7 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye S6 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease S8 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease S9 Unknown [†] Comparison of Efficacy. Safety and Anti-Inflammatory Effect Between Topical 0.05%/Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye S9 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye op	54	Recruiting	The Effect of Hinge Location of	on Corneal Sensation and Dry
Intervention: 55 Recruiting Transplantation of Acellular Corneal Matrix to Treat Corneal. Ulcer 56 Recruiting Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome Intervention: Dry Eye Syndrome 56 Recruiting Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome Condition: Dry Eye Syndrome 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients. With Dry Eye 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients. With Dry Eye 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye. Drop Formulation With OPTIVE [™] in Subjects With Dry Eye Disease 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye. Drop Formulation With OPTIVE [™] in Subjects With Dry Eye Disease 59 Unknown [†] Comparison of Efficacy.Safety and Anti-Inflammatory Effect Between Topical 0.05%/Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye 60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye.			Eye After LASIK: A Systematic	c Review and Meta-analysis
55 Recruiting Transplantation of Acellular Corneal Matrix to Treat Corneal. Ulcer 56 Recruiting Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome Condition: Dry Eye Syndrome Interventions: Drug: DA-6034 3%; Drug: D A-6034 5%; Drug: DA-6034 Placebo 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Intervention: Dry Eye Intervention: Dry Eye Intervention: Device: Punctal Plug 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 59 Unknown [†] Comparison of Efficacy. Safety and Anti-Inflammatory Effect Between Topical 0.05% cyclosporine and REFRESH® in Patients With Moderate to Severe Dry Eyes Intervention: Dry Eye 60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye			Condition:	Dry Eye
Ulcer Condition: Corneal Ulcer Intervention: Device: acellular corneal ma trix 56 Recruiting Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome Condition: Dry Eye Syndrome Interventions: Drug: DA-6034 3%; Drug: D A-6034 5%; Drug: DA-6034 Placebo 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Vith Dry Eye Intervention: Dry Eye Intervention: Device: Punctal Plug 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease Condition: Dry Eye Disease Interventions: Drug: Carboxymethycellulose Based Eye Drop Formulation A; Drug: Carboxymethycellulose Based Preservative-Free Lubricant Eye Drops 59 Unknown [†] Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%/Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Drug: 0.05% cyclosporin eye dr op			Intervention:	
S6 Recruiting Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome Condition: Dry Eye Syndrome Interventions: Drug: DA-6034 3%; Drug: D A-6034 5%; Drug: DA-6034 Placebo 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Intervention: Dry Eye Intervention: Dry Eye Intervention: Device: Punctal Plug 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 59 Unknown [†] Comparison of Efficacy. Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Dry Eye 60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye	55	Recruiting	Transplantation of Acellular C	Corneal Matrix to Treat Corneal
Intervention: Device: acellular corneal ma trix 56 Recruiting Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome Interventions: Dry Eye Syndrome Intervention: Dry Eye Syndrome Interventions: Drug: DA-6034 3%; Drug: DA-6034 Placebo 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients. With Dry Eye With Dry Eye 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 59 Unknown [†] Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: 59 Unknown [†] Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: 60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye			<u>Ulcer</u>	
56 Recruiting Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome Condition: Dry Eye Syndrome Interventions: Drug: DA-6034 3%; Drug: D A-6034 5%; Drug: DA-6034 Placebo 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 59 Unknown [†] Comparison of Efficacy. Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye 59 Unknown [†] Comparison of Efficacy. Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye 60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye.			Condition:	Corneal Ulcer
56 Recruiting Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome Condition: Dry Eye Syndrome Interventions: Drug: DA-6034 3%; Drug: D A-6034 5%; Drug: DA-6034 Placebo 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients. With Dry Eye Condition: Dry Eye Intervention: Device: Punctal Plug 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 59 Unknown [↑] Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%/Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye 60 Unknown [↑] Corneal Epitheliotropic Factors in Autologous Serum Eye			Intervention:	Device: acellular corneal ma
Condition: Dry Eye Syndrome Interventions: Drug: DA-6034 3%; Drug: D A-6034 5%; Drug: DA-6034 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients. With Dry Eye Condition: Dry Eye 1 Intervention: Device: Punctal Plug 58 Not yet A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 1 Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease Condition: Dry Eye Disease Interventions: Drug: Carboxymethycellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%/Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Drug: 0.05% cyclosporine ye dr op 60 Unknown † Corneal Epitheliotropic Factors in Autologous Serum Eye				trix
Interventions: Drug: DA-6034 3%; Drug: D A-6034 5%; Drug: DA-6034 Placebo 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Condition: Dry Eye Intervention: Device: Punctal Plug 58 Not yet A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease Interventions: Dry Eye Disease Interventions: Drug: Carboxymethycellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Dry Eye Intervention: Dry Eye	56	Recruiting	Phase II Study of DA-6034 Eye	e Drops in Dry Eye Syndrome
A-6034 5%; Drug: DA-6034 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients. With Dry Eye Condition: Dry Eye Intervention: Device: Punctal Plug 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye. Drop Formulation With OPTIVE™ in Subjects With Dry Eye. Disease Drop Formulation With OPTIVE™ in Subjects With Dry Eye. Disease Interventions: Interventions: Drug: Carboxymethycellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops Softer Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Dry Eye Intervention: Dry Eye 60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye			Condition:	Dry Eye Syndrome
57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients. With Dry Eye 57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients. With Dry Eye 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease 60 Unknown [†] Comparison of Efficacy. Safety and Anti-Inflammatory Effect Drop Formulation 0.5% Cyclosporin eye dr op 60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye			Interventions:	Drug: DA-6034 3%; Drug: D
57 Recruiting Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Condition: Dry Eye Intervention: Device: Punctal Plug 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease Interventions: Dry Eye Disease Interventions: Drug: Carboxymethycellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops 59 Unknown [†] Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: 60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye				A-6034 5%; Drug: DA-6034
With Dry Eye With Dry Eye Condition: Dry Eye Intervention: Device: Punctal Plug 58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye. Disease Condition: Condition: Dry Eye Disease Interventions: Drug: Carboxymethycellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops 59 Unknown [†] Comparison of Efficacy. Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Drug: 0.05% cyclosporin eye dr op O				Placebo
Condition: Dry Eye Intervention: Device: Punctal Plug 58 Not yet A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease Disease Condition: Dry Eye Disease Interventions: Drug: Carboxymethycellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05% Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye 60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye	57	Recruiting	Safety and Efficacy of Puncta	I Plug Insertion in Patients
Intervention: Device: Punctal Plug 58 Not yet A Study to Compare the Safety and Efficacy of A New Eye precruiting Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease Disease Interventions: Drug: Carboxymethycellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Drug: 0.05% cyclosporin eye dr op Op				
58 Not yet recruiting A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease Condition: Dry Eye Disease Interventions: Drug: Carboxymethycellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops 59 Unknown [↑] Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: 60 Unknown [↑] Corneal Epitheliotropic Factors in Autologous Serum Eye			Condition:	Dry Eye
recruiting Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease Condition: Dry Eye Disease Interventions: Drug: Carboxymethycellulose Based Eye Drop Formulation A; A; Drug: Carboxymethylcellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops 59 Unknown [↑] Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Drug: 0.05% cyclosporin eye dr op Op			Intervention:	Device: Punctal Plug
Disease Condition: Dry Eye Disease Interventions: Drug: Carboxymethycellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops Enterventions: 59 Unknown [†] Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Drug: 0.05% cyclosporin eye dr op Op	58	Not yet	A Study to Compare the Safet	y and Efficacy of A New Eye
60 Unknown † Condition: Dry Eye Disease Interventions: Drug: Carboxymethycellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops 59 Unknown † Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Drug: 0.05% cyclosporin eye dr op Op		recruiting		E [™] in Subjects With Dry Eye
60 Unknown [†] Interventions: Drug: Carboxymethycellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops 59 Unknown [†] Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: 60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye				
60 Unknown † Corneal Epitheliotropic Factors in Autologous Serum Eye 60 Unknown † Corneal Epitheliotropic Factors in Autologous Serum Eye			Condition:	Dry Eye Disease
A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops 59 Unknown [†] Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Drug: 0.05% cyclosporin eye dr op 0			Interventions:	• • •
60 Unknown † Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Drug: 0.05% cyclosporin eye dr op Corneal Epitheliotropic Factors in Autologous Serum Eye				· ·
59 Unknown † Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Drug: 0.05% cyclosporin eye dr op Corneal Epitheliotropic Factors in Autologous Serum Eye				•
Lubricant Eye Drops 59 Unknown † Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Drug: 0.05% cyclosporin eye dr op 0 60 Unknown † Corneal Epitheliotropic Factors in Autologous Serum Eye				
59 Unknown † Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Drug: 0.05% cyclosporin eye dr op 0 0 Unknown † Corneal Epitheliotropic Factors in Autologous Serum Eye				
Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Drug: 0.05% cyclosporin eye dr op 60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye	50	Unknown †	Comparison of Efficacy Safet	
REFRESH® in Patients With Moderate to Severe Dry Eyes Condition: Dry Eye Intervention: Drug: 0.05% cyclosporin eye dr op 60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye	55	OIRHOWH		
Condition: Dry Eye Intervention: Drug: 0.05% cyclosporin eye dr op 60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye				
60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye				
60 Unknown † Corneal Epitheliotropic Factors in Autologous Serum Eye			Intervention:	
60 Unknown [†] Corneal Epitheliotropic Factors in Autologous Serum Eye				
	60	Unknown [†]	Corneal Epitheliotropic Factor	-
brops in nonautoininune and stevens-joinison syndronie				

		With Dry Eye
		Condition: Stevens-Johnson Syndrome
		Intervention:
61	Unknown [†]	The Evaluation of Thiol Redox Status in Conjunctiva of Dry
		Eye Patients
		Condition: Dry Eye Disease
		Intervention:
62	Unknown [†]	Antibiotic Susceptibility of Conjunctival Bacterial Isolates
		From Refractive Surgery Patients
		Condition: Bacterial Keratitis
		Intervention:
63	Unknown [†]	Reliability of Pachymetry Measurement With FD-oCT, ORA,
		Confoscan 4 and Ultrasound
		Condition: Keratitis
		Intervention:
64	Unknown [†]	The Pathogenesis of Superior Limbic Keratoconjunctivitis
		Condition: Superior Limbic Keratoconjun
		ctivitis
		Intervention:

Rank	Status	Study	
1	Completed	Acupuncture for Dry Eye Syndrome	
	Has Results	Condition:	Dry Eye Syndromes
	published	Interventions:	Device: Standardized Acupuncture; Device:
	in journals		Non-acupuncture point shallow penetration acupuncture
2	Completed	Efficacy and Safety Study of C	Cyclosporine 0.010% to Treat Atopic
	Has Results	Keratoconjunctivitis	
	published	Condition:	Atopic Conjunctivitis
	on website	Interventions:	Drug: Cyclosporine Vehicle; Drug: Cyclospor ine 0.010%
3	Completed	Efficacy, Tolerability, and Con	nfort of 0.3% Hypromellose Eyedrops in
	Has Results	Patients Undergoing LASIK S	urgery
	published	Condition:	Dry Eye Syndromes
	on website	Interventions:	Drug: Pre-LASIK 0.3% hypromellose; Drug: Post-LASIK 0.3% hypromellose
4	Completed	Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome	
	no results	Conditions:	Dry Eye Syndromes; Keratoconjunctivitis Si
	published		сса
	yet	Interventions:	Drug: AT01; Drug: AT02; Drug: AT03; Drug: AT04
5	Completed	A Phase II, Dose Ranging Stu	dy Of CP-690,550 Eye Drops In Patients With
	no results	Dry Eye Disease	
	published	Condition:	Dry Eye Syndromes
	yet	Interventions:	Drug: CP-690,550 Eye drops; Drug: CP-69 0,550 Eye drops-vehicle; Drug: Sodium Hy aluronate
6	Completed	Acupuncture for Dry Eye	
	no results	Condition:	Dry Eye
	published yet	Interventions:	Device: Acupuncture; Drug: Refresh Plus
7	Completed	Evaluation of the Effect and T	olerance of Preservative Free NAAGA on the
	no results	Inflammatory Component and	Symptoms of Dry Eye Syndrome in Allergic
	published	Conjunctivitis Patients	
	yet	Condition:	Allergic Conjunctivitis
		Interventions:	Drug: NAABAK eyedrops; Drug: Saline eye drops
8	Completed	Study of DE-089 Ophthalmic S	Solution in Patients With Dry Eye
	no results		

44. Keratoconjunctivitis

	published	Condition:	Dry Eye
	yet	Interventions:	
			Drug: diquafosol ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic
			solution.
9	Completed	The Effect of Punctal Plugs or	
Ũ	no results	Condition:	Dry Eye Syndromes
	published	Intervention:	Device: Temporary Collagen Inserts
	yet		Device. Temporary Collagen insens
10	Completed	A Study to Evaluate the Tolera	ability of Eye Drop DA-6034 in Healthy
	no results	<u>Volunteers</u>	
	published	Condition:	Dry Eye Syndrome
	yet	Interventions:	Drug: DA-6034; Drug: Placebo
11	Completed	Comparison of Autologous Se	erum and Umbilical Cord Serum Eyedrops for
	no results	Dry Eye Syndrome	
	published	Condition:	Dry Eye Syndrome
	yet	Interventions:	Drug: Umbilical cord serum eyedrops; Drug
			: Autologous serum eyedrops
12	Completed	CXCL9, CXCL10, CXCL11, and CXCR3 in Dry Eye Syndrome	
	no results	Condition:	Dry Eye Syndrome
	published	Intervention:	
	yet		
13	Completed		imus(FK506) Ophthalmic Suspension in
	no results	Patients With Vernal Keratoco	
	published	Conditions:	Keratoconjunctivitis; Conjunctivitis
	yet		Drug: FK506; Drug: placebo
14	Completed		New Eye Drop Formulations With Refresh
	no results	Tears® in Patients With Dry E	
	published	Condition:	Dry Eye Syndromes
	yet	Interventions:	Drug: Formulation 1: Eye Drops New
			Platform (EDNP) -
			1; Drug: Formulation 2: EDNP - 2; Drug:
			carboxymethylcellulose sodium based artificial tear
15	Completed	To Evaluate the Physical Effec	cts of Systane(R) Lubricant Eye Drops
15	no results	Compared to Refresh Tears(R	
	published	Condition:	Dry Eye
	yet	Interventions:	Other: Systane; Other: Refresh Tears
16	Completed	Moisture Chamber Glasses fo	•
10	no results	moisture Graniber Glasses 10	
	no results		

	published	Condition:	Dry Eye
	yet	Intervention:	Device: 7eye(Panoptx)™ moisture chambe
			r glasses
17	Completed	Phase III, Long-Term, Open-Label, Extension Study of 0.1%	
	no results	Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal	
	published	Keratoconjunctivitis	
	yet	Conditions:	Keratoconjunctivitis; Conjunctivitis
		Intervention:	Drug: FK506
18	Completed	Late Phase 2 Study of OPC-12	2759 Ophthalmic Suspension
	no results	Condition:	Dry Eye Syndromes
	published	Intervention:	Drug: OPC-12759
	yet		
19	Completed	Long Term Administration Stu	udy of OPC-12759 Ophthalmic Suspension
	no results	Condition:	Dry Eye Syndromes
	published	Intervention:	Drug: OPC-12759 Ophthalmic suspension
	yet		Deficience With Days Free Complements
20	Completed no results		Patients With Dry Eye Syndromes
	published	Condition:	Dry Eye Syndromes
	yet	Interventions:	Drug: Placebo; Drug: KLS-0611
21	Completed	Confirmatory Study of OPC-12	2759 Ophthalmic Suspension
	no results	Condition:	Dry Eye Syndromes
	published	Interventions:	Drug: OPC-12759 Ophthalmic suspension; D
	yet		lein Mini Ophthalmic solution
22	Completed	Late Phase II Confirmatory St	udy of DE-089 Ophthalmic Solution in
	no results	Patients With Dry Eye	
	published	Condition:	Dry Eye
	yet	Interventions:	Drug: DE-089 ophthalmic solution; Drug: Pl
			acebo ophthalmic solution
23	Completed	A Study of KCT-0809 in Patier	nts With Dry Eye Syndromes
	no results	Condition:	Dry Eye Syndromes
	published	Interventions:	Drug: KCT-0809; Drug: Placebo
	yet		
24	Completed	Dose-Response Study of OPC	-12759 Ophthalmic Suspension
	no results	Condition:	Dry Eye Syndromes
	published	Intervention:	Drug: OPC-12759
25	yet Completed	Phase III Confirmatory Study	of DE-089 Ophthalmic Solution in Patients
23	no results	With Dry Eye	DE-003 Ophinalinic Solution in Patients
	101630113		

	and the set			
	published	Condition:	Dry Eye	
	yet	Interventions:	Drug: 3% DE-089 ophthalmic solution; Drug: 0	
			ium hyaluronate ophthalmic solution	
26	Completed		Cyclosporine in Vernal Keratoconjunctivits	
	no results	<u>(VKC)</u>		
	published	Condition:	Keratoconjunctivitis, Vernal	
	yet	Interventions:	Drug: tacrolimus; Drug: cyclosporins	
27	Completed	Treatment of Epidemic Kerato	conjunctivitis With 2% Povidone-iodine	
	no results	Condition:	Viral Conjunctivitis	
	published	Intervention:	Drug: 2% povidone-iodine	
	yet			
28	Completed		Solution in Patients With Dry Eye	
	no results	Condition:	Dry Eye	
	published	Interventions:	Drug: diquafosol ophthalmic solution; Drug:	
	yet		0.1% sodium hyaluronate ophthalmic	
			solution.	
29	Completed		efront Aberrations in Dry Eyes	
	no results	Condition:	Dry Eye	
	published	Interventions:	Drug: 0.18% sodium hyaluronate; Drug: 0.9	
	yet		% sodium chloride solution	
30	Completed	Comparative Study of 0.5% Carboxymethylcellulose With 0.005%		
	no results	Stabilized Oxychlorocomplex		
	published	Carboxymethylcellulose in the		
	yet	Condition:	Dry Eye Syndromes	
		Intervention:	Drug: 0.5% carboxymethylcellulose (CMC)	
			with purite and CMC alone	
31	Completed	Safety Study of OPC-12759 Op	ohthalmic Solution	
	no results	Condition:	on: Dry Eye Syndromes	
			Dry Eye Syndromes	
	published	Interventions:	Drug: OPC-12759 Ophthalmic solution; Dru	
	published yet	Interventions:		
32	-	Interventions: TearLab Core Validation Study	Drug: OPC-12759 Ophthalmic solution; Dru g: OPC-12759 Ophthalmic suspension	
32	yet		Drug: OPC-12759 Ophthalmic solution; Dru g: OPC-12759 Ophthalmic suspension	
32	yet Enrolling	TearLab Core Validation Study	Drug: OPC-12759 Ophthalmic solution; Dru g: OPC-12759 Ophthalmic suspension	
32	yet Enrolling by	TearLab Core Validation Study Condition: Intervention:	Drug: OPC-12759 Ophthalmic solution; Dru g: OPC-12759 Ophthalmic suspension	
	yet Enrolling by invitation	TearLab Core Validation Study Condition: Intervention:	Drug: OPC-12759 Ophthalmic solution; Dru g: OPC-12759 Ophthalmic suspension Dry Eye Disease	
	yet Enrolling by invitation Active, not	TearLab Core Validation Study Condition: Intervention: A Phase II Study of KCT-0809 Condition:	Drug: OPC-12759 Ophthalmic solution; Dru g: OPC-12759 Ophthalmic suspension Dry Eye Disease in Patients With Dry Eye Syndrome Dry Eye Syndromes	
	yet Enrolling by invitation Active, not	TearLab Core Validation Study Condition: Intervention: A Phase II Study of KCT-0809 Condition: Interventions:	Drug: OPC-12759 Ophthalmic solution; Dru g: OPC-12759 Ophthalmic suspension Dry Eye Disease in Patients With Dry Eye Syndrome	

		Condition:	Dry Eye
		Intervention:	
35	Recruiting		nflammatory Drugs in Treatment of
	Ŭ	Moderate and Severe Dry Eye Disease	
		Condition:	Moderate to Severe Dry Eye Disease
		Interventions:	Drug: nonsteroid anti-inflammatory drops
			plus artificial tear substitute; Drug:
			corticosteroids plus artificial tear
			substitute; Drug: artificial tear substitute
36	Recruiting	Hydroxychloroquine Treatmer	nt of Dry Eyes in Patients With Primary
		Sjögren's Syndrome	
		Conditions:	Autoimmune Diseases; Sjogren's Syndrom e; Dry Eye
		Interventions:	Drug: Hydroxychloroquine; Drug: Placebo
37	Recruiting	Phase II Study of DA-6034 Eye	Drops in Dry Eye Syndrome
		Condition:	Dry Eye Syndrome
		Interventions:	Drug: DA-6034 3%; Drug: DA-6034 5%;
			Drug: DA-6034 Placebo
38	Recruiting	Confirmatory Study of OPC-12	2759 Ophthalmic Solution
		Condition:	Dry Eye
		Interventions:	Drug: OPC-12759; Drug: Placebo
39	Recruiting	A Parallel Group Phase II Stud	ly of KCT-0809 in Patients With Dry Eye
		<u>Syndromes</u>	
		Condition:	Dry Eye Syndromes
		Interventions:	Drug: KCT-0809; Drug: Placebo
40	Not yet		y and Efficacy of A New Eye Drop
	recruiting	Formulation With OPTIVE™ in	Subjects With Dry Eye Disease
		Condition:	Dry Eye Disease
		Interventions:	Drug: Carboxymethycellulose Based Eye
			Drop Formulation A; Drug:
			Carboxymethylcellulose Based
	.		Preservative-Free Lubricant Eye Drops
41	Recruiting		Plug Insertion in Patients With Dry Eye
		Condition:	Dry Eye
		Intervention:	Device: Punctal Plug
42	Recruiting		of Anterior Segment Optical Coherence
		Tomography (AS-OCT) and Th	
		Condition:	Dry Eye Syndromes

		Intervention:	Device: EyeGiene
43	Unknown [†]	Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between	
		Topical 0.05%Cyclosporine A	Emulsion and REFRESH® in Patients With
		Moderate to Severe Dry Eyes	
		Condition:	Dry Eye
		Intervention:	Drug: 0.05% cyclosporin eye drop
44	Unknown [†]	Corneal Epitheliotropic Factor	rs in Autologous Serum Eye Drops in
		Nonautoimmune and Stevens	-Johnson Syndrome With Dry Eye
		Condition:	Stevens-Johnson Syndrome
		Intervention:	
45	Unknown [†]	The Evaluation of Thiol Redox	Status in Conjunctiva of Dry Eye Patients
		Condition:	Dry Eye Disease
		Intervention:	
46	Unknown [†]	The Pathogenesis of Superior	Limbic Keratoconjunctivitis
		Condition:	Superior Limbic Keratoconjunctivitis
		Intervention:	

45. Keratoconjunctivitis Sicca

Rank	Status	Study	
1	Completed	Acupuncture for Dry Eye Synd	drome_
	Has Results	Condition:	Dry Eye Syndromes
	published in	Interventions:	Device: Standardized Acupunct
	journals		e: Non-acupuncture point shall
			penetration acupuncture
2	Completed	Efficacy, Tolerability, and Con	nfort of 0.3% Hypromellose
	Has Results	Eyedrops in Patients Undergo	bing LASIK Surgery
	published on	Condition:	Dry Eye Syndromes
	website	Interventions:	Drug: Pre-LASIK 0.3% hyprome
			Post-LASIK 0.3% hypromellos
3	Completed	Trial to Compare the Efficacy	of Systane Ultra and Refresh
	Has Results	Drop in the Treatment of Dry B	<u>Eye in Asian Eyes</u>
	published on	Conditions:	Xerophthalmia; Blepharitis
	website	Interventions:	Drug: Systane Ultra eyedrops;
			eye drops
4	Completed	Study of DE-089 Ophthalmic S	Solution in Patients With Dry
	no results	Eye	
	published	Condition:	Dry Eye
	yet	Interventions:	Drug: diquafosol ophthalmic sol
			: 0.1% sodium hyaluronate oph
			solution.
5	Completed	Efficacy and Safety Study of A	ATs in Patients With Dry Eye
	no results	<u>Syndrome</u>	
	published	Conditions:	Dry Eye Syndromes; Keratoc
	yet		са
		Interventions:	Drug: AT01; Drug: AT02; D
			rug: AT04
6	Completed	Acupuncture for Dry Eye	
	no results	Condition:	Dry Eye
	published yet	Interventions:	Device: Acupuncture; Drug: F
7	Completed	A Phase II, Dose Ranging Stu	dv Of CP-690.550 Eve Drops
	no results	In Patients With Dry Eye Disea	
	published	Condition:	Dry Eye Syndromes
	yet	Interventions:	Drug: CP-690,550 Eye drops;
			Eye drops-vehicle; Drug: Sod
8	Completed	CXCL9, CXCL10, CXCL11, and	I CXCR3 in Dry Eye Syndrome
	no results		

	published	Condition:	Dry Eye Syndrome
	yet	Intervention:	
9	Completed	Comparison of Autologous Se	erum and Umbilical Cord
	no results	Serum Eyedrops for Dry Eye	Syndrome
	published	Condition:	Dry Eye Syndrome
	yet	Interventions:	Drug: Umbilical cord serum eye
			tologous serum eyedrops
10	Completed	A Study to Evaluate the Tolera	ability of Eye Drop DA-6034 in
	no results	Healthy Volunteers	
	published	Condition:	Dry Eye Syndrome
	yet	Interventions:	Drug: DA-6034; Drug: Placeb
11	Completed	Evaluation of the Effect and T	olerance of Preservative Free
	no results	NAAGA on the Inflammatory (
	published	Dry Eye Syndrome in Allergic	
	yet	Condition:	Allergic Conjunctivitis
		Interventions:	Drug: NAABAK eyedrops; Dr
			drops
12	Completed	Phase 2 Study of KLS-0611 in	Patients With Dry Eye
	no results published	Syndromes Condition:	Dry Evo Syndromoo
	yet		Dry Eye Syndromes
13	-	Interventions:	Drug: Placebo; Drug: KLS-06
15	Completed no results	A Phase II, Dose Ranging Stud In Patients With Dry Eye Disea	
	published	Condition:	Dry Eye Syndromes
	yet	Interventions:	Drug: CP-690,550 Eye drops;
			drops-vehicle; Drug: Sodium
14	Completed	A Study of KCT-0809 in Patier	· · · · ·
	no results	Condition:	Dry Eye Syndromes
	published	Interventions:	Drug: KCT-0809; Drug: Place
	yet		.
15	Completed	Late Phase II Confirmatory St	
	no results	Solution in Patients With Dry	
	published	Condition:	Dry Eye
	yet	Interventions:	Drug: DE-089 ophthalmic soluti
			phthalmic solution
16	Completed	Phase III Confirmatory Study	
	no results	Solution in Patients With Dry	
	published	Condition:	Dry Eye

	yet	Interventions:	Drug: 3% DE-089 ophthalmic so
			dium hyaluronate ophthalmic so
17	Completed	Confirmatory Study of OPC-12	2759 Ophthalmic Suspension
	no results	Condition:	Dry Eye Syndromes
	published	Interventions:	Drug: OPC-12759 Ophthalmic
	yet		alein Mini Ophthalmic solution
18	Completed	Long Term Administration Stu	udy of OPC-12759 Ophthalmic
	no results	<u>Suspension</u>	
	published	Condition:	Dry Eye Syndromes
	yet	Intervention:	Drug: OPC-12759 Ophthalmic s
19	Completed	Late Phase 2 Study of OPC-12	2759 Ophthalmic Suspension
	no results	Condition:	Dry Eye Syndromes
	published	Intervention:	Drug: OPC-12759
	yet		
20	Completed	Dose-Response Study of OPC	C-12759 Ophthalmic
	no results published	Suspension	
	yet	Condition:	Dry Eye Syndromes
		Intervention:	Drug: OPC-12759
21	Completed	Safety Study of OPC-12759 Op	
	no results published	Condition:	Dry Eye Syndromes
	yet	Interventions:	Drug: OPC-12759 Ophthalmic s
	_		2759 Ophthalmic suspension
22	Completed	Clinical Pharmacological Stud	
	no results published	Product in Subjects With Sho Time	rtened Tear Film Break Up
	yet	Condition:	Dry Eye Disease
	,	Interventions:	Drug: Hydroxypropyl Guar Gala
			% sodium hyaluronate ophthaln
23	Completed	Exploratory Study for Dry Mor	uth in Patients With Sjögren's
	no results	Syndrome	
	published	Conditions:	Xerostomia; Sjogren's Syndro
	yet	Intervention:	Drug: Rebamipide
24	Completed	Safety and Efficacy Study of N	• ·
	no results	With Refresh Tears® in Patier	
	published	Condition:	Dry Eye Syndromes
	yet	Interventions:	Drug: Formulation 1: Eye Drops
	· · · · · · · · · · · · · · · · · · ·		
			Platform (EDNP) -

			Drug: carboxymethylcellulose s
			based artificial tear
25	Completed	Study of DE-089 Ophthalmic S	Solution in Patients With Dry
	no results	<u>Eye</u>	
	published	Condition:	Dry Eye
	yet	Interventions:	Drug: diquafosol ophthalmic sol
			: 0.1% sodium hyaluronate oph
			solution.
26	Completed	Moisture Chamber Glasses fo	r Dry Eye in Asian Population
	no results	Condition:	Dry Eye
	published	Intervention:	Device: 7eye(Panoptx)™ mois
	yet		asses
27	Completed	To Evaluate the Physical Effect	cts of Systane(R) Lubricant
	no results	Eye Drops Compared to Refre	esh Tears(R) Lubricant Eye
	published	Drops	
	yet	Condition:	Dry Eye
		Interventions:	Other: Systane; Other: Refree
28	Completed	The Effect of Punctal Plugs or	n Tear Volume and Osmolality
	no results	Condition:	Dry Eye Syndromes
	published yet	Intervention:	Device: Temporary Collagen In:
29	Completed	Use of Autologous Serum Eye	e-drops as Tears in Patients
	no results	With Recalcitrant Dry Eye	
	published	Condition:	Xerophthalmia
	yet	Intervention:	Drug: Autologous serum eyedro
30	Completed	Sodium Hyaluronate and Wav	efront Aberrations in Dry
	no results	<u>Eyes</u>	
	published	Condition:	Dry Eye
	yet	Interventions:	Drug: 0.18% sodium hyaluronat
			chloride solution
31	Completed	Efficacy of 0.05% Cyclosporin	Eye Drop in Stevens
	no results	Johnson Syndrome Patient W	/ith Chronic Dry Eye
	published	Condition:	Stevens-Johnson Syndrome
	yet	Intervention:	Drug: 0.05%cyclosporin eye dro
32	Completed	Comparative Study of 0.5% Ca	
	no results	0.005% Stabilized Oxychloroc	
	published	0.5% Carboxymethylcellulose	
	yet	Condition:	Dry Eye Syndromes

		Intervention:	Drug: 0.5% carboxymethylcellulos
			(CMC) with purite and CMC alone
33	Enrolling by	TearLab Core Validation Stud	Y
	invitation	Condition:	Dry Eye Disease
		Intervention:	
34	Enrolling by	Confocal Microscopy and Lac	rimal Gland in Sjogren's
	invitation	Syndrome	
		Condition:	Primary Sjogren's Syndrome
		Intervention:	
35	Active, not	A Phase II Study of KCT-0809	in Patients With Dry Eye
	recruiting	Syndrome	
		Condition:	Dry Eye Syndromes
		Interventions:	Drug: KCT-0809; Drug: Place
36	Recruiting	The Effect of Hinge Location	on Corneal Sensation and Dry
		Eye After LASIK: A Systemati	c Review and Meta-analysis
		Condition:	Dry Eye
		Intervention:	
37	Recruiting	Efficacy of Nonsteroidal Anti-	inflammatory Drugs in
		Treatment of Moderate and Se	evere Dry Eye Disease
		Condition:	Moderate to Severe Dry Eye Di
		Interventions:	Drug: nonsteroid anti-inflammat
			plus artificial tear substitute;
			corticosteroids plus artificial tea
			substitute; Drug: artificial tear
38	Recruiting	Phase II Study of DA-6034 Eye	e Drops in Dry Eye Syndrome
		Condition:	Dry Eye Syndrome
		Interventions:	Drug: DA-6034 3%; Drug: DA
			g: DA-6034 Placebo
39	Recruiting		nt of Dry Eyes in Patients With
		Primary Sjögren's Syndrome	
		Conditions:	Autoimmune Diseases; Sjogr Dry Eye
		Interventions:	Drug: Hydroxychloroquine; D
40	Recruiting	Using Impression Cytology to	Observe the Cytological
			ells in Various Ocular Surface
		<u>Disorders</u>	
		Conditions:	Pterygium; Dry Eye; Tumor
		Intervention:	

41	Recruiting	A Parallel Group Phase II Stud	ly of KCT-0809 in Patients	
	reorating	With Dry Eye Syndromes		
			Dry Eye Syndromes	
		Interventions:	Drug: KCT-0809; Drug: Place	
42	Recruiting	Confirmatory Study of OPC-12	<u> </u>	
	recording	Condition:	Dry Eye	
		Interventions:	Drug: OPC-12759; Drug: Pla	
43	Recruiting		<u> </u>	
43	Recruiting	Safety and Efficacy of Punctal With Dry Eye	r riug insertion in ratients	
			Dry Eye	
		Intervention:	Device: Punctal Plug	
44	Recruiting	Repeatability and Agreement		
44	Recruiting	Coherence Tomography (AS-0		
			Dry Eye Syndromes	
		Intervention:	Device: EyeGiene	
45	Not yet	A Study to Compare the Safet		
	recruiting	Drop Formulation With OPTIV	E ^{IM} in Subjects With Dry Eye	
		Disease		
			Dry Eye Disease	
		Interventions:	Drug:	
			Carboxymethycellulose	
			Based Eye Drop	
			Formulation A; Drug:	
			Carboxymethylcellulose	
			Based	
			Preservative-Free	
			Lubricant Eye Drops	
46	Unknown [†]	Comparison of Efficacy, Safet		
			Cyclosporine A Emulsion and	
		REFRESH® in Patients With M		
		Condition:	Dry Eye	
		Intervention:	Drug: 0.05% cyclosporin eye dr	
47	Unknown [†]	Corneal Epitheliotropic Factor	rs in Autologous Serum Eye	
		Drops in Nonautoimmune and	Stevens-Johnson Syndrome	
		With Dry Eye		
		Condition:	Stevens-Johnson Syndrome	
		Intervention:		
48	Unknown [†]	The Evaluation of Thiol Redox	Status in Conjunctiva of Dry	

		Eye Patients		
		Condition:	Dry Eye Disease	
		Intervention:		
49	Unknown [†]	Allogeneic Mesenchymal Stem Cells Transplantation for		
		Primary Sjögren's Syndrome (pSS)		
		Conditions:	Sjogren's Syndrome; Mesend	
		ells		
		Intervention: Biological: Allogeneic Mesench		
			Cells (AlloMSC)	

46. Keratoconus

Rank	Status	Study	
1	Completed	A Clinical Study of Keratoconus in Asian Patients and	
	no results	Assessment of Different Topo	graphic Patterns of
	published	Keratoconus in Asian Patients	<u>5</u>
	yet	Condition:	Keratoconus
		Intervention:	
2	Unknown [†]	Intacs for Keratoconus	
		Condition:	Keratoconus
		Intervention:	Device: Intacs intracorneal ring
			insertion for the treatment of
			keratoconus
3	Unknown [†]	Riboflavin-UVA Induced Colla	gen Crosslinking Treatment
		for Corneal Ectasia	
		Condition:	Corneal Ectasia
		Interventions:	Procedure: riboflavin-induced
			collagen cross-linking
			treatment; Device:
			Riboflavin-UVA induced
			collagen cross-linking
			treatment for corneal ectasia

Rank	Status	Study		
1	Completed	Efficacy, Tolerability, and Comfort of 0.3% Hypromellose		
	Has	Eyedrops in Patients Undergo	bing LASIK Surgery	
	Results	Condition:	Dry Eye Syndromes	
	published	Interventions:	Drug: Pre-LASIK 0.3% hypromellos	
	on website		e; Drug: Post-LASIK 0.3% hyprom	
			ellose	
2	Completed	Acupuncture for Dry Eye Synd	drome	
	Has	Condition:	Dry Eye Syndromes	
	Results	Interventions:	Device: Standardized Acupuncture;	
	published		Device: Non-acupuncture point	
	on journals		shallow penetration acupuncture	
3	Completed	Trial to Compare the Efficacy	of Systane Ultra and Refresh Drop	
	Has	in the Treatment of Dry Eye in	Asian Eyes	
	Results	Conditions:	Xerophthalmia; Blepharitis	
	published	Interventions:	Drug: Systane Ultra eyedrops; Dr	
	on website		ug: Refresh eye drops	
4	Completed	A Phase II, Dose Ranging Stud	dy Of CP-690,550 Eye Drops In	
	no results	Patients With Dry Eye Disease	2	
	published	Condition:	Dry Eye Syndromes	
	yet	Interventions:	Drug: CP-690,550 Eye drops; Dru	
			g: CP-690,550 Eye drops-vehicle;	
			Drug: Sodium Hyaluronate	
5	Completed	Acupuncture for Dry Eye		
	no results	Condition:	Dry Eye	
	published	Interventions:	Device: Acupuncture; Drug: Refre	
	yet		sh Plus	
6	Completed		olerance of Preservative Free	
	no results			
	published	Eye Syndrome in Allergic Con		
	yet	Condition:	Allergic Conjunctivitis	
		Interventions:	Drug: NAABAK eyedrops; Drug: S	
	• • • •		aline eyedrops	
7	Completed	Safety and Efficacy Study of New Eye Drop Formulations With		
	no results <u>Refresh Tears® in Patients With Dry Eye Disease</u>			
	published yet	Condition:	Dry Eye Syndromes	
	yeı	Interventions:	Drug: Formulation 1: Eye Drops New Platform (EDNP) -	

47. Lacrimal Apparatus Diseases

Image: Solution based artificial tear Solutibasolution basolution based artificial tear				1; Drug: Formulation 2: EDNP - 2;
8 Completed no results published yet The Safety and Efficacy of Lacrimal Silicone Intubation for the Management of Epiphora 9 Completed no results published yet To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops 10 Completed no results published yet Moisture Chamber Glasses for Dry Eye Intervention: Other: Refresh T ears 10 Completed no results published yet Moisture Chamber Glasses for Dry Eye (Panoptx)™ moisture chamber glasses 11 Completed no results published yet Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 11 Completed no results published yet A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers 12 Completed no results published yet A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers 13 Completed no results published yet Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes Interventions: Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution 14 Completed no results published yet Completed no results Completed no results Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes Drug: 0.9% sodium chloride solution 14 Completed no results published yet Completed no results Completed no results				• • •
no results Management of Epiphora published Condition: Epiphora yet Intervention: Device: Lacrimal Tube 9 Completed To Evaluate the Physical Effects of Systane(R) Lubricant Eye published Drops Compared to Refresh Tears(R) Lubricant Eye Drops published Condition: Dry Eye yet Interventions: Other: Systane; Other: Refresh Tears 10 Completed Moisture Chamber Glasses for Dry Eye in Asian Population no results published Condition: Dry Eye no results Condition: Dry Eye no results Condition: Dry Eye published Syndrome Syndrome vet Completed A Study to Evaluate the Tolerability of Eye Drop DA-6034 in no results Published Condition: Dry Eye Syndrome published Yet Condition: Dry Eye Syndrome interventions: Drug: DA-6034; Drug: Placebo 13 Completed A Study to Evaluate the Tolerability of Eye Drop DA-6034; in Drug: Placebo 14 Completed Sodium Hyaluronate and Wavefron				sodium based artificial tear
published yetCondition:Epiphora9Completed no results published yetTo Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops Ordition:10Completed yetInterventions:Other: Systane; Other: Refresh T ears10Completed no results published yetMoisture Chamber Glasses for Dry Eye in Asian Population Dry Eye10Completed no results yetMoisture Chamber Glasses for Dry Eye in Asian Population Device: 7eye(Panoptx)™ moisture chamber glasses11Completed no results published yetEfficacy and Safety Study of ATs in Patients With Dry Eye Syndrome; Neratoconju nctivitis Sicca12Completed no results published yetA Study to Evaluate the Tolexability of Eye Drop DA-6034 in Healthy Volunteers13Completed yetA Study to Evaluate the Tolexability of Eye Drup DA-6034; Drug: AT03; Drug: AT04;13Completed yetSodium Hyaluronate and Wavefront Aberrations in Dry Eyes Drug: 0.18% sodium hyaluronate; yet14Completed no results published publishedCondition: Drug: 0.18% sodium hyaluronate; Drug: 0.18% sodium chloride solution14Completed no results published publishedCondition: Condition: Dry Eye Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone14Completed no results published publishedCondition: Condition: Dry Eye Syndromes Dry Eye Syndromes Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone	8	-		crimal Silicone Intubation for the
yet Intervention: Device: Lacrimal Tube 9 Completed no results published yet To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops 10 Completed yet Moisture Chamber Glasses for Dry Eye Interventions: Other: Systane; Other: Refresh T ears 10 Completed no results published yet Moisture Chamber Glasses for Dry Eye in Asian Population no results 11 Completed no results Moisture Chamber Glasses for Dry Eye in Asian Population Device: 7eye(Panoptx)™ moisture chamber glasses 11 Completed no results Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 11 Completed no results Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 12 Completed no results A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers 12 Completed no results A Study to Evaluate the Tolerability of Eye Drop DA-6034; Drug: Placebo 13 Completed no results Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes Drug: 0.18% sodium hyaluronate; Drug: 0.18% sodium chloride solution 14 Completed no results Completed Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5%. Carboxymethylcellulose in the Treatment of Dry Eye Stabilized Oxychlorocomplex (PURITE™) Versus 0.5%. Car				
9 Completed no results published To Evaluate the Physical Effects of Systane(R) Lubricant Eye no results 9 Completed no results Drops Compared to Refresh Tears(R) Lubricant Eye Drops Condition: Dry Eye 9 Completed yet Moisture Chamber Glasses for Dry Eye in Asian Population no results Other: Systane; Other: Refresh T ears 10 Completed no results Moisture Chamber Glasses for Dry Eye in Asian Population no results Device: 7eye(Panoptx)™ moisture chamber glasses 11 Completed no results Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome Syndrome 9 Vet Syndrome Interventions: Dry Eye Syndromes; Keratoconju netivitis Sicca 11 Completed no results A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers 9 Vet Interventions: Dry Eye Syndrome yet Drug: OA33; Drug: Placebo 13 Completed no results Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes no results Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution 14 Completed no results Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5%. Carboxymethylcellulose in the Treatment of Dry Eye yet Condition: Dry Eye Syndromes Intervention: Drug: 0.5% carboxymethylcellulose		-	Condition:	Epiphora
no results published yetDrops Compared to Refresh Tears(R) Lubricant Eye Drops Orndition: Dry Eye Interventions: Other: Systane; Other: Refresh T ears10Completed no results published yetMoisture Chamber Glasses for Dry Eye in Asian Population Dry Eye Intervention: Dry Eye Intervention: Device: 7eye(Panoptx) TM moisture chamber glasses11Completed no results published yetEfficacy and Safety Study of ATs in Patients With Dry Eye Syndrome11Completed no results published yetEfficacy and Safety Study of ATs in Patients With Dry Eye Syndrome12Completed no results published yetA Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers Drug: Dry Eye Syndrome AT03; Drug: AT0412Completed no results published yetA Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers13Completed no results published yetSodium Hyaluronate and Wavefront Aberrations in Dry Eyes Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution14Completed no results published yetCompleted of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE TM) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Stabilized Oxychlorocomplex (PURITE TM) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Stabilized Oxychlorocomplex (PURITE TM) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Stabilized Oxychlorocomplex (PURITE TM) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Stabilized Oxychlorocomplex (PURITE TM) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye		yet	Intervention:	Device: Lacrimal Tube
published yetCondition:Dry Eye10Completed no resultsMoisture Chamber Glasses for Dry Eye in Asian Population or results10Completed yetMoisture Chamber Glasses for Dry Eye in Asian Population Device: 7eye(Panoptx)™ moisture chamber glasses11Completed yetEfficacy and Safety Study of ATs in Patients With Dry Eye Syndrome11Completed no results publishedEfficacy and Safety Study of ATs in Patients With Dry Eye Syndrome12Completed no results publishedA Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers12Completed no results publishedA Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers13Completed no results 	9	Completed		
yet Interventions: Other: Systane; Other: Refresh T 10 Completed no results yet Moisture Chamber Glasses for Dry Eye in Asian Population 11 Completed yet Intervention: Device: 7eye(Panoptx)™ moisture chamber glasses 11 Completed no results published Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 11 Completed no results Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 11 Completed no results Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 11 Completed no results A Study to Evaluate the Tolerability of Eye Syndromes; Keratoconju nctivitis Sicca 12 Completed no results A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers 12 Completed yet Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes Interventions: 13 Completed no results published yet Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes Stabilized Oxychlorccomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Stabilized Oxychlorccomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye 14 Completed yet Condition: Dry Eye Syndromes Intervention: Dry Eye Syndromes 14 Completed yet Study of DE-089 Ophthalmic Solution in Patients With Dry Eye				
10 Completed no results yet Moisture Chamber Glasses for Dry Eye in Asian Population Condition: Dry Eye Intervention: Device: 7eye(Panoptx)™ moisture chamber glasses 11 Completed yet Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 11 Completed no results published yet Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 11 Completed no results Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 12 Completed no results A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers 13 Completed no results A Study to Evaluate and Wavefront Aberrations in Dry Eyes no results 14 Completed no results Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes Interventions: Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution 14 Completed no results Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5%. Carboxymethylcellulose in the Treatment of Dry Eye Yet 14 Completed yet Comparative Study of 0.5% Carboxymethylcellulose (CMC) with purite and CMC alone 15 Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye		_	Condition:	Dry Eye
10 Completed no results published yet Moisture Chamber Glasses for Dry Eye in Asian Population 11 Completed no results published yet Intervention: Device: 7eye(Panoptx)™ moisture chamber glasses 11 Completed no results published yet Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 12 Completed no results published yet A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers 13 Completed no results published yet A Study to Evaluate and Wavefront Aberrations in Dry Eyes Interventions: Dry Eye Syndrome Dry Eye Syndrome 14 Completed no results published yet Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes Interventions: Dry Eye Dry Eye 14 Completed no results published yet Completed Condition: Dry Eye Dry Eye 14 Completed no results published yet Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Intervention: Dry Eye Syndromes Dry Eye Syndromes Intervention: 14 Completed no results published yet Comparative Study of 0.5% Carboxymethylcellulose (CMC) with purite and CMC alone 15 Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye		yet	Interventions:	Other: Systane; Other: Refresh T
no results published yet Condition: Dry Eye Device: 7eye(Panoptx)™ moisture chamber glasses 11 Completed no results published yet Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 11 Completed no results Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 12 Completed no results Conditions: Dry Eye Syndromes; Keratoconju nctivitis Sicca 12 Completed no results A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers 13 Completed no results Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes Interventions: Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution 14 Completed no results published yet Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye yet 14 Completed yet Condition: Dry Eye Syndromes Intervention: 14 Completed yet Condition: Dry Eye Syndromes Intervention: 14 Completed yet Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye (CMC) with purite and CMC alone 15 Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye				
published yet Intervention: Dry Eye 11 Completed no results Efficacy and Safety Study of ATs in Patients With Dry Eye published yet Syndrome published yet Conditions: Dry Eye Syndromes; Keratoconju no results Efficacy and Safety Study of ATs in Patients With Dry Eye published yet Conditions: Dry Eye Syndromes; Keratoconju nctivitis Sicca Interventions: Drug: AT01; 12 Completed no results A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers published yet A Study to Evaluate and Wavefront Aberrations in Dry Eyes 13 Completed no results Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes published yet Interventions: Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution 14 Completed no results published yet Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE TM) Versus 0.5%. Carboxymethylcellulose in the Treatment of Dry Eye (CMC) with purite and CMC alone 14 Completed no results Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone 15 Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye	10	_		
yet chamber glasses 11 Completed no results published yet Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 11 Completed no results Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 12 Completed no results Conditions: Dry Eye Syndromes; 12 Completed no results A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers 13 Completed no results A Study to Evaluate and Wavefront Aberrations in Dry Eyes published 14 Completed no results Sodium Hyaluronate and Wavefront Aberrations in Dry Eye published 14 Completed no results Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE TM) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye yet 14 Completed yet Study of DE-089 Ophthalmic Solution in Patients With Dry Eye			Condition:	Dry Eye
11 Completed no results published yet Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 11 Completed no results Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome 12 Completed no results Conditions: Interventions: Dry Eye Syndromes; Keratoconju nctivitis Sicca 12 Completed no results A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers 13 Completed no results Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes published Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution 14 Completed no results Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye yet 14 Completed no results Comparative Study of 0.5% Carboxymethylcellulose (CMC) with purite and CMC alone 15 Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye		-	Intervention:	
no results published yetSyndrome Conditions:Dry Eye Syndromes; Keratoconju nctivitis Sicca12Completed no resultsA Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers12Completed yetA Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers13Completed yetSodium Hyaluronate and Wavefront Aberrations in Dry Eyes Drug: 0.18% sodium hyaluronate; prug: 0.9% sodium chloride solution14Completed yetComparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITETM) Versus 0.5%. Carboxymethylcellulose in the Treatment of Dry Eye yet15CompletedStudy of DE-089 Ophthalmic Solution in Patients With Dry Eye		-		
published yetConditions:Dry Eye Syndromes;Keratoconju nctivitis Sicca12Completed no results publishedA Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers12Completed yetA Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers13Completed no results publishedSodium Hyaluronate and Wavefront Aberrations in Dry Eyes Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution14Completed no results publishedComparative Study of 0.5% Carboxymethylcellulose with 0.005% Stabilized Oxychlorocomplex (PURITETM) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye yet14Completed yetCondition:Dry Eye Syndromes Drug: 0.9% sodium chloride solution14Completed yetComparative Study of 0.5% Carboxymethylcellulose Stabilized Oxychlorocomplex (PURITETM) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye yet15CompletedStudy of DE-089 Ophthalmic Sulution in Patients With Dry Eye	11	_		ATs in Patients With Dry Eye
yet nctivitis Sicca Interventions: Drug: AT01; Drug: AT02; Drug: AT03; Drug: AT04 12 Completed no results published A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers 13 Completed no results published Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes 13 Completed no results published Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes 14 Completed no results published yet Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose 14 Completed yet Condition: Dry Eye Syndromes 14 Completed no results published yet Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose 14 Completed yet Condition: Dry Eye Syndromes 15 Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye				
Interventions:Drug: AT01; Drug: AT02; Drug: AT0412Completed no results published yetA Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers Drug: DA-6034; Drug: DA-6034; Drug: Placebo13Completed no results published yetSodium Hyaluronate and Wavefront Aberrations in Dry Eyes Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution14Completed no results published yetComparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Intervention:14Completed yetComparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Intervention:15Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye		-	Conditions:	
AT03; Drug: AT0412Completed no results publishedA Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers13Completed yetCondition: Dry Eye Syndrome Drug: DA-6034; Drug: Placebo13Completed no results published yetSodium Hyaluronate and Wavefront Aberrations in Dry Eyes Drug: 0.48% sodium hyaluronate; Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution14Completed no results published uo results published yetComparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Urg: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone14Completed yetCondition: Dry Eye Syndromes Lintervention: Dry Eye Syndromes Lintervention: Dry Eye Syndromes15Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye		yet		
12 Completed no results published yet A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers 13 Completed no results published yet Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes 13 Completed no results published yet Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes 14 Completed no results published yet Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye 14 Completed yet Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye 14 Completed yet Condition: Dry Eye Syndromes 14 Completed no results published yet Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye (Condition: 15 Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye			Interventions:	
no results published yetHealthy Volunteers Condition:Dry Eye Syndrome Drug: DA-6034;Healthy Volunteers Drug: Placebo13Completed no resultsSodium Hyaluronate and Wavefront Aberrations in Dry Eyes Drug: 0.18% sodium hyaluronate; Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution14Completed no resultsComparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITETM) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Untervention:14Completed yetCondition:Dry Eye Syndromes Drug: 0.9% sodium chloride solution14Completed yetComparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITETM) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye yet15CompletedStudy of DE-089 Ophthalmic Solution in Patients With Dry Eye	12	Completed	A Study to Evaluate the Toler:	· 3
published yetCondition:Dry Eye Syndrome13Completed no resultsSodium Hyaluronate and Wavefront Aberrations in Dry Eyes13Completed no resultsSodium Hyaluronate and Wavefront Aberrations in Dry Eyespublished yetInterventions:Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution14Completed no results published yetComparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye14Completed yetCondition:Drug: 0.5% carboxymethylcellulose14Completed yetCondition:Drug: 0.5% carboxymethylcellulose14Completed yetCondition:Dry Eye Syndromes15CompletedStudy of DE-089 Ophthalmic Solution in Patients With Dry Eye	12	_		ability of Lye Drop DA-0034 III
yetInterventions:Drug: DA-6034;Drug: Placebo13Completed no results published yetSodium Hyaluronate and Wavefront Aberrations in Dry Eyes Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution14Completed no results published yetComparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITETM) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Urig: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone15Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye				Dry Eve Syndrome
13 Completed no results Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes 13 Completed no results Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes 14 Completed no results Interventions: Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution 14 Completed no results Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye 15 Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye		yet		
no results published yetCondition:Dry Eye14Completed no results published yetComparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Condition:Drug: 0.5% carboxymethylcellulose Drug: 0.5% carboxymethylcellulose Dry Eye Syndromes Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone15CompletedStudy of DE-089 Ophthalmic Solution in Patients With Dry Eye	13	Completed		.
published yetInterventions:Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution14Completed no results published yetComparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Condition:14Completed no results published yetComparative Study of 0.5% Carboxymethylcellulose Carboxymethylcellulose in the Treatment of Dry Eye Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone15Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye		-		
yetDrug: 0.9% sodium chloride solution14Completed no results published yetComparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Condition: Dry Eye Syndromes Intervention: Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone15Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye		published		
14 Completed no results published yet Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Condition: Dry Eye Syndromes Intervention: Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone 15 Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye		yet		o
no results Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% published Carboxymethylcellulose in the Treatment of Dry Eye yet Condition: Dry Eye Syndromes Intervention: Drug: 0.5% carboxymethylcellulose 15 Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye	14	Completed	Comparative Study of 0.5% Ca	Ŭ
published yet Carboxymethylcellulose in the Treatment of Dry Eye Condition: Dry Eye Syndromes Intervention: Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone 15 Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye		-		
Intervention: Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone 15 Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye		published		
15 Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye		yet	Condition:	Dry Eye Syndromes
15 Completed Study of DE-089 Ophthalmic Solution in Patients With Dry Eye			Intervention:	Drug: 0.5% carboxymethylcellulose
				(CMC) with purite and CMC alone
	15	Completed	Study of DE-089 Ophthalmic S	Solution in Patients With Dry Eye
Condition: Dry Eye		no results	Condition:	Dry Eye

	published	Interventions:	Drug: diquafosol ophthalmic solution	
	yet		; Drug: 0.1% sodium hyaluronate ophthalmic solution.	
16	Completed	Comparison of Autologous Serum and Umbilical Cord Serum		
	no results	Eyedrops for Dry Eye Syndror	<u>me</u>	
	published	Condition:	Dry Eye Syndrome	
	yet	Interventions:	Drug: Umbilical cord serum eyedrop	
			s; Drug: Autologous serum eyedro	
			ps	
17	Completed	CXCL9, CXCL10, CXCL11, and	<u>d CXCR3 in Dry Eye Syndrome</u>	
	no results	Condition:	Dry Eye Syndrome	
	published yet	Intervention:		
18	Completed	A Phase II, Dose Ranging Stud	dy Of CP-690,550 Eye Drops In	
	no results	Patients With Dry Eye Disease	2	
	published	Condition:	Dry Eye Syndromes	
	yet	Interventions:	Drug: CP-690,550 Eye drops; Dru	
			g: CP-690,550 Eye drops-vehicle;	
			Drug: Sodium Hyaluronate	
19	Completed	Late Phase 2 Study of OPC-12	2759 Ophthalmic Suspension	
	no results	Condition:	Dry Eye Syndromes	
	published yet	Intervention:	Drug: OPC-12759	
20	Completed	Long Term Administration Stu	udy of OPC-12759 Ophthalmic	
	no results	Suspension		
	published	Condition:	Dry Eye Syndromes	
	yet	Intervention:	Drug: OPC-12759 Ophthalmic susp ension	
21	Completed	Phase 2 Study of KLS-0611 in	Patients With Dry Eye Syndromes	
	no results	Condition:	Dry Eye Syndromes	
	published	Interventions:	Drug: Placebo; Drug: KLS-0611	
	yet			
22	Completed	Confirmatory Study of OPC-12	2759 Ophthalmic Suspension	
	no results	Condition:	Dry Eye Syndromes	
	published	Interventions:	Drug: OPC-12759 Ophthalmic susp	
	yet		ension; Drug: Hyalein Mini Ophth almic solution	
23	Completed	Late Phase II Confirmatory Stu	udy of DE-089 Ophthalmic Solution	
	no results	in Patients With Dry Eye		

	published	Condition:	
	yet		Dry Eye
	yer	Interventions:	Drug: DE-089 ophthalmic solution;
			Drug: Placebo ophthalmic solution
24	Completed	A Study of KCT-0809 in Patien	
	no results	Condition:	Dry Eye Syndromes
	published yet	Interventions:	Drug: KCT-0809; Drug: Placebo
25	Completed	Exploratory Study for Dry Mou	uth in Patients With Sjögren's
	no results	<u>Syndrome</u>	
	published	Conditions:	Xerostomia; Sjogren's Syndrome
	yet	Intervention:	Drug: Rebamipide
26	Completed	Dose-Response Study of OPC	-12759 Ophthalmic Suspension
	no results	Condition:	Dry Eye Syndromes
	published	Intervention:	Drug: OPC-12759
	yet		
27	Completed	Phase III Confirmatory Study of	of DE-089 Ophthalmic Solution in
	no results	Patients With Dry Eye	
	published	Condition:	Dry Eye
	yet	Interventions:	Drug: 3% DE-089 ophthalmic solutio
			n; Drug: 0.1% sodium hyaluronate
			ophthalmic solution
28	Completed	Safety Study of OPC-12759 Op	ohthalmic Solution
	no results	Condition:	Dry Eye Syndromes
	published	Interventions:	Drug: OPC-12759 Ophthalmic soluti
	yet		on; Drug: OPC-12759 Ophthalmic
			suspension
29	Completed	The Effect of Punctal Plugs or	n Tear Volume and Osmolality
	no results	Condition:	Dry Eye Syndromes
	published yet	Intervention:	Device: Temporary Collagen Inserts
30	Completed	Study of DE-089 Ophthalmic S	Solution in Patients With Dry Eye
	no results	Condition:	Dry Eye
	published	Interventions:	Drug: diquafosol ophthalmic solution
	yet		; Drug: 0.1% sodium hyaluronate
			ophthalmic solution.
31	Completed	Use of Autologous Serum Eve	e-drops as Tears in Patients With
	no results	Recalcitrant Dry Eye	
	published	Condition:	Xerophthalmia
	yet	Intervention:	Drug: Autologous serum eyedrops

32	Completed	The Microbiological Spectrum	in Acute Dacryocystitis
	no results	Condition:	Dacryocystitis
	published	Intervention:	
	yet		
33	Enrolling	Confocal Microscopy and Lac	rimal Gland in Sjogren's Syndrome
	by	Condition:	Primary Sjogren's Syndrome
	invitation	Intervention:	
34	Enrolling	TearLab Core Validation Stud	Y
	by	Condition:	Dry Eye Disease
	invitation	Intervention:	
35	Active, not	A Phase II Study of KCT-0809	in Patients With Dry Eye Syndrome
	recruiting	Condition:	Dry Eye Syndromes
		Interventions:	
36	Recruiting	Repeatability and Agreement	
	j	Coherence Tomography (AS-0	
		Condition:	Dry Eye Syndromes
		Intervention:	
37	Recruiting		inflammatory Drugs in Treatment
	j	of Moderate and Severe Dry E	
		Condition:	Moderate to Severe Dry Eye Diseas
			е
		Interventions:	Drug: nonsteroid anti-inflammatory
			drops plus artificial tear
			substitute; Drug: corticosteroids
			plus artificial tear
			substitute; Drug: artificial tear sub
			stitute
38	Recruiting		Plug Insertion in Patients With Dry
		Eye	
		Condition:	Dry Eye
		Intervention:	Device: Punctal Plug
39	Recruiting		nt of Dry Eyes in Patients With
		Primary Sjögren's Syndrome	
		Conditions:	Autoimmune Diseases; Sjogren's
		_	Syndrome; Dry Eye
		Interventions:	Drug: Hydroxychloroquine; Drug:
	D		Placebo
40	Recruiting	The Effect of Hinge Location of	on Corneal Sensation and Dry Eye

		After LASIK: A Systematic Review and Meta-analysis		
		Condition:	Dry Eye	
		Intervention:		
41	Recruiting	A Parallel Group Phase II Stud	ly of KCT-0809 in Patients With Dry	
		Eye Syndromes		
		Condition:	Dry Eye Syndromes	
		Interventions:	Drug: KCT-0809; Drug: Placebo	
42	Recruiting	Confirmatory Study of OPC-12	2759 Ophthalmic Solution	
		Condition:	Dry Eye	
		Interventions:	Drug: OPC-12759; Drug: Placebo	
43	Recruiting	Phase II Study of DA-6034 Eye	e Drops in Dry Eye Syndrome	
		Condition:	Dry Eye Syndrome	
		Interventions:	Drug: DA-6034 3%; Drug: DA-6034	
44	Not yet	A Study to Compare the Safet	y and Efficacy of A New Eye Drop	
	recruiting	Formulation With OPTIVE™ in	Subjects With Dry Eye Disease	
		Condition:	Dry Eye Disease	
		Interventions:	Drug: Carboxymethycellulose Based	
			Eye Drop Formulation A; Drug:	
			Carboxymethylcellulose Based	
			Preservative-Free Lubricant Eye	
45	Unknown [†]	Allogeneic Mesenchymal Sten	Drops n Cells Transplantation for Primary	
	Onknown	Sjögren's Syndrome (pSS)	in ochs fransplantation för i finnary	
		Conditions:	Sjogren's Syndrome; Mesenchym	
			al Stem Cells	
		Intervention:	Biological: Allogeneic Mesenchymal	
			Stem Cells (AlloMSC)	
46	Unknown [†]	The Evaluation of Thiol Redox	Status in Conjunctiva of Dry Eye	
		Patients		
		Condition:	Dry Eye Disease	
		Intervention:		
47	Unknown [†]	Comparison of Efficacy, Safet	y and Anti-Inflammatory Effect	
		Between Topical 0.05%Cyclos		
		REFRESH® in Patients With N		
		Condition:	Dry Eye	
	··· · ·	Intervention:	Drug: 0.05% cyclosporin eye drop	
48	Unknown †		rs in Autologous Serum Eye Drops	
		in Nonautoimmune and Steve	ns-Johnson Syndrome With Dry	

	Eye	
	Condition:	Stevens-Johnson Syndrome
	Intervention:	

48. Lens Diseases

Rank	Status	Study
1	Completed	Guangdong Uptake of Surgery Trial
	Has Results	Condition: Cataract
	published	Intervention: Behavioral: Video and counseling for
	in journals	cataract patients
2	Completed	Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in
	Has Results	India
	published	Conditions: Glaucoma; Cataract
	in journals	Intervention: Device: OculusGen Biodegradable
		Collagen Matrix Implant
3	Completed	Study of Phacodepth Required for Safe and Effective Chop During
	Has Results	Phacoemulsification for Cataract.
	published	Condition: Cataract
	on website	Intervention:
4	Completed	Effect of Phacoemulsification on Ocular Blood Flow in Human
	no results	Conditions: Cataract; Hypertension; Diabetes
	published	Intervention:
	yet	
5	Completed	Effect of Mobile Communication on Childhood Cataract Follow-up
	no results published	Adherence
	yet	Condition: Cataract
	-	Intervention: Other: Mobile short message service
6	Completed	Outcomes of 3 Incision-size-dependent Phacoemulsification Systems
	no results published	Condition: Cataract
	yet	Intervention:
7	Completed	Evaluation of the Rotational Stability of The AcrySof Toric Intraocular
	no results	Lens in the Capsular Bag in High Myopic Subjects
	published	Condition: Cataract
	yet	Intervention: Procedure: Cataract Surgery
8	Completed	Combined Intracameral Lidocaine for Manual Small Incision Cataract
	no results	Surgery Under Topical Anesthesia
	published	Condition: Cataract
	yet	Interventions: Procedure: MSICS under topical
		anesthesia with intracameral
		lidocaine; Procedure: MSICS under
		topical anesthesia with intracameral
		balanced salt solution.
9	Completed	Study of Intracameral Adrenaline for Pupil Dilation Without Topical

	no results	Mydriatics in Refractive Catar	act Surgery
	published	Condition:	Cataract
	yet	Intervention:	Drug: adrenalin
10	Completed	Nepafenac Compared to Place	ebo for Ocular Pain and Inflammation
	no results	Condition:	Cataract
	published	Interventions:	Drug: Nepafenac; Other: Nepafenac
	yet		Vehicle
11	Completed	Comparative Study of Three IC	DL Power Calculation Formulae for Asian
	no results	Eyes Shorter Than 22mm or L	onger Than 25mm
	published	Condition:	Cataract
	yet	Intervention:	Procedure: IOL calculation formula
12	Completed	Comparison of the Quality of	Vision Provided by AMO Tecnis Z9000
	no results		Acrysof Posterior Chamber Intraocular
	published	Lenses	
	yet	Condition:	
		Interventions:	Device: Tecnis Z9000 intraocular lens;
			Device: MA60 intraocular lens
13	Completed		ntraocular Pressure Reduction Before
	no results published	Phacoemulsification Condition:	Cataract
	yet	Intervention:	
14	-		Procedure: Honan balloon application
14	Completed no results	Effect on Wound Healing of Vi Condition:	Cataract Extraction
	published	Interventions:	Drug: Moxifloxacin 0.5% ophthalmic
	yet	interventions:	solution (Vigamox); Drug:
			Levofloxacin 0.5% ophthalmic
			solution (Cravit)
15	Completed	The Effect of a Blue Light Filte	ering IOL
	no results	Conditions:	to Compare the Effect of Two Types o
	published		f IOLs; on the Incidence of Cystoid
	yet		Macular Edema; After Cataract Sur
			gery
		Intervention:	Procedure: intraocular lens implantati
			on
16	Completed		ess of DYME as an Agent for Selective
	no results	Staining of the Anterior Capsu	
	published	Condition:	Mature Cataracts
	yet	Intervention:	Drug: DYME

17	Completed	DY002: Safety and Effectiveness of DYME as an Agent for Selective	
	no results	Staining of the Anterior Capsule During Cataract Surgery	
	published	Condition:	Mature Cataracts
	yet	Intervention:	Drug: DYME
18	Completed	AquaLase Capsule Wash for Pediatric Eyes	
	no results	Conditions:	Cataract; Pediatric Cataract
	published yet	Intervention:	
19	Completed	Clinical Evaluation of a New Cartridge for the Implantation of Foldable	
	no results	Intraocular Lenses	
	published	Condition:	Cataract
	yet	Intervention:	Procedure: cartridge
20	Completed	Posterior Capsule Opacification	on (PCO) With Single Piece Hydrophobic
	no results Versus Hydrophillic Intraocular Lens (IOL)		ar Lens (IOL)
	published	Condition:	Posterior Capsule Opacification
	yet	Intervention:	Procedure: Phacoemulsification
21	Completed	Outcome Following Phacoemulsification Versus Small Incision	
	no results	Cataract Surgery (SICS)	
	published	Conditions:	Visual Outcomes; Quality of Life
	yet	Interventions:	Procedure: phacoemulsification and SI
			CS; Procedure: manual small incisio
			n surgery; Procedure: phacoemulsific
			ation
22	Completed	Three Intraocular Lenses Designed to Improve Distance, Intermediate	
	no results and Near Vision Following Lens Extraction		
	published yet	Condition:	Cataract
	yet	Interventions:	Device: Crystalens AO; Device: ReS
			TOR 3.0; Device: AMO Tecnis Multif
	Completed	ocal	
23	Completed no results	Condition Custoid Magular Edgma Following Cata	
	published	Condition:	Cystoid Macular Edema Following Cata ract Surgery
	yet	Intervention	• •
		Intervention:	Procedure: microcoaxial phacoemulsifi cation
24	Completed	Aphakia Versus Pseudophakia in Children Under 2 Years Undergoing	
	no results	Bilateral Congenital Cataract Surgery	
	published	Condition:	Congenital Cataract
	yet	Interventions:	Device: Intraocular Lens (Acrysof IOL);

			Device: No IOL	
25	Completed	A Single Centre Study to Com	pare the Efficacy and Safety of	
	no results	Femtosecond Laser-Assisted Versus Manual Cataract Surgery		
	published	Condition:	Cataract	
	yet	Interventions:	Procedure: Lens Fragmentation by	
			means of a	
			femtosecondlaser; Procedure: Manu	
			al Phacoemulsification	
26	Completed	Prospective Study of Cionni R	ting and In-the-bag IOL Implantation for	
	no results	Subluxated Lenses		
	published	Condition:	Lens Subluxation	
	yet	Intervention:	Device: Cionni Modified Capsule Tensi	
			on Ring	
27	Completed	Aurolab Hydrophobic Foldabl	e Intraocular Lens Study	
	no results	Condition:	Cataract	
	published	Intervention:	Device: Intraocular Lens	
	yet			
28	Completed		atory Effect of Low-Molecular Weight	
	no results	Heparin in Pediatric Cataract	Surgery	
	published	Condition:	Inflammation	
	yet	Interventions:	Drug: Enoxaparin; Drug: Balanced S	
			alt Solution	
29	Completed	The Role of Capsular Tension	Ring (CTR) in Anterior Capsular	
	no results	Contraction		
	published	Conditions:	Retinitis Pigmentosa; Cataract	
	yet	Intervention:	Procedure: IOL surgery	
30	Completed	Intraoperative and Postoperat	ive Outcomes of Three Ophthalmic	
	no results	Viscosurgical Devices During	Phacoemulsification	
	published	Condition:	Intraoperative Performance and	
	yet		Postoperative Outcomes Following Catarac	
			Surgery	
		Intervention:	Procedure: Microcoaxial Phacoemulsification	
31	Completed	Outcomes of Phacoemulsifica	tion With Torsional Ultrasound	
	no results	Condition:	Cataract	
	published	Interventions:	Procedure: Torsional ultrasound (INFINITI,	
	yet		Alcon, USA); Procedure: Longitudinal U/	
			(Infiniti system, Alcon, USA); Procedure:	
			Longitudinal U/S (LEGACY 20000, Alcon,	

			USA)
32	Completed	Posterior Capsule Opacification	on (PCO) With AcrySof Single-Piece IOL
	no results	Condition:	Posterior Capsule Opacification
	published	Intervention:	Procedure: Phaco
	yet		
33	Completed	Posterior Capsule Opacification Study	
	no results	Condition:	Cataract
	published	Interventions:	Device: Square edge PMMA IOL; Device
	yet		L; Device: Acrysof IOL; evice: square E
			ce: Square Edge PMMA IOL
34	Completed	Posterior Assisted Levitation	
	no results	Condition:	Cataract
	published yet	Intervention:	
35	Terminated	Visual Function After Implanta	ation of AcrySof® Toric Lens
		Condition:	Cataract
		Intervention:	Device: AcrySof Toric In
			traocular Lens
36	Enrolling	Antioxidants for Prevention of	f Cataracts Follow-up Study
	by	Condition:	Effect of Antioxidants on Occurrence of Ca
	invitation		taracts
		Intervention:	
37	Enrolling	The Effect of Cataract Extract	ion on the Contractility of Ciliary Muscle
	by	Conditions:	Presbyopia; Cataract
	invitation	Intervention:	Other: UBM with pilocarpine in
			presbyopia
38	Active, not	Efficacy of a Capsular Tension	n Ring in Preventing Anterior Capsule
	recruiting	Shrinkage After Cataract Surg	ery in Exfoliation Syndrome
		Condition:	Cataract With Exfoliation Syndrome
		Intervention:	
39	Active, not	Visual Quality Following Asph	neric Intraocular Lens (IOL) Implantation
	recruiting	- a Comparative Clinical Study	L
		Conditions:	Aphakia; Cataract
		Interventions:	Device: Study IOL; Device: Hoya iSe
			rt 751; Device: Negatively aspheric I
			OL .
40	Recruiting		of Families With Congenital or Hereditary
		<u>Cataracts</u>	

		Condition:	Cataract	
		Intervention:		
41	Recruiting	Intraoperative Dexamethason	e Implant Improves Outcome of Cataract	
	_	Surgery With Diabetic Macular Edema		
		Conditions:	Macular Edema, Cystoid; Vision Diso rders; Diabetic Macular Edema; Cy stoid Macular Edema Following Catara ct Surgery; Cataract	
		Interventions:	Drug: Dexamethasone Drug delivery system (Ozurdex); Procedure: Cataract surg ery	
42	Recruiting	A Study to Evaluate New or W	orsening Lens Opacifications in	
		Subjects With Non-metastatic	Prostate Cancer Receiving Denosumab	
		for Bone Loss Due to Androge	en-Deprivation Therapy	
		Conditions:	Cancer; Cataract; Low Bone Miner	
			al Density; Osteopenia; Osteoporo sis; Prostate Cancer	
		Interventions:	Biological: Denosumab; Biological: Pl	
			acebo	
43	Recruiting		of Families With Congenital or Hereditary	
		Cataracts		
		Condition:	Cataract	
		Intervention:		
44	Recruiting		nulsification With 1.8 & 2.2mm Incision:	
		Randomized Clinical Trial		
		Condition:	Cataract	
		Intervention:		
	De la		cation	
45	Recruiting		orsening Lens Opacifications in	
		for Bone Loss Due to Androge	Prostate Cancer Receiving Denosumab	
		Conditions:	Cancer; Cataract; Low Bone Mi	
		Conditions.	neral Density; Osteopenia; Oste	
			oporosis; Prostate Cancer	
		Interventions:	Biological: Denosumab; Biological: Placebo	
46	Recruiting	A Study to Evaluate New or W	orsening Lens Opacifications in	
			Prostate Cancer Receiving Denosumab	

		for Bone Loss Due to Androg	en-Deprivation Therapy
		Conditions:	Cancer; Cataract; Low Bone Miner al Density; Osteopenia; Osteoporo sis; Prostate Cancer
		Interventions:	Biological: Denosumab; Biological: Pl acebo
47	Recruiting	Prospective Evaluation of Circ	cularity and Diameter of Femtosecond
		Laser Versus Manual Anterior	Capsulotomy in Singapore National Eye
		<u>Centre</u>	
		Condition:	Primary Disease: Cataract
		Interventions:	Device: Femtosecond Laser
			(VICTUS™ Femtosecond Laser
			Platform); Device: Manual (CCC
			technique with Utrata forcepes)
48	Recruiting		ricity on Refractive Outcome of
		<u>Pseudophakia</u>	
		Conditions:	Astigmatism; Cataract
		Interventions:	Procedure: phacoemulsification; Device:
			lus,Germany)examination
49	Recruiting	Evaluate Capsular Apposition	to Intraocular Lens
		Conditions:	Capsule Opacification; Tissue Adhesions
			Capsule Present; Opacification of Intrao
		Intervention:	
50	Recruiting		of Families With Congenital or Hereditary
		Cataracts	
		Condition:	Cataract
		Intervention:	
51	Not yet		um Barbarum Supplements on the
	recruiting	-	t in Hong Kong Chinese Population
		Condition:	Lens Opacity
		Interventions:	Dietary Supplement: Starch; Dietary Sup
			itamin C; Dietary Supplement: Lycium Ba
52	Unknown [†]		on Intraocular Lens Power Calculation
		for Subsequent Cataract Oper	
		Conditions:	Pterygium; Cataract; Astigmatism
		Intervention:	Procedure: pterygium excision
53	Unknown [†]		rent Cataract and Primary Pterygium
		Conditions:	Pterygium; Cataract; Lenses, Intraocul

		Interventions:	Procedure: combined pterygium and catarac operation; Procedure: pterygium excision followed by cataract operation	
54	Unknown [†]	Oculusgen (Ologen) Collagen Matrix Implant for		
01		Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study		
		Conditions:	Cataract; Glaucoma	
		Intervention:	Device: ologen™ Collagen Matrix	
			Implant as an aid in	
			phacotrabeculectomy surgery	
55	Unknown [†]	Combined Phacotube vs Phac	cotrabeculectomy: A Randomized	
		Controlled Trial		
		Conditions:	Glaucoma; Cataract	
		Interventions:	Procedure: Glaucoma Implant Surgery; F	
			culectomy; Procedure: phacoemulsificati	
56	Unknown [†]		hthalamic Solution in Patients With Loss	
		of Visual Function Due to Age		
		Condition:	Nuclear Cataract	
		Interventions:	Drug: LiquiTears; Drug	
			: C-KAD Ophthalmic Solu tion	
57	Unknown [†]	Comparison of Manual Super	Small Incision Cataract Surgery and	
57	UIKIIUWII	Phacoemulsification	Smail incision Cataract Surgery and	
		Conditions:	Cataract; Phacoemulsification	
			Procedure: MSSICS; Procedure: Phacoe	
			n	
58	Unknown [†]	Effect of Minimising Ultrasour	nd Power to 1% During Cataract Surgery	
		on Corneal Endothelium.		
		Condition:	Cataract	
		Interventions:	Procedure: one percent ultrasound power i	
			ICS; Procedure: 40 percent ultrasound p	
			in CMICS	
59	Unknown [†]	Comparison of Functional Vis	ion Provided by AMO Tecnis Z9000 and	
		Alcon SA60AT Acrysof		
		Condition:	Cataract	
		Interventions:	Device: AMO Tecnis Z9000; Devic	
			e: Alcon SA60AT Acrysof	

49. Low Tension Glaucoma

Rank	Status	Study	
1	Completed	Systemic Glutathione Level in	Normal Tension Glaucoma
	Has Results	Condition:	Normal Tension Glaucoma
	no results	Intervention:	
	published yet		
2	Recruiting	Analysis of Clinical Profiles of	f Chinese Patients With
		Normal Tension Glaucoma	
		Condition:	Glaucoma
		Intervention:	
3	Recruiting	Efficacy and Safety Study of C	Combigan and 0.5% Timoptic
		in Normal Tension Glaucoma	
		Condition:	Normal Tension Glaucoma
		Interventions:	Drug: Brimonidine/Timolol mix
			g: Timolol
4	Unknown †	Psychopathology of Normal-tension	n Glaucoma in Hong Kong
		Chinese Out-patient	
		Condition:	Glaucoma
		Intervention:	
5	Unknown †	Intraocular Pressure and Ocular Per	fusion Pressure of Cosopt in
		Normal Tension Glaucoma	
		Condition:	Normal Tension Glaucoma
		Interventions:	Drug: dorzolamide/timolol fixe
			atanoprost

50. Macular Degeneration

Rank	Status	Study	
1	Completed	Efficacy and Safety of Vertepo	orfin Added to Ranibizumab in the
	Has Results	Treatment of Symptomatic Ma	acular Polypoidal Choroidal
	published in	<u>Vasculopathy</u>	
	journal	Condition:	Polypoidal Choroidal Vasculopathy
		Interventions:	Drug: Verteporfin Photodynamic Th
			erapy; Drug: Ranibizumab
2	Completed	Efficacy and Safety of Ranibiz	umab (Intravitreal Injections) in
	Has Results	Patients With Visual Impairme	ent Due to Diabetic Macular Edema
	published on	Condition:	Diabetic Macular Edema
	website	Interventions:	Drug: Ranibizumab; Procedure:
			Laser photocoagulation; Drug: S
			ham ranibizumab; Procedure: S
			ham laser photocoagulation
3	Completed	Vascular Endothelial Growth I	Factor (VEGF) Trap-Eye:
	Has Results	Investigation of Efficacy and S	Safety in Wet Age-Related Macular
	published on	Degeneration (AMD)	
	website	Condition:	Macular Degeneration
		Interventions:	Drug: Ranibizumab; Biological:
			Aflibercept Injection (EYLEA, VEGF
			Trap-Eye, BAY86-5321)
4	Completed	Safety and Efficacy of a New	Treatment as Adjunctive Therapy to
	Has Results	Anti-vascular Endothelial Grov	wth Factor (Anti-VEGF) Treatment in
	published on	Patients With Age-Related Ma	cular Degeneration (AMD)
	website	Conditions:	Choroidal Neovascularization; Age-
			Related Maculopathy
		Interventions:	Drug: dexamethasone; Biological: r
			anibizumab; Other: sham
5	Completed	Vascular Endothelial Growth I	Factor (VEGF) Trap-Eye:
	Has Results	Investigation of Efficacy and S	Safety in Central Retinal Vein
	published on	Occlusion (CRVO)	
	website	Condition:	Retinal Vein Occlusion
		Interventions:	Biological: Aflibercept Injection
			(EYLEA, VEGF Trap-Eye,
			BAY86-5321); Other: Sham treat
			ment
6	Completed		Sodium (EYE001) For Wet-Type
	Has Results	Age-Related Macular Degener	ation
	published on	Condition:	Macular Degeneration

	website	Intervention:	Drug: pegaptanib sodium	
7	Terminated	A Study Using Intravitreal Inje	ections of a Small Interfering RNA in	
	Has Results	Patients With Age-Related Macular Degeneration		
	published on	Conditions:	Choroid Neovascularization; Ag	
	website		e-Related Macular Degeneration	
		Interventions:	Drug: AGN 211745; Drug: Ranib	
			izumab 500µg	
8	Completed	Safety and Efficacy of Ranibizumab in Japanese Patients With		
	Has Results	Subfoveal Choroidal Neovasc	ularization Secondary to	
	published in	Age-related Macular Degenera	ation	
	journal	Condition:	Subfoveal Choroidal	
			Neovascularization(CNV)	
			Secondary to Age-related Macular	
			Degeneration (AMD)	
		Intervention:	Drug: Ranibizumab	
9	Completed	Safety and Efficacy of a New	Therapy as Adjunctive Therapy to	
	Has Results	Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects		
	published on	With Wet Age-Related Macular Degeneration (AMD)		
	website	Conditions:	Choroidal Neovascularization; A	
			ge-Related Maculopathy	
		Interventions:	Drug: dexamethasone; Biologica	
			l: ranibizumab	
10	Completed	Changes in Retinal Function After Intravitreal Ranibizumab for		
	Has Results	Age-related Macular Degenera	ation	
	published in	Condition: Age-relate	ed Macular Degeneration	
	journal	Intervention: Drug: ran	ibizumab	
11	Completed	A Study of the Safety and Effic	cacy of a New Treatment for Macular	
	Has Results	Edema Resulting From Retina	Il Vein Occlusion	
	published on	Conditions:	Macular Edema; Retinal Vein Occ	
	website		lusion	
		Interventions:	Drug: Dexamethasone; Drug: Sha	
			m injection	
12	Completed	A Multi-Center Trial To Evalua	te The Safety And Efficacy Of	
	Has Results) Injected Into The Eye Every 6	
	published on	Weeks For Up To 2 Years For Macular Swelling Associated With		
	website	Diabetes, With An Open-Labe		
		Condition:	Macular Edema Associated With Di	
			abetes Mellitus	

		Interventions:	Drug: Standard of Care; Drug: Ma cugen
13	Terminated	Macugen Observational Study	<u>/</u>
	Has Results published on	Conditions:	Vascular Endothelial Growth Factor; Macular Degeneration
	website	Intervention:	Other: No intervention
14	Completed	Bevacizumab for Neovascular	Age-related Macular Degeneration
	no results published	Condition:	Exudative Age-related Macular Dege neration
	yet	Interventions:	Drug: Bevacizumab 1; Drug: Bevaci zumab
15	Completed	Evaluation of Safety and Effic	acy of Once Monthly Ranibizumab
	no results	Injections in Chinese Patients	With Wet Age Related Macular
	published	Degeneration (AMD) Patients	
	yet	Condition:	Age Related Macular Degeneration
		Intervention:	Drug: ranibizumab 0.5 mg
16	Completed	A Study Assessing the Safety	and Efficacy of Multiple Intravitreal
	no results	KH902 in Patients With CNV D	ue to AMD
	published	Condition:	Neovascular Age-related Macular De
	yet		generation
		Intervention:	Biological: Intravitreal injection of KH9 02
17	Completed	A Population-based Study of I	Macular Choroidal
	no results	Neovascularization in a Chine	se Population
	published	Conditions:	Geographic Atrophy; Wet Macular
	yet		Degeneration; Retinal Drusen
		Intervention:	Other: Follow-up observation
18	Completed	Safety and Efficacy of Intravit	
	no results	Implants in Patients With Diab	
	published	Condition:	Diabetic Macular Edema
	yet	Interventions:	Drug: 0.59 mg fluocinolone acetonide
			intravitreal implant; Drug: 2.1 mg fluocinolone acetonide intravitreal
			implant; Procedure: standard of
			care laser photocoagulation
19	Completed	Phase II Open Label Multicent	er Study For Age Related Macular
	no results		04523655 Versus Lucentis In The
	published	Treatment Of Subjects With C	

	yet	Condition:	Age Related Macular Degeneration
		Interventions:	Drug: 0.5 mg ranibizumab; Drug: 3
			mg PF-04523655; Drug: 1 mg PF-0
			4523655
20	Completed	EXTEND III - Efficacy and Safe	ety of Ranibizumab in Patients With
	no results	Subfoveal Choroidal Neovasc	ularization (CNV) Secondary to
	published	Age-related Macular Degenera	ation (AMD)
	yet	Conditions:	ý 5
			e-Related Macular Degeneration
		Intervention:	Drug: ranibizumab
21	Completed	Combination of Ranibizumab	and Verteporfin Therapy in
	no results	Neovascular Age-related Mac	ular Degeneration
	published	Condition:	Neovascular Age-related Macular De
	yet		generation
		Intervention:	Drug: ranibizumab
22	Completed	Safety and Efficacy of Brimon	idine Intravitreal Implant in Patients
	no results	With Geographic Atrophy Due	e to Age-related Macular
	published	Degeneration (AMD)	
	yet	Condition:	Macular Degeneration
		Interventions:	Drug: Brimonidine Tartrate Implant; Drug: Sham
23	Completed	LOC387715/HTRA1 and the Co	ombined Photodynamic Therapy
20	no results	With Intravitreal Bevacizumab	
	published	Vasculopathy	
	yet	Condition:	Age-Related Macular Degeneration
		Intervention:	
24	Completed	Vascular Endothelial Growth	Factor (VEGF) & LOC387715/HTRA1
	no results	Polymorphism in Polypoidal (Choroidal Vasculopathy
	published	Condition:	Age-Related Macular Degeneration
	yet	Intervention:	
25	Completed	LOC387715/HTRA1 Variants in	n Polypoidal Choroidal
	no results	Vasculopathy in a Korean Pop	
	published	Condition:	Age-Related Macular Degeneration
	yet	Intervention:	Genetic: LOC387715/HTRA1 genotyp
			ing
26	Completed	Major and Macular Branched	
	no results	Condition:	Macular Edema
	published	Intervention:	Procedure: intravitreal bevacizumab

	yet		
27	Completed	Changes in Ciliary Body Thick	kness in Patients With Diabetic
	no results	Macular Edema After Vitrector	my
	published	Condition:	Diabetic Macular Edema
	yet	Intervention:	Procedure: Pars Plana Vitrectomy
28	Completed	Sequentially Combined Vitrec	tomy, IVTA and Macular Focal Laser
	no results	Photocoagulation for Diabetic	: Macular Edema
	published	Condition:	Diabetic Macular Edema
	yet	Interventions:	Procedure: vitrectomy; Drug: intravi
			treal triamcinolone acetonide; Proc
			edure: macular focal laser photocoag
			ulation
29	Completed	Reduction in the Occurrence	of Center-Involved Diabetic Macular
	no results	<u>Edema</u>	
	published	Condition:	Diabetic Retinopathy
	yet	Interventions:	Drug: ruboxistaurin; Drug: placebo
30	Completed	Clinical Study Of EYE001 For	Wet-Type AMD (Age-Related
	no results	Macular Degeneration)	
	published	Condition:	Macular Degeneration
	yet	Intervention:	Drug: pegaptanib sodium
31	Completed	Photodynamic Therapy Alone	Versus Combined With Intravitreal
	no results	Bevacizumab for Age-related	Macular Degeneration
	published	Condition:	Age-Related Macular Degeneration
	yet	Intervention:	Drug: Bevacizumab
32	Completed	PDT Study for Exudative AMD	With PCV
	no results	Condition:	Age Related Macular Degeneration
	published	Intervention:	Procedure: Ocular photodynamic
	yet		therapy with verteporfin
33	Completed	A Study of the Safety and Effic	cacy of a New Treatment for Macular
	no results	Edema Resulting From Branc	h Retinal Vein Occlusion
	published	Conditions:	Macular Degeneration; Macular E
	yet		dema; Branch Retinal Vein Occlu
			sion
		Intervention:	Drug: dexamethasone
34	Completed	Anti-VEGFR Vaccine Therapy	in Treating Patients With
	no results	Neovascular Maculopathy	
	published	Conditions:	Neovascular Maculopathy; Age Rel
1	yet		ated Macular Degeneration

		Intervention:	Biological: VEGFR1 and VEGFR2
35	Completed		The Efficacy And Safety Of 0.3 MG
	no results		Injections In Subjects With Diabetic
	published	Macular Edema	
	yet	Conditions:	Macular Edema; Diabetic Mellitus; Retinal Disease
		Interventions:	Drug: pegaptanib sodium; Other: sh am injection
36	Completed	A Study of the Safety and Efficiency	cacy of SK-0503 for Diabetic
	no results	Macular Edema	
	published	Condition:	Diabetic Macular Edema
	yet	Intervention:	Drug: dexamethasone
37	Completed	The Effect of a Blue Light Filte	ering IOL
	no results	Conditions:	to Compare the Effect of Two Types
	published		of IOLs; on the Incidence of Cyst
	yet		oid Macular Edema; After Catarac
			t Surgery
		Intervention:	Procedure: intraocular lens implanta
			tion
38	Completed	Vitrectomy for Branch Retinal	Vein Occlusion
	no results	Condition:	Vitrectomy
	published	Intervention:	Procedure: Vitrectomy w/o ILM
	yet		peeling for macular edema with BRVO
39	Completed	A Study to Compare rhuFab V	2 With Verteporfin Photodynamic in
	no results	Treating Subfoveal Neovascu	lar Macular Degeneration
	published	Condition:	Macular Degeneration
	yet	Intervention:	Drug: rhuFab V2 (ranibizumab)
40	Completed	Safety and Efficacy of Oral PT	K787 in Patients With Subfoveal
	no results	Choroidal Neovascularization	Secondary to Age-Related Macular
	published	Degeneration (AMD)	
	yet	Condition:	Wet Age-Related Macular Degenera
			tion
		Interventions:	Drug: PTK787; Drug: Placebo
41	Completed	An Extension to Study MD710	<u>8240</u>
	no results	Condition:	Macular Degeneration
	published	Intervention:	Drug: Pazopanib
	yet		

42	Completed	Safety and Tolerability of Ran	ibizumab in Patients With Subfoveal
	no results	Choroidal Neovascularization	Secondary to Age-related Macular
	published	Degeneration	
	yet	Conditions:	Subfoveal Choroidal Neovascularizati
			on (CNV); Secondary to
			Age-related Macular Degeneration
			(AMD)
		Intervention:	Drug: ranibizumab
43	Completed	To Evaluate the Pharmacodyn	amics, Safety, and
	no results	Pharmacokinetics of Pazopan	ib Drops in Adult Subjects With
	published	Neovascular AMD	
	yet	Condition:	Macular Degeneration
		Intervention:	Drug: Pazopanib
44	Completed	Study to Investigate the Safet	y and Efficacy of Ranibizumab in
	no results	Patients With Choroidal Neova	ascularisation Due to Causes Other
	published	Than Age Related Macular De	<u>generation</u>
	yet	Conditions:	Choroidal Neovascularization; R
			etinal Pigment Epithelial Detachme
			nt
		Intervention:	Drug: Ranibizumab
45	Completed	Safety and Efficacy Study of T	Topical Administration of FOV2304
	no results	(High Dose or Low Dose) for t	he Treatment of Center-involving
	published	Clinically Significant Macular	Edema Associated With Diabetic
	yet	<u>Retinopathy</u>	
		Condition:	Diabetic Macular Edema
		Interventions:	Drug: 2304 Eye Drops High Dose;
			Drug: 2304 Eye Drops Low Dose;
- 10		later the state to be stated as free	Drug: Placebo Eye Drops
46	Completed		Clinically Significant Diabetic
	no results		s After Laser Treatment (TDMO)
	published	Condition:	Diabetic Macular Oedema
	yet	Intervention:	Drug: Triamcinolone acetate
47	Completed		Treatment in Vitrectomized Subjects
	no results	With Diabetic Macular Edema	
	published	Conditions:	Diabetic Macular Edema; Vitre
	yet		ctomy
		Intervention:	Drug: Dexamethasone
48	Completed	Open Label Extension of a Cli	nical Trial of Intravitreal

	no results	Triomoinglong for Disbetic Mo	And the second sec
		Triamcinolone for Diabetic Ma	
	published yet	Condition:	Diabetic Macular Oedema
	yet	Intervention:	Drug: Triamcinolone acetate
49	Completed		inical Trial of Laser Treatment Plus
	no results	Intravitreal Triamcinolone for	Diabetic Macular Oedema
	published	Condition:	Diabetic Macular Oedema
	yet	Intervention:	Drug: Triamcinolone acetate
50	Completed	Intravitreal Bevacizumab and	Triamcinolone in Diabetic Macular
	no results	<u>Edema</u>	
	published	Condition:	Diabetic Macular Edema
	yet	Intervention:	Procedure: Intravitreal injection
51	Completed	Sheathotomy vs. Intravitreal T	riamcinolone for Branch Retinal
	no results	Vein Occlusion	
	published	Conditions:	Macular Edema; Branch Retinal
	yet		Vein Occlusion
		Interventions:	Procedure: Arteriovenous Crossin
			g Sheathotomy; Procedure:
			Intravitreal Triamcinolone
			Acetonide Injection
52	Completed	Triple Therapy of Pars Plana	/itrectomy and Grid/Focal Laser for
	no results	Diabetic Macular Edema (DME	<u>=)</u>
	published	Conditions:	Diabetic Retinopathy; Macular Ed
	yet		ema
		Intervention:	Procedure: Triple therapy of
			vitrectomy, IVTA and grid/focal laser
			photocoagulation
53	Completed	Vascular Endothelial Growth	Factor (VEGF) Trap-Eye:
	no results	Investigation of Efficacy and	Safety in Central Retinal Vein
	published	Occlusion (CRVO)	
	yet	Condition:	Macular Edema Secondary to
			Central Retinal Vein Occlusion
		Interventions:	Biological: VEGF Trap-Eye 2.0mg;
			Drug: Sham
64	Completed	Effect of Intravitreal Long Act	ing Dexamethasone Implant,
	no results	Ozurdex in Patients With Diab	etic Macular Edema
	published	Conditions:	Diabetic Macular Edema; Mac
	yet		ular Edema, Cystoid; Vision Di
			sorders; Clinically Significant M

			acular Edema
		Intervention:	Drug: long acting intravitreal
			dexamethasone implant
65	Completed	CME With Different Fluidic Pa	·
	no results	Condition:	Cystoid Macular Edema Followi
	published		ng Cataract Surgery
	yet	Intervention:	Procedure: microcoaxial phaco
			emulsification
66	Completed	Effect of Intraoperative Dexan	nethasone Implant in Taut Posterior
	no results	Hyaloid Removal in Diabetic M	<u> Aacular Edema</u>
	published	Conditions:	Diabetic Macular Edema; Visi
	yet		on Disorders
		Intervention:	Drug: Dexamethasone Drug
			delivery system (Ozurdex)
67	Terminated	A Study Of The Safety And Ef	ficacy Of AG-013,958 In Subjects
			ovascularization Associated With
		Age-Related Macular Degener	
		Condition:	Age-Related Macular Degeneration
		Intervention:	Drug: AG-013,958
68	Terminated		Safety of PF-04523655 Versus
		Laser in Subjects With Diabet	
		Conditions:	Diabetic Retinopathy; Diabetes
			Complications
		Interventions:	Procedure: Laser Treatment; D
			rug: PF-04523655 high; Drug: PF-04523655 middle; Drug: PF
			-04523655 low
69	Enrolling by	Effect of Intravitreal Ranibizur	mab Injection With Retinal Vein
	invitation	Occlusion (RVO)	
		Conditions:	Macular Edema; Retinal Vein Occ
			lusion
		Intervention:	Drug: ranibizumab
70	Withdrawn	Combination Therapy for Neo	vascular Age Related Macular
		Degeneration	
		Condition:	Macular Degeneration
		Intervention:	Drug: intravitreal bevacizumab and tria
71	Active, not	Study to Assess the Effective	ness of Existing Anti vascUlar
	recruiting		nti VEGF) in Patients With Wet

		Age-related Macular Degeneration (wAMD) (AURA)		
		Condition:	Ophthalmology, Macular Degene	
			ration	
		Intervention:	Drug: Ranibizumab	
72	Active, not	A Study of the Safety and Efficiency	cacy of a New Treatment for Diabetic	
	recruiting	Macular Edema		
		Condition:	Diabetic Macular Edema	
		Interventions:	Drug: Dexamethasone; Drug: Sham	
73	Active, not	Dose Ranging Study of Pazop		
	recruiting	Age-Related Macular Degener		
		Condition:	Macular Degeneration	
		Interventions:	Drug: pazopanib eye drops; Dru	
			g: placebo; Biological: ranibizum	
			ab intravitreal injection	
74	Active, not	Japanese Safety Study of VEC	GF Trap-Eye in DME (Diabetic	
	recruiting	Macular Edema)		
		Condition:	Macular Edema	
		Intervention:	Biological: VEGF Trap-Eye (BAY86-5 321)	
75	Active, not	VEGF Trap-Eye in Vision Impa	airment Due to DME	
	recruiting	Conditions:	Diabetes Mellitus; Macular Edema	
		Interventions:	Biological: VEGF Trap-Eye (BAY86-	
			5321); Procedure: Laser treatmen	
			t	
76	Active, not		zumab in Japanese Patients With	
	recruiting	Retinal Vein Occlusion	Ratinal Vain Occlusion	
		Condition:	Retinal Vein Occlusion	
77	A other mot	Intervention:	Drug: ranibizumab	
77	Active, not recruiting	A Randomized, Double-maske	ed, Multicenter, Controlled Study of With Neovascular AMD	
	reoranng	Condition:	Neovascular Age-related Macular D	
			egeneration	
		Intervention:	Biological: intravitreal injection of KH	
			902	
78	Active, not	Safety and Efficacy by Multiple	e Injection of KH902 in Patients With	
	recruiting	Diabetic Macular Edema (DME	<u>=)</u>	
		Condition:	Diabetic Macular Edema	

		Intervention:	Biological: KH902
79	Active, not	An Open-label Extension Stud	
	recruiting		Treatment for Visual Impairment
	J	Due to Diabetic Macular Edem	
		Conditions:	Diabetic Macular Edema;
			Visual Impairment
		Intervention:	Drug: ranibizumab
80	Active, not	Intravitreal Bevacizumab (Ava	
80	recruiting		for Persistent Diabetic Macular
	recruiting	Oedema	
		Conditions:	Diabetic Retinopathy; Macular E
		Conditions.	dema
		Interventioner	
		Interventions:	Drug: bevacizumab; Drug: dexa methasone
81	Active, not		8397 in the Treatment of Macular
	recruiting	Edema Associated With Retin	
		Conditions:	Macular Edema; Retinal Vein Oc
			clusion
		Interventions:	Drug: AGN208397 intravitreal injec
			tion; Drug: dexamethasone intra
	D		vitreal implant
82	Recruiting	Safety and Efficacy Study of r	
		Exudative Age-Related Macul	
		Conditions:	Macular Degeneration; Age-re
			lated Maculopathies; Age-relat ed Maculopathy; Maculopathi
			ed Maculopathy; Maculopathi es,Age-related; Maculopathy,
			Age-related; Retinal Degenera
			tion; Retinal Neovascularizatio
			n; Eye Diseases
		Interventions:	Biological: rAAV.sFlt-1; Other:
			Control (ranibizumab alone)
83	Recruiting	Efficacy and Safety of Betame	ethasone Microsphere in Patients
00	Recruiting		g Branch Retinal Vein Occlusion
		(HIKARI)	
		Condition:	Macular Edema Following Branch
		Condition.	Retinal Vein Occlusion
		Interventions:	
		interventions:	Drug: Betamethasone Microsphere (DE-102) Low Dose; Drug:
			$DL^{-1}UZ / LOW DOSE, Dlug.$

			Betamethasone Microsphere (DE-102) High
			Dose; Drug: Sham
84	Recruiting	Effects of Lutein and Zeaxant	hin Supplementation on Early
		Age-related Macular Degenera	ation
		Condition:	Age-related Macular Degeneration
		Interventions:	Dietary Supplement: placebo; Dietar
			s lutein
85	Recruiting	Efficacy and Safety of Betame	ethasone Microsphere in Patients
		With Diabetic Macular Edema	(TSUBASA)
		Condition:	Diabetic Macular Edema
		Interventions:	Drug: Betamethasone Microsphe
			re (DE-102) Low Dose; Drug:
			Betamethasone Microsphere
			(DE-102) High
			Dose; Drug: Sham
86	Recruiting		gle-Center, Prospective Study to
		Determine the Safety and Tole	
			bryonic Stem Cell Derived Retinal
		Pigmented Epithelial(MA09-hl Advanced Dry Age-related Ma	-
		Condition:	Dry Age Related Macular Degenerat
			ion
		Intervention:	Biological: MA09-hRPE
87	Recruiting	Intravitreal Ranibizumab in Ex	
•••		Degeneration With Posterior	
		Condition:	Neovascular Age-related Macular
			Degeneration
		Intervention:	Procedure: Intravitreal expansile
			gas and ranibizumab injection
88	Recruiting	Safety and Tolerability of MAC	9-hRPE Cells in Patients With
		Stargardt's Macular Dystroph	<u>y(SMD)</u>
		Condition:	Stargardt's Macular Dystrophy
		Intervention:	Biological: MA09-hRPE
89	Recruiting	Autologous Plasmin and Fibri	inolytic System in Diabetic
		<u>Retinopathy</u>	
		Condition:	Macular Edema
		Intervention:	Procedure: Intravitreal injection
	-		

90	Recruiting	Safety and Efficacy Study of I	Dexamethasone in the Treatment of	
		Patients With Macular Edema Following Retinal Vein Occlusion		
		<u>(RVO)</u>		
		Condition:	Macular Edema	
		Interventions:	Drug: 700 μg Dexamethasone;	
			Other: Sham	
91	Recruiting		ed, Multicenter, Sham-controlled,	
			H902 in Patients With Wet AMD	
		Condition:	Neovascular Age-related Macular D	
		In terms of terms	egeneration	
		Intervention:	Biological: Recombinant Human VEGF Receptor-Fc Fusion Protein	
92	Recruiting	VEGE Tran-Ever Investigation	of Efficacy and Safety in Chinese	
52	Recruiting		Related Macular Degeneration)	
		Condition:	Macular Degeneration	
		Interventions:	Biological: VEGF Trap-Eye (BAY86-	
			5321); Drug: Visudyne	
93	Recruiting	Effect of Intravitreal Anti-VEG	F on Retinal Vessels Diameter	
		Condition:	Age Related Macular Degeneration	
		Interventions:	Drug: Intravitreal Ranibizumab; Dr	
			ug: Intravitreal bevacizumab	
94	Recruiting	Effects of Lutein and Zeaxant	hin Supplementation on Age-related	
		Macular Degeneration		
		Condition:	Age-related Macular Degeneration	
		Interventions:	Dietary Supplement: lutein; Dietar	
			y Supplement: Lutein; Dietary Sup	
			plement: placebo; Drug: Lutein an d zeaxanthin	
95	Recruiting	Intraoperative Devamethason	e Implant Improves Outcome of	
55	Recruiting	Cataract Surgery With Diabeti		
		Conditions:		
			n Disorders; Diabetic Macular	
			Edema; Cystoid Macular Edem	
			a Following Cataract Surgery;	
			Cataract	
		Interventions:	Drug: Dexamethasone Drug	
			delivery system	
			(Ozurdex); Procedure: Catarac	
			t surgery	

96	Recruiting	Evaluation of AGN-150998 in	Exudative Age-related Macular	
	_	Degeneration (AMD)		
		Condition:	Age-related Macular Degeneration	
		Interventions:	Drug: AGN-150998; Drug: ranibi	
			zumab	
97	Recruiting	Observe the Effectiveness and	d Safety of Ranibizumab in Real Life	
		Setting		
		Conditions:	5 5	
			eration; Diabetic Macular Ede	
			ma; Retinal Vein Occlusion	
	D	Intervention:		
98	Recruiting	A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema		
		Condition:		
		Interventions:	Drug: darapladib; Drug: placeb	
99	Recruiting	Efficacy and Safety of Ranibiz	zumab With or Without Laser in	
		Comparison to Laser in Branc		
		Condition:	Branch Retinal Vein Occlusion	
		Interventions:	Drug: Ranibizumab; Procedure	
			: Laser	
100	Recruiting	Ranibizumab Intravitreal Injec	tions in Patients With Visual	
			dema Secondary to Central Retinal	
		Vein Occlusion		
		Conditions:	Macular Edema; Central Retinal Vein Occlusion	
		Intervention:	Drug: Ranibizumab 0.5 mg/0.05	
			ml, intravitreal injection	
101	Unknown [†]	To Compare Visual Field Impa	airment in Conventional Double	
		Frequency Nd: YAG Panretina	al Photocoagulation With PASCAL	
		Panretinal Photocoagulation		
		Conditions:	Macular Edema; Diabetic Retin	
			opathy; Visual Field Loss	
		Interventions:	Procedure: PASCAL laser; Pro	
			cedure: Conventional laser	
102	Unknown [†]	Intravitreal Bevacizumab for F		
		Conditions:	Wet AMD; Macular Oedema;	

			Proliferative Diabetic Retinopathy
		Intervention:	Drug: Bevacizumab (Avastin)
103	Unknown [†]	Micropulse 577 nm Laser Pho	tocoagulation Versus Conventional
		532 nm Laser Photocoagulation	on for Diabetic Macular Oedema
		Condition:	Diabetic Macular Edema
		Interventions:	Device: Micropulse 577 nm yellow dio
104	Unknown [†]	Comparison of Intravitreal Ra	nibizumab and Macular Laser
		Photocoagulation for ME Follo	owing Branch Retinal Vein
		Occlusion (BRVO)	
		Condition:	Branch Retinal Vein Occlusion
		Interventions:	Drug: Ranibizumab; Procedure: mag

51. Macular Edema

Rank	Status	Study		
1	Completed	Efficacy and Safety of Ranibiz	umab (Intravitreal Injections) in Patients	
	Has Results	With Visual Impairment Due to	Diabetic Macular Edema	
	published	Condition:	Diabetic Macular Edema	
	on website	Interventions:	Drug: Ranibizumab; Procedure: Laser photocoagulation; Drug: Sham ranibizu mab; Procedure: Sham laser photocoa gulation	
2	Completed	Vascular Endothelial Growth I	Factor (VEGF) Trap-Eye: Investigation of	
-	Has Results	Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)		
	published	Condition:	Retinal Vein Occlusion	
	on website	Interventions:	Biological: Aflibercept Injection	
		interventions.	(EYLEA, VEGF Trap-Eye,	
			BAY86-5321); Other: Sham treatmen	
			t	
3	Completed	A Multi-Center Trial To Evalua	te The Safety And Efficacy Of	
	Has Results	Pegaptanib Sodium(Macugen)	Injected Into The Eye Every 6 Weeks	
	published	For Up To 2 Years For Macula	r Swelling Associated With Diabetes,	
	on website	With An Open-Label Macugen	Year Extension.	
		Condition:	Macular Edema Associated With Diabe tes Mellitus	
		Interventions:	Drug: Standard of Care; Drug: Macu gen	
4	Completed	A Study of the Safety and Efficiency	cacy of a New Treatment for Macular	
	Has Results	Edema Resulting From Retina	I Vein Occlusion	
	published on website	Conditions:	Macular Edema; Retinal Vein Occlusi on	
		Interventions:	Drug: Dexamethasone; Drug: Sham i njection	
5	Completed	Safety and Efficacy of Intravit	real Fluocinolone Acetonide Implants in	
	no results	Patients With Diabetic Macula		
	published	Condition:	Diabetic Macular Edema	
	yet	Interventions:	Drug: 0.59 mg fluocinolone acetonide	
			intravitreal implant; Drug: 2.1 mg	
			fluocinolone acetonide intravitreal	
			implant; Procedure: standard of care	
			laser photocoagulation	
6	Completed	Triple Therapy of Pars Plana	/itrectomy and Grid/Focal Laser for	
	no results	Diabetic Macular Edema (DME	<u>=)</u>	

	week Baland		
	published	Conditions:	Diabetic Retinopathy; Macular Edem
	yet		а
		Intervention:	Procedure: Triple therapy of vitrectomy,
			IVTA and grid/focal laser
			photocoagulation
7	Completed		Triamcinolone in Diabetic Macular
	no results	<u>Edema</u>	
	published	Condition:	Diabetic Macular Edema
	yet	Intervention:	Procedure: Intravitreal injection
8	Completed	Sequentially Combined Vitrec	tomy, IVTA and Macular Focal Laser
	no results	Photocoagulation for Diabetic	Macular Edema
	published	Condition:	Diabetic Macular Edema
	yet	Interventions:	Procedure: vitrectomy; Drug: intravitr
			eal triamcinolone acetonide; Procedu
			re: macular focal laser photocoagulatio
			n
9	Completed	Changes in Ciliary Body Thick	kness in Patients With Diabetic Macular
	no results	Edema After Vitrectomy	
	published	Condition:	Diabetic Macular Edema
	yet	Intervention:	Procedure: Pars Plana Vitrectomy
10	Completed	Major and Macular Branched I	Retinal Venous Occlusion
	no results	Condition:	Macular Edema
	published	Intervention:	Procedure: intravitreal bevacizumab
	yet		
11	Completed	Sheathotomy vs. Intravitreal T	riamcinolone for Branch Retinal Vein
	no results	<u>Occlusion</u>	
	published	Conditions:	Macular Edema; Branch Retinal Vein
	yet		Occlusion
		Interventions:	Procedure: Arteriovenous Crossing Sh
			eathotomy; Procedure: Intravitreal
			Triamcinolone Acetonide Injection
12	Completed	Reduction in the Occurrence of	of Center-Involved Diabetic Macular
	no results	<u>Edema</u>	
	published	Condition:	Diabetic Retinopathy
	yet	Interventions:	Drug: ruboxistaurin; Drug: placebo
13	Completed	A Phase 3 Study To Compare	The Efficacy And Safety Of 0.3 MG
	no results	Pegaptanib Sodium To Sham	Injections In Subjects With Diabetic
	published	Macular Edema	
	yet		

		Conditions:	Macular Edema; Diabetic Mellitus; R etinal Disease
		Interventions:	Drug: pegaptanib sodium; Other: sham injection
14	Completed	A Study of the Safety and Efficient	cacy of a New Treatment for Macular
	no results	Edema Resulting From Branc	h Retinal Vein Occlusion
	published	Conditions:	Macular Degeneration; Macular Ede
	yet		ma; Branch Retinal Vein Occlusion
		Intervention:	Drug: dexamethasone
15	Completed	A Study of the Safety and Efficient	cacy of SK-0503 for Diabetic Macular
	no results	<u>Edema</u>	
	published	Condition:	Diabetic Macular Edema
	yet	Intervention:	Drug: dexamethasone
16	Completed	The Effect of a Blue Light Filte	ering IOL
	no results	Conditions:	to Compare the Effect of Two Types of
	published		IOLs; on the Incidence of Cystoid Ma
	yet		cular Edema; After Cataract Surgery
		Intervention:	Procedure: intraocular lens implantatio
			n
17	Completed	Vitrectomy for Branch Retinal	Vein Occlusion
	no results	Condition:	Vitrectomy
	published	Intervention:	Procedure: Vitrectomy w/o ILM peeling
	yet		for macular edema with BRVO
18	Completed	Safety and Efficacy Study of 1	opical Administration of FOV2304 (High
	no results		eatment of Center-involving Clinically
	published		sociated With Diabetic Retinopathy
	yet	Condition:	Diabetic Macular Edema
		Interventions:	Drug: 2304 Eye Drops High Dose; Dru
			g: 2304 Eye Drops Low Dose; Drug: Pl
			acebo Eye Drops
19	Completed		acebo Eye Drops nical Trial of Laser Treatment Plus
19	no results	Intravitreal Triamcinolone for	acebo Eye Drops nical Trial of Laser Treatment Plus Diabetic Macular Oedema
19	no results published		acebo Eye Drops nical Trial of Laser Treatment Plus
19	no results	Intravitreal Triamcinolone for	acebo Eye Drops nical Trial of Laser Treatment Plus Diabetic Macular Oedema
19 20	no results published yet Completed	Intravitreal Triamcinolone for Condition: Intervention: Intravitreal Triamcinolone for	acebo Eye Drops <u>nical Trial of Laser Treatment Plus</u> <u>Diabetic Macular Oedema</u> Diabetic Macular Oedema Drug: Triamcinolone acetate <u>Clinically Significant Diabetic Macular</u>
	no results published yet Completed no results	Intravitreal Triamcinolone for Condition: Intervention: Intravitreal Triamcinolone for Oedema That Persists After La	acebo Eye Drops nical Trial of Laser Treatment Plus Diabetic Macular Oedema Diabetic Macular Oedema Drug: Triamcinolone acetate Clinically Significant Diabetic Macular aser Treatment (TDMO)
	no results published yet Completed	Intravitreal Triamcinolone for Condition: Intervention: Intravitreal Triamcinolone for	acebo Eye Drops <u>nical Trial of Laser Treatment Plus</u> <u>Diabetic Macular Oedema</u> Diabetic Macular Oedema Drug: Triamcinolone acetate <u>Clinically Significant Diabetic Macular</u>

21	Completed	Open Label Extension of a Cli	nical Trial of Intravitreal Triamcinolone
	no results	for Diabetic Macular Oedema-	TDMX Study
	published	Condition:	Diabetic Macular Oedema
	yet	Intervention:	Drug: Triamcinolone acetate
22	Completed	Safety and Efficacy of a New T	Freatment in Vitrectomized Subjects With
	no results	Diabetic Macular Edema	
	published	Conditions:	Diabetic Macular Edema; Vitrectomy
	yet	Intervention:	Drug: Dexamethasone
23	Completed	Effect of Intravitreal Long Act	ing Dexamethasone Implant, Ozurdex in
	no results	Patients With Diabetic Macula	r Edema
	published	Conditions:	Diabetic Macular Edema; Macular Ede
	yet		ma, Cystoid; Vision Disorders; Clinic
			ally Significant Macular Edema
		Intervention:	Drug: long acting intravitreal
			dexamethasone implant
24	Completed		nethasone Implant in Taut Posterior
	no results	Hyaloid Removal in Diabetic M	<u>lacular Edema</u>
	published	Conditions:	Diabetic Macular Edema; Vision Diso
	yet		rders
		Intervention:	Drug: Dexamethasone Drug delivery
			system (Ozurdex)
25	Completed no results		Factor (VEGF) Trap-Eye: Investigation of Potinal Voin Occlusion (CPVO)
	published	Condition:	Retinal Vein Occlusion (CRVO)
	yet	Condition:	Macular Edema Secondary to Central Retinal Vein Occlusion
	,	Interventions:	
			Biological: VEGF Trap-Eye 2.0mg; D rug: Sham
26	Completed	CME With Different Fluidic Pa	•
	no results	Condition:	Cystoid Macular Edema Following Cata
	published		ract Surgery
	yet	Intervention:	Procedure: microcoaxial phacoemulsifi
			cation
27	Completed	Diabetic Retinopathy and Diak	petic Macular Edema Screening by
	no results	Non-Physicians With Limited	Training
	published	Condition:	Diabetic Retinopathy
	yet	Interventions:	Device: Digital retina image; Device:
			direct ophthalmoscopy; Procedure: c
			omprehensive eye exam

28	Terminated	Study Evaluating Efficacy and	Safety of PF-04523655 Versus Laser in	
		Subjects With Diabetic Macular Edema		
		Conditions:	Diabetic Retinopathy; Diabetes Com	
			plications	
		Interventions:	Procedure: Laser Treatment; Drug: P	
			F-04523655 high; Drug: PF-0452365	
			5 middle; Drug: PF-04523655 low	
29	Enrolling		nab Injection With Retinal Vein	
	by invitation	Occlusion (RVO)		
	Invitation	Conditions:	Macular Edema; Retinal Vein Occlusi on	
		Intervention:	Drug: ranibizumab	
30	Active, not	A Study of the Safety and Efficient	cacy of a New Treatment for Diabetic	
	recruiting	Macular Edema		
		Condition:	Diabetic Macular Edema	
		Interventions:	Drug: Dexamethasone; Drug: Sham	
31	Active, not		umab in Japanese Patients With Retinal	
	recruiting	Vein Occlusion		
		Condition:	Retinal Vein Occlusion	
	• • •	Intervention:	Drug: ranibizumab	
32	Active, not	VEGF Trap-Eye in Vision Impa		
	recruiting	Conditions:	Diabetes Mellitus; Macular Edema	
		Interventions:	Biological: VEGF Trap-Eye (BAY86-53 21); Procedure: Laser treatment	
33	Active, not	Safety and Efficacy of AGN20	21); Procedure: Laser treatment 8397 in the Treatment of Macular Edema	
55	recruiting	Associated With Retinal Vein		
	. .	Conditions:	Macular Edema; Retinal Vein Occlusi	
			on	
		Interventions:	Drug: AGN208397 intravitreal injection;	
			Drug: dexamethasone intravitreal im	
			plant	
34	Active, not	Intravitreal Bevacizumab (Ava	stin®) Versus Intravitreal	
	recruiting		or Persistent Diabetic Macular Oedema	
		Conditions:	Diabetic Retinopathy; Macular Edem a	
		Interventions:	Drug: bevacizumab; Drug: dexameth asone	
35	Active, not	An Open-label Extension Stuc	ly to Evaluate the Safety of Ranibizumab	

	recruiting	as Symptomatic Treatment for	r Visual Impairment Due to Diabetic
	J	Macular Edema in Patients	
		Conditions:	Diabetic Macular Edema; Visual Imp
			airment
		Intervention:	Drug: ranibizumab
36	Active, not	Safety and Efficacy by Multipl	e Injection of KH902 in Patients With
	recruiting	Diabetic Macular Edema (DME	<u>=)</u>
		Condition:	Diabetic Macular Edema
		Intervention:	Biological: KH902
37	Active, not	Japanese Safety Study of VEC	GF Trap-Eye in DME (Diabetic Macular
	recruiting	Edema)	
		Condition:	Macular Edema
		Intervention:	Biological: VEGF Trap-Eye (BAY86-5 321)
38	Recruiting	Observe the Effectiveness and	d Safety of Ranibizumab in Real Life
		Setting	
		Conditions:	5 5
			n; Diabetic Macular Edema; Retina
			I Vein Occlusion
	Den iting	Intervention:	Other: Ranibizumab
39	Recruiting	Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion	
		Condition:	Branch Retinal Vein Occlusion
		Interventions:	Drug: Ranibizumab; Procedure: Laser
40	Recruiting		e Implant Improves Outcome of Cataract
	Ū	Surgery With Diabetic Macula	
		Conditions:	Macular Edema, Cystoid; Vision Disor
			ders; Diabetic Macular Edema; Cyst
			oid Macular Edema Following Cataract S
			urgery; Cataract
		Interventions:	Drug: Dexamethasone Drug delivery
			system
			(Ozurdex); Procedure: Cataract surger
41	Recruiting	Efficacy and Safety of Betamo	y ethasone Microsphere in Patients With
	Recruiting	Diabetic Macular Edema (TSU	
		Condition:	Diabetic Macular Edema
		Interventions:	Drug: Betamethasone Microsphere (DE
L	1		J

			-102) Low Dose; Drug:
			Betamethasone Microsphere (DE-102)
			High Dose; Drug: Sham
42	Recruiting	Efficacy and Safety of Betame	thasone Microsphere in Patients With
		Macular Edema Following Bra	nch Retinal Vein Occlusion (HIKARI)
		Condition:	Macular Edema Following Branch Retinal Vein Occlusion
		Interventions:	Drug: Betamethasone Microsphere (DE- 102) Low Dose; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham
43	Recruiting	A Phase 2 Clinical Study to In	vestigate Effects of Darapladib in
43	Recruiting	Subjects With Diabetic Macula	
		Condition:	Retinopathy, Diabetic
		Interventions:	Drug: darapladib; Drug: placebo
44	Recruiting	Ranibizumab Intravitreal Injec	tions in Patients With Visual Impairment
		Due to Macular Edema Second	dary to Central Retinal Vein Occlusion
		Conditions:	Macular Edema; Central Retinal Vein Occlusion
		Intervention:	Drug: Ranibizumab 0.5 mg/0.05 ml,
			intravitreal injection
45	Recruiting		or Subtenon Triamcinolone Acetonide
			for Macular Edema Secondary to Branch
		Retinal Vein Occlusion Condition:	Branch Retinal Vein Occlusion
		Interventions:	Procedure: intravitreal bevacizumab
		interventions.	monotherapy; Procedure:
			combined therapy of posterior
			subtenon triamcinolone acetonide
			and intravitreal bevacizumab
			injection
46	Recruiting		mab on Focal Edema With Hard
		Exudates Secondary to Diabe	
		Condition:	Diabetes Complications
		Intervention:	Drug: Avastin (bevacizumab)
47	Recruiting		nolytic System in Diabetic Retinopathy
		Condition:	Macular Edema
		Intervention:	Procedure: Intravitreal injection

48	Recruiting	Safety and Efficacy Study of I	Dexamethasone in the Treatment of
		Patients With Macular Edema	Following Retinal Vein Occlusion (RVO)
		Condition:	Macular Edema
		Interventions:	Drug: 700 µg Dexamethasone; Other:
			Sham
49	Unknown [†]	To Compare Visual Field Impa	airment in Conventional Double
		Frequency Nd: YAG Panretina	I Photocoagulation With PASCAL
		Panretinal Photocoagulation	
		Conditions:	Macular Edema; Diabetic Retinopat
			hy; Visual Field Loss
		Interventions:	Procedure: PASCAL laser; Procedu
			re: Conventional laser
50	Unknown [†]	Comparison of Intravitreal Ranibizumab and Macular Laser	
		Photocoagulation for ME Follo	owing Branch Retinal Vein Occlusion
		<u>(BRVO)</u>	
		Condition:	Branch Retinal Vein Occlusion
		Interventions:	Drug: Ranibizumab; Procedure: mac
			ular laser photocoagulation
51	Unknown [†]	Intravitreal Bevacizumab for F	Retinal Disorders
		Conditions:	Wet AMD; Macular Oedema; Prolif
			erative Diabetic Retinopathy
		Intervention:	Drug: Bevacizumab (Avastin)
52	Unknown [†]	Micropulse 577 nm Laser Pho	tocoagulation Versus Conventional 532
		nm Laser Photocoagulation for	or Diabetic Macular Oedema
		Condition:	Diabetic Macular Edema
		Interventions:	Device: Micropulse 577 nm yellow dio
			de laser; Device: 532 nm green dio
			de laser

52. Mydriasis

Rank	Status	Study	
1	Completed	Study of Intracameral Adrenaline for Pupil Dilation Without	
	no results	Topical Mydriatics in Refractive Cataract Surgery	
	published	Condition: Cataract	
	yet	Intervention: Drug: adrenalin	
2	Completed	Comparison of Instillation and Packing in Mydriasis for	
	no results	Premature Infants	
	published	Condition: Preterm Infants	
	yet	Intervention: Drug: 1% tropicamide and 2.5% phenylephrine	
3	Completed	2.5% and 10% Phenylephrine for Mydriasis in Diabetic	
	no results	Patients With Darkly Pigmented Irides	
	published	Condition: Diabetes Mellitus	
	yet	Intervention: Drug: 2.5% or 10% phenylephrine	
4	Completed	Single Dose of 1% Tropicamide and 10% Phenylephrine for	
	no results	Pupillary Dilation	
	published	Condition: Eye Diseases	
	yet	Intervention: Drug: 1% tropicamide and 10% phenylephrine	

Rank	Status	Study	
1	Completed	Comparative Performance of	PureVision Lens Designs
	Has Results	Condition:	Муоріа
	published	Interventions:	Device: Currently Marketed
	on website		PureVision Contact Lens.; Device:
			Alternate Design of the PureVision
			Contact Lens.
2	Completed	Product Performance of a Tor	ic Contact Lens
	Has Results	Conditions:	Myopia; Astigmatism
	published	Interventions:	Device: SofLens DD Toric; Device:
	on website		Ciba Vision Focus Dailies Toric
			Contact Lens
3	Completed	Two Week Cross-Over Study	Comparing Two Daily Disposable
	Has Results	Contact Lenses	
	published	Condition:	Муоріа
	on website	Interventions:	Device: etafilcon A; Device: omafilco
			n A
4	Completed	Contact Lens in Pediatrics (Cl	LIP) in an Asian Population Study
	no results	Condition:	Муоріа
	published	Intervention:	Device: Johnson&Johnson Acuevue
	yet		daily disposable lenses
5	Completed	Comparative Study of Cyclop	legic Refraction and Subjective
	no results	Refraction With Fogging in Sc	chool Age Children
	published	Conditions:	Myopia; Refractive Error
	yet	Intervention:	
6	Completed	Myopia Control With Simultan	eous Vision Approach
	no results	Condition:	Муоріа
	published	Intervention:	Device: Defocus Incorporated Soft
	yet		Contact (DISC) lens
7	Completed	Evaluation of Effectiveness of	f Correcting Refractive Error With
	no results	Ready-made Spectacles	
	published	Conditions:	Myopia; Hyperopia; Astigmatism
	yet	Interventions:	Device: Ready-made spectacles; De
			vice: Spectacles
8	Completed	A Comprehensive Assessmer	nt of Anterior Corneal Power by
	no results	Different Devices	
	published	Condition:	Муоріа
	yet	Intervention:	Device: Corneal power measurement

53. Myopia

9	Completed	Efficacy and Safety of Ranibiz	umab in Patients With Visual
	no results	Impairment Due to Choroidal	Neovascularization Secondary to
	published	Pathologic Myopia	
	yet	Condition:	Pathological Myopia
		Interventions:	Drug: 0.5 mg ranibizumab driven by
			disease activity; Drug: 0.5 mg
			ranibizumab driven by stabilization
			criteria; Drug: verteporfin PDT
10	Completed	The Effect of Myopic Optical E	Defocus on the Humphrey Matrix 30-2
	no results	Test	
	published	Condition:	Муоріа
	yet	Intervention:	
11	Completed	Myopia Control by Combining	Auricular Acupoint and Atropine
	no results	Eyedrops	
	published	Condition:	Муоріа
	yet	Interventions:	Drug: 0.25 % atropine; Drug: 0.5
			% atropine; Procedure: 0.25 % atr
			opine+auricular acupoints
12	Completed	Surgical Outcome of Vitrector	ny for Myopic Traction Maculopathy
	no results	in Highly Myopic Eyes	
	published	Conditions:	Maculopathy; High Myopia; Surg
	yet		ery
		Intervention:	Procedure: vitrectomy
13	Completed	Changes in Invitro and ex Vive	b Lens Metrology With Daily Wear
	no results	Contact Lenses	
	published	Condition:	Муоріа
	yet	Interventions:	Device: Air Optix Aqua; Device: Bio
			finity; Device: Proclear; Device: A
			cuvue Oasys; Device: Acuvue 2;
			Device: Purevision
14	Completed		Contact Lens Maintenance Systems
	no results	for Hydrogel Lenses	
	published	Conditions:	Myopia; Hyperopia
	yet	Interventions:	Device: Silicone Hydrogel Contact Le
			nses; Device: 1x PMBH preserved
			MPS; Device: 1x Polyquad/Aldox M PS
15	Completed	Comparativo Study of Three K	
15	Completed no results		OL Power Calculation Formulae for
	no results	Asian Eyes Shorter Than 22m	III OF LUNGEF FRANZONNI

	published	Condition:	Cataract
	yet	Intervention:	Procedure: IOL calculation formula
16	Completed	Myopic Macular Haemorrhage	<u>PS</u>
	no results	Condition:	Myopic Macular Haemorrhages
	published	Intervention:	
	yet		
17	Completed		I Swelling During Wear of Galyfilcon A
	no results	Lenses	· · ·
	published	Condition:	Муоріа
	yet	Interventions:	Device: galyfilcon A; Device: galyf
			ilcon A plus; Device: lotrafilcon A;
			Device: polymacon; Other: spe ctacles
18	Completed	Comparison of Contact Long	Maintenance Systems for Silicone
10	no results	Hydrogel Lenses	maintenance bystems for bincone
	published	Conditions:	Myopia; Hyperopia
	yet	Intervention:	Device: Silicone hydrogel contact lens
19	Completed		ded Wear Silicone Hydrogel Lenses
19	no results	Condition:	Myopia
	published	Intervention:	Device: Silicone hydrogel contact lens
	yet		Device. Oncone nyaroger contact tens
20	Completed	The Effect of Silicone Hydrog	el Contact Lenses on Conjunctival
	no results	<u>Flora</u>	
	published	Condition:	Муоріа
	yet	Intervention:	Device: Silicone hydrogel contact lens
21	Completed	Clinical Evaluation of Ocular	Responses With Contact Lens Wear
	no results	Condition:	Муоріа
	published	Interventions:	Device: narafilcon B; Device: Poly
	yet		macon; Device: Lotrafilcon A; O
			ther: Spectacles
22	Completed		erformance of Silicone Hydrogel
	no results	Contact Lenses During Contin	
	published yet	Condition:	Myopia
	-	Intervention:	Device: Silicone hydrogel contact lens
23	Completed	A Study to Assess the Safety, Tolerability and Effect of Nexagon™	
	no results published	Applied to the Eye After PRK Nearsightedness	Laser Eye Surgery for
	yet	Condition:	Corneal re-Epithelialization
	,	Condition.	

		Intervention:	Drug: Nexagon™ or Nexagon™ vehicle
24	Completed	Clinical Trial of Several Conta	<u>ct Lenses in Extended Wear</u>
	no results	Condition:	Муоріа
	published	Interventions:	Device: senofilcon A; Device: lotra
	yet		filicon A; Device: lotrafilcon B; D
			evice: balafilcon A; Device: comfil
			con A; Device: etafilcon A
25	Completed	Three Intraocular Lenses Des	igned to Improve Distance,
	no results	Intermediate and Near Vision	Following Lens Extraction
	published	Condition:	Cataract
	yet	Interventions:	Device: Crystalens AO; Device: ReST
26	Completed	Pilot Study of Neurovision to	Improve Vision and Slow Myopia
	no results	Progression in Children With	<u>Myopia</u>
	published	Condition:	Муоріа
	yet	Intervention:	Device: NeuroVision
27	Completed	A Singapore Pilot Study to As	sess Neurovision in Treatment of Low
	no results	<u>Myopia</u>	
	published	Condition:	Муоріа
	yet	Intervention:	Device: Neurovision
28	Completed	A Singapore Study to Assess	How Neurovision Improve the Vision
	no results	of Adults With Low to Modera	te Myopia
	published	Condition:	Муоріа
	yet	Intervention:	Device: Neurovision
29	Completed	Efficacy of LASIK Versus PRK	(in Asians With Mild and Moderate
	no results	<u>Myopia</u>	
	published	Condition:	Муоріа
	yet	Interventions:	Procedure: Laser in Situ Keratomile
			usis (LASIK); Procedure: Photoref
			ractive Keratectomy (PRK)
30	Completed	Optical Coherence Tomograp	hy Imaging of the Posterior Segment
	no results	<u>in High Myopia.</u>	
	published	Conditions:	Myopia; Maculopathy; Glaucoma
	yet	Intervention:	
31	Completed	Pilot Study to Assess the Efficient	cacy of Short Exposure to Defocus to
	no results	Slow the Progression of Myor	<u>bia in Children</u>
	published	Condition:	Муоріа
	yet	Intervention:	Device: Hyperopic lens
32	Terminated	Silicone Hydrogel Contact Lei	nses on Low Astigmatism in Japan

		Conditions:	Refractive Error; Myopia; Astigm atism
		Interventions:	Device: senofilcon A toric soft contact
			lens; Device: senofilcon A sphere s
			oft contact lens
33	Active, not	Trial of a Novel Family-Based	Intervention to Increase Outdoor
	recruiting	Time and Fitness	
		Conditions:	Myopia; Obesity
		Intervention:	Behavioral: Family-based Outdoor pr
			ogram
34	Active, not	VEGF Trap-Eye in Choroidal N	leovascularization Secondary to
	recruiting	Pathologic Myopia (mCNV)	
		Condition:	Myopia, Pathological
		Interventions:	Biological: VEGF Trap-Eye (BAY86-5
			321); Procedure: No Drug
35	Enrolling	Guangzhou Outdoor Activity	Longitudinal Study
	by	Condition:	Муоріа
	invitation	Intervention:	Behavioral: Outdoor activity
36	Enrolling	The Children's WEAR Trial(Ph	
	by	Condition:	Myopia
	invitation	Interventions:	Procedure: group1; Procedure: gr
			oup2; Procedure: group3; Proc
			edure: group4
37	Active, not	Toric Orthokeratology - Slowi	ng Eye Elongation
	recruiting	Conditions:	Myopia; Astigmatism
		Interventions:	Device: Toric Orthokeratology lenses;
			Device: Single-vision spectacles
38	Active, not	Peripheral Optics in Myopia a	nd Orthokeratology
	recruiting	Condition:	Муоріа
		Interventions:	Device: Orthokeratology lenses; Devic
39	Recruiting		n Families With Myopia and Related
		Diseases	
		Condition:	Муоріа
		Intervention:	
40	Recruiting		rial Comparing SMILE and LASIK
		Conditions:	Myopia; Astigmatism; Hypermetro
			pia
		Interventions:	Procedure: Femtosecond LASIK; Pro
L	1		

			cedure: Small incision lenticule
			extraction (SMILE)
41	Recruiting	Presbyonic Supracor Treatme	ent for Near Myopic/Hyperopic
	Recruiting	Pseudophakic Eyes	at to real wyopic type opic
		Conditions:	Myopia; Hyperopia; Presbyopia
		Intervention:	Device: Supracor
42	Recruiting	Evaluate Capsular Apposition	
	rtooraning	Conditions:	Capsule Opacification; Tissue Adhe
			ions; Aphakia - Lens Capsule Prese
			t; Opacification of Intraocular Lens
		Intervention:	
43	Recruiting	Discontinuation of Orthokerat	ology on Eyeball Elongation in
		Myopic Children	
		Condition:	Муоріа
		Intervention:	Procedure: Switching of
			orthokeratology and single-vision
			glasses
44	Recruiting	Discontinuation of Lens Wear	in New Ortho-k Children (DOEE2)
		Condition:	Муоріа
		Intervention:	Procedure: Switching of
			single-vision spectacles to
			orthokeratology
45	Recruiting	Early Vitrectomy for Macular	
		Condition:	Myopia, Degenerative
		Intervention:	Procedure: Early vitrectomy
46	Unknown [†]		r Layer (RNFL) / Retinal Thickness
			Spectral -Domain Technology as a
		Diagnostic Predictor of Glauc	
		Conditions:	Glaucoma; Myopia
47		Intervention:	52/ 0.42/ 0.0.040/ 4/
47	Unknown [†]	Safety and Efficacy Study of C	
		Treatment to Both Eyes In Tree Condition:	
			Myopia
40	Unknown [†]	Intervention:	Drug: Atropine Eye drops
48	UNKNOWN '	Laser In Situ Keratomileusis	/isumax Femtosecond Laser for
		Condition:	Муоріа
		Intervention:	тури

49	Unknown [†]	The Role of SNP of ECM and MMP on the Development of
		Pathological High Myopia
		Condition: Myopia
		Intervention:
50	Unknown †	Ocular Response Analyzer Assessment of Intraocular Pressure
50	UIRIOWI	and Corneal Biomechanical Properties in Myopic and
		Anisometropic Patients Under Atropine Treatment
		Conditions: Myopia; Anisometropia
		Intervention:
51	Unknown †	Aberration-Free Refraction Correction
		Condition: Myopia
		Intervention:
52	Unknown [†]	Compare Anterior Chamber Biometry in Healthy and Post-LASIK
02		Patients
		Conditions: Myopia; Astigmatism
		Intervention:
53	Unknown †	Ocular Imaging With Spectral Domain Optical Coherence
		Tomography
		Conditions: Healthy; Myopia; Hypermetropia
		Intervention: Device: Spectral domain-OCT (Cirrus™
		Carl Zeiss Meditec AG)
54	Unknown [†]	Corrected Measurement of the Retinal Nerve Fiber Layer
		Thickness by Optic Disc Configuration With the Cirrus HD OCT
		Conditions: Glaucoma; Myopia
		Intervention:
55	Unknown †	Normative Database of the Retinal Nerve Fiber Layer Thickness
		Measured by the Cirrus HD OCT in Asians
		Condition: Glaucoma
		Intervention:
56	Unknown †	Genomewide Screening of Pathological Myopia
		Condition: Pathological Myopia
		Intervention:
57	Unknown [†]	Study of Myopia Prevention in Children With Low Concentration of
		Atropine
		Condition: Myopia
		Interventions: Drug: atropine; Drug: tropicamide
58	Unknown [†]	Randomized, Prospective Comparison of the Outcome of Toric

		Implantable Contact Long (TIC	CL) and Q-LASIK for the Correction
		of Myopia With Astigmatism	c) and Q-LASIK for the correction
		Conditions:	Muchice Actionation
			Myopia; Astigmatism
		Interventions:	Procedure: the implantation of toric
			implantable collamer
			lens; Procedure: customized
			laser-assisted in situ keratomileusis
59	Unknown [†]	Retardation of Myopia in Orth	
		Condition:	Муоріа
		Interventions:	Device: Orthokeratology lenses,
			Menicon Z Night
			Lens; Device: spherical plastic len
			ses
60	Unknown [†]	Comparative Study of the Wea	aring Satisfaction of Two Soft
		Contact Lens Designs.	
		Condition:	Муоріа
		Interventions:	Device: Currently marketed
			PureVision soft contact
			lens.; Device: Alternate design of
			PureVision soft contact lens.
61	Unknown [†]	Intravitreal Pegaptanib in Trea	atment of Choroidal
		Neovascularisation Secondary	y to Pathologic Myopia
		Condition:	Myopic Choroidal Neovascular M
			embrane
		Intervention:	Drug: Intravitreal Pegaptanib
62	Unknown [†]	Myopic Control for High Myop	es Using Orthokeratology
		Condition:	Муоріа
		Interventions:	Device: Orthokeratology lenses, Drea
			mLite lenses; Device: Single-vision
			spectacle lenses

54. Neuromyelitis Optica

Rank	Status	Study		
1	Recruiting	Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell		
		Therapy for Patients With Progressive Multiple Sclerosis and		
		Neuromyelitis Optica		
		Conditions: Progressive Multiple Sclerosis; Neuromyelitis Optica.		
		Intervention: Biological: human umbilical cord mesenchymal stem		
			cells	

55. Night Blindness

Rank	Status	Study	
1	Completed	Impact of Maternal Vitamin A	or Beta-Carotene
	Has Results	Supplementation on Maternal	and Infant Mortality in
	published	Bangladesh	
	in journals	Conditions:	Vitamin A Deficiency; Matern
			al Mortality; Infant Mortality
		Intervention:	Dietary Supplement: Vitamin A or Beta-Carotene Supplements
2	Completed	Dietary Vitamin A Requiremer	nt in Chinese Children and the
	no results	New Technology of Dietary As	ssessment
	published	Condition:	Vitamin A Deficiency
	yet	Intervention:	
3	Completed	Vitamin A Bioavailability in La	actating Women With Marginal
	no results	Vitamin A Status	
	published	Condition:	Vitamin A Deficiency
	yet	Interventions:	Other: 0 mg retinol activity eq
			uivalents; Other: 12 mg of B
			C; Other: 6 mg of CX; Oth
			er: 1.0 mg RAE
4	Completed	A Study on Immunological Eff	fect of Vitamin A and Zinc in a
	no results	Placebo Controlled 4 Cell Tria	<u>II</u>
	published	Conditions:	Immunity; Diarrhea; Respir
	yet		atory Tract Infections
		Intervention:	Drug: Zinc, or Vitamin A or both
5	Completed	Newborn Vitamin A (VA) Supp	plementation Pilot Project,
	no results	<u>Pakistan</u>	
	published	Condition:	Vitamin A Deficiency
	yet	Interventions:	Dietary Supplement: Vitamin A;
			Dietary Supplement: Placeb
			0
6	Completed	Efficacy of Vitamin A in Fortif	ied Extruded Rice in School
	no results	<u>Children</u>	
	published	Condition:	Vitamin A Deficiency
	yet	Intervention:	Dietary Supplement: Triple
			fortified extruded tice (Fe, Zn
			and vitamin A)
7	Completed	An Efficacy Trial of Iron, Zinc	and Vitamin A Fortified Rice in
	no results	Children in Satun, Thailand	
	published		

	yet	Conditions:	Vitamin A Deficiency; Iron De
			ficiency; Zinc Deficiency
		Intervention:	Dietary Supplement: fortified ex
			truded rice
8	Terminated	Community Trial of Newborn	Vitamin A Supplementation to
		Reduce Infant Mortality in Run	al Bangladesh
		Conditions:	Infant Mortality; Vitamin A De
			ficiency
		Intervention:	Drug: vitamin A supplementatio
			n (50,000 IU)
9	Recruiting	Efficacy of Newborn Vitamin	A Supplementation in
		Improving Immune Function	
		Condition:	Vitamin A Deficiency
		Interventions:	Dietary Supplement: retinyl pa
			Imitate; Dietary Supplement
			: Placebo

56. Nystagmus, Pathologic

Rank	Status	Study	
1	Completed	Treatment of Apogeotropic Ho	orizontal Canal Benign Paroxysmal
	Has Results	Positional Vertigo	
	published	Condition:	HC-BPPV
	in journals	Interventions:	Procedure: Gufoni maneuver; Proc
			edure: Head-shaking maneuver; Pi
			ocedure: sham maneuver
2	Completed	Treatment of Geotropic Horizo	ontal Canal Benign Paroxysmal
	no results	Positional Vertigo	
	published	Condition:	Benign Paroxysmal Positional Vertige
	yet	Interventions:	Procedure: Gufoni; Procedure: Sha
			; Procedure: Barbecue

57. Ocular Hypertension

Rank	Status	Study	
1	Completed	Safety and Efficacy of Brimor	nidine Tartrate/Timolol Fixed
	Has Results	Combination in Patients With	Glaucoma or Ocular
	published	Hypertension	
	on website	Conditions:	Glaucoma; Ocular Hypertension
		Interventions:	Drug: brimonidine tartrate/timolol
			fixed combination ophthalmic
			solution; Drug: brimonidine tartra
			te ophthalmic solution; Drug: tim
			olol ophthalmic solution; Other: fi
			xed combination vehicle
2	Completed	Safety and Efficacy of Bimato	pprost Timolol Ophthalmic
	Has Results	Solution in Patients With Ope	en Angle Glaucoma or Ocular
	published	Hypertension	
	on website	Conditions:	Open-angle Glaucoma; Ocular
			Hypertension
		Interventions:	Drug: 0.03% Bimatoprost/0.5%
			Timolol Ophthalmic
			Solution; Drug: 0.03%
			Bimatoprost Ophthalmic Solution
			and 0.5% Timolol Ophthalmic
			Solution
3	Completed	Systemic Glutathione Level in	n Normal Tension Glaucoma
	Has Results	Condition:	Normal Tension Glaucoma
	published	Intervention:	
	on website		
4	Completed		omized, Double-Masked, 12-Week,
	Has Results		atric Subjects With Glaucoma.
	published on website	Condition:	Glaucoma
		Interventions:	Drug: Timolol; Drug: latanoprost
5	Completed		And Xalatan In Patients With
	Has Results		na (POAG) Or Ocular Hypertension
	published	<u>(OH).</u>	
	on website	Conditions:	Glaucoma, Primary Open Angle (
			POAG); Ocular Hypertension
		Interventions:	Drug: Xalacom (KP2035); Drug
			: Xalatan
6	Completed	Ologen (OculusGen)-Phacotra	abeculectomy Historical Control
	Has Results	Study in India	

	nublished	0	
	published in journals	Conditions:	Glaucoma; Cataract
	in journais	Intervention:	Device: OculusGen
			Biodegradable Collagen Matrix
			Implant
7	Completed	Investigation of Genetic Disea	se Marker Associated With
	no results	Korean Glaucoma Patients	
	published	Condition:	Single-nucleotide Polymorphism
	yet		(SNP) for Glaucoma
		Intervention:	Genetic: SNP analysis of the DN
			A
8	Completed		Unfixed Latanoprost And Timolol
	no results	In Subjects With Open-Angle	<u>Glaucoma Or Ocular</u>
	published	<u>Hypertension</u>	
	yet	Conditions:	Glaucoma, Open Angle; Ocula
			r Hypertension
		Interventions:	Drug: Xalacom; Drug: unfixed
			Latanoprost and Timolol
9	Completed	DuoTrav® Eye Drops As Repla	
	no results	Conditions:	Open-angle Glaucoma; Ocular
	published		Hypertension
	yet	Intervention:	Drug: DuoTrav
10	Completed	Ologen (OculusGen)-Glaucom	
	no results	Control Study in Beijing Remi	
	published	Conditions:	Glaucoma; Pterygium
	yet	Intervention:	Device: OculusGen
			Biodegradable Collagen Matrix
			Implant
11	Completed	Ologen (OculusGen)-Glaucom	
	no results	Control Study in China Zhong	-
	published	Conditions:	Glaucomas; Pterygium
	yet	Intervention:	Device: OculusGen
			Biodegradable Collagen Matrix
			Implant
12	Completed	Ologen (OculusGen)-Glaucom	
	no results	Control Study in China Beijing	
	published	Conditions:	Glaucoma; Pterygium
	yet	Intervention:	Device: OculusGen Biodegradable
			Collagen Matrix Implant

13	Completed	Safety and Efficacy of Triple C	Combination Therapy in Patients
	no results	With Glaucoma or Ocular Hyp	ertension
	published	Conditions:	Glaucoma; Ocular Hypertensio
	yet		n
		Intervention:	Drug: bimatoprost/brimonidine
			tartrate/timolol fixed combination
			ophthalmic solution
14	Completed	A Study Comparing The Effica	acy, Safety And Tolerability Of
	no results	Latanoprost 75, 100 And 125 u	<u>ig/ml To Xalatan In The Treatment</u>
	published	Of Primary Open-Angle Glauc	oma And Ocular Hypertension
	yet	Conditions:	Primary Open Angle Glaucoma;
			Ocular Hypertension
		Interventions:	Drug: latanoprost 75 ug; Drug:
			latanoprost 100 ug; Drug: latan
			oprost 125 ug; Drug: latanopro
			st 50 ug
15	Completed	Ologen (OculusGen)-Glaucom	na MMC Control in Pakistan
	no results	Conditions:	Glaucoma; Trabeculectomy
	published	Interventions:	Device: ologen collagen matrix in
	yet		glaucoma filtering
			surgery; Drug: MMC in glauco
			ma filtering surgery
16	Completed		and Peripapillary Retinal Blood
	no results	Flow in Medically Controlled (
	published	Condition:	Open-Angle Glaucoma
	yet	Intervention:	
17	Completed	ELAZOP Switching Study in K	Corea
	no results	Condition:	Open Angle Glaucoma
	published	Intervention:	Drug: Elazop (Azarga)
18	yet Completed	Long-Torm IOP Eluctuation ar	nd VF Progression After Triple
10	no results	Procedure	IN TELESSION ALLER TIPLE
	published	Conditions:	Glaucoma; Filtering Surgery;
	yet	Conditions.	Intraocular Pressure
	,	Intervention:	
10	Completed		mil Aroa, South Karaa
19	Completed no results	Screening for Glaucoma in Na	
	published	Conditions:	Glaucoma; Intraocular Pressur e; Optic Nerve Head; Visual
	yet		Field
	,		i ioiu

		Intervention:	
20	Completed	A Study to Evaluate Efficacy a	nd Safety Effects Using Mikelan®
	no results	LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE	
	published	Ophthalmic Solution (OS) 0.5%	<u>% in Ocular Hypertension Patients</u>
	yet	Condition:	Glaucoma
		Intervention:	Drug: carteolol (Mikelan), timolol
			(Timoptol), latanoprost (Xalatan)
21	Terminated	OculusGen-Glaucoma Historio	cal Control Study in Taiwan
		Condition:	Glaucoma
		Intervention:	Device: OculusGen
			Biodegradable Collagen Matrix
			Implant
22	Completed	Comparison of Anterior Cham	ber Paracentesis and
	no results	Conventional Mannitol Infusio	on in Patients With Primary Acute
	published	Angle-closure Glaucoma	
	yet	Conditions:	Glaucoma; Acute Primary Angl
			e-closure Glaucoma
		Intervention:	
23	Completed	A 5-Year Postmarketing Safety	y Study Of Xalcom In Patients
	no results	With Open Angle Glaucoma O	r Ocular Hypertension
	published	Conditions:	Glaucoma, Open-Angle; Ocula
	yet		r Hypertension
		Intervention:	Drug: Xalacom
24	Completed	Tolerability, Safety and Efficat	cy of SAD448 in Subjects With
	no results	Ocular Hypertension	
	published	Condition:	Ocular Hypertension
	yet	Intervention:	Drug: SAD448
25	Completed	Safety and Efficacy of a New F	
	no results	Bimatoprost/Timolol Ophthaln	
	published	Bimatoprost/Timolol Ophthalmic Solution in Patients With	
	yet	Glaucoma or Ocular Hyperten	
		Conditions:	Glaucoma; Ocular Hypertensio
		Interventions	n Drug: himatoprost /timolol
		Interventions:	Drug: bimatoprost /timolol formulation A ophthalmic
			solution; Drug: Ganfort®
			(bimatoprost 0.03%/timolol 0.5%
			ophthalmic solution)

26	Completed	A Safety and Efficacy Study of Travoprost 0.004% Compared to
	no results	Latanoprost 0.005% in Patients With Chronic Angle-Closure
	published	Glaucoma
	yet	Conditions: Glaucoma, Angle-Closure; Ocu
		lar Hypertension
		Interventions: Drug: Travoprost (0.004%); Dr
		ug: Latanoprost (0.005%)
27	Completed	IOP-Lowering Efficacy of Brinzolamide 1.0% Added to
	no results	Travoprost 0.004%/Timolol 0.5% Fixed Combination as
	published	Adjunctive Therapy
	yet	Condition: Glaucoma
		Intervention: Drug: Azopt
28	Completed	Optic Nerve Compliance Study
	no results	Condition: Glaucoma
	published	Intervention: Procedure: Brief Elevation of IOP
	yet	
29	Completed	A Study of Ganfort Versus Duotrav in Patients With Primary
	no results	Open Angle Glaucoma or Ocular Hypertension
	published	Conditions: Ocular Hypertension; Primary
	yet	Open Angle Glaucoma
		Interventions: Drug: Ganfort; Drug: Duotrav
30	Completed	Results of Mass Switch From Latanoprost to Travoprost
	no results	Condition: Glaucoma
	published	Intervention:
	yet	
31	Completed	Laser Iridotomy Versus Phacoemulsification in Acute Angle
	no results	Closure
	published	Condition: Angle Closure Glaucoma
	yet	Intervention: Procedure: Laser Preipheral
		Iridotomy and
		phacoemulsification
32	Completed	Role of Polymorphisms in the IL-1 Gene Cluster
	no results	Condition: Glaucoma
	published	Intervention:
	yet	Onticel Coherence Temorrowhy Incoming of the Destantics
33	Completed no results	Optical Coherence Tomography Imaging of the Posterior Segment in High Myopia.
	published	
	yet	Conditions: Myopia; Maculopathy; Glauc
	yer	oma

		Intervention:	
34	Completed	5FU vs 5FU With Viscoelastic	Formulation for the Prevention of
	no results	Scarring Post-trabeculectomy	<u>r</u>
	published yet	Conditions:	Glaucoma; Trabeculectomy; Wound Healing
		Interventions:	Drug: 5 Fluorouracil with hyaluro nic acid; Drug: 5 Fluorouracil
35	Completed	Sequential Laser Iridotomy Us	sing Argon and Q-Switched 532
	no results	nm Frequency Doubled Neody	ymium Yag Laser: A Pilot Study
	published	Conditions:	Chronic Angle Closure Glaucoma
	yet		; Primary Angle Closure; Pri
			mary Angle Closure Suspect; F
			ellow Eyes of Acute Angle Closur
			e Glaucoma
		Intervention:	Procedure: Q-switched fd Nd:yag
			in Laser Iridotomy
36	Completed	The Performances of Spectral	
	no results	Tomography (OCT) for Disting	
	published	Conditions:	Glaucoma Patient; Glaucoma
	yet		Suspect Patient; Normal Popul ation; RNFL Thickness by Loc
			ation; Macular Thickness by Loc
			cation
		Intervention:	
37	Terminated	Study of Brimonidine and Tim	olol Ophthalmic Solution With
		Latanoprost Compared With L	_atanoprost in Glaucoma Patients
		Condition:	Glaucoma, Angle-Closure
		Interventions:	Drug: brimonidine 0.2%/timolol
			0.5% fixed combination
			ophthalmic
			solution; Drug: latanoprost
38	Completed	A Phase 2, Dose Finding Stud	y of PF-03187207 in Patients With
	no results	Primary Open Angle Glaucom	
	published	Conditions:	Primary Open Angle Glaucoma;
	yet		Ocular Hypertension
		Interventions:	Drug: PF-03187207; Drug: Lat
			anoprost
39	Completed		Efficacy of DE-104 Ophthalmic
	no results	Solution to Treat Open-Angle	Glaucoma or Ocular

	published	Hypertension	
	yet	Conditions:	Open-Angle Glaucoma; Ocular Hypertension
		Interventions:	Drug: DE-104 ophthalmic solutio n; Drug: DE-104 vehicle
40	Completed	Safety and Efficacy Study of E	DE-104 Ophthalmic Solution to
	no results	Treat Open-Angle Glaucoma o	or Ocular Hypertension
	published	Conditions:	Open-Angle Glaucoma; Ocular
	yet		Hypertension
		Interventions:	Drug: DE-104 ophthalmic
			solution, low
			concentration; Drug: DE-104
			ophthalmic solution, medium concentration; Drug: DE-104
			ophthalmic solution, high
			concentration; Drug: DE-104 v
			ehicle
41	Completed	DE-111 Against Timolol Ophth	nalmic Solution 0.5%
	no results	Conditions:	Open Angle Glaucoma; Ocular
	published		Hypertension
	yet	Interventions:	Drug: DE-111 ophthalmic solutio
			n; Drug: Timolol ophthalmic sol ution 0.5%
42	Completed	DE-111 Against Tafluprost Op	hthalmic Solution 0.0015% Alone
	no results	and Concomitant Use of Taflu	prost Ophthalmic Solution
	published	0.0015% Plus Timolol Ophthal	Imic Solution 0.5%
	yet	Conditions:	Open Angle Glaucoma; Ocular Hypertension
		Interventions:	Drug: DE-111 ophthalmic solutio n; Drug: Tafluprost ophthalmic
			solution 0.0015%; Drug:
			Concomitant use of tafluprost
			ophthalmic solution 0.0015% plus
43	Completed	Safaty and Efficiency of Travers	timolol ophthalmic solution 0.5%
43	Completed no results	Safety and Efficacy of Travopu Conditions:	Open-angle Glaucoma; Ocular
	published	Conditions.	Hypertension
	yet	Interventions:	Drug: Travoprost 0.004%/Timolol
			0.5% BAC-free Ophthalmic

			Solution; Drug: Travoprost		
			0.004%/Timolol 0.5% Ophthalmic		
			Solution (DuoTrav®)		
44	Completed	Safety and Efficacy of Brinzol	· · · · ·		
	no results	Dorzolamide Dosed TID in Reducing Intraocular Pressure in			
	published		ucoma or Ocular Hypertension		
	yet	Conditions:	Glaucoma; Ocular Hypertension		
		Interventions:	Drug: Azopt; Drug: Cosopt		
45	Completed	Study of PGA Suture in Ophth	almology		
	no results	Condition:	Glaucoma		
	published	Intervention:	Device: Polyglycolic acid suture		
	yet				
46	Enrolling	The High Cup/Disc Ratio in Ch	<u>nildren</u>		
	by	Condition:	Glaucoma		
	invitation	Intervention:			
47	Active, not	Clinical Evaluation of Safety a	nd Efficacy of Refrigeration Free		
	recruiting	<u>Latanoprost</u>			
		Conditions:	Glaucoma, Open-Angle; Ocula		
			r Hypertension		
		Interventions:	Drug: refrigeration free latanopro		
			st; Drug: latanoprost eye drops		
48	Active, not		trol Implant: Randomized Trial for		
	recruiting	Refractory Glaucoma			
		Conditions:	Glaucoma; Glaucoma, Open A ngle		
		Interventions:	Device: SOLX Gold Shunt GMS-		
		interventions.	plus; Device: Ahmed FP7 Glau		
			coma Valve		
49	Enrolling	Impact of Health Literacy and			
	by	Patient Adherence in South In			
	invitation	Conditions:	Patient Noncompliance; Health		
			Literacy; Glaucoma		
		Intervention:			
50	Active, not	A Safety and Efficacy Study o	f Bimatoprost 0.01% in Primary		
	recruiting	Open-Angle Glaucoma (POAG	i) or Ocular Hypertension (OH)		
		Conditions:	Glaucoma, Open-Angle; Ocula		
			r Hypertension		
		Intervention:	Drug: Bimatoprost 0.01%		

51	Not yet	Post-operative Satisfaction With Glaucoma Surgery Trial		
51	recruiting		Condition:	Glaucoma
	looraning		rventions:	Behavioral: film and trained coun
		Inte	iventions.	seling; Other: traditional couns
				eling
52	Not yet	Safety and Efficacy of Triple Combination Therapy With		
	recruiting	Dorzolamide Hydro	ochloride / E	Brimonidine Tartrate / Timolol
		Ophthalmic Solution in Patients With Glaucoma or Ocular		
		Hypertension		
		С	onditions:	Glaucoma; Ocular Hypertensio n
		Int	ervention:	Drug: dorzolamide hydrochloride
				2.0%/brimonidine tartrate
				0.2%/timolol 0.5% ophthalmic
				solution (Triple Combination Therapy)
53	Recruiting	Evaluation of Safe	ty and Effic	acy of Glaucoma Shunt (Aurolab
	ricorating			Refractory Glaucoma
			Condition:	Glaucoma
		Int	ervention:	Device: Artificial drainage implant
54	Recruiting	Clinical Evaluation	of Efficacy	of SLT to Topical Medication in
		Lowering IOP		
			Condition:	Glaucoma
		Inte	rventions:	Drug: Latanoprost; Procedure: SLT
55	Recruiting	Clinical and Molec	ular Studies	s in Families With Glaucoma and
		Related Diseases		
			Condition:	Glaucoma
			ervention:	
56	Recruiting			Ophthalmic Formulation of
		Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension		
		Conditions:	Open-Anal	e Glaucoma;
		conditions.	Ocular Hyp	
		Interventions:		toprost ophthalmic
		formulation A; Drug: bimatopr		
			ost ophtha	Imic formulation B;
			Drug: bima	toprost ophthalmic
			formulation	n C;

1				
		Drug: bima	atoprost ophthalmic	
		formulatior	n D; Drug: bimatopr	
		ost ophtha	Imic formulation	
		E; Drug:	bimatoprost ophthalm	
		ic formulat	ion F; Drug: Sham;	
		Drug: time	olol 0.5%; Drug:	
		bimatoprost ophthalmic solution		
		0.03%;	Drug: latanoprost	
		0.005%;	Drug: timolol vehicle (placebo)	
57	Recruiting	Ologen (OculusGen)-Glaucom	na Case Control Trial in India	
		Condition:	Glaucoma	
		Intervention:	Device: OculusGen	
			Biodegradable Collagen Matrix	
			Implant	
58	Recruiting	DE-111 Ophthalmic Solution i	•	
	, C	Glaucoma or Ocular Hyperten		
		Condition:		
			Hypertension	
		Intervention:	Drug: DE-111 ophthalmic solutio	
		intervention.		
59	Recruiting	Preservative-Free Tafluprost ((MK-2452) for the Treatment of	
		Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002		
		AM1)		
		Conditions:	Glaucoma; Ocular Hypertensio	
			n	
		Interventions:	Drug: Preservative-Free Taflupro	
			st or vehicle; Drug: Preservativ	
			e-Free Timolol maleate	
60	Recruiting	Results of Adjunctive Intraop	erative Bevacizumab Injection on	
	itteria	Trabeculectomy Outcome		
		Condition:	Glaucoma	
		Interventions:	Drug: Bevacizumab; Drug: Mit	
		interventions.	omycin C	
61	Recruiting	Efficacy and Safety Study of C	Combigan and 0.5% Timoptic in	
		Normal Tension Glaucoma		
		Condition:	Normal Tension Glaucoma	
		Interventions:	Drug: Brimonidine/Timolol mixed	
			combination; Drug: Timolol	
62	Recruiting	Hydroxypropylmethylcellulos	e 0.3% and Sodium Hyaluronate	

		0.18% for Ocular Surface Disease in Glaucoma		
		Conditions:	Ocular Surface Disease; Glauc	
			oma	
		Interventions:	Drug: hydroxypropylmethylcellulo	
			se; Drug: sodium hyaluronate	
63	Recruiting	The Effect of "Eye Drop Guide	e" on the Success Rate of Eye	
		Drops Self-instillation in Glau	coma Patients	
		Condition:	Eye Drops Self-instillation	
		Interventions:	Device: Eye Drop Guide techniqu	
			e; Behavioral: Routine self-insti	
			llation technique	
64	Recruiting		f Chinese Patients With Normal	
		Tension Glaucoma Condition:	Clausama	
			Glaucoma	
	Descritions	Intervention:		
65	Recruiting		and Ocular Hypotensive Efficacy Elevated Intraocular Pressure for	
		<u>3 Months</u>		
		Conditions:	Ocular Hypertension; Open-an	
			gle Glaucoma	
		Interventions:	Drug: AR-12286 Ophthalmic Solu	
			tion 0.7%; Drug: AR-12286 Op	
			hthalmic Solution 0.5%; Drug:	
			Timolol maleate ophthalmic soluti	
			on 0.5%	
66	Recruiting	Ologen (OculusGen)-Glaucom		
		Condition:	Glaucoma	
		Interventions:	Device: OculusGen	
			Biodegradable Collagen Matrix Implant; Drug: Trabeculectomy	
			with MMC	
67	Recruiting	A Study of the Safety and Effi	cacy of Bimatoprost Ophthalmic	
		Solution in Paediatric Patients		
		Condition:	Glaucoma	
		Interventions:	Drug: bimatoprost ophthalmic	
			solution formulation A,	
			bimatoprost	
			vehicle; Drug: timolol ophthalm	
			ic solution	

68	Recruiting	A Study of the Safety and Effi	cacy of Bimatoprost Ophthalmic	
	5	Solution in Paediatric Patients With Glaucoma		
		Condition:	Glaucoma	
		Interventions:	Drug: bimatoprost ophthalmic solution formulation A, bimatoprost vehicle; Drug: timolol ophthalm ic solution	
69	Recruiting	A Study of the Safety and Effi		
	g	A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma		
		Condition:	Glaucoma	
		Interventions:	Drug: bimatoprost ophthalmic solution formulation A, bimatoprost vehicle; Drug: timolol ophthalmic solution	
70	Unknown [†]	The Effect of Bevacizumab on		
		Condition:	Glaucoma	
		Intervention:	Drug: intraocular injections of bev acizumab	
71	Unknown [†]	Efficacy of Retinal Nerve Fibe	r Layer (RNFL) / Retinal	
		Thickness Ratio by Cirrus OC		
		Technology as a Diagnostic P		
		Conditions:	Glaucoma; Myopia	
		Intervention:		
72	Unknown [†]	Personality Characteristics an Antiglaucoma Medication	id Compliance With	
		Condition:	Glaucoma	
		Intervention:	Cladoonia	
73	Unknown [†]	Retinal Nerve Fiber Layer Thic	kness Measurement on	
		Parapapillary Atrophy With the		
		Optical Coherence Tomograp	<u>hy (OCT)</u>	
		Condition:	Glaucoma	
		Intervention:		
74	Unknown [†]	Combigan Ophthalmic Solution	on(Brimonidine 0.2% and Timolol	
		0.5%)With Latanoprost Compa	ared With Latanoprost	
		<u>Monotherapy</u>		
		Condition:	Glaucoma	
		Intervention:	Drug: Combigan Ophthalmic Sol	

			utiom	
75	Unknown [†]	Intraocular Pressure and Ocu	lar Perfusion Pressure of Cosopt	
		in Normal Tension Glaucoma		
		Condition:	Normal Tension Glaucoma	
		Interventions:	Drug: dorzolamide/timolol fixed co mbination; Drug: latanoprost	
76	Unknown [†]	Normative Database of the Re	tinal Nerve Fiber Layer Thickness	
		Measured by the Cirrus HD O		
		Condition:	Glaucoma	
		Intervention:		
77	Unknown [†]	Corneal Endothelium After Gla	aucoma Surgery	
		Conditions:	Glaucoma; Corneal Damage; I	
		Intervention:		
78	Unknown [†]	The Genetic Characteristics in	n South Korean Patients With	
		Primary Congenital Glaucoma	<u>a</u>	
		Condition:	Primary Congenital Glaucoma	
		Intervention:		
79	Unknown [†]	Efficacy of Retinal Nerve Fibe	r Layer (RNFL) / Ganglion Cell	
		Layer Thickness Ratio by RT-View Utilizing Spectral -Domain		
		Technology as a Diagnostic Predictor of Glaucoma.		
		Condition:	Primary Open Angle Glaucoma	
		Intervention:		
80	Unknown [†]	Psychopathology of Normal-te	ension Glaucoma in Hong Kong	
		Chinese Out-patient		
		Condition:	Glaucoma	
		Intervention:		
81	Unknown [†]	Ologen(Oculusgen)-Glaucoma	a and Pterygium Historical	
		Control Study in China Shang	hai Sixth People's Hospital	
		Conditions:	Glaucomas; Pterygium	
		Intervention:	Device: ologen™ Collagen	
			matrix implantation in glaucoma	
			filtering surgery	
82	Unknown [†]	The Genetic Study of Primary		
		Condition:	Glaucoma	
		Intervention:		
83	Unknown [†]	Corrected Measurement of the		
		Thickness by Optic Disc Configuration With the Cirrus HD OCT		

		Conditions:	Glaucoma; Myopia
		Intervention:	
84	Unknown [†]	Comparison of Bimatoprost a	nd Latanoprost in Patients With
		Chronic Angle-Closure Glauce	oma: A Randomized Cross-Over
		<u>Study</u>	
		Condition:	Glaucoma, Angle-Closure
		Interventions:	Drug: Latanoprost-Bimatoprost;
			Drug: Bimatoporost-Latanoprost
85	Unknown [†]	Oculusgen (Ologen) Collagen	Matrix Implant for
		Phaco-Trabeculectomy in Prin	mary Glaucoma: A Case-Control
		<u>Study</u>	
		Conditions:	Cataract; Glaucoma
		Intervention:	Device: ologen™ Collagen Matrix
			Implant as an aid in
			phacotrabeculectomy surgery
86	Unknown [†]	Intraocular Pressure (IOP) Lov	wering Effect of Selective Laser
		Trabeculoplasty Versus Prost	aglandin Analogues in Angle
		Closure Glaucoma	
		Condition:	Glaucoma
		Interventions:	Procedure: Selective Laser Trabec
			uloplasty; Drug: Travoprost/ Tim
			olol/ Azopt/ Brimonidine
87	Unknown [†]		Versus Micropulse Transscleral
		Cyclophotocoagulation in Tre	
			Advanced Glaucoma; Refractory
		Interventions:	Procedure: Micropulse Transscleral
			Cyclophotocoagulation; Procedur
			Conventional Transscleral
00	Unknown †	Combined Desetute us Direc	Cyclophotocoagulation
88		Combined Phacotube vs Phac	cotrabeculectomy:A Randomized
		Conditions:	Glaucoma: Cataract
			,
		Interventions:	Procedure: Glaucoma Implant Sur
			gery; Procedure: trabeculectomy ; Procedure: phacoemulsification
89	Unknown [†]	Imaging Abmed Clausome Tu	bes With a Pericardial Graft and
09	UIKIUWII	Tissue Glue or Partial-Thickne	
		Conditions:	Advanced Glaucoma; Failed Tr
		Conditions.	Auvanueu Glaucoma, Talleu II

			abeculectomies	
		Interventions:	Procedure: Pericardial graft & tis	
			sue glue; Procedure: scleral fla	
			p & sutures	
90	Unknown [†]	Relationship Between Topiran	nate Use and Ocular Angle Status	
		Condition:	Glaucoma, Angle-Closure	
		Intervention:	Drug: Topiramate	
91	Unknown [†]	Subconjunctival Bevacizumat	o to Prevent Bleb Failure After	
		Glaucoma Filtration Surgery		
		Condition:	Glaucoma	
		Intervention:	Drug: Subconjunctival Bevacizuma	
			b	
92	Unknown [†]	Argon Laser Peripheral Iridop	lasty for Primary Angle Closure	
		<u>Glaucoma</u>		
		Condition:	Glaucoma	
		Interventions:	Procedure: Argon Laser Iridoplas	
			ty; Drug: Travatan/ Timolol/Azo	
			pt	
93	Unknown [†]	ALPI vs Medical Therapy Effect	cts on Optic Nerve Structure &	
		Function		
		Condition:	Glaucoma	
		Interventions:	Procedure: Argon laser Iridoplasty;	
			etazolamide	
94	Unknown [†]	External Micropulse Diode Las	ser Transscleral Trabeculoplasty	
		(EMDLT) for Severe Open Ang	<u>le Glaucoma</u>	
		Condition:	Primary Open Angle Glaucoma	
		Intervention:	Device: EXTERNAL	
			MICROPULSE DIODE LASER	
			TRANSSCLERAL	
			TRABECULOPLASTY	
95	Unknown [†]	Prospective Evaluation of the Efficacy of Pascal Laser		
		Iridotomy and Pascal Laser Po	eripheral Iridoplasty: A Pilot	
		<u>Study</u>		
		Condition:	Glaucoma	
		Intervention:	Procedure: pattern scanning	
			laser iridotomy and iridoplasty	
96	Unknown [†]	Comparison of Retinal Nerve Fiber Layer (RNFL) Thickness		
		Measurements by Time-Domain and Spectral-Domain OCT In		

		Glaucoma Patients
		Condition: Primary Open Angle Glaucoma
		Intervention:
97	Unknown [†]	Discriminating Ability of the Cirrus High Definition (HD) Optical
		Coherence Tomography (OCT) for Glaucoma
		Condition: Glaucoma
		Intervention:
98	Unknown †	Retinal Nerve Fiber Layer Thickness Analysis With Cirrus HD
		OCT Versus Stratus Optical Coherence Tomography (OCT)
		Condition: Glaucoma
		Intervention:

58. Ocular Motility Disorders

Rank	Status	Study		
1	Completed	Under-correction in Refractive	Accommodative Esotropia	
	no results	Condition:	Accommodative Esotropia	
	published	Intervention:	Device: Glasses prescription	
	yet			
2	Completed	Long-Term Outcomes in the T		
	no results	Acquired Esotropia With Botu		
	published	Condition:	Esotropia	
	yet	Intervention:		
3	Completed		ufficiency Intermittent Exotropia	
	no results	Condition:	Complications	
	published	Interventions:	· · · · · · · · · · · · · · · · · · ·	
	yet		ery; Procedure: Orthoptics; Procedure: Postop orthoptics;	
			Procedure: Post exercises surg	
			ery	
4	Active, not	Study to Evaluate the Safety a	and Efficacy of Davunetide for the	
	recruiting	Treatment of Progressive Sup		
		Condition:	Progressive Supranuclear Palsy	
		nterventions:	Drug: Davunetide; Drug: Place	
			bo	
5	Recruiting	The Effect of Dexmedetomidine on Decreasing Emergence		
		Agitation and Delirium in Pedi	iatric Patients Undergoing	
		Strabismus Surgery		
		Condition:	Strabismus	
		Interventions:	Drug: Dexmedetomidine;	
			Drug: placebo group	
6	Recruiting	A Study on the Effects of Mida	azolam on Delirium After	
		Sevoflurane Anesthesia in Pe	diatric Strabismus Surgery	
		Conditions:	Child; Anesthesia Morbidit	
			y; Delirium on Emergence	
		Interventions:	Drug: Midazolam 0.03mg/kg;	
			Drug: Midazolam 0.05mg/	
			kg; Drug: Placebo	
7	Recruiting	Efficacy and Safety of GSK13	58820 (Botulinum Toxin Type A)	
		in Patients With Strabismus		
		Condition:	Strabismus	
		Intervention:	Drug: GSK1358820	
8	Recruiting	International Guillain-Barré Sy	<u>/ndrome Outcome Study</u>	

		Conditions:	Guillain-Barré Syndrome;
			Miller Fisher Syndrome
		Intervention:	
9	Recruiting	Cyclophosphamide and Prednisone With or Without	
		Immunoglobulin in Treating A	bnormal Muscle Movement in
		Children With Neuroblastoma	
		Condition:	Neuroblastoma
		Interventions:	Biological: therapeutic im
			mune globulin; Other: c
			linical observation
10	Recruiting	International Guillain-Barré Sy	yndrome Outcome Study
		Conditions:	Guillain-Barré Syndrome
			; Miller Fisher Syndro
			me
		Intervention:	
11	Recruiting	Study of Non-surgical Treatm	ent Versus Observation in Asian
		Children With Intermittent Exc	otropia
		Condition:	Intermittent Exotropia
		Intervention:	Procedure: Non surgical ther
			ару
12	Recruiting	Assessing the Functional and	Psychosocial Impact of
		Strabismus in Asian Children	Using the AS-20 and IXTQ
		Questionnaires	
		Condition:	Strabismus
		Intervention:	

59. Ophthalmoplegia

Rank	Status	Study	
1	Completed	Efficacy of Aurosling in Frontalis Sling Suspension Surgery	
	no results	Condition: Ptosis, Eyelid	
	published vet	Intervention: Procedure: Aurosling	
2	Active, not	Study to Evaluate the Safety and Efficacy of Davunetide for	
	recruiting	the Treatment of Progressive Supranuclear Palsy	
		Condition: Progressive Supranuclear Palsy	
		Interventions: Drug: Davunetide; Drug: Placebo	

60. Opsoclonus-Myoclonus Syndrome

Rank	Status	Study	
1	Recruiting	Cyclophosphamide and Prednisone With or Without	
		Immunoglobulin in Treating Abnormal Muscle Movement in	
		Children With Neuroblastoma	
		Condition: Neuroblastoma	
		Interventions:	Biological: therapeutic immune gl
			obulin; Other: clinical observati
			on

61. Optic Atrophies

Rank	Status	Study	
1	Recruiting	Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber	
		Hereditary Optic Neuropathy (LHON)	
		Condition: Leber Hereditary Optic Neuropathy	
		Intervention: Drug: rAAV2-ND4	
1	Unknown [†]	Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung	
		Adenocarcinoma	
		Condition: Lung Adenocarcinoma	
		Intervention:	
1	Unknown [†]	A Randomized, Double-Blind, Placebo-Controlled Trial of	
		Curcumin in Leber's Hereditary Optic Neuropathy (LHON)	
		Condition: Optic Atrophy, Hereditary, Leber	
		Intervention: Drug: curcumin	

62_Optic Nerve Diseases

Rank	Status	Study	
1	Completed	Systemic Glutathione Level in Normal Tension Glaucoma	
	Has Results	Condition:	Normal Tension Glaucoma
	published on	Intervention:	
	website		
2	Completed	TLR-9 Antagonism in Steroid	Resistant Optic Neuritis
	no results	Condition:	Optic Neuritis
	published	Intervention:	Drug: Mycobacterium
	yet		w.(Mw)-freeze dried extract
			0.5ml
3	Terminated	Atacicept in Optic Neuritis, Ph	nase II
		Condition:	Optic Neuritis
		Interventions:	Drug: Atacicept; Drug: Pla
			cebo
4	Recruiting	Safety and Efficacy Study of r	AAV2-ND4 Treatment of Leber
		Hereditary Optic Neuropathy (<u>'LHON)</u>
		Condition:	Leber Hereditary Optic Neur
			opathy
		Intervention:	Drug: rAAV2-ND4
5	Recruiting	PDE5 Inhibitor Use and Non-a	rteritic Anterior Ischemic
		Optic Neuropathy (NAION)	
		Condition:	Anterior Ischemic Optic Neu
			ropathy
		Intervention:	Drug: Diagnostic procedure
			S
6	Recruiting	Safety and Efficacy of Umbilio	al Cord Mesenchymal Stem
		Cell Therapy for Patients With	Progressive Multiple
		Sclerosis and Neuromyelitis C	<u> Optica</u>
		Conditions:	Progressive Multiple Scleros
			is; Neuromyelitis Optica.
		Intervention:	Biological: human umbilical
			cord mesenchymal stem
			cells
7	Recruiting	Analysis of Clinical Profiles of	f Chinese Patients With
		Normal Tension Glaucoma	
		Condition:	Glaucoma
		Intervention:	
8	Recruiting	Efficacy and Safety Study of C	Combigan and 0.5% Timoptic
		in Normal Tension Glaucoma	

Condition: Normal Tension Glaucoma Interventions: Drug: Brimonidine/Timolol m ixed combination; Drug: Ti molol Precruiting 2150N201 BllB033 In Acute Optic Neuritis (AON) P Not yet 2150N201 BllB033 In Acute Optic Neuritis (AON) Intervention: Biological: BllB033 10 Unknown † Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient Condition: Glaucoma Intervention: Glaucoma Intervention: Glaucoma Intervention: Glaucoma				
9 Not yet 215ON201 BIIB033 In Acute Optic Neuritis (AON) 9 Not yet 215ON201 BIIB033 In Acute Optic Neuritis (AON) Condition: Acute Optic Neuritis Intervention: Biological: BIIB033 10 Unknown † Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient Condition: Glaucoma Intervention:			Condition: Normal Tension Glaucom	a
molol 9 Not yet recruiting 215ON201 BIIB033 In Acute Optic Neuritis (AON) Condition: Acute Optic Neuritis Intervention: Biological: BIIB033 10 Unknown † Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient Condition: Glaucoma Intervention: Glaucoma			Interventions: Drug: Brimonidine/Timolo	l m
9 Not yet recruiting 215ON201 BIIB033 In Acute Optic Neuritis (AON) Condition: Acute Optic Neuritis Intervention: Biological: BIIB033 10 Unknown † Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient Condition: Glaucoma Intervention:			ixed combination; Drug	: Ti
recruiting Condition: Acute Optic Neuritis Intervention: Biological: BIIB033 10 Unknown ⁺ Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient Condition: Glaucoma Intervention: Glaucoma			molol	
Intervention: Biological: BIIB033 10 Unknown [†] Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient Condition: Glaucoma Intervention: Glaucoma	9 Not yet	9	215ON201 BIIB033 In Acute Optic Neuritis (AON)	
10 Unknown [†] Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient Condition: Glaucoma Intervention:	recruitin		Condition: Acute Optic Neuritis	
Kong Chinese Out-patient Condition: Glaucoma Intervention:			Intervention: Biological: BIIB033	
Condition: Glaucoma Intervention:	10 Unknown	10	Psychopathology of Normal-tension Glaucoma in Hong	1
Intervention:			Kong Chinese Out-patient	
			Condition: Glaucoma	
11 Unknown [†] Intraocular Pressure and Ocular Perfusion Pressure of			Intervention:	
	11 Unknown	11	Intraocular Pressure and Ocular Perfusion Pressure of	-
Cosopt in Normal Tension Glaucoma			Cosopt in Normal Tension Glaucoma	
Condition: Normal Tension Glaucoma			Condition: Normal Tension Glaucom	a
Interventions: Drug: dorzolamide/timolol fix			Interventions: Drug: dorzolamide/timolol	l fix
ed combination; Drug: lat			ed combination; Drug: I	lat
anoprost			anoprost	
12 Unknown [†] Expression of Optic Atrophy Type 1 (OPA1) Protein in Lun	12 Unknown	12	Expression of Optic Atrophy Type 1 (OPA1) Protein in L	_ung
Adenocarcinoma			Adenocarcinoma	
Condition: Lung Adenocarcinoma			Condition: Lung Adenocarcinoma	
Intervention:			Intervention:	

63. Optic Neuritis

Rank	Status	Study	
1	Completed	TLR-9 Antagonism in Steroid Resistant Optic Neuritis	
	no results	Condition:	Optic Neuritis
	published	Intervention:	Drug: Mycobacterium
	yet		w.(Mw)-freeze dried extract
			0.5ml
2	Terminated	Atacicept in Optic Neuritis, Ph	nase II
		Condition:	Optic Neuritis
		Interventions:	Drug: Atacicept; Drug: Placeb
			0
3	Recruiting	Safety and Efficacy of Umbilical Cord Mesenchymal Stem	
		Cell Therapy for Patients With Progressive Multiple Sclerosis	
		and Neuromyelitis Optica	
		Conditions:	Progressive Multiple Sclerosis;
			Neuromyelitis Optica.
		Intervention:	Biological: human umbilical
			cord mesenchymal stem cells
4	Not yet	215ON201 BIIB033 In Acute O	ptic Neuritis (AON)
	recruiting	Condition:	Acute Optic Neuritis
		Intervention:	Biological: BIIB033

64. Optic Neuropathy, Ischemic

Rank	Status	Study	
1	Recruiting	PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic	
		Neuropathy (NAION)	
		Condition: Anterior Ischemic Optic Neuropathy	
		Intervention:	Drug: Diagnostic procedures

65. Orbital Diseases

Rank	Status	Study	
1	Completed	Function of Regulatory T Cells Improved by Dexamethasone in	
	no results	Graves' Patients	
	published	Condition:	Graves' Disease
	yet	Intervention:	Drug: Dexamethasone
2	Completed	Pilot Study to Determine Safe	ty and Efficacy of Orbital Injections
	no results	of LIPO-102 in Patients With S	Symptomatic Exophthalmos
	published	Associated With Thyroid-related Eye Disease (TED)	
	yet	Condition:	Thyroid-Related Eye Disease
		Interventions:	Drug: LIPO-102; Drug: Placebo
3	Completed	Thyroid-Associated Ophthalm	nopathy Subtypes and Orbital
	no results	<u>Antibodies</u>	
	published	Condition:	Graves' Ophthalmopathy
	yet	Intervention:	Drug: Carbimazole, radio-active iodi
			ne (l131)
4	Completed	Thyroid Treatment Trial	
	no results	Condition:	Graves Ophthalmopathy
	published	Intervention:	Drug: Intravenous
	yet		Methylprednisolone + Oral
			Methotrexate vs Intravenous
			Methylprednisolone + Placebo
5	Completed	Is the Routine Pressure Dressing After Thyroidectomy	
	no results	Necessary?	
	published	Conditions:	Thyroid Neoplasms; Thyroid Nodul
	yet		es; Graves Disease; Goiter
		Interventions:	Procedure: Pressure dressing; Proc
			edure: Normal dressing
6	Recruiting	The Prospective Study of Star	ndard Treatment of Graves Disease
		Iodine 131 and Prevention of A	Adverse Reactions
		Conditions:	Hypothyroidism; Exophthalmos
		Intervention:	Radiation: lodine 131
7	Recruiting	Doxycycline Treatment in Gra	ves' Orbitopathy
		Conditions:	Graves Ophthalmopathy; Graves
			Disease; Eye Diseases; Thyroid
			Diseases; Endocrine System Dis
			eases; Eye Diseases, Hereditary;
			Hyperthyroidism; Autoimmune
			Diseases; Immune System Disea

			Ses
		Intervention:	Drug: Doxycycline
8	Recruiting	Differential Diagnosis Value of PSV of Thyroid Superior Artery	
		Using Color Flow Doppler Sonography in Transient	
		Thyrotoxicosis	
		Conditions:	Thyrotoxicosis; Peak Systolic Vel
			ocity of Superior Thyroid Artery; T
			hyroiditis; Graves Disease
		Intervention:	
9	Recruiting	Treatment of Upper Eyelid Ret	traction Related to
		Thyroid-associated Ophthalm	opathy Using Subconjunctival
		Triamcinolone Injections	
		Condition:	Thyroid-associated Ophthalmopathy
		Intervention:	Drug: subconjunctival triamcinolone
			injection
10	Recruiting	Application of Digital Infrared Thermal Imaging (DITI) in Graves'	
		Disease	
		Condition:	Graves' Disease
		Intervention:	
11	Recruiting	Polycaprolactone / Tricalcium	Phosphate (PCL/TCP) v Titanium
		Orbital Implant : Randomised	Trial
		Conditions:	Fractures; Enophthalmos; Diplo
			pia
		Interventions:	Device: Polycaprolactone / Tri-Calci
			um Phosphate; Device: Titanium
			Mesh
12	Unknown [†]	The Role of TSH Receptor, PP	AR-r, IGF-1R, IGF and Cytokines in
		Different Stages of Graves'Op	hthalmopathy
		Condition:	Graves' Ophthalmopathy
		Intervention:	

66. Panuveitis

Rank	Status	Study	
1	Completed	A Study of the Safety and Efficacy of a New Treatment	
	Has Results	for Non-Infectious Intermedia	te or Posterior Uveitis
	published in	Conditions:	Intermediate Uveitis; P
	journals		osterior Uveitis
		Interventions:	Drug: Dexamethasone;
			Drug: dexamethasone;
			Drug: Sham injection
2	Completed	Phase III Study in Refractory	Behcet's Disease
	no results	Condition:	Behcet Disease
	published yet	Interventions:	Drug: AIN457; Drug:
			Placebo
3	Completed	A Multi-center Study to Asses	ss the Efficacy and Safety
	no results	of LX211 in Active Non-infect	ious Anterior Uveitis
	published yet	Conditions:	Uveitis, Anterior; Panuv eitis
		Interventions:	Drug: Placebo; Drug: L X211
4	Completed	Safety and Efficacy Study of	ontophoresis and
	no results	Dexamethasone Phosphate to Treat Anterior Uveitis	
	published yet	Condition: Uveitis, Anterior	
		Interventions: Drug: EGP-437 1.6 mA-min at 0.4 with	
		EyeGate® II System; Drug: EGP-437	
		4.8 mA-min a	t 1.2 mA with EyeGate® II
			ug: EGP-437 10.0 mA-min
			h EyeGate® II
			rug: EGP-437 14.0 mA-min
			h EyeGate® II System
5	Completed	A Study of LX211 in Clinically	
	no results published yet	Non-infectious Intermediate, Posterior or Pan-Uveitis	Anterior and intermediate,
	published yet	Conditions:	Uveitis, Posterior; Uv
		Conditions.	eitis, Intermediate; Pa
			nuveitis
		Interventions:	Drug: Placebo; Drug:
			LX211
6	Enrolling by	A Study of the Long-term Saf	
	invitation	Adalimumab in Subjects With	

		or Pan-uveitis	
		Condition:	Uveitis
		Intervention:	Drug: adalimumab
7	Active, not	A Study of Adalimumab in Ja	panese Subjects With
	recruiting	Intestinal Behçet's Disease.	
		Condition:	Intestinal Behcet's Diseas
			е
		Intervention:	Biological: Adalimumab
8	Terminated	Safety and Efficacy of AIN457	in Patients With Active
		Non-infectious Uveitis Condition:	Uveitis
		Interventions:	Biological: AIN457; Biol ogical: Placebo
9	Terminated	Extension Study to Assess Sa	-
		AIN457 in Patients With Active	
		Condition:	Uveitis
		Interventions:	Biological: AIN457; Bi
			ological: Placebo
10	Terminated	Safety and Efficacy of AIN457	in Behçet's Patients With
		Posterior or Panuveitis	
		Condition:	Uveitis
		Interventions:	Biological: AIN457; Dr ug: Placebo
11	Terminated	Safety and Efficacy of AIN457	3
		Quiescent Non-infectious Uve	
		Condition:	Non-infectious Uveitis
		Interventions:	Biological: AIN457; Dru
			g: Placebo
12	Recruiting	Topical Administration of 0.15	5% Ganciclovir Gel for
		CMV Anterior Uveitis / Endoth	
		Conditions:	Cytomegalovirus Anterior
			Segment Infection; Ant erior Uveitis; Endothelii
			tis
		Intervention:	Drug: Ganciclovir
13	Recruiting	Clinical Outcomes of Topical	-
		Cytomegalovirus Anterior Uve	
		Condition:	Anterior Uveitis

		Intervention:	
14	Recruiting	Efficacy and Safety of Adalim	umab in Subjects With
		Inactive Uveitis	
		Condition:	Uveitis
		Interventions:	Drug: adalimumab; Dr
			ug: prednisone; Drug:
			adalimumab placebo
15	Recruiting	Efficacy and Safety of Adalim	umab in Subjects With
		Active Uveitis	
		Condition:	Uveitis
		Interventions:	Drug: adalimumab; Dru
			g: prednisone; Drug: ad
			alimumab placebo
16	Recruiting	Clinical Study of TA-650 in Pa	tients With Behcet's
		Disease (BD) With Special Les	sions
		Conditions:	Behcet's Disease; Beh
			cet Syndrome; Neuro-B
			ehcet's Disease
		Intervention:	Drug: TA-650
17	Unknown [†]	Flucinolone Acetonide Implan	t for Treating Refractory
		Ocular Behcet's Disease	
		Conditions:	Ocular Behcet's Diseas
			e,; Non-Infectious Uv
			eitis; Refractory Uveiti
			S
		Intervention:	Drug: flucinolone aceton
			ide

67. Pars Planitis

Rank	Status	Study	
1	Completed	A Study of the Safety and Effi	cacy of a New Treatment
	Has Results	for Non-Infectious Intermediat	te or Posterior Uveitis
	published in	Conditions:	Intermediate Uveitis; Pos
	journals		terior Uveitis
		Interventions:	Drug: Dexamethasone;
			Drug: dexamethasone; D
			rug: Sham injection
2	Completed	Phase III Study in Refractory I	Behcet's Disease
	no results	Condition:	Behcet Disease
	published yet	Interventions:	Drug: AIN457; Drug: Pla cebo
3	Enrolling by	A Study of the Long-term Safe	
	invitation	Adalimumab in Subjects With	
		or Pan-uveitis	
		Condition:	Uveitis
		Intervention:	Drug: adalimumab
4	Terminated	Safety and Efficacy of AIN457	in Behçet's Patients With
		Posterior or Panuveitis	
		Condition:	Uveitis
		Interventions:	Biological: AIN457; Dru
			g: Placebo
5	Terminated	Extension Study to Assess Sa	fety and Efficacy of AIN457
		in Patients With Active Non-in	fectious Uveitis
		Condition:	Uveitis
		Interventions:	Biological: AIN457; Biol
			ogical: Placebo
6	Terminated	Safety and Efficacy of AIN457	in Patients With Quiescent
		Non-infectious Uveitis Study	
		Condition:	Non-infectious Uveitis
		Interventions:	Biological: AIN457; Drug: Placebo
7	Terminated	Safety and Efficacy of AIN457	
		Non-infectious Uveitis	
		Condition:	Uveitis
		Interventions:	Biological: AIN457; Biolo
			gical: Placebo
		I	U

68. Presbyopia

Rank	Status	Study		
1	Enrolling	The Effect of Cataract Extraction on the Contractility of Ciliary		
	by	Muscle		
	invitation	Conditions: Presbyopia; Cataract		
		Intervention: Other: UBM with pilocarpine in presbyopia		
2	Enrolling	Near and Intermediate Vision and Binocular Defocus Curves		
	by	Before and After the LaserACE® Procedure		
	invitation	Condition: Presbyopia		
		Intervention: Procedure: LaserACE(R)		
3	Active, not	Safety and Effectiveness of the AcuFocus Corneal Inlay ACI		
	recruiting	7000PDT in Presbyopes		
		Condition: Presbyopia		
		Intervention: Device: AcuFocus Corneal Inlay ACI 7000PDT		
4	Recruiting	Presbyopic Supracor Treatment for Near Myopic/Hyperopic		
		Pseudophakic Eyes		
		Conditions: Myopia; Hyperopia; Presbyopia		
		Intervention: Device: Supracor		

69. Pterygium

Rank	Status	Study		
1	Completed	Safety and Efficacy of Cyclos	porine Ophthalmic Emulsion in	
	Has Results	Patients With Primary Pterygi	Patients With Primary Pterygium	
	published	Condition:	Pterygium	
	on website	Interventions:	Drug: cyclosporine ophthalmic er	
			ulsion 0.05%; Drug: Vehicle	
2	Completed	Randomized Controlled Trial of	of Subconjunctival	
	no results	Bevacizumab Injection in Imp	ending Recurrent Pterygium	
	published	Condition:	Pterygium of the Conjunctiva an	
	yet		d Cornea	
		Interventions:	Drug: Fluorometholone; Drug	
			: Bevacizumab	
3	Completed	Ologen (OculusGen)-Glaucom	a and Pterygium Historical	
		Control Study in China Beijing	<u>g Hospital</u>	
		Conditions:	Glaucoma; Pterygium	
		Intervention:	Device: OculusGen	
			Biodegradable Collagen	
			Matrix Implant	
4	Completed	Ologen (OculusGen)-Glaucom	a and Pterygium Historical	
		Control Study in China Zhong-Shan Hospital		
		Conditions:	Glaucomas; Pterygium	
		Intervention:	Device: OculusGen	
			Biodegradable Collagen	
			Matrix Implant	
5	Completed	To Compare Fibrin Glue and S		
		Excision With Amniotic Memb	prane Transplantation	
		Condition:	Pterygium	
		Intervention:	Procedure: Amniotic membrane	
			transplantation using fibrin glue	
6	Completed	Ologen (OculusGen)-Glaucoma and Pterygium Historical		
		Control Study in Beijing Remin Hospital		
		Conditions:	Glaucoma; Pterygium	
		Intervention:	Device: OculusGen	
			Biodegradable	
			Collagen Matrix Implant	
7	Completed	Polyglactin Sutures Versus Ny	ylon Sutures for Suturing of	
			ygium Surgery: a Randomised	
		Controlled Trial		

		Condition	
		Condition:	Pterygium
		Interventions:	Procedure: Polyglactin sutures
			for suturing of conjunctival
			autograft in pterygium
			surgery; Procedure: Nylon
			sutures for suturing of
			conjunctival autograft in
			pterygium surgery
8	Completed	Rotational Narrow Strip Versu	<u>is Full Conjunctival Graft in</u>
		Pterygium Excision	_
		Condition:	Pterygium
		Interventions:	Procedure: Rotational Narrow
			Strip Conjunctival
			Graft; Procedure: Full Conjun
			ctival Graft
9	Completed	Assessment of Fibrin Glue in	Pterygium Surgery and Other
		Forms of External Eye Surger	<u>х</u>
		Conditions:	Pterygium; Ocular Surface Ci
			catrizing Diseases
		Intervention:	Device: Tisseel fibrin adhesive
10	Completed	Autologous ex Vivo Conjunct	ival Epithelial Cell Expansion
		for Ocular Surface Transplant	ation
		Conditions:	Pterygium; Ocular Surface
			Disease; Stevens Johnson
			Syndrome; Chemical Injury
		Intervention:	Procedure: Cultivated
			conjunctival transplantation
11	Withdrawn	The Application of Fibrin Glue	e in Ocular Surface Diseases
		Conditions:	Pterygium; Corneal Ulcer
		Intervention:	Drug: tissue fibrin glue applica
			tion (Tisseel)
12	Recruiting	Using Impression Cytology to	Observe the Cytological
		Changes of Ocular Surface Ce	ells in Various Ocular Surface
		<u>Disorders</u>	
		Conditions:	Pterygium; Dry Eye; Tum
			or
		Intervention:	
13	Recruiting	Risk Factors and Biomarkers	Associated With Recurrence
	_	After Excision of Primary Pter	ygium

		Condition:	Pterygium
		Intervention:	
14	Recruiting	Topical Bevacizumab for Prev	venting Recurrent Pterygium
		Conditions:	Pterygium; Bevacizumab; VEGF; Anti-VEGF
		Interventions:	Drug: bevacizumab eye drop 0.05%; Drug: normal saline 0.9%
15	Recruiting	Intralesional Bevacizumab Inj	ection on Primary Pterygium
		Conditions:	Pterygium; Inflammation
		Interventions:	Drug: Intralesional injection of b evacizumab; Drug: Topical a ntihistamine and vasoconstricto
16	Unknown [†]	Effect of Pterygium Excision of	on Intraocular Lens Power
		Calculation for Subsequent Ca	ataract Operation
		Conditions:	Pterygium; Cataract; Astig matism
		Intervention:	Procedure: pterygium excision
17	Unknown [†]	Surgical Treatment of Concur	rent Cataract and Primary
		Pterygium	
		Conditions:	Pterygium; Cataract; Lense s, Intraocular
		Interventions:	Procedure: combined pterygium
			and cataract
			operation; Procedure:
			pterygium excision followed by
18	Unknown [†]	Ologen(Oculusgen)-Glaucoma	cataract operation
10	UIKIIOWII	Control Study in China Shang	
		Conditions:	Glaucomas; Pterygium
		Intervention:	Device: ologen™ Collagen
			matrix implantation in
			glaucoma filtering surgery
19	Unknown [†]	Comparison of Glue With Sute	ures for Pterygium Surgery
		Condition:	Pterygium
		Intervention:	Procedure: Pterygium excision
			and conjunctival autograft

70. Refractive Errors

1	Completed		
		Comparative Performance of PureVision Lens Designs	
	Has Results	Condition:	Муоріа
	published	Interventions:	Device: Currently Marketed
	on website		PureVision Contact
			Lens.; Device: Alternate
			Design of the PureVision
			Contact Lens.
2	Completed	Product Performance of a Tor	ic Contact Lens
	Has Results	Conditions:	Myopia; Astigmatism
	published	Interventions:	Device: SofLens DD Toric;
	on website		Device: Ciba Vision Focus
			Dailies Toric Contact Lens
3	Completed	Clinical Evaluation of Two Dai	ly Disposable Contact Lenses
	Has Results	Condition:	Refractive Error
	published	Interventions:	Device: etafilcon A; Device: c
	on website		
4	Completed	Two Week Cross-Over Study (Comparing Two Daily
	Has Results	Disposable Contact Lenses	
	published	Condition:	Муоріа
	on website	Interventions:	Device: etafilcon A; Device: o
5	Completed	Comparative Study of Cyclop	egic Refraction and
	no results	Subjective Refraction With Fo	gging in School Age Children
	published	Conditions:	Myopia; Refractive Error
	yet	Intervention:	
6	Completed	Evaluation of Effectiveness of	Correcting Refractive Error
	no results	With Ready-made Spectacles	
	published	Conditions:	Myopia; Hyperopia; Astigm
	yet	Interventions:	Device: Ready-made spectacle
			acles
7	Completed	A Singapore Study to Assess	How Neurovision Improve the
	no results	Vision of Adults With Low to M	Moderate Myopia
	published	Condition:	Муоріа
	yet	Intervention:	Device: Neurovision
6	Completed	Myopia Control With Simultan	eous Vision Approach
	no results	Condition:	Муоріа
	published	Intervention:	Device: Defocus Incorporated
	yet		Soft Contact (DISC) lens

9	Completed	Dilet Study to Access the Effi	and the set Expension to
9	Completed no results	Pilot Study to Assess the Efficacy of Short Exposure to Defocus to Slow the Progression of Myopia in Children	
	published	_	
	yet	Condition:	Муоріа
	-	Intervention:	Device: Hyperopic lens
10	Completed	Efficacy of LASIK Versus PRK	(in Asians With Mild and
	no results	Moderate Myopia	
	published	Condition:	Муоріа
	yet	Interventions:	Procedure: Laser in Situ Kerato
			e: Photorefractive Keratectomy
11	Completed	Optical Coherence Tomograp	hy Imaging of the Posterior
	no results	Segment in High Myopia.	
	published	Conditions:	Myopia; Maculopathy; Glau
	yet	Intervention:	
12	Completed	Changes in Invitro and ex Viv	o Lens Metrology With Daily
	no results	Wear Contact Lenses	
	published	Condition:	Муоріа
	yet	Interventions:	Device: Air Optix Aqua; Devi
			ofinity; Device: Proclear; D
			: Acuvue Oasys; Device: Acu
			2; Device: Purevision
13	Completed	Evaluation of Daytime Cornea	I Swelling During Wear of
	no results	Galyfilcon A Lenses	
	published	Condition:	Муоріа
	yet	Interventions:	Device: galyfilcon A; Device:
			ilcon A plus; Device: lotrafilco
			Device: polymacon; Other
			ctacles
14	Completed	Comparison of Contact Lens	Maintenance Systems for
	no results	Silicone Hydrogel Lenses	
	published	Conditions:	Myopia; Hyperopia
	yet	Intervention:	Device: Silicone hydrogel con
			tact lens
15	Completed	Clinical Performance of Exten	ded Wear Silicone Hydrogel
	no results	<u>Lenses</u>	
	published	Condition:	Муоріа
	yet	Intervention:	Device: Silicone hydrogel con
			tact lens
17	Completed	The Effect of Silicone Hydroge	el Contact Lenses on

	no results	Conjunctival Flora	
	published	Condition:	Муоріа
	yet	Intervention:	Device: Silicone hydrogel con
			tact lens
18	Completed	Clinical Evaluation of Ocular F	Responses With Contact Lens
	no results	Wear	
	published	Condition:	Муоріа
	yet	Interventions:	Device: narafilcon B; Device:
			lymacon; Device: Lotrafilcon
			Other: Spectacles
19	Completed	Investigation of the Clinical Pe	erformance of Silicone
	no results	Hydrogel Contact Lenses Dur	ing Continuous Wear
	published	Condition:	Муоріа
	yet	Intervention:	Device: Silicone hydrogel con
			tact lens
20	Completed	Clinical Trial of Contact Lense	es in Extended Wear
	no results	Condition:	Astigmatism
	published	Interventions:	Device: senofilcon A toric conta
	yet		ens; Device: balafilcon A torio
			ontact lens
21	Completed	Time Course Comparison of C	
	no results	Systems for Hydrogel Lenses	
	published	Conditions:	Myopia; Hyperopia
	yet	Interventions:	Device: Silicone Hydrogel Cont
			enses; Device: 1x PMBH pre
			ed MPS; Device: 1x Polyquae ox MPS
22	Completed	Efficacy and Safety of Ranibiz	
	no results	Impairment Due to Choroidal	
	published	Secondary to Pathologic Myo	
	yet	Condition:	Pathological Myopia
		Interventions:	Drug: 0.5 mg ranibizumab drive
			by disease activity; Drug: 0.5
			mg ranibizumab driven by
			stabilization
			criteria; Drug: verteporfin PD
23	Completed	Pilot Study of Neurovision to	mprove Vision and Slow
	no results	Myopia Progression in Childre	en With Myopia
	published		

	yet	Condition:	Муоріа
		Intervention:	Device: NeuroVision
24	Completed	Clinical Trial of Several Conta	ct Lenses in Extended Wear
	no results	Condition:	Муоріа
	published	Interventions:	Device: senofilcon A; Device:
	yet		otrafilcon B; Device: balafilco
			A; Device: etafilcon A
25	Completed	Three Intraocular Lenses Des	igned to Improve Distance,
	no results	Intermediate and Near Vision	Following Lens Extraction
	published	Condition:	Cataract
	yet	Interventions:	Device: Crystalens AO; Devic
			TOR 3.0; Device: AMO Tecni
			ocal
26	Completed	Construction of Computerized	d Intraoperative Keratometer
	no results	and Experimental Study	
	published	Conditions:	Corneal Astigmatism; Orienta
	yet	Intervention:	Device: computerized intraoper
27	Completed	A Comprehensive Assessmer	nt of Anterior Corneal Power
	no results	by Different Devices	
	published	Condition:	Муоріа
	yet	Intervention:	Device: Corneal power measure
28	Completed	Surgical Outcome of Vitrector	my for Myopic Traction
	no results	Maculopathy in Highly Myopic	<u>: Eyes</u>
	published	Conditions:	Maculopathy; High Myopia;
	yet	Intervention:	Procedure: vitrectomy
29	Completed	Contact Lens in Pediatrics (Cl	LIP) in an Asian Population
	no results	<u>Study</u>	
	published	Condition:	Муоріа
	yet	Intervention:	Device: Johnson&Johnson Acu
			daily disposable lenses
30	Completed	A Singapore Pilot Study to As	sess Neurovision in
	no results	Treatment of Low Myopia	
	published	Condition:	Муоріа
	yet	Intervention:	Device: Neurovision
31	Completed	The Effect of Myopic Optical I	Defocus on the Humphrey
	no results	Matrix 30-2 Test	
	published	Condition:	Муоріа
	yet	Intervention:	

32	Completed	Myopia Control by Combining	Auricular Acupoint and
	no results	Atropine Eyedrops	
	published	Condition:	Муоріа
	yet	Interventions:	Drug: 0.25 % atropine; Drug:
			edure: 0.25 % atropine+auricul
33	Terminated	Silicone Hydrogel Contact Lei	nses on Low Astigmatism in
		<u>Japan</u>	
		Conditions:	Refractive Error; Myopia; A
		Interventions:	Device: senofilcon A toric soft of
			vice: senofilcon A sphere soft c
34	Enrolling	The Children's WEAR Trial(Ph	nase 1&2)
	by	Condition:	Муоріа
	invitation	Interventions:	Procedure: group1; Procedu
			e: group3; Procedure: group4
35	Enrolling	The Effect of Cataract Extract	ion on the Contractility of
	by	Ciliary Muscle	
	invitation	Conditions:	Presbyopia; Cataract
		Intervention:	Other: UBM with pilocarpine in
36	Enrolling	Near and Intermediate Vision	
	by	Curves Before and After the L	
	invitation	Condition:	Presbyopia
		Intervention:	Procedure: LaserACE(R)
37	Enrolling	Guangzhou Outdoor Activity	
	by	Condition:	Муоріа
	invitation	Intervention:	Behavioral: Outdoor activity
38	Active, not	Peripheral Optics in Myopia a	nd Orthokeratology
	recruiting	Condition:	Муоріа
		Interventions:	Device: Orthokeratology lenses
			acles
39	Active, not	Toric Orthokeratology - Slowi	ng Eye Elongation
	recruiting	Conditions:	Myopia; Astigmatism
		Interventions:	Device: Toric Orthokeratology I
			gle-vision spectacles
40	Active, not	VEGF Trap-Eye in Choroidal N	Neovascularization Secondary
	recruiting	to Pathologic Myopia (mCNV)	
		Condition:	Myopia, Pathological
		Interventions:	Biological: VEGF Trap-Eye (BA
			dure: No Drug

41	Active, not	Trial of a Novel Family-Based	Intervention to Increase
	recruiting	Outdoor Time and Fitness	
		Conditions:	Myopia; Obesity
		Intervention:	Behavioral: Family-based Outde
42	Active, not	Safety and Effectiveness of th	e AcuFocus Corneal Inlay ACI
	recruiting	7000PDT in Presbyopes	
		Condition:	Presbyopia
		Intervention:	Device: AcuFocus Corneal Inla
43	Recruiting	Discontinuation of Orthokerat	tology on Eyeball Elongation
		in Myopic Children	
		Condition:	Муоріа
		Intervention:	Procedure: Switching of
			orthokeratology and single-visio
			glasses
44	Recruiting	Clinical and Genetic Studies in Related Diseases	n Families With Myopia and
		Related Diseases	Muonio
		Condition:	Муоріа
45	Deenviting	Intervention:	tressuler Long Made by
45	Recruiting	Clinical Evaluation of Toric Int Aurolab	traocular Lens Made by
		Condition:	Astigmatism
		Intervention:	Procedure: intra ocular lens
46	Recruiting		ent for Near Myopic/Hyperopic
	j	Pseudophakic Eyes	
		Conditions:	Myopia; Hyperopia; Presby
			pia
		Intervention:	Device: Supracor
47	Recruiting	Early Vitrectomy for Macular	Tractional Maculopathy
		Condition:	Myopia, Degenerative
		Intervention:	Procedure: Early vitrectomy
48	Recruiting	Discontinuation of Lens Wear	n New Ortho-k Children
		(DOEE2)	
		Condition:	Муоріа
		Intervention:	Procedure: Switching of
			single-vision spectacles to
			orthokeratology
49	Recruiting	Effect of Posterior Corneal To	oricity on Refractive Outcome
		of Pseudophakia	

		Conditions:	Astigmatism; Cataract
		Interventions:	Procedure: phacoemulsification
			(Oculus,Germany)examination
50	Recruiting	Randomized, Non-inferiority T	rial Comparing SMILE and
		LASIK	
		Conditions:	Myopia; Astigmatism; Hype
		Interventions:	Procedure: Femtosecond LASI
			Small incision lenticule extraction
51	Unknown [†]	Prospective Evaluation of Lim	bal Relaxing Incision (LRI) in
		Conjunction With Phacoemuls	sification Surgery for
		Astigmatic Correction in Chin	<u>ese Eyes</u>
		Condition:	Corneal Astigmatism
		Intervention:	Procedure: Limbal relaxing incis
52	Unknown [†]	Effect of Pterygium Excision of	on Intraocular Lens Power
		Calculation for Subsequent Calculation	ataract Operation
		Conditions:	Pterygium; Cataract; Astigr
		Intervention:	Procedure: pterygium excision
53	Unknown †	Comparison of Intralase and V	/isumax Femtosecond Laser
		for Laser In Situ Keratomileus	sis
		Condition:	Муоріа
		Intervention:	
54	Unknown [†]	Randomized, Prospective Cor	mparison of the Outcome of
		Toric Implantable Contact Ler	ns (TICL) and Q-LASIK for the
		Correction of Myopia With Ast	tigmatism
		Conditions:	Myopia; Astigmatism
		Interventions:	Procedure: the implantation of
			toric implantable collamer
			lens; Procedure: customized
			laser-assisted in situ
			keratomileusis
55	Unknown [†]	Myopic Control for High Myop	es Using Orthokeratology
		Condition:	Муоріа
		Interventions:	Device: Orthokeratology lenses
			Device: Single-vision spectacle
56	Unknown †	Retardation of Myopia in Orthokeratology	
		Condition:	Муоріа
		Interventions:	Device: Orthokeratology lenses
			Menicon Z Night

+		Lens; Device: spherical plast
Unknown ^T	Safety and Efficacy Study of 0.5%, 0.1% & 0.01% Atropine	
	Condition:	Муоріа
	Intervention:	Drug: Atropine Eye drops
Unknown [†]	Comparative Study of the Wea	aring Satisfaction of Two Soft
	Contact Lens Designs.	
	Condition:	Муоріа
	Interventions:	Device: Currently marketed
		PureVision soft contact
		lens.; Device: Alternate
		design of PureVision soft
		contact lens.
Unknown [†]	Ocular Imaging With Spectral	Domain Optical Coherence
	Tomography	
	Conditions:	Healthy; Myopia; Hyperme
	Intervention:	Device: Spectral domain-OCT
		(Cirrus™ HD-OCT, Carl Zeiss
		Meditec AG)
Unknown [†]	Corrected Measurement of the Retinal Nerve Fiber Layer	
	Thickness by Optic Disc Conf	iguration With the Cirrus HD
	<u>OCT</u>	
	Conditions:	Glaucoma; Myopia
	Intervention:	
Unknown [†]	Efficacy of Retinal Nerve Fibe	r Layer (RNFL) / Retinal
	Thickness Ratio by Cirrus OC	T Utilizing Spectral -Domain
	Technology as a Diagnostic P	redictor of Glaucoma
	Conditions:	Glaucoma; Myopia
	Intervention:	
Unknown [†]	Ocular Response Analyzer As	sessment of Intraocular
	Pressure and Corneal Biomed	
		hanical Properties in Myopic
	Pressure and Corneal Biomec	hanical Properties in Myopic
	Pressure and Corneal Biomed and Anisometropic Patients U	chanical Properties in Myopic Inder Atropine Treatment
Unknown [†]	Pressure and Corneal Biomed and Anisometropic Patients U Conditions:	<u>hanical Properties in Myopic</u> Inder Atropine Treatment Myopia; Anisometropia
Unknown [†]	Pressure and Corneal Biomed and Anisometropic Patients U Conditions: Intervention:	<u>hanical Properties in Myopic</u> Inder Atropine Treatment Myopia; Anisometropia
Unknown [†]	Pressure and Corneal Biomed and Anisometropic Patients U Conditions: Intervention: Aberration-Free Refraction Co	<u>Anical Properties in Myopic</u> Inder Atropine Treatment Myopia; Anisometropia
	Unknown † Unknown † Unknown †	Image: Construction of the second

		Post-LASIK Patients	
		Conditions:	Myopia; Astigmatism
		Intervention:	
65	Unknown [†]	The Role of SNP of ECM and M	MMP on the Development of
		Pathological High Myopia	
		Condition:	Муоріа
		Intervention:	
66	Unknown †	Genomewide Screening of Par	thological Myopia
		Condition:	Pathological Myopia
		Intervention:	

Rank	Status	Study	
1	Recruiting	Obstructive Sleep Apnea, Retinal Vein Occlusion, Retinal	
		Artery Occlusion	
		Condition:	Retinal Vascular Occlusion
		Intervention:	Device: Watchpat 100

72. Retina	l Degeneration
------------	----------------

Rank	Status	Study		
1	Completed	Efficacy and Safety of Ranibizumab (Intravitreal Injections) in		
	Has Results	Patients With Visual Impairment Due to Diabetic Macular Edema		
	published on	Condition:	Diabetic Macular Edema	
	website	Interventions:	Drug: Ranibizumab; Procedure:	
			Laser photocoagulation; Drug: S	
			ham ranibizumab; Procedure: S	
			ham laser photocoagulation	
2	Completed	Vascular Endothelial Growth I	Factor (VEGF) Trap-Eye:	
	Has Results	Investigation of Efficacy and S	Safety in Central Retinal Vein	
	published on	Occlusion (CRVO)		
	website	Condition:	Retinal Vein Occlusion	
		Interventions:	Biological: Aflibercept Injection	
			(EYLEA, VEGF Trap-Eye,	
			BAY86-5321); Other: Sham treat	
			ment	
3	Completed	Safety and Efficacy of a New Therapy as Adjunctive Therapy to		
	Has Results	Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subject		
	published on	With Wet Age-Related Macula		
	website	Conditions:	Choroidal Neovascularization; A	
			ge-Related Maculopathy	
		Interventions:	Drug: dexamethasone; Biologica I: ranibizumab	
4	Completed	Vascular Endothelial Growth Factor (VEGF) Trap-Eye:		
	Has Results	Investigation of Efficacy and Safety in Wet Age-Related Macular		
	published on	Degeneration (AMD)		
	website	Condition:	Macular Degeneration	
		Interventions:	Drug: Ranibizumab; Biological:	
			Aflibercept Injection (EYLEA,	
			VEGF Trap-Eye, BAY86-5321)	
5	Completed	Changes in Retinal Function A	After Intravitreal Ranibizumab for	
	Has Results	Age-related Macular Degenera	ation	
	published in	Condition:	Age-related Macular Degeneration	
	journals	Intervention:	Drug: ranibizumab	
6	Terminated	A Study Using Intravitreal Inje	ections of a Small Interfering RNA	
	Has Results	in Patients With Age-Related I	Macular Degeneration	
	published on	Conditions:	Choroid Neovascularization; Ag	
	website		e-Related Macular Degeneration	
		Interventions:	Drug: AGN 211745; Drug: Ranib	

			izumab 500µg	
7	Completed	A Multi-Center Trial To Evalua	te The Safety And Efficacy Of	
	Has Results) Injected Into The Eye Every 6	
	published on	Weeks For Up To 2 Years For Macular Swelling Associated With		
	website	Diabetes, With An Open-Label Macugen Year Extension.		
		Condition:	Macular Edema Associated With D	
			iabetes Mellitus	
		Interventions:	Drug: Standard of Care; Drug: M	
			acugen	
8	Completed		Freatment as Adjunctive Therapy to	
	Has Results		wth Factor (Anti-VEGF) Treatment	
	published on	in Patients With Age-Related I		
	website	Conditions:	Choroidal Neovascularization; A	
			ge-Related Maculopathy	
		Interventions:	Drug: dexamethasone; Biologica	
	Tomain at a d	New of the section of	I: ranibizumab; Other: sham	
9	Terminated Has Results	Macugen Observational Study	_	
	published on	Conditions:	Vascular Endothelial Growth Facto r; Macular Degeneration	
	website	Intervention:	r; Macular Degeneration Other: No intervention	
10	Completed			
10	Completed Has Results	Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration		
	published on	Condition:	Macular Degeneration	
	website	Intervention:	Drug: pegaptanib sodium	
11	Completed	A Study of the Safety and Effi		
	Has Results	Macular Edema Resulting Fro		
	published on	Conditions:	Macular Edema; Retinal Vein Oc	
	website		clusion	
		Interventions:	Drug: Dexamethasone; Drug: Sh	
			am injection	
12	Completed	Safety and Efficacy of Ranibiz	umab in Japanese Patients With	
	Has Results	Subfoveal Choroidal Neovasc	ularization Secondary to	
	published in	Age-related Macular Degenera	ation	
	journals	Condition:	Subfoveal Choroidal	
			Neovascularization(CNV)	
			Secondary to Age-related Macular	
			Degeneration (AMD)	
		Intervention:	Drug: Ranibizumab	

13	Completed	Evaluation of Safety and Effic	acy of Once Monthly Ranibizumab	
	no results	Injections in Chinese Patients With Wet Age Related Macular		
	published	Degeneration (AMD) Patients		
	yet	Condition:	Age Related Macular Degeneration	
		Intervention:	Drug: ranibizumab 0.5 mg	
14	Completed	Reduction in the Occurrence	of Center-Involved Diabetic	
	no results	Macular Edema		
	published	Condition:	Diabetic Retinopathy	
	yet	Interventions:	Drug: ruboxistaurin; Drug: plac	
			ebo	
15	Completed	Effect of Intravitreal Long Act	ing Dexamethasone Implant,	
	no results	Ozurdex in Patients With Diab	etic Macular Edema	
	published	Conditions:	Diabetic Macular Edema; Macul	
	yet		ar Edema, Cystoid; Vision Disor	
			ders; Clinically Significant Macul	
			ar Edema	
		Intervention:	Drug: long acting intravitreal	
			dexamethasone implant	
16	Completed	CME With Different Fluidic Pa	rameters	
	no results	Condition:	Cystoid Macular Edema Following	
	published		Cataract Surgery	
	yet	Intervention:	Procedure: microcoaxial phacoem	
			ulsification	
17	Completed	Safety and Efficacy of Intravit	real Fluocinolone Acetonide	
	no results	Implants in Patients With Diab	oetic Macular Edema	
	published	Condition:	Diabetic Macular Edema	
	yet	Interventions:	Drug: 0.59 mg fluocinolone	
			acetonide intravitreal	
			implant; Drug: 2.1 mg	
			fluocinolone acetonide intravitreal	
			implant; Procedure: standard of	
			care laser photocoagulation	
18	Completed	A Study Assessing the Safety		
	no results	Intravitreal KH902 in Patients		
	published	Condition:	Neovascular Age-related Macular	
	yet		Degeneration	
		Intervention:	Biological: Intravitreal injection of K	
			H902	
19	Completed	A Population-based Study of Macular Choroidal		

	no results	Neovascularization in a Chinese Population	
	published	Conditions:	Geographic Atrophy; Wet Macul
	yet		ar Degeneration; Retinal Drusen
		Intervention:	Other: Follow-up observation
20	Completed	Bevacizumab for Neovascular	Age-related Macular Degeneration
	no results	Condition:	Exudative Age-related Macular De
	published		generation
	yet	Interventions:	Drug: Bevacizumab 1; Drug: Be
			vacizumab
21	Completed	Phase II Open Label Multicent	er Study For Age Related Macular
	no results	Degeneration Comparing PF-0	04523655 Versus Lucentis In The
	published	Treatment Of Subjects With C	NV (MONET Study).
	yet	Condition:	Age Related Macular Degeneratio
			n
		Interventions:	Drug: 0.5 mg ranibizumab; Drug:
			3 mg PF-04523655; Drug: 1 mg
			PF-04523655
22	Completed	EXTEND III - Efficacy and Safe	ety of Ranibizumab in Patients With
	no results	Subfoveal Choroidal Neovascularization (CNV) Secondary to	
	published	Age-related Macular Degenera	ation (AMD)
	yet	Conditions:	Choroidal Neovascularization; A
			ge-Related Macular Degeneration
		Intervention:	Drug: ranibizumab
23	Completed	Major and Macular Branched	
	no results	Condition:	Macular Edema
	published yet	Intervention:	Procedure: intravitreal bevacizumab
24	Completed	Changes in Ciliary Body Thick	mess in Patients With Diabetic
	no results	Macular Edema After Vitrector	<u>my</u>
	published	Condition:	Diabetic Macular Edema
	yet	Intervention:	Procedure: Pars Plana Vitrectomy
25	Completed	Sequentially Combined Vitrectomy, IVTA and Macular Focal	
	no results	Laser Photocoagulation for Di	iabetic Macular Edema
	published	Condition:	Diabetic Macular Edema
	yet	Interventions:	Procedure: vitrectomy; Drug: intr
			avitreal triamcinolone acetonide;
			Procedure: macular focal laser pho
			tocoagulation

26	Completed	Combination of Ranibizumab	and Verteporfin Therapy in
	no results	Neovascular Age-related Macular Degeneration	
	published	Condition:	Neovascular Age-related Macular
	yet		Degeneration
		Intervention:	Drug: ranibizumab
27	Completed	LOC387715/HTRA1 and the Co	ombined Photodynamic Therapy
	no results	With Intravitreal Bevacizumab	in Polypoidal Choroidal
	published	<u>Vasculopathy</u>	
	yet	Condition:	Age-Related Macular Degeneration
		Intervention:	
28	Completed	Safety and Efficacy of Brimon	idine Intravitreal Implant in
	no results	Patients With Geographic Atro	ophy Due to Age-related Macular
	published	Degeneration (AMD)	
	yet	Condition:	Macular Degeneration
		Interventions:	Drug: Brimonidine Tartrate Implant
			; Drug: Sham
29	Completed	Vascular Endothelial Growth I	Factor (VEGF) &
	no results	LOC387715/HTRA1 Polymorpl	hism in Polypoidal Choroidal
	published	Vasculopathy	
	yet	Condition:	Age-Related Macular Degeneration
		Intervention:	
30	Completed	LOC387715/HTRA1 Variants in	<u>n Polypoidal Choroidal</u>
	no results	Vasculopathy in a Korean Pop	oulation
	published	Condition:	Age-Related Macular Degeneratio
	yet		n
		Intervention:	Genetic: LOC387715/HTRA1 geno
			typing
31	Completed	Intravitreal Bevacizumab and	Triamcinolone in Diabetic Macular
	no results	<u>Edema</u>	
	published	Condition:	Diabetic Macular Edema
	yet	Intervention:	Procedure: Intravitreal injection
32	Completed	Sheathotomy vs. Intravitreal T	riamcinolone for Branch Retinal
	no results	Vein Occlusion	
	published	Conditions:	Macular Edema; Branch Retinal
	yet		Vein Occlusion
		Interventions:	Procedure: Arteriovenous Crossin
			g Sheathotomy; Procedure:
			Intravitreal Triamcinolone

			Acetonide Injection	
33	Completed	Triple Therapy of Pars Plana Vitrectomy and Grid/Focal Laser for		
	no results	Diabetic Macular Edema (DME)		
	published	Conditions:	Diabetic Retinopathy; Macular	
	yet		Edema	
		Intervention:	Procedure: Triple therapy of	
			vitrectomy, IVTA and grid/focal	
			laser photocoagulation	
34	Completed	Study of the Correlation Between Macular Thickness Analyzed		
	no results	by Optical Coherence Tomogr	aphy and the Visual Functions in	
	published	Retinitis Pigmemtosa		
	yet	Condition:	Retinitis Pigmentosa	
		Intervention:		
35	Completed	Safety and Efficacy of Oral PT	K787 in Patients With Subfoveal	
	no results	Choroidal Neovascularization	Secondary to Age-Related	
	published	Macular Degeneration (AMD)		
	yet	Condition:	Wet Age-Related Macular Degene	
			ration	
		Interventions:	Drug: PTK787; Drug: Placebo	
36	Completed	Clinical Study Of EYE001 For Wet-Type AMD (Age-Related		
	no results	Macular Degeneration)		
	published	Condition:	Macular Degeneration	
	yet	Intervention:	Drug: pegaptanib sodium	
37	Completed	A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG		
	no results	Pegaptanib Sodium To Sham	Injections In Subjects With	
	published	Diabetic Macular Edema		
	yet	Conditions:	Macular Edema; Diabetic Mellitu	
			s; Retinal Disease	
		Interventions:	Drug: pegaptanib sodium; Other:	
			sham injection	
38	Completed	PDT Study for Exudative AMD	With PCV	
	no results	Condition:	Age Related Macular Degeneratio	
	published		n	
	yet	Intervention:	Procedure: Ocular photodynamic	
			therapy with verteporfin	
39	Completed	A Study of the Safety and Effi	cacy of SK-0503 for Diabetic	
	no results	Macular Edema		
	published	Condition:	Diabetic Macular Edema	

	yet	Intervention:	Drug: dexamethasone	
40	Completed	A Study of the Safety and Efficient	cacy of a New Treatment for	
	no results	Macular Edema Resulting From Branch Retinal Vein Occlusion		
	published	Conditions:	Macular Degeneration; Macular	
	yet		Edema; Branch Retinal Vein Oc	
			clusion	
		Intervention:	Drug: dexamethasone	
41	Completed	Photodynamic Therapy Alone	Versus Combined With Intravitreal	
	no results	Bevacizumab for Age-related	Macular Degeneration	
	published	Condition:	Age-Related Macular Degeneration	
	yet	Intervention:	Drug: Bevacizumab	
42	Completed	The Effect of a Blue Light Filte	ering IOL	
	no results	Conditions:	to Compare the Effect of Two Types	
	published		of IOLs; on the Incidence of Cyst	
	yet		oid Macular Edema; After Catarac	
			t Surgery	
		Intervention:	Procedure: intraocular lens implanta	
			tion	
43	Completed	Anti-VEGFR Vaccine Therapy	in Treating Patients With	
	no results	Neovascular Maculopathy		
	published	Conditions:	Neovascular Maculopathy; Age	
	yet		Related Macular Degeneration	
		Intervention:	Biological: VEGFR1 and VEGFR2	
44	Completed	Vitrectomy for Branch Retinal Vein Occlusion		
	no results	Condition:	Vitrectomy	
	published	Intervention:	Procedure: Vitrectomy w/o ILM	
	yet		peeling for macular edema with	
			BRVO	
45	Completed		opical Administration of FOV2304	
	no results		he Treatment of Center-involving	
	published		Edema Associated With Diabetic	
	yet	<u>Retinopathy</u>	Dish stis Massulas Educa	
		Condition:	Diabetic Macular Edema	
		Interventions:	Drug: 2304 Eye Drops High Dose;	
			Drug: 2304 Eye Drops Low Dose;	
			Drug: Placebo Eye Drops	
46	Completed	A Study to Compare rhuFab V	2 With Verteporfin Photodynamic	

		1		
	no results	in Treating Subfoveal Neovascular Macular Degeneration		
	published	Condition:	Macular Degeneration	
	yet	Intervention:	Drug: rhuFab V2 (ranibizumab)	
47	Completed	To Evaluate the Pharmacodyn	amics, Safety, and	
	no results	Pharmacokinetics of Pazopan	ib Drops in Adult Subjects With	
	published	Neovascular AMD		
	yet	Condition:	Macular Degeneration	
		Intervention:	Drug: Pazopanib	
48	Completed	An Extension to Study MD710	<u>8240</u>	
	no results	Condition:	Macular Degeneration	
	published	Intervention:	Drug: Pazopanib	
	yet		<u> </u>	
49	Completed	Intravitreal Triamcinolone for	Clinically Significant Diabetic	
	no results	Macular Oedema That Persist	s After Laser Treatment (TDMO)	
	published	Condition:	Diabetic Macular Oedema	
	yet	Intervention:	Drug: Triamcinolone acetate	
50	Completed	Safety and Efficacy of a New	Freatment in Vitrectomized	
	no results	Subjects With Diabetic Macular Edema		
	published	Conditions:	Diabetic Macular Edema; Vitrecto	
	yet		my	
		Intervention:	Drug: Dexamethasone	
51	Completed	Open Label Extension of a Cli	nical Trial of Intravitreal	
	no results	Triamcinolone for Diabetic Ma	cular Oedema-TDMX Study	
	published	Condition:	Diabetic Macular Oedema	
	yet	Intervention:	Drug: Triamcinolone acetate	
52	Completed	Study to Investigate the Safet	y and Efficacy of Ranibizumab in	
	no results	Patients With Choroidal Neova	ascularisation Due to Causes Other	
	published	Than Age Related Macular De	generation	
	yet	Conditions:	Choroidal Neovascularization; R	
			etinal Pigment Epithelial Detachme	
			nt	
		Intervention:	Drug: Ranibizumab	
53	Completed	Safety and Tolerability of Ran	ibizumab in Patients With	
	no results	Subfoveal Choroidal Neovasc	ularization Secondary to	
	published	Age-related Macular Degeneration		
	yet	Conditions:	Subfoveal Choroidal Neovasculari	
			zation (CNV); Secondary to	
			Age-related Macular Degeneration	

			(AMD)	
		Intervention:	Drug: ranibizumab	
54	Completed		nical Trial of Laser Treatment Plus	
	no results	Intravitreal Triamcinolone for		
	published	Condition:	Diabetic Macular Oedema	
	yet	Intervention:	Drug: Triamcinolone acetate	
55	Completed	The Role of Capsular Tension	Ring (CTR) in Anterior Capsular	
	no results	Contraction		
	published	Conditions:	Retinitis Pigmentosa; Cataract	
	yet	Intervention:	Procedure: IOL surgery	
56	Completed	Effect of Intraoperative Dexam	nethasone Implant in Taut Posterior	
	no results	Hyaloid Removal in Diabetic M	lacular Edema	
	published	Conditions:	Diabetic Macular Edema; Vision	
	yet		Disorders	
		Intervention:	Drug: Dexamethasone Drug	
			delivery system (Ozurdex)	
57	Active, not	A Study of the Safety and Efficiency	cacy of a New Treatment for	
	recruiting	Diabetic Macular Edema		
		Condition:	Diabetic Macular Edema	
		Interventions:	Drug: Dexamethasone; Drug: Sh	
			am	
58	Active, not		ness of Existing Anti vascUlar	
	recruiting	Endothelial Growth Factor (Anti VEGF) in Patients With Wet		
		Age-related Macular Degenera		
		Condition:	Ophthalmology, Macular Degenera tion	
		Intervention:	Drug: Ranibizumab	
59	Active, not		8397 in the Treatment of Macular	
	recruiting	Edema Associated With Retin		
		Conditions:	Macular Edema; Retinal Vein Oc	
			clusion	
		Interventions:	Drug: AGN208397 intravitreal injec	
			tion; Drug: dexamethasone intra	
			vitreal implant	
60	Active, not	An Open-label Extension Stuc	ly to Evaluate the Safety of	
	recruiting		Treatment for Visual Impairment	
		Due to Diabetic Macular Edem		
		Conditions:	Diabetic Macular Edema; Visual	

			Impairment	
		Intervention:	Drug: ranibizumab	
61	Active, not	VEGF Trap-Eye in Vision Impa	airment Due to DME	
	recruiting	Conditions:	Diabetes Mellitus; Macular Ede	
			ma	
		Interventions:	Biological: VEGF Trap-Eye (BAY8	
			6-5321); Procedure: Laser treat	
			ment	
62	Active, not		zumab in Japanese Patients With	
	recruiting	Retinal Vein Occlusion Condition:	Retinal Vein Occlusion	
		Intervention:		
63	Activo not		Drug: ranibizumab	
03	Active, not recruiting	Dose Ranging Study of Pazop Age-Related Macular Degener		
		Condition:	Macular Degeneration	
		Interventions:	Drug: pazopanib eye drops; Dru	
			g: placebo; Biological: ranibizum	
			ab intravitreal injection	
64	Active, not	Intravitreal Bevacizumab (Ava	stin®) Versus Intravitreal	
	recruiting	Dexamethasone (Ozurdex™) for Persistent Diabetic Macular_		
		<u>Oedema</u>		
		Conditions:	Diabetic Retinopathy; Macular E dema	
		Interventions:		
		interventions:	Drug: bevacizumab; Drug: dexa methasone	
65	Enrolling by	Feasibility and Safety of Adult	t Human Bone Marrow-derived	
	invitation		ntravitreal Injection in Patients	
		With Retinitis Pigmentosa		
		Condition:	Retinitis Pigmentosa	
		Intervention:	Other: Intravitreal injection of	
			bone marrow-derived	
			mesenchymal stem cells	
66	Enrolling by		mab Injection With Retinal Vein	
	invitation	Occlusion (RVO) Conditions:	Magular Edomo: Botinal Visio Os	
		Conditions:	Macular Edema; Retinal Vein Oc clusion	
		Intervention:	Drug: ranibizumab	
67	Enrolling by	Efficacy and Safety of Oral Va	-	
		<u></u> of order values of or		

	invitation	Pigmentosa	
		Conditions:	Retinitis Pigmentosa; Retinal Dis eases; Eye Diseases; Eye Dis ease, Hereditary; Retinal Degen eration
		Intervention:	Drug: Valproic Acid
68	Active, not	Japanese Safety Study of VEC	GF Trap-Eye in DME (Diabetic
	recruiting	Macular Edema)	
		Condition:	Macular Edema
		Intervention:	Biological: VEGF Trap-Eye (BAY86- 5321)
69	Active, not	Safety and Efficacy by Multipl	e Injection of KH902 in Patients
	recruiting	With Diabetic Macular Edema	(DME)
		Condition:	Diabetic Macular Edema
		Intervention:	Biological: KH902
70	Active, not		iclear Cell Transplant to Treat
	recruiting	Chronic Spinal Cord Injury	
		Condition:	Spinal Cord Injuries
		Interventions:	Biological: Umbilical Cord Blood M ononuclear Cell; Biological: Umbilical Cord Blood Mononuclear
			Cell, Methylprednisolone; Biological:
			Umbilical Cord Blood Mononuclear
			Cell, Methylprednisolone, Lithium Carbonate
71	Active, not	Safety and Feasibility of Limbi	ilical Cord Blood Cell Transplant
	recruiting	Into Injured Spinal Cord	
		Condition:	Spinal Cord Injuries
		Interventions:	Biological: Umbilical Cord Blood M ononuclear Cell; Drug: Methylpr
			ednisolone; Drug: Lithium
72	Active, not		ed, Multicenter, Controlled Study of
	recruiting	Intravitreal KH902 in Patients	
		Condition:	Neovascular Age-related Macular Degeneration
		Intervention:	Biological: intravitreal injection of K H902
73	Active, not	Lithium, Cord Blood Cells and	I the Combination in the Treatment

	recruiting	of Acute & Sub-acute Spinal C	Cord Injury
	_	Condition:	Spinal Cord Injury
		Interventions:	Procedure: Conventional Treatme
			nt; Drug: Lithium Carbonate; B iological: Cord Blood Cell; Other:
			Placebo
74	Withdrawn	Combination Therapy for Neo	vascular Age Related Macular
		Degeneration	
		Condition:	Macular Degeneration
		Intervention:	Drug: intravitreal bevacizumab and
			triamcinolone acetonide
75	Terminated		ficacy Of AG-013,958 In Subjects
			ovascularization Associated With
		Age-Related Macular Degener	
		Condition:	Age-Related Macular Degeneration
		Intervention:	Drug: AG-013,958
76	Terminated		I Safety of PF-04523655 Versus
		Laser in Subjects With Diabet	
		Conditions:	Diabetic Retinopathy; Diabetes Complications
		Interventions:	Procedure: Laser Treatment; Dr
			ug: PF-04523655 high; Drug: PF
			-04523655 middle; Drug: PF-04 523655 low
77	Recruiting	Effects of Lutein and Zeaxanthin Supplementation on Early	
		Age-related Macular Degenera	ation
		Condition:	Age-related Macular Degeneration
		Interventions:	Dietary Supplement: placebo; Dieta
78	Recruiting	Molecular Genetics of Retinal	Degenerations
		Conditions:	Retinal Degeneration; Retinitis P
			igmentosa
		Intervention:	
79	Recruiting	Pilot Study of a Suprachoroid	al Retinal Prosthesis
		Conditions:	Retinitis Pigmentosa; Choroider emia
		Intervention:	Device: Prototype wide view
			suprachoroidal retinal prosthesis
80	Recruiting	VEGF Trap-Eye: Investigation	of Efficacy and Safety in Chinese

		Subjects With Wet AMD (Age-	Related Macular Degeneration)
		Condition:	Macular Degeneration
		Interventions:	Biological: VEGF Trap-Eye (BAY8
			6-5321); Drug: Visudyne
81	Recruiting	A Randomized, Double-maske	ed, Multicenter,Sham-controlled,
		Safty and Efficacy Study of K	H902 in Patients With Wet AMD
		Condition:	Neovascular Age-related Macular
			Degeneration
		Intervention:	Biological: Recombinant Human
	D 1/1		VEGF Receptor-Fc Fusion Protein
82	Recruiting		Dexamethasone in the Treatment of Following Retinal Vein Occlusion
		(RVO)	Following Retinal Vent Occiusion
		Condition:	Macular Edema
		Interventions:	Drug: 700 µg Dexamethasone; Ot
			her: Sham
83	Recruiting	Evaluation of AGN-150998 in I	Exudative Age-related Macular
		Degeneration (AMD)	
		Condition:	Age-related Macular Degeneration
		Interventions:	Drug: AGN-150998; Drug: ranibi
			zumab
84	Recruiting	Efficacy and Safety of Ranibizumab With or Without Laser in	
		Comparison to Laser in Brand	Branch Retinal Vein Occlusion
		Condition:	
		Interventions:	Drug: Ranibizumab; Procedure: L aser
85	Recruiting	Safety and Efficacy Study of r	
	j	Exudative Age-Related Macula	
		Conditions:	Macular Degeneration; Age-relate
			d Maculopathies; Age-related Mac
			ulopathy; Maculopathies,Age-relat
			ed; Maculopathy,Age-related; R
			etinal Degeneration; Retinal Neov
		Interrentions	ascularization; Eye Diseases
		Interventions:	Biological: rAAV.sFlt-1; Other: Co ntrol (ranibizumab alone)
86	Recruiting	A Phase 2 Clinical Study to In	vestigate Effects of Darapladib in
		Subjects With Diabetic Macula	

		Condition	Datingnethy Dishetia
		Condition:	Retinopathy, Diabetic
		Interventions:	Drug: darapladib; Drug: placebo
87	Recruiting		ethasone Microsphere in Patients
		With Diabetic Macular Edema	
		Condition:	Diabetic Macular Edema
		Interventions:	Drug: Betamethasone Microsphere (
			DE-102) Low Dose; Drug:
			Betamethasone Microsphere
			(DE-102) High
			Dose; Drug: Sham
88	Recruiting		ethasone Microsphere in Patients
			g Branch Retinal Vein Occlusion
		(HIKARI)	
		Condition:	Macular Edema Following Branch
			Retinal Vein Occlusion
		Interventions:	Drug: Betamethasone Microsphere
			(DE-102) Low Dose; Drug:
			Betamethasone Microsphere
			(DE-102) High
			Dose; Drug: Sham
89	Recruiting		Physical Activity) Hands-On:
			tation After Spinal Cord Injury
		Condition:	Spinal Cord Injury
		Interventions:	Device: ReJoyce Workstation; O
			ther: Standard Care
90	Recruiting		d Safety of Ranibizumab in Real
		Life Setting	
		Conditions:	Wet Age Related Macular Degener
			ation; Diabetic Macular Edema;
			Retinal Vein Occlusion
		Intervention:	Other: Ranibizumab
91	Recruiting	Ranibizumab Intravitreal Injec	
			dema Secondary to Central Retinal
		Vein Occlusion	
		Conditions:	Macular Edema; Central Retinal
			Vein Occlusion
		Intervention:	Drug: Ranibizumab 0.5 mg/0.05
			ml, intravitreal injection
92	Recruiting	Effect of Intravitreal Anti-VEG	F on Retinal Vessels Diameter

		Condition:	Age Related Macular Degeneratio
			n
		Interventions:	Drug: Intravitreal Ranibizumab;
			Drug: Intravitreal bevacizumab
93	Recruiting	Intraoperative Dexamethason	e Implant Improves Outcome of
		Cataract Surgery With Diabeti	<u>c Macular Edema</u>
		Conditions:	Macular Edema, Cystoid; Vision
			Disorders; Diabetic Macular Ede
			ma; Cystoid Macular Edema Foll
			owing Cataract Surgery; Catarac t
		Interventions:	Drug: Dexamethasone Drug
			delivery system
			(Ozurdex); Procedure: Cataract surgery
94	Recruiting	Macular Tractional Retinoschi	sis in Proliferative Diabetic
		<u>Retinopathy</u>	
		Condition:	Proliferative Diabetic Retinopathy
		Intervention:	
95	Recruiting	Safety and Tolerability of MA09-hRPE Cells in Patients With	
		Stargardt's Macular Dystrophy	
		Condition:	Stargardt's Macular Dystrophy
		Intervention:	Biological: MA09-hRPE
96	Recruiting	Effects of Lutein and Zeaxanthin Supplementation on	
		Age-related Macular Degenera	
		Condition:	Age-related Macular Degeneration
		Interventions:	Dietary Supplement: lutein; Dietar
			y Supplement: Lutein; Dietary Sup
			plement: placebo; Drug: Lutein an
97	Recruiting	Difforonce Retween Robebilits	d zeaxanthin
31	Recruiting	Difference Between Rehabilita Transplantation in Patients W	ith Spinal Cord Injury in China
		Condition:	Spinal Cord Injuries
		Interventions:	Procedure: rehabilitation of limb fu
			nction; Procedure: Stem Cells Tr
			ansplantation
98	Recruiting	Safety & Efficacy of Subretina	I Implants for Partial Restoration of
	5	Vision in Blind Patients	

		Conditions:	Retinal Degeneration,; Retinitis
		Intervention	Pigmentosa
		Intervention:	Procedure: surgical implantation of subretinal device
99	Recruiting	Intravitreal Ranibizumab in Ex	
	3	Degeneration With Posterior \	
		Condition:	Neovascular Age-related Macular
			Degeneration
		Intervention:	Procedure: Intravitreal expansile
			gas and ranibizumab injection
100	Recruiting	Autologous Plasmin and Fibri	nolytic System in Diabetic
		Retinopathy	
		Condition:	Macular Edema
		Intervention:	Procedure: Intravitreal injection
101	Recruiting		gle-Center, Prospective Study to
		Determine the Safety and Tole	bryonic Stem Cell Derived Retinal
		Pigmented Epithelial(MA09-hF	
		Advanced Dry Age-related Ma	
		Condition:	Dry Age Related Macular Degen
			eration
		Intervention:	Biological: MA09-hRPE
102	Unknown [†]	Micropulse 577 nm Laser Pho	tocoagulation Versus
		Conventional 532 nm Laser Pl	hotocoagulation for Diabetic
		Macular Oedema	
		Condition:	Diabetic Macular Edema
		Interventions:	Device: Micropulse 577 nm yello
			w diode laser; Device: 532 nm green diode laser
103	Unknown [†]	To Compare Visual Field Impa	airment in Conventional Double
100	CIRCIOWI		I Photocoagulation With PASCAL
		Panretinal Photocoagulation	
		Conditions:	Macular Edema; Diabetic Retinop
			athy; Visual Field Loss
		Interventions:	Procedure: PASCAL laser; Proce
			dure: Conventional laser
104	Unknown [†]	Intravitreal Bevacizumab for R	
		Conditions:	Wet AMD; Macular Oedema;

			Proliferative Diabetic Retinopathy
		Intervention:	Drug: Bevacizumab (Avastin)
105	Unknown [†]	Comparison of Intravitreal Ra	nibizumab and Macular Laser
		Photocoagulation for ME Follo	owing Branch Retinal Vein
		Occlusion (BRVO)	
		Condition:	Branch Retinal Vein Occlusion
		Interventions:	Drug: Ranibizumab; Procedure
			: macular laser photocoagulation

73. Retinal Detachment

Rank	Status	Study	
1	Completed	Gas injection versus vitrectomy v	vith gas for treating retinal detachment
	Has results	owing to macular hole in high my	70pes.
	published	Condition:	Retinal Detachment
	in journals	Interventions:	Procedure: gas
			injection; Procedure: Vitrectomy with
			Gas
2	Completed	Pneumatic Retinopexy Versus	s Vitrectomy With Gas for Retinal
	no results	Detachment Due to Myopic Ma	acular Hole
	published	Condition:	Retinal Detachment
	yet	Interventions:	Procedure: Pneumatic Retinopexy;
			Procedure: Vitrectomy with Gas
3	Completed	Safety and Efficacy of Brimon	idine Tartrate Posterior Segment
	no results	Drug Delivery System in Impr	oving Visual Function
	published	Condition:	Rhegmatogenous Macula-off Retinal
	yet		Detachment
		Interventions:	Drug: 200 µg Brimonidine Tartrate
			Posterior Segment Drug Delivery
			system; Drug: 400 µg Brimonidine
			Tartrate Posterior Segment Drug
			Delivery
			system; Drug: Sham Posterior Seg
			ment Drug Delivery system
4	Completed		y and Efficacy of Ranibizumab in
	no results		ascularisation Due to Causes Other
	published	Than Age Related Macular De	
	yet	Conditions:	Choroidal Neovascularization; Reti
			nal Pigment Epithelial Detachment
		Intervention:	Drug: Ranibizumab
5	Completed	Macular Function After Sclera	I Buckle
	no results	Condition:	Rhegmatogenous Retinal Detachment
	published	Intervention:	Procedure: Scleral buckling
	yet	0	
6	Completed no results		sile Gas in Pneumatic Retinopexy
	published	Condition:	Retinal Detachment
	yet	Interventions:	Procedure: air; Procedure: expansil
	-		e gas
7	Completed	Vitrectomy for Optic Disc Pit I	
	no results	Condition:	Optic Disc Pit Maculopathy

published yet Intervention: Procedure: vitrectomy without laser or gas tamponade 8 Completed no results published Optical Coherence Tomography in Gas-filled Eyes Condition: Macular Hole 9 Recruiting Clinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment 9 Recruiting Clinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment 10 Recruiting Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body				
8 Completed no results published yet Optical Coherence Tomography in Gas-filled Eyes 9 Recruiting Condition: Macular Hole Intervention: Procedure: Vitreous surgery 9 Recruiting Clinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment 10 Recruiting Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body		-	Intervention:	Procedure: vitrectomy without laser or
no results published yetCondition:Macular Hole Procedure: Vitreous surgery Procedure: Vitreous surgery of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment9RecruitingClinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment9RecruitingClinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment10RecruitingMacular Tractional Retinoschiss in Proliferative Diabetic Retinopathy Intervention:11Unknown †The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body Condition:11Unknown 1The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body Condition:11Unknown 1The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body11Unknown 1The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body11Intervention:Device: foldable capsular vitreous bo		yet		gas tamponade
published yet Intervention: Integrative Disordure: Vitreous surgery yet 9 Recruiting Clinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment 9 Recruiting Clinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment 10 Recruiting Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy 10 Recruiting Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body Condition: Retinal Detachment Intervention: Device: foldable capsular vitreous bo	8	Completed	Completed Optical Coherence Tomography in Gas-filled Eyes	
9 Recruiting Clinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment 0 Recruiting Condition: Retinal Detachment 10 Recruiting Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy 10 Recruiting Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body 11 Unknown [†] The Exploratory Clinical Trials for the Seasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body 11 Unknown [†] The Exploratory Clinical Trials for the Seasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body		no results	Condition:	Macular Hole
of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment Condition: Retinal Detachment Intervention: Device: foldable capsular vitreous bo dy(FCVB) 10 Recruiting Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy Retinopathy Condition: Proliferative Diabetic Retinopathy 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body Condition: Retinal Detachment Intervention: Device: foldable capsular vitreous bo		-	Intervention:	Procedure: Vitreous surgery
Image: Problem state in the state in th	9	Recruiting	Clinical Trials for the Evaluati	on of Flexibility, Efficacy, and Safety
Image: Condition:Retinal DetachmentImage: Condition:Retinal DetachmentImage: Condition:Device: foldable capsular vitreous bo dy(FCVB)10RecruitingMacular Tractional Retinoschisis in Proliferative Diabetic Retinopathy10RecruitingMacular Tractional Retinoschisis in Proliferative Diabetic Retinopathy11Unknown †The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body11Image: Condition:Retinal Detachment Intervention:12Image: Condition:Retinal Detachment Intervention:13Unknown †The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body11Image: Condition:Retinal Detachment Intervention:12Image: Condition:Retinal Detachment Device: foldable capsular vitreous bo			of a Foldable Capsular Vitreou	us Body in the Treatment of Severe
Intervention: Device: foldable capsular vitreous bo dy(FCVB) 10 Recruiting Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy Image: Recruiting in the second structure in the sec			Retinal Detachment	
10 Recruiting Macular Tractional Retinoschisis in Proliferative Diabetic. Retinopathy 10 Recruiting Macular Tractional Retinoschisis in Proliferative Diabetic. Retinopathy 10 Recruiting Macular Tractional Retinoschisis in Proliferative Diabetic. Retinopathy 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body 11 Intervention: Condition: 12 Intervention: 13 Unknown [†]			Condition:	Retinal Detachment
Retinopathy Retinopathy Condition: Proliferative Diabetic Retinopathy Intervention: Intervention: 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body Condition: Retinal Detachment Intervention: Device: foldable capsular vitreous bo			Intervention:	·
Condition: Proliferative Diabetic Retinopathy Intervention: Intervention: 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body Condition: Retinal Detachment Intervention: Device: foldable capsular vitreous bo	10	Recruiting	Macular Tractional Retinoschisis in Proliferative Diabetic	
Intervention: 11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body Condition: Retinal Detachment Intervention: Device: foldable capsular vitreous bo			Retinopathy	
11 Unknown [†] The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body Condition: Retinal Detachment Intervention: Device: foldable capsular vitreous bo			Condition:	Proliferative Diabetic Retinopathy
and Efficacy of Foldable Capsular Vitreous Body Condition: Retinal Detachment Intervention: Device: foldable capsular vitreous bo			Intervention:	
Condition:Retinal DetachmentIntervention:Device: foldable capsular vitreous bo	11	Unknown [†]	The Exploratory Clinical Trials	s for the Feasibility, Primary Safety
Intervention: Device: foldable capsular vitreous bo			and Efficacy of Foldable Capsular Vitreous Body	
			Condition:	Retinal Detachment
dy(FCVB)			Intervention:	Device: foldable capsular vitreous bo
				dy(FCVB)

74. Retinal Drusen

Rank	Status	Study		
1	Completed	A Population-based Study of Macular Choroidal		
	no results	Neovascularization in a Chinese Population		
	published	Conditions:	Geographic Atrophy;	Wet Macular Degeneratio
	yet		etinal Drusen	-
		Intervention:	Other: Follow-up obse	ervation

75. Retinal Dystrophies

Rank	Status	Study	
1	Completed	Study of the Correlation Between Macular Thickness	
	no results	Analyzed by Optical Coherence Tomography and the	
	published	Visual Functions in Retinitis Pigmemtosa	
	yet	Condition: Retinitis Pigmentosa	
		Intervention:	
2	Completed	The Role of Capsular Tension Ring (CTR) in Anterior	
	no results	Capsular Contraction	
	published	Conditions: Retinitis Pigmentosa; Cataract	
	yet	Intervention: Procedure: IOL surgery	
3	Active, not	Umbilical Cord Blood Mononuclear Cell Transplant to	
	recruiting	Treat Chronic Spinal Cord Injury	
		Condition: Spinal Cord Injuries	
		Interventions: Biological: Umbilical Cord Blood Mononu	
		clear Cell; Biological: Umbilical Cord	
		Blood Mononuclear Cell,	
		Methylprednisolone; Biological:	
		Umbilical Cord Blood Mononuclear Cell,	
		Methylprednisolone, Lithium Carbonate	
4	Active, not	Lithium, Cord Blood Cells and the Combination in the	
	recruiting	Treatment of Acute & Sub-acute Spinal Cord Injury	
		Condition: Spinal Cord Injury	
		Interventions: Procedure: Conventional Treatment; D	
		rug: Lithium Carbonate; Biological: Cor	
		d Blood Cell; Other: Placebo	
5	Active, not	Safety and Feasibility of Umbilical Cord Blood Cell	
	recruiting	Transplant Into Injured Spinal Cord	
		Condition: Spinal Cord Injuries	
		Interventions: Biological: Umbilical Cord Blood Mon	
		onuclear Cell; Drug: Methylpredniso	
		lone; Drug: Lithium	
6	Enrolling	Efficacy and Safety of Oral Valproic Acid for Retinitis	
	by	Pigmentosa	
	invitation	Conditions: Retinitis Pigmentosa; Retinal Disea	
		ses; Eye Diseases; Eye Disease,	
		Hereditary; Retinal Degeneration	
		Intervention: Drug: Valproic Acid	
7	Enrolling	Feasibility and Safety of Adult Human Bone	
	by	Marrow-derived Mesenchymal Stem Cells by Intravitreal	

	invitation	Injection in Patients With Retinitis Pigmentosa		
	invitation	Condition:	Retinitis Pigmentosa	
		Intervention:	Other: Intravitreal injection of bone	
			marrow-derived mesenchymal stem cells	
8	Recruiting		d Injury and Physical Activity	
		Hands-On: Early Intensive Hand Rehabilitation After		
		Spinal Cord Injury		
		Condition: Spinal Cord Injury		
		Interventions	,	
			r: Standard Care	
9	Recruiting	Pilot Study of a Su	uprachoroidal Retinal Prosthesis	
		Conditions:	Retinitis Pigmentosa; Choroideremia	
		Intervention:	Device: Prototype wide view	
			suprachoroidal retinal prosthesis	
10	Recruiting	Molecular Genetics of Retinal Degenerations		
		Conditions:	Retinal Degeneration; Retinitis Pigm	
			entosa	
		Intervention:		
11	Recruiting	Difference Between Rehabilitation Therapy and Stem		
		Cells Transplantat	tion in Patients With Spinal Cord Injury	
		<u>in China</u>		
		Condition:	Spinal Cord Injuries	
		Interventions:	Procedure: rehabilitation of limb functio	
			n; Procedure: Stem Cells Transplant	
			ation	
12	Recruiting	Safety & Efficacy	of Subretinal Implants for Partial	
		Restoration of Vis	ion in Blind Patients	
		Conditions:	Retinal Degeneration,; Retinitis Pigm	
			entosa	
		Intervention:	Procedure: surgical implantation of	
			subretinal device	

76. Retinal Hemorrhage

Rank	Status	Study	
1	Completed	Intravitreal Bevacizumab P	retreatment for Reducing
	no results	Preretinal Hemorrhage in Diabetic Vitrectomy	
	published yet	Condition:	Proliferative Diabetic Retinopathy
		Intervention:	

77. Retinal Neoplasms

Rank	Status	Study	
1	Completed	Efficacy of Prophy	lactic Itraconazole in High-Dose
	no results	Chemotherapy and	Autologous Hematopoietic Stem Cell
	published yet	Transplantation	
		Conditions:	Neuroblastoma; Brain Tumor; Retino
			blastoma; Wilms Tumor; Mycoses
		Intervention:	Drug: itraconazole
2	Completed	Rebeccamycin Analogue in Treating Children With Solid	
	no results	Tumors or Non-Ho	dgkin's Lymphoma
	published yet	Conditions: Brain and Central Nervous System Tur	
			rs; Lymphoma; Neuroblastoma; R
			etinoblastoma; Sarcoma; Unspecifie
			d Childhood Solid Tumor, Protocol
		Specific	
		Intervention: Drug: becatecarin	
3	Completed	Vincristine, Carboplatin, and Etoposide or Observation	
	no results	Only in Treating Patients Who Have Undergone Surgery	
	published yet	for Newly Diagnosed Retinoblastoma	
		Condition:	Retinoblastoma
		Interventions: Drug: carboplatin; Drug: etoposide;	
			Drug: vincristine sulfate; Other: clinical
		observation	
4	Active, not	Cixutumumab in Treating Patients With Relapsed or	
	recruiting	Refractory Solid T	umors
		Conditions:	Adrenocortical Carcinoma; Kidney Can
			cer; Liver Cancer; Neuroblastoma;
			Retinoblastoma; Sarcoma
		Interventions:	Biological: cixutumumab; Other: labora
			tory biomarker analysis
5	Active, not	Systemic Vincristin	ne, Carboplatin, and Etoposide,
	recruiting	Subtenon Carbople	atin, and Local Ophthalmic Therapy in
		Treating Children With Intraocular Retinoblastoma	
		Condition: Retinoblastoma	
		Interventions:	Biological: filgrastim; Drug: carboplatin;
			Drug: etoposide; Drug: vincristine s
			ulfate; Procedure: cryosurgery; Proc
			edure: laser surgery
6	Active, not	Trial Comparing Ty	wo Carboplatin Doses in Groups C and
	recruiting	D Intraocular Retinoblastoma	

		Condition:	Intraocular Retinoblastoma
		Intervention:	Drug: carboplatin
7	Recruiting	Combination Chemotherapy and Cyclosporine Followed	
		By Cryotherapy and/or Laser Therapy in Treating Patients	
			osed Retinoblastoma in Both Eyes
		Condition:	Retinoblastoma
		Interventions:	Biological: filgrastim; Drug: carboplatin;
			Drug: cyclosporine; Drug: etoposide
			; Drug: vincristine sulfate; Procedure
			: cryosurgery; Procedure: laser therapy
			; Procedure: neoadjuvant therapy
8	Recruiting	Combination Chen	notherapy, Autologous Stem Cell
		Transplant, and/or	Radiation Therapy in Treating Young
		Patients With Extra	aocular Retinoblastoma
		Condition:	Retinoblastoma
		Interventions:	Biological: filgrastim; Drug: carboplatin;
			Drug: cisplatin; Drug: cyclophospha
		mide; Drug: etoposide; Drug: thiotep	
			a; Drug: vincristine sulfate; Procedur
			e: autologous bone marrow transplantati
		on; Procedure: autologous	
		hematopoietic stem cell	
			transplantation; Procedure: peripheral
			blood stem cell
			transplantation; Radiation: radiation th
			erapy
9	Unknown [†]	Flavopiridol in Tre	ating Children With Relapsed or
		Refractory Solid T	umors or Lymphomas
		Conditions:	Brain and Central Nervous System Tu
			mors; Childhood Germ Cell Tumor;
			Kidney Cancer; Liver Cancer; Lym
			phoma; Neuroblastoma; Retinobla
			stoma; Sarcoma; Unspecified
			Childhood Solid Tumor, Protocol
			Specific
		Intervention:	Drug: alvocidib

78. Retinal Neovascularization

Rank	Status	Study		
1	Terminated	Clinical Research on Retinal Neovascularization of Diabetic		
		Retinopathy		
		Conditions:	The Mechanism of Retinal	
			Neovascularization of	
			Diabetic; Retinopathy.	
		Intervention:	Genetic: genetic analyzer	
2	Recruiting	Safety and Efficacy Study of rAAV.sFlt-1 in Patients With		
		Exudative Age-Related Macular Degeneration		
		Conditions:	Macular Degeneration; Age-r	
			elated Maculopathies; Age-r	
			elated Maculopathy; Maculo	
			pathies,Age-related; Maculo	
			pathy,Age-related; Retinal D	
			egeneration; Retinal Neovas	
			cularization; Eye Diseases	
		Interventions:	Biological: rAAV.sFlt-1; Othe	
			r: Control (ranibizumab alone)	

79. Retinal Perforations

1Completed no results published yetPneumatic Retinopexy Versus Vitrectomy With Gas for Retinal Detachment Due to Myopic Macular Hole Condition:1Completed no results published yetCondition:Retinal Detachment Retinopexy; Proced e: Vitrectomy with Gas2Completed no results published yetFoveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery Condition:Visual Recovery After Macular Hole Surgery Retinopexy; Procedure: Vitreous s gery for macular hole3Completed no results published yetObservation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery Condition:Macular Holes Macular Holes	no results published yet Completed no results published yet Completed no results		no results published yet Completed
published yetCondition:Retinal DetachmentInterventions:Procedure: Pneumation Retinopexy;Procedure: Pneumation Retinopexy;2Completed no results published yetFoveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery Condition:3Completed no results published yetObservation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery Condition:	published yet Completed no results published yet Completed no results	2	published yet Completed
Interventions: Procedure: Pneumatic Retinopexy; Proced e: Vitrectomy with Gas 2 Completed no results Foveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery published yet Condition: 3 Completed no results Intervention: published yet Observation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery Condition: Macular Holes	Completed no results published yet Completed no results	2	Completed
Retinopexy;Proced e: Vitrectomy with Gas2Completed no results published yetFoveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery Condition:3Completed no results published yetObservation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery Condition:3Completed no results published yetObservation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery 	no results published yet Completed no results	2	
2Completed no results published yetFoveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery Condition:Macular Hole Surgery Macular Holes3Completed no results published yetObservation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery Condition:	no results published yet Completed no results	2	
2 Completed no results published yet Foveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery Condition: Macular Holes 3 Completed no results published yet Observation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery Condition: Macular Hole Surgery Microstructures After Macular Hole Surgery Condition: Macular Holes	no results published yet Completed no results	2	
no results published yetVisual Recovery After Macular Hole Surgery Condition: Macular Holes Intervention: Procedure: Vitreous s gery for macular hole3Completed no results published yetObservation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery Condition: Macular Holes	no results published yet Completed no results	2	
published yet Condition: Macular Holes Intervention: Procedure: Vitreous s gery for macular hole 3 Completed no results published yet Observation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery Condition:	published yet Completed no results		
3 Completed no results published yet Observation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery Condition: Macular Holes	Completed no results		no results
3 Completed no results published yet Observation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery Condition: Macular Holes	no results		published yet
3 Completed no results published yet Observation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery Condition:	no results		
no results published yetMicrostructures After Macular Hole Surgery Condition:Microstructures After Macular Holes	no results		
published yet Condition: Macular Holes		3	Completed
	published yet		no results
			published yet
Intervention: Procedure: Vitrectomy			
4 Completed Evaluation of Anatomic and Visual Outcomes of	Completed	4	Completed
no results Initially Closed Macular Holes	no results		no results
published yet Condition: Macular Holes	published yet		published yet
Intervention:			
5 Completed Elongation of Foveal Tissue After Macular Hole	Completed	5	Completed
no results <u>Surgery</u>	no results		no results
published yet Condition: Macular Holes	published yet		published yet
Intervention: Procedure: pars plana			
vitrectomy and fluid ga			
exchange			
6 Completed Macular Hole in Diabetic Retinopathy	Completed	6	Completed
no results Conditions: Macular Hole; Prolif	no results		no results
published yet erative Diabetic Retine	published yet		published yet
pathy			
Intervention:			
7 Completed Optical Coherence Tomography in Gas-filled Eyes	Completed	7	Completed
no results Condition: Macular Hole	no results		no results
published yet Intervention: Procedure: Vitreous s	published yet		published yet
gery			
8 Completed Macular Hole Reopening		8	Completed
no results Condition: Vitrectomy	Completed		
published yet Intervention: Procedure: Vitrectomy	-		published vet

9	Not yet recruiting	Study of the Surgical Timing of Hole	of Traumatic Macular
		Condition:	Traumatic Macular Hol
			е
		Intervention:	Procedure: vitrectomy
			surgery
10	Recruiting	Macular Hole Surgery With an	d Without Internal
		Limiting Membrane Peeling: A	Systematic Review and
		<u>Meta-analysis</u>	
		Condition:	Macular Holes
		Intervention:	
11	Recruiting	Early Vitrectomy for Impending Macular Hole	
		Condition:	Retinal Perforation
		Intervention:	Procedure: Pars plana
			vitrectomy with ILM p
			eeling

80. Retinal Vein Occlusion

Rank	Status	Study	
1	Completed	Vascular Endothelial Growth	Factor (VEGF) Trap-Eye:
	Has Results	Investigation of Efficacy and Safety in Central Retinal Vein	
	published	Occlusion (CRVO)	
	on website	Condition:	Retinal Vein Occlusion
		Interventions:	Biological: Aflibercept Injection
			(EYLEA, VEGF Trap-Eye,
			BAY86-5321); Other: Sham
			treatment
2	Completed	A Study of the Safety and Effi	cacy of a New Treatment for
	Has Results	Macular Edema Resulting Fro	m Retinal Vein Occlusion
	published	Conditions:	Macular Edema; Retinal Vei
	on website		n Occlusion
		Interventions:	Drug: Dexamethasone; Dru
			g: Sham injection
3	Completed	Sheathotomy vs. Intravitreal Triamcinolone for Branch	
	no results	Retinal Vein Occlusion	
	published	Conditions:	Macular Edema; Branch Reti
	yet	Interventions:	Procedure: Arteriovenous Cros
	-	interventions.	Procedure: Intravitreal Triamo
			Injection
4	Completed	A Study of the Safety and Effi	-
-	no results	Macular Edema Resulting Fro	
	published	Occlusion	
	yet	Conditions:	Macular Degeneration; Macu
	yee	oonations.	Retinal Vein Occlusion
		Intervention:	
-	Ormulated		Drug: dexamethasone
5	Completed no results	Vitrectomy for Branch Retinal	
	published	Condition:	Vitrectomy
	yet	Intervention:	Procedure: Vitrectomy w/o ILM
	yet		peeling for macular edema with
			BRVO
6	Completed	Triamcinolone or Bevacizuma	b for Central Retinal Vein
	no results	Occlusion With Poor Vision	
	published	Condition:	Central Retinal Vein Occlusion
	yet		With 20/200 or Worse Visual
			Acuity
		Intervention:	Procedure: intravitreal injection
7	Completed	Major and Macular Branched	Retinal Venous Occlusion

	no results	Condition:	Macular Edema
	published yet	Intervention:	Procedure: intravitreal bevacizu
8	Completed	Vascular Endothelial Growth	Factor (VEGF) Trap-Eye:
	no results	Investigation of Efficacy and S	Safety in Central Retinal Vein
	published	Occlusion (CRVO)	
	yet	Condition:	Macular Edema Secondary to Central Retinal Vein Occlusion
		Interventions:	Biological: VEGF Trap-Eye 2. 0mg; Drug: Sham
9	Enrolling	Effect of Intravitreal Ranihizur	<u> </u>
5	by	Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)	
	invitation	Conditions:	Macular Edema; Retinal V ein Occlusion
		Intervention:	Drug: ranibizumab
10	Active, not	Efficacy and Safety of Ranibiz	umab in Japanese Patients
	recruiting	With Retinal Vein Occlusion	
		Condition:	Retinal Vein Occlusion
		Intervention:	Drug: ranibizumab
11	Active, not	Safety and Efficacy of AGN208397 in the Treatment of	
	recruiting	Macular Edema Associated With Retinal Vein Occlusion	
		<u>(RVO)</u>	
		Conditions:	Macular Edema; Retinal V ein Occlusion
		Interventions:	Drug: AGN208397 intravitre al injection; Drug: dexame thasone intravitreal implant
12	Recruiting	Observe the Effectiveness and	d Safety of Ranibizumab in
		Dool Life Setting	
		Real Life Setting	
		Conditions:	Wet Age Related Macular Deg eneration; Diabetic Macular Edema; Retinal Vein Occlus ion
			eneration; Diabetic Macular Edema; Retinal Vein Occlus
13	Recruiting	Conditions:	eneration; Diabetic Macular Edema; Retinal Vein Occlus ion Other: Ranibizumab
13	Recruiting	Conditions: Intervention:	eneration; Diabetic Macular Edema; Retinal Vein Occlus ion Other: Ranibizumab
13	Recruiting	Conditions: Intervention: Safety and Efficacy Study of E	eneration; Diabetic Macular Edema; Retinal Vein Occlus ion Other: Ranibizumab
13	Recruiting	Conditions: Intervention: Safety and Efficacy Study of E Treatment of Patients With Ma	eneration; Diabetic Macular Edema; Retinal Vein Occlus ion Other: Ranibizumab

Interventions: Drug: Ranibizumab; Procedure: Laser 15 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion 16 Recruiting Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion 16 Recruiting Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) 16 Recruiting Efficacy of Hatter Edema Following Branch Retinal Vein Occlusion 11 Conditions: Macular Edema Following Branch Retinal Vein Occlusion 16 Recruiting Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone				; Other: Sham	
Condition: Branch Retinal Vein Occlusion Interventions: Drug: Ranibizumab; Procedure: Laser IS Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion Intervention: Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal injection If Recruiting Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion Intervention: Drug: Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion Interventions: Drug: Betamethasone Microsphere in Occlusion Interventions: Drug: Betamethasone Microsphere (DE-102) Low Dose ; Drug: Betamethasone Microsphere (DE-102) Low Dose ; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham I7 Recruiting Combined Therapy of Posterior Subtenon Triancinolone Actentide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal beva	14	Recruiting	Efficacy and Safety of Ranibiz	umab With or Without Laser	
Interventions: Drug: Ranibizumab; Procedure: Laser 15 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion 16 Recruiting Conditions: Macular Edema; Central Retinal Vein Occlusion 16 Recruiting Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion 16 Recruiting Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion 16 Recruiting Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion 17 Recruiting Condition: Macular Edema Following Branch Retinal Vein Occlusion 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 18 Interventions: Procedure: intravitreal bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 19 Interventions: Procedure: combined therapy of posterior subtenon triamcinolone acetonide and i			in Comparison to Laser in Branch Retinal Vein Occlusion		
Image:			Condition:	Branch Retinal Vein Occlusion	
Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion Conditions: Macular Edema; Central R etinal Vein Occlusion Intervention: Drug; Ranibizumab 0.5 mg/0.05 ml, intravitreal injection 16 Recruiting Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) Condition: Macular Edema Following Branch Retinal Vein Occlusion Interventions: Drug: Betamethasone Micro sphere (DE-102) Low Dose ; Drug: Betamethasone Microsphere (DE-102) Low Dose ; Drug: Sham 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 11 Retruiting Condition: Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevacizumab monotherapy; Pro cedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab			Interventions:	•	
Retinal Vein Occlusion Conditions: Macular Edema; Central R etinal Vein Occlusion Intervention: Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal injection 16 Recruiting Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) Condition: Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) Condition: Macular Edema Following Branch Retinal Vein Occlusion Interventions: Drug: Betamethasone Micro sphere (DE-102) Low Dose ; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 17 Recruiting Condition: Branch Retinal Vein Occlusion 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 18 Interventions: Procedure: intravitreal bevac izumab monotherapy; 19 Interventions: Procedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab	15	Recruiting	Ranibizumab Intravitreal Injec	tions in Patients With Visual	
Conditions: Macular Edema; Central R etinal Vein Occlusion Intervention: Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal injection 16 Recruiting Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) Condition: Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) Condition: Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) Condition: Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) Condition: Macular Edema Following Branch Retinal Vein Occlusion Interventions: Drug: Betamethasone Micro sphere (DE-102) Low Dose ; Drug: Betamethasone Micro sphere (DE-102) Low Dose; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham 17 Recruiting Combined Therapy of Posterior Subtenon Triancinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 17 Recruiting Condition: Branch Retinal Vein Occlusion 17 Recruiting Combined Therapy of Posterior Subtenon Triancinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion on Interventions: Procedure: intravitreal bevacizumab intravitreal			Impairment Due to Macular Ec	dema Secondary to Central	
etinal Vein Occlusion Intervention: Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal injection 16 Recruiting Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) 16 Recruiting Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) 16 Recruiting Condition: Macular Edema Following Branch Retinal Vein Occlusion 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone. Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone. Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 17 Interventions: Procedure: intravitreal bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 17 Interventions: Procedure: intravitreal bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 18 Interventions: Procedure: intravitreal bevacizumab 19 Interventions: Procedure: intravitreal bevacizumab			Retinal Vein Occlusion		
mg/0.05 ml, intravitreal injection 16 Recruiting Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) Condition: Macular Edema Following Branch Retinal Vein Occlusion Interventions: Drug: Betamethasone Micro sphere (DE-102) Low Dose ; Drug: Betamethasone Microsphere (DE-102) Low Dose ; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Procedure: intravitreal bevaci zumab monotherapy; Pro cedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab			Conditions:	,	
16 Recruiting Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) Condition: Macular Edema Following Branch Retinal Vein Occlusion Interventions: Drug: Betamethasone Micro sphere (DE-102) Low Dose ; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevac izumab monotherapy; Pro cedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab			Intervention:	Drug: Ranibizumab 0.5	
Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) Condition: Macular Edema Following Branch Retinal Vein Occlusion Interventions: Drug: Betamethasone Micro sphere (DE-102) Low Dose ; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevac izumab monotherapy; Pro cedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab				U	
Vein Occlusion (HIKARI) Condition: Macular Edema Following Branch Retinal Vein Occlusion Interventions: Drug: Betamethasone Micro sphere (DE-102) Low Dose ; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevaci izumab monotherapy; Pro cedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab	16	Recruiting	Efficacy and Safety of Betame	ethasone Microsphere in	
Condition: Macular Edema Following Branch Retinal Vein Occlusion Interventions: Drug: Betamethasone Micro sphere (DE-102) Low Dose ; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Image: Condition: Br			Patients With Macular Edema Following Branch Retinal		
Branch Retinal Vein Occlusion Interventions: Drug: Betamethasone Micro sphere (DE-102) Low Dose ; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevac izumab monotherapy; Pro cedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab			Vein Occlusion (HIKARI)		
sphere (DE-102) Low Dose ; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusi on Interventions: Procedure: intravitreal bevac izumab monotherapy; Pro cedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab			Condition:	Branch Retinal Vein	
sphere (DE-102) Low Dose ; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusi on Interventions: Procedure: intravitreal bevac izumab monotherapy; Pro cedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab			Interventions:	Drug: Betamethasone Micro	
Microsphere (DE-102) High Dose; Drug: Sham 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevac izumab monotherapy; Procedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab				-	
Dose; Drug: Sham 17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevac izumab monotherapy; Pro on Interventions: Procedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab				; Drug: Betamethasone	
17 Recruiting Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevac izumab monotherapy; Pro cedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab				Microsphere (DE-102) High	
Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusi on Interventions: Procedure: intravitreal bevac izumab monotherapy; Procedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab				Dose; Drug: Sham	
Secondary to Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusi on Interventions: Procedure: intravitreal bevac izumab monotherapy; Procedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab	17	Recruiting	Combined Therapy of Posterie	or Subtenon Triamcinolone	
Condition: Branch Retinal Vein Occlusi on Interventions: Procedure: intravitreal bevac izumab monotherapy; Pro cedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab			Acetonide and Intravitreal Bevacizumab for Macular Edema		
on Interventions: Procedure: intravitreal bevac izumab monotherapy; Pro cedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab			Secondary to Branch Retinal	Vein Occlusion	
Interventions: Procedure: intravitreal bevac izumab monotherapy; Pro cedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab			Condition:	Branch Retinal Vein Occlusi	
izumab monotherapy; Pro cedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab				-	
cedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab			Interventions:	Procedure: intravitreal bevac	
posterior subtenon triamcinolone acetonide and intravitreal bevacizumab					
triamcinolone acetonide and intravitreal bevacizumab					
intravitreal bevacizumab				·	
18 Recruiting Obstructive Sleep Apnea, Retinal Vein Occlusion, Retinal	18	Recruiting	Obstructive Sleen Annea Ret	-	
Artery Occlusion		Recruiting			

		Condition:	Retinal Vascular Occlusion
		Intervention:	Device: Watchpat 100
19	Unknown [†]	Comparison of Intravitreal Ra	nibizumab and Macular Laser
		Photocoagulation for ME Follo	owing Branch Retinal Vein
		Occlusion (BRVO)	
		Condition:	Branch Retinal Vein Occlusi
			on
		Interventions:	Drug: Ranibizumab; Proce
			dure: macular laser photoco
			agulation

81. Retinitis

Rank	Status	Study	
1	Completed	Study of the Correlation Betw	een Macular Thickness Analyzed
	no results	by Optical Coherence Tomogr	raphy and the Visual Functions in
	published yet	Retinitis Pigmemtosa	
		Condition:	Retinitis Pigmentosa
		Intervention:	
2	Completed	The Role of Capsular Tension	Ring (CTR) in Anterior Capsular
	no results	Contraction	
	published yet	Conditions:	Retinitis Pigmentosa; Cataract
		Intervention:	Procedure: IOL surgery
3	Active, not	Safety and Feasibility of Umb	ilical Cord Blood Cell Transplant
	recruiting	Into Injured Spinal Cord	
		Condition:	Spinal Cord Injuries
		Interventions:	Biological: Umbilical Cord Blood
			Mononuclear Cell; Drug: Met
			hylprednisolone; Drug: Lithiu
			m
4	Enrolling by	Efficacy and Safety of Oral Valproic Acid for Retinitis	
	invitation	<u>Pigmentosa</u>	
		Conditions:	5
			iseases; Eye Diseases; Eye
			Disease, Hereditary; Retinal D
			egeneration
		Intervention:	Drug: Valproic Acid
5	Active, not	Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury	
	recruiting		
		Condition:	Spinal Cord Injury
		Interventions:	Procedure: Conventional Treatm ent; Drug: Lithium Carbonate;
			Biological: Cord Blood Cell;
			Other: Placebo
6	Active, not	Umbilical Cord Blood Mononuclear Cell Transplant to Treat	
	recruiting	Chronic Spinal Cord Injury	
	_	Condition:	Spinal Cord Injuries
		Interventions:	Biological: Umbilical Cord Blood
			Mononuclear Cell; Biological:
			Umbilical Cord Blood
			Mononuclear Cell,
			Methylprednisolone; Biological:

			Umbilical Cord Blood
			Mononuclear Cell,
			Methylprednisolone, Lithium
			Carbonate
7	Enrolling by	Feasibility and Safety of Adult	t Human Bone Marrow-derived
	invitation	Mesenchymal Stem Cells by I	ntravitreal Injection in Patients
		With Retinitis Pigmentosa	
		Condition:	Retinitis Pigmentosa
		Intervention:	Other: Intravitreal injection of
			bone marrow-derived
			mesenchymal stem cells
8	Recruiting	Pilot Study of a Suprachoroid	al Retinal Prosthesis
		Conditions:	Retinitis Pigmentosa; Choroide
			remia
		Intervention:	Device: Prototype wide view
			suprachoroidal retinal prosthesis
9	Recruiting	SCIPA (Spinal Cord Injury and Physical Activity) Hands-On:	
		Early Intensive Hand Rehabilitation After Spinal Cord Injury	
		Condition:	Spinal Cord Injury
		Interventions:	Device: ReJoyce Workstation;
			Other: Standard Care
10	Recruiting	Molecular Genetics of Retinal Degenerations	
		Conditions:	Retinal Degeneration; Retinitis
			Pigmentosa
		Intervention:	
11	Recruiting	Difference Between Rehabilita	ation Therapy and Stem Cells
		Transplantation in Patients W	ith Spinal Cord Injury in China
		Condition:	Spinal Cord Injuries
		Interventions:	Procedure: rehabilitation of limb f
			unction; Procedure: Stem Cells
			Transplantation
12	Recruiting	Molecular Genetics of Retinal Degenerations	
		Conditions:	Retinal Degeneration; Reti
		Conditions:	Retinal Degeneration; Reti nitis Pigmentosa
		Conditions: Intervention:	•
13	Recruiting	Intervention:	•
13	Recruiting	Intervention:	nitis Pigmentosa

	Pigmentosa	
Intervention:	Procedure: surgical implantation	
	of subretinal device	

82. Retinitis Pigmentosa

Rank	Status	Study	
1	Completed	The Role of Capsular Tension	Ring (CTR) in Anterior
	no results	Capsular Contraction	
	published yet	Conditions:	Retinitis Pigmentosa; Catar
			act
		Intervention:	Procedure: IOL surgery
2	Completed	Study of the Correlation Betw	een Macular Thickness
	no results	Analyzed by Optical Coherence	ce Tomography and the Visual
	published yet	Functions in Retinitis Pigmer	ntosa
		Condition:	Retinitis Pigmentosa
		Intervention:	
3	Enrolling by	Efficacy and Safety of Oral Va	Iproic Acid for Retinitis
	invitation	Pigmentosa	
		Conditions:	Retinitis Pigmentosa; Retin
			al Diseases; Eye Diseases;
			Eye Disease, Hereditary;
			Retinal Degeneration
		Intervention:	Drug: Valproic Acid
4	Enrolling by	Feasibility and Safety of Adult Human Bone Marrow-derived	
	invitation	Mesenchymal Stem Cells by Intravitreal Injection in Patients	
		With Retinitis Pigmentosa	
		Condition:	Retinitis Pigmentosa
		Intervention:	Other: Intravitreal injection of
			bone marrow-derived
5	Activo not	Umbiliaal Card Blood Monon	mesenchymal stem cells
5	Active, not recruiting	Chronic Spinal Cord Injury	iclear Cell Transplant to Treat
	reorating	Condition:	Spinal Cord Injuries
		Interventions:	Biological: Umbilical Cord Blood
			Cell; Biological: Umbilical Cord
			Mononuclear Cell,
			Methylprednisolone; Biologica
			Cord Blood Mononuclear Cell,
			Methylprednisolone, Lithium Car
6	Active, not	Lithium, Cord Blood Cells and	the Combination in the
	recruiting	Treatment of Acute & Sub-acu	ite Spinal Cord Injury
		Condition:	Spinal Cord Injury
		Interventions:	Procedure: Conventional Treatm
			m Carbonate; Biological: Cord

			er: Placebo
7	Active, not	Safety and Feasibility of Umb	ilical Cord Blood Cell
	recruiting	Transplant Into Injured Spinal Cord	
		Condition: Spinal Cord Injuries	
		Interventions: Biological: Umbilical Cord Blood Mon	
		onucl	lear Cell; Drug: Methylprednis
		olone; Drug: Lithium	
8	Recruiting	Pilot Study of a Suprachoroidal Retinal Prosthesis	
		Conditions:	Retinitis Pigmentosa; Choro ideremia
		Intervention:	Device: Prototype wide view
			suprachoroidal retinal
			prosthesis
9	Recruiting	Safety & Efficacy of Subretina	
		Restoration of Vision in Blind	
		Conditions:	Retinal Degeneration,; Reti
			nitis Pigmentosa
		Intervention:	Procedure: surgical
			implantation of subretinal device
10	Recruiting	SCIPA (Spinal Cord Injury and	d Physical Activity) Hands-On:
		Early Intensive Hand Rehabilitation After Spinal Cord Injury	
		Condition:	Spinal Cord Injury
		Interventions:	Device: ReJoyce Workstation;
			Other: Standard Care
11	Recruiting	SCIPA (Spinal Cord Injury and Physical Activity) Hands-On:	
		Early Intensive Hand Rehabili	tation After Spinal Cord Injury
		Condition:	Spinal Cord Injury
		Interventions:	Device: ReJoyce Workstation;
			Other: Standard Care
12	Recruiting	Molecular Genetics of Retinal Degenerations	
		Conditions:	Retinal Degeneration; Retin
			itis Pigmentosa
		Intervention:	
13	Recruiting	Molecular Genetics of Retinal	Degenerations
		Conditions:	Retinal Degeneration; Retin
			itis Pigmentosa
		Intervention:	

14	Recruiting	Molecular Genetics of Retinal Degenerations	
		Conditions:	Retinal Degeneration; Retinitis
			а
		Intervention:	
15	Recruiting	Difference Between Rehabilitation Therapy and Stem Cells	
		Transplantation in Patients With Spinal Cord Injury in China	
		Condition:	Spinal Cord Injuries
		Interventions:	Procedure: rehabilitation of limb
			edure: Stem Cells Transplantation

83. Retinoblastoma

Rank	Status	Study	
1	Completed	Efficacy of Prophylactic Itracc	onazole in High-Dose
	no results	Chemotherapy and Autologou	us Hematopoietic Stem Cell
	published	Transplantation	
	yet	Conditions:	Neuroblastoma; Brain Tumor;
			Retinoblastoma; Wilms Tu
			mor; Mycoses
		Intervention:	Drug: itraconazole
2	Completed	Vincristine, Carboplatin, and I	Etoposide or Observation Only
	no results	in Treating Patients Who Have	e Undergone Surgery for Newly
	published	Diagnosed Retinoblastoma	
	yet	Condition:	Retinoblastoma
		Interventions:	Drug: carboplatin; Drug: etop
			oside; Drug: vincristine sulfat
			e; Other: clinical observation
3	Completed	Rebeccamycin Analogue in Treating Children With Solid	
	no results	Tumors or Non-Hodgkin's Lyr	nphoma
	published	Conditions:	Brain and Central Nervous Syst
	yet		em Tumors; Lymphoma; N
			euroblastoma; Retinoblastom
			a; Sarcoma; Unspecified
			Childhood Solid Tumor,
			Protocol Specific
		Intervention:	Drug: becatecarin
4	Active, not	Systemic Vincristine, Carbopl	atin, and Etoposide, Subtenon
	recruiting	Carboplatin, and Local Ophth	almic Therapy in Treating
		Children With Intraocular Reti	noblastoma
		Condition:	Retinoblastoma
		Interventions:	Biological: filgrastim; Drug:
			carboplatin; Drug: etoposid
			e; Drug: vincristine sulfate;
			Procedure: cryosurgery; P
			rocedure: laser surgery
5	Active, not	Cixutumumab in Treating Pati	ients With Relapsed or
	recruiting	Refractory Solid Tumors	
		Conditions:	Adrenocortical Carcinoma; Ki
			dney Cancer; Liver Cancer;
			Neuroblest and D.S. 11.
			Neuroblastoma; Retinoblasto

ma; Sarcoma Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis 6 Active, not recruiting Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma Intraocular Retinoblastoma Condition: Intraocular Retinoblastoma 1 Intervention: Drug: carboplatin 7 Recruiting Combination Chemotherapy and Cyclosporine Followed By Cryotherapy and/or Laser Therapy in Treating Patients With
6 Active, not recruiting Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma Intraocular Retinoblastoma 7 Recruiting Combination Chemotherapy and Cyclosporine Followed By
6 Active, not recruiting Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma 6 Active, not recruiting Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma 1 Condition: Intraocular Retinoblastoma 1 Intervention: Drug: carboplatin 7 Recruiting Combination Chemotherapy and Cyclosporine Followed By
6 Active, not recruiting Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma Intraocular Retinoblastoma Condition: Intraocular Retinoblastoma Intervention: Drug: carboplatin 7 Recruiting Combination Chemotherapy and Cyclosporine Followed By
recruiting Intraocular Retinoblastoma Condition: Intraocular Retinoblastoma Intervention: Drug: carboplatin 7 Recruiting Combination Chemotherapy and Cyclosporine Followed By
Condition: Intraocular Retinoblastoma Intervention: Drug: carboplatin 7 Recruiting Combination Chemotherapy and Cyclosporine Followed By
Intervention: Drug: carboplatin 7 Recruiting Combination Chemotherapy and Cyclosporine Followed By
7 Recruiting <u>Combination Chemotherapy and Cyclosporine Followed By</u>
Cryotherapy and/or Laser Therapy in Treating Patients With
Newly Diagnosed Retinoblastoma in Both Eyes
Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: ca
rboplatin; Drug: cyclosporine;
Drug: etoposide; Drug: vin
cristine sulfate; Procedure: cr
yosurgery; Procedure: laser t
herapy; Procedure: neoadjuv
ant therapy
8 Recruiting <u>Combination Chemotherapy, Autologous Stem Cell</u>
Transplant, and/or Radiation Therapy in Treating Young
Patients With Extraocular Retinoblastoma
Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug:
carboplatin; Drug: cisplatin;
Drug: cyclophosphamide;
Drug: etoposide; Drug: thiot
epa; Drug: vincristine sulfat
e; Procedure: autologous b one marrow transplantation;
Procedure: autologous
hematopoietic stem cell
transplantation; Procedure:
peripheral blood stem cell
transplantation; Radiation: r
adiation therapy
9 Recruiting Study of Late-Occurring Complications in Childhood Cancer
<u>Survivors</u>

r			
		Condition:	Cancer
		Interventions:	Genetic: cytogenetic analysis;
			Genetic: mutation analysis; G
			enetic: polymorphism analysis;
			Other: questionnaire administr
			ation
10	Unknown [†]	Flavopiridol in Treating Childr	en With Relapsed or
		Refractory Solid Tumors or Ly	<u>/mphomas</u>
		Conditions:	Brain and Central Nervous Sy
			stem Tumors; Childhood G
			erm Cell Tumor; Kidney Ca
			ncer; Liver Cancer; Lymp
			homa; Neuroblastoma; R
			etinoblastoma; Sarcoma;
			Unspecified Childhood Solid
			Tumor, Protocol Specific
		Intervention:	Drug: alvocidib
11	Unknown [†]	Colony-Stimulating Factors in	Treating Children With
		Recurrent or Refractory Solid	Tumors
		Condition:	Cancer
		Interventions:	Biological: filgrastim; Biologi
			cal: recombinant human thro
			mbopoietin; Drug: carboplat
			in; Drug: etoposide; Drug:
			ifosfamide

Rank	Status	Study	
1			Francfucion (PINT)
	Completed no results	Premature Infants in Need of	
		Condition:	Anemia of Prematurity
	published	Intervention:	Procedure: Red blood cell trans
	yet		fusion
2	Recruiting	Appropriate Oxygen Levels for	r Extremely Preterm Infants: a
		Prospective Meta-analysis	
		Conditions:	Infant, Premature, Diseases;
			Bronchopulmonary Dysplasia;
			Retinopathy of Prematurity; I
			nfant, Newborn, Diseases; Inf
			ant, Very Low Birth Weight
		Interventions:	Procedure: Higher oxygen
			saturation target range
			(91%-95%); Procedure: Lowe
			r oxygen saturation (85%-89%)
3	Unknown [†]	Recombinant Erythropoietin f	or Neuroprotection in Very
		Preterm Infants	
		Conditions:	Infant, Premature; Leukomala
			cia, Periventricular; Intraventr
			icular Hemorrhage; Retinopat
			hy of Prematurity
		Interventions:	Drug: recombinant human eryth
			ropoietin (rhEpo); Drug: Norm
			al saline

84. Retinopathy of Prematurity

85. Retinoschisis

Rank	Status	Study	
1	Recruiting	Macular Tractional Retinoschi	sis in Proliferative Diabetic
		<u>Retinopathy</u>	
		Condition:	Proliferative Diabetic Retinopathy
		Intervention:	

86. Scotoma

Rank	Status	Study	
1	Unknown [†]	Efficacy of Retinal Nerve Fibe	r Layer (RNFL) / Ganglion
		Cell Layer Thickness Ratio by RT-View Utilizing Spectral	
		-Domain Technology as a Diag	gnostic Predictor of
		<u>Glaucoma.</u>	
		Condition:	Primary Open Angle Glauco
			ma
		Intervention:	
2	Unknown [†]	To Compare Visual Field Impairment in Conventional	
		Double Frequency Nd: YAG Panretinal Photocoagulation	
		With PASCAL Panretinal Photocoagulation	
		Conditions:	Macular Edema; Diabetic
			Retinopathy; Visual Field
			Loss
		Interventions: Procedure: PASCAL laser;	
			Procedure: Conventional I
			aser

87. Sjogren's Syndrome

Rank	Status	Study	
1	Completed	Exploratory Study for Dry Mor	uth in Patients With
	no results	Sjögren's Syndrome	
	published yet	Conditions:	Xerostomia; Sjogren's Syn drome
		Intervention:	Drug: Rebamipide
2	Enrolling by	Confocal Microscopy and Lac	rimal Gland in Sjogren's
	invitation	<u>Syndrome</u>	
		Condition:	Primary Sjogren's Syndrome
		Intervention:	
3	Recruiting	Hydroxychloroquine Treatment of Dry Eyes in Patients	
		With Primary Sjögren's Syndrome	
		Conditions:	Autoimmune Diseases; Sj
			ogren's Syndrome; Dry Ey
			е
		Interventions:	Drug: Hydroxychloroquine;
			Drug: Placebo
4	Unknown [†]	Allogeneic Mesenchymal Ster	n Cells Transplantation for
		Primary Sjögren's Syndrome (pSS)	
		Conditions:	Sjogren's Syndrome; Mes
			enchymal Stem Cells
		Intervention:	Biological: Allogeneic
			Mesenchymal Stem Cells
			(AlloMSC)

88. Strabismus

Rank	Status	Study	
1	Completed	Long-Term Outcomes in the T	reatment of Infantile and
	no results	Acquired Esotropia With Botu	llinum Toxin
	published	Condition:	Esotropia
	yet	Intervention:	
2	Completed	Under-correction in Refractive	Accommodative Esotropia
	no results	Condition:	Accommodative Esotropia
	published	Intervention:	Device: Glasses prescription
	yet		
3	Completed	Surgery and Convergence Ins	ufficiency Intermittent
	no results	<u>Exotropia</u>	
	published	Condition:	Complications
	yet	Interventions:	Procedure: Post exercise Su
			rgery; Procedure: Orthopti
			cs; Procedure: Postop ort
			hoptics; Procedure: Post e
			xercises surgery
4	Recruiting	The Effect of Dexmedetomidine on Decreasing Emergence	
		Agitation and Delirium in Pedi	iatric Patients Undergoing
		Strabismus Surgery	
		Condition:	Strabismus
		Interventions:	Drug: Dexmedetomidine;
			Drug: placebo group
5	Recruiting	A Study on the Effects of Mida	azolam on Delirium After
		Sevoflurane Anesthesia in Pe	diatric Strabismus Surgery
		Conditions:	Child; Anesthesia Morbidit
			y; Delirium on Emergence
		Interventions:	Drug: Midazolam 0.03mg/kg;
			Drug: Midazolam 0.05mg/
			kg; Drug: Placebo
6	Recruiting	Efficacy and Safety of GSK13	58820 (Botulinum Toxin Type
		A) in Patients With Strabismu	<u>s</u>
		Condition:	Strabismus
		Intervention:	Drug: GSK1358820
7	Recruiting	Assessing the Functional and	Psychosocial Impact of
		Strabismus in Asian Children	Using the AS-20 and IXTQ
		<u>Questionnaires</u>	
		Condition:	Strabismus
		Intervention:	

8	Recruiting	Study of Non-surgical Treatment Versus Observation in Asian Children With Intermittent Exotropia		
		Condition:	Intermittent Exotropia	
		Intervention:	Procedure: Non surgical ther	
			ару	

89. Supranuclear Palsy, Progressive

Rank	Status	Study		
1	Active, not	Study to Evaluate the Safety and Efficacy of Davunetide for		
	recruiting	the Treatment of Progressive Supranuclear Palsy		
		Condition: Progressive Supranuclear Palsy		
		Interventions:	Drug: Davunetide; Drug: Placebo	

90. Usher Syndromes

Rank	Status	Study		
1	Recruiting	Molecular Genetics of Retinal Degenerations		
		Conditions:	Retinal Degeneration;	Retinitis Pigmentosa
		Intervention:		

91. Uveal Diseases

Rank	Status	Study		
1	Completed	A Study of the Safety and Effi	cacy of a New Treatment for	
	Has Results	Non-Infectious Intermediate o	r Posterior Uveitis	
	published in	Conditions:	Intermediate Uveitis; Posterior Uveit	
	journal	Interventions:	Drug: Dexamethasone; Drug: dexam	
			e; Drug: Sham injection	
2	Completed	Safety and Efficacy of a New	Therapy as Adjunctive Therapy to	
	Has Results	Anti-vascular Endothelial Gro	wth Factor (Anti-VEGF) in Subjects	
	published on	With Wet Age-Related Macula	r Degeneration (AMD)	
	website	Conditions:	Choroidal Neovascularization; Age-F athy	
		Interventions:	Drug: dexamethasone; Biological: ra	
3	Completed	Safety and Efficacy of a New	Freatment as Adjunctive Therapy to	
	Has Results	Anti-vascular Endothelial Gro	wth Factor (Anti-VEGF) Treatment in	
	published on	Patients With Age-Related Ma	cular Degeneration (AMD)	
	website	Conditions:	Choroidal Neovascularization; Age-F	
			Maculopathy	
		Interventions:	Drug: dexamethasone; Biological: ra	
			mab; Other: sham	
4	Completed	A Study of the Safety and Efficacy of a New Treatment for		
	Has Results	Non-Infectious Intermediate o	r Posterior Uveitis	
	Published in	Conditions:	Intermediate Uveitis; Posterior Uveit	
	journal	Interventions:	Drug: Dexamethasone; Drug: dexan	
			e; Drug: Sham injection	
5	Completed	Clinical Study Of Pegaptanib	Sodium (EYE001) For Wet-Type	
	Has Results	Age-Related Macular Degener	ation	
	published on	Condition:	Macular Degeneration	
	website	Intervention:	Drug: pegaptanib sodium	
6	Completed	Multicenter Uveitis Steroid Tre	eatment (MUST) Trial	
	Has Results	Condition:	Uveitis	
	published in	Interventions:	Drug: fluocinolone acetonide intraocula	
	journals		ant; Drug: oral corticosteroid with	
			immunosuppressive agents as needed	
7	Terminated	A Study Using Intravitreal Inje	ections of a Small Interfering RNA in	
	Has Results	Patients With Age-Related Ma	cular Degeneration	
	published on	Conditions:	Choroid Neovascularization; Age-Re	
	website		acular Degeneration	
		Interventions:	Drug: AGN 211745; Drug: Ranibizur	

			μg
8	Completed	Safety and Efficacy of Ranibiz	umab in Japanese Patients With
	Has Results	Subfoveal Choroidal Neovasc	ularization Secondary to
	published in	Age-related Macular Degenera	ation
	journals	Condition:	Subfoveal Choroidal
			Neovascularization(CNV)
			Secondary to Age-related Macular
			Degeneration (AMD)
		Intervention:	Drug: Ranibizumab
9	Completed	Safety and Efficacy of a New	Treatment as Adjunctive Therapy to
	Has Results	Anti-vascular Endothelial Gro	wth Factor (Anti-VEGF) Treatment in
	published on	Patients With Age-Related Ma	cular Degeneration (AMD)
	website	Conditions:	Choroidal Neovascularization; A
			ge-Related Maculopathy
		Interventions:	Drug: dexamethasone; Biologica
			I: ranibizumab; Other: sham
10	Completed	Evaluation of Safety and Effic	acy of Once Monthly Ranibizumab
	no results	Injections in Chinese Patients	With Wet Age Related Macular
	published	Degeneration (AMD) Patients	
	yet	Condition:	Age Related Macular Degeneration
		Intervention:	Drug: ranibizumab 0.5 mg
11	Completed	A Study Assessing the Safety	and Efficacy of Multiple Intravitreal
	no results	KH902 in Patients With CNV D	Due to AMD
	published	Condition:	Neovascular Age-related Macular D
	yet		egeneration
		Intervention:	Biological: Intravitreal injection of K
			H902
12	Completed	Safety and Efficacy Study of I	ontophoresis and Dexamethasone
	no results	Phosphate to Treat Anterior U	lveitis
	published	Condition:	Uveitis, Anterior
	yet	Interventions:	Drug: EGP-437 1.6 mA-min at 0.4
			with EyeGate® II System; Drug:
			EGP-437 4.8 mA-min at 1.2 mA
			with EyeGate® II System; Drug:
			EGP-437 10.0 mA-min at 2.5 mA
			with EyeGate® II System; Drug:
			EGP-437 14.0 mA-min at 3.5 mA
			with EyeGate® II System
13	Completed	A Study of LX211 in Clinically	Quiescent Non-infectious

	no results	Intermediate, Anterior and Inter	ermediate, Posterior or Pan-Uveitis
	published	Conditions:	Uveitis, Posterior; Uveitis, Interm
	yet		ediate; Panuveitis
		Interventions:	Drug: Placebo; Drug: LX211
14	Completed	Safety and Efficacy of AIN457	in Patients With Active
	no results	Non-infectious Uveitis	
	published	Condition:	Uveitis
	yet	Interventions:	Biological: AIN457; Biological: Pl
			acebo
15	Completed	A Multi-center Study to Asses	s the Efficacy and Safety of LX211 in
	no results	Active Non-infectious Anterio	<u>r Uveitis</u>
	published	Conditions:	Uveitis, Anterior; Panuveitis
	yet	Interventions:	Drug: Placebo; Drug: LX211
16	Completed	Phase II Open Label Multicent	er Study For Age Related Macular
	no results	Degeneration Comparing PF-(04523655 Versus Lucentis In The
	published	Treatment Of Subjects With C	NV (MONET Study).
	yet	Condition:	Age Related Macular Degeneration
		Interventions:	Drug: 0.5 mg ranibizumab; Drug:
			3 mg PF-04523655; Drug: 1 mg P
			F-04523655
17	Completed	Phase III Study in Refractory I	Behcet's Disease
	no results	Condition:	Behcet Disease
	published	Interventions:	Drug: AIN457; Drug: Placebo
	yet		
18	Completed	A Population-based Study of	
	no results	Neovascularization in a Chine	
	published	Conditions:	Geographic Atrophy; Wet Macul
	yet		ar Degeneration; Retinal Drusen
		Intervention:	Other: Follow-up observation
19	Completed	Observation on the Treg in the	e Uveitis Patients
	no results	Condition:	Uveitis
	published	Intervention:	
	yet	Coloby and Efficiency of Our PE	WZ0Z in Definition Mith. C. 1 (s. s. s.
20	Completed no results		K787 in Patients With Subfoveal
	published	Degeneration (AMD)	Secondary to Age-Related Macular
	yet	Condition:	Wat Age Polated Macular Degase
	yer	Condition:	Wet Age-Related Macular Degene ration
		Intonionationa-	
		Interventions:	Drug: PTK787; Drug: Placebo

21	Completed	Study to Investigate the Safet	y and Efficacy of Ranibizumab in	
	no results	Patients With Choroidal Neovascularisation Due to Causes Other		
	published	Than Age Related Macular De	generation	
	yet	Conditions:	Choroidal Neovascularization; R	
			etinal Pigment Epithelial Detachme	
			nt	
		Intervention:	Drug: Ranibizumab	
22	Completed	Safety and Tolerability of Ran	ibizumab in Patients With Subfoveal	
	no results	Choroidal Neovascularization	Secondary to Age-related Macular	
	published	Degeneration		
	yet	Conditions:	Subfoveal Choroidal Neovasculari	
			zation (CNV); Secondary to	
			Age-related Macular Degeneration	
			(AMD)	
		Intervention:	Drug: ranibizumab	
23	Completed	Clinical Study Of EYE001 For	Wet-Type AMD (Age-Related	
	no results	Macular Degeneration)		
	published	Condition:	Macular Degeneration	
	yet	Intervention:	Drug: pegaptanib sodium	
24	Completed	EXTEND III - Efficacy and Safety of Ranibizumab in Patients V		
	no results	Subfoveal Choroidal Neovasc	ularization (CNV) Secondary to	
	published	Age-related Macular Degenera	ation (AMD)	
	yet	Conditions:	Choroidal Neovascularization; Ag	
			e-Related Macular Degeneration	
		Intervention:	Drug: ranibizumab	
25	Completed	Efficacy and Safety of Ranibiz	umab in Patients With Visual	
	no results		Neovascularization Secondary to	
	published	Pathologic Myopia		
	yet	Condition:	Pathological Myopia	
		Interventions:	Drug: 0.5 mg ranibizumab driven	
			by disease activity; Drug: 0.5 mg	
			ranibizumab driven by stabilization	
			criteria; Drug: verteporfin PDT	
26	Completed		ght Threatening, Non-infectious	
	no results	Intermediate-, Anterior and Int	termediate-, Posterior-, or	
	published	Pan-Uveitis		
	yet	Conditions:	Uveitis, Posterior; Uveitis, Interme	
			diate; Panuveitis	
		Interventions:	Drug: Placebo; Drug: LX211	

27	Enrolling by	A Study of the Long-term Safe	ety and Efficacy of Adalimumab in	
	invitation	Subjects With Intermediate-, Posterior-, or Pan-uveitis		
		Condition:	Uveitis	
		Intervention:	Drug: adalimumab	
28	Terminated	A Study Of The Safety And Ef	ficacy Of AG-013,958 In Subjects	
		With Subfoveal Choroidal Nec	ovascularization Associated With	
		Age-Related Macular Degener	ration	
		Condition:	Age-Related Macular Degeneration	
		Intervention:	Drug: AG-013,958	
29	Terminated	Safety and Efficacy of AIN457	in Behçet's Patients With Posterior	
		or Panuveitis		
		Condition:	Uveitis	
		Interventions:	Biological: AIN457; Drug: Placebo	
30	Terminated	Safety and Efficacy of AIN457	in Patients With Quiescent	
		Non-infectious Uveitis Study		
		Condition:	Non-infectious Uveitis	
		Interventions:	Biological: AIN457; Drug: Placebo	
31	Active, not	VEGF Trap-Eye in Choroidal N	Neovascularization Secondary to	
	recruiting	Pathologic Myopia (mCNV)		
		Condition:	Myopia, Pathological	
		Interventions:	Biological: VEGF Trap-Eye (BAY86-	
			5321); Procedure: No Drug	
32	Active, not		panese Subjects With Intestinal	
	recruiting	Behçet's Disease.		
		Condition:	Intestinal Behcet's Disease	
		Intervention:	Biological: Adalimumab	
33	Active, not	Efficacy of a Capsular Tension		
	recruiting	Capsule Shrinkage After Cata Syndrome	ract Surgery in Extendition	
		Condition:	Cataract With Exfoliation Syndrome	
		Intervention:		
34	Activo not		Steroid-sparing Treatment Uveitis	
54	Active, not recruiting	Pilot Trial	steroid-sparing freatment overus	
		Condition:	Uveitis	
		Interventions:	Drug: Methotrexate; Drug: Mycop	
			henolate mofetil	
35	Active, not	Natural History of IOL in Pseu		
	recruiting	Condition:	Pseudo Exfoliation Syndrome	
L	L –			

		Intervention:	Device: Capsular Tension Ring
36	Recruiting	Efficacy and Safety of Adalim	umab in Subjects With Inactive
		<u>Uveitis</u>	
		Condition:	Uveitis
		Interventions:	Drug: adalimumab; Drug: prednis
			one; Drug: adalimumab placebo
37	Recruiting	Efficacy and Safety of Adalim	umab in Subjects With Active Uveitis
		Condition:	Uveitis
		Interventions:	Drug: adalimumab; Drug: prednis
			one; Drug: adalimumab placebo
38	Recruiting	Pilot Study of a Suprachoroid	al Retinal Prosthesis
		Conditions:	Retinitis Pigmentosa; Choroidere
			mia
		Intervention:	Device: Prototype wide view
			suprachoroidal retinal prosthesis
39	Recruiting	Mycophenolate Sodium (Myfo	
		Corticosteroid-refractory Auto	
		Condition:	Uveitis
40	Deenviting	Intervention:	Drug: Myfortic
40	Recruiting	<u>Clinical Outcomes of Topical Ganciclovir Treatment in</u> <u>Cytomegalovirus Anterior Uveitis</u>	
		Condition:	Anterior Uveitis
		Intervention:	
41	Recruiting	LOXL1 Polymorphism in Pseu	Idoexfoliation Syndrome
••	liteorating	Condition:	Pseudoexfoliation Syndrome
		Intervention:	
42	Recruiting		ed, Multicenter, Sham-controlled,
	J		H902 in Patients With Wet AMD
		Condition:	Neovascular Age-related Macular D
			egeneration
		Intervention:	Biological: Recombinant Human
			VEGF Receptor-Fc Fusion Protein
43	Recruiting	Efficacy and Safety of Adalim	umab in Subjects With Active Uveitis
		Condition:	Uveitis
		Interventions:	Drug: adalimumab; Drug: prednis
			one; Drug: adalimumab placebo
44	Recruiting	Study Assessing Double-mas	ked Uveitis Treatment

		Condition:	Uvea; Posterior, Disorder
		Intervention:	Drug: DE-109
45	Recruiting	Clinical Study of TA-650 in Pa	tients With Behcet's Disease (BD)
		With Special Lesions	
		Conditions:	Behcet's Disease; Behcet Syndro
			me; Neuro-Behcet's Disease
		Intervention:	Drug: TA-650
46	Recruiting	Topical Administration of 0.15	6% Ganciclovir Gel for CMV Anterior
		<u>Uveitis / Endotheliitis</u>	
		Conditions:	Cytomegalovirus Anterior Segment I
			nfection; Anterior Uveitis; Endot
			heliitis
		Intervention:	Drug: Ganciclovir
47	Unknown [†]	Intravitreal Pegaptanib in Trea	atment of Choroidal
		Neovascularisation Secondary	<u>y to Pathologic Myopia</u>
		Condition:	Myopic Choroidal Neovascular Me
			mbrane
		Intervention:	Drug: Intravitreal Pegaptanib
48	Unknown [†]	Flucinolone Acetonide Implan	t for Treating Refractory Ocular
		Behcet's Disease	
		Conditions:	Ocular Behcet's Disease,; Non-Inf
			ectious Uveitis; Refractory Uveitis
		Intervention:	Drug: flucinolone acetonide

Rank	Status	Study	
1	Completed	A Study of the Safety and Effi	cacy of a New Treatment for
	Has Results	Non-Infectious Intermediate o	r Posterior Uveitis
	Published in	Conditions:	Intermediate Uveitis; Posterio
	journal		r Uveitis
		Interventions:	Drug: Dexamethasone; Drug:
			dexamethasone; Drug: Sha
			m injection
2	Completed	Phase III Study in Refractory I	
	no results	Condition:	Behcet Disease
	published yet	Interventions:	Drug: AIN457; Drug: Placebo
3	Completed	Observation on the Treg in the	e Uveitis Patients
	no results	Condition:	Uveitis
	published yet	Intervention:	
4	Completed	A Study of LX211 in Clinically	
	no results	Intermediate, Anterior and Inter	ermediate, Posterior or
	published yet	Pan-Uveitis	
		Conditions:	Uveitis, Posterior; Uveitis, Int
			ermediate; Panuveitis
-	Operation	Interventions:	Drug: Placebo; Drug: LX211
5	Completed no results	A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or	
	published yet	Pan-Uveitis	
		Conditions:	Uveitis, Posterior; Uveitis, In
			termediate; Panuveitis
		Interventions:	Drug: Placebo; Drug: LX21
			1
6	Completed	Phase III Study in Refractory I	Behcet's Disease
	no results	Condition:	Behcet Disease
	published yet	Interventions:	Drug: AIN457; Drug: Placebo
7	Completed	Safety and Efficacy Study of I	ontophoresis and
	no results	Dexamethasone Phosphate to Treat Anterior Uveitis	
	published yet	Condition: Uveitis, An	terior
		Interventions: Drug: EGP	P-437 1.6 mA-min at 0.4 with
		-	II System; Drug: EGP-437 4.8
			1.2 mA with EyeGate® II
		System;	Drug: EGP-437 10.0 mA-min at
		2.5 mA wit	h EyeGate® II System; Drug:

92. Uveitis

			14.0 mA-min at 3.5 mA with
		EyeGate®	-
8	Completed	A Multi-center Study to Asses	
	no results	LX211 in Active Non-infectiou	
	published yet	Conditions:	, ,
		Interventions:	Drug: Placebo; Drug: LX211
9	Terminated	Safety and Efficacy of AIN457	in Behçet's Patients With
		Posterior or Panuveitis	
		Condition:	Uveitis
		Interventions:	Biological: AlN457; Drug: Pla cebo
10	Terminated	Safety and Efficacy of AIN457	in Patients With Active
		Non-infectious Uveitis	
		Condition:	Uveitis
		Interventions:	Biological: AIN457; Biological : Placebo
11	Terminated	Extension Study to Assess Safety and Efficacy of AIN457 in	
		Patients With Active Non-infectious Uveitis	
		Condition:	Uveitis
		Interventions:	Biological: AlN457; Biological : Placebo
12	Terminated	Safety and Efficacy of AIN457	in Patients With Quiescent
		Non-infectious Uveitis	
		Condition:	Non-infectious Uveitis
		Interventions:	Biological: AIN457; Drug: Pl
			acebo
13	Terminated	Safety and Efficacy of AIN457	in Patients With Quiescent
		Non-infectious Uveitis Study	
		Condition:	Non-infectious Uveitis
		Interventions:	Biological: AIN457; Drug: Pla cebo
14	Enrolling by	A Study of the Long-term Safe	ety and Efficacy of Adalimumab
	invitation	in Subjects With Intermediate	-, Posterior-, or Pan-uveitis
		Condition:	Uveitis
		Intervention:	Drug: adalimumab
15	Active, not	A Study of Adalimumab in Jap	panese Subjects With Intestinal
	recruiting	Behçet's Disease.	
		Condition:	Intestinal Behcet's Disease

		Intervention:	Biological: Adalimumab
16	Active, not	First-line Antimetabolites as S	U
	recruiting	Uveitis Pilot Trial	sterend sparing readment
	J	Condition:	Uveitis
		Interventions:	Drug: Methotrexate; Drug: Myco
			til
17	Recruiting	Clinical Outcomes of Topical	Ganciclovir Treatment in
		Cytomegalovirus Anterior Uve	eitis
		Condition:	Anterior Uveitis
		Intervention:	
18	Recruiting	Mycophenolate Sodium (Myfo	ortic®) in the Treatment of
		Corticosteroid-refractory Auto	pimmune Uveitis:Pilot Study
		Condition:	Uveitis
		Intervention:	Drug: Myfortic
19	Recruiting	Study Assessing Double-mas	ked Uveitis Treatment
		Condition:	Uvea; Posterior, Disorder
		Intervention:	Drug: DE-109
20	Recruiting	Topical Administration of 0.15	5% Ganciclovir Gel for CMV
		Anterior Uveitis / Endotheliitis	<u>></u>
		Conditions:	Cytomegalovirus Anterior Segm
			ent Infection; Anterior Uveitis;
			Endotheliitis
		Intervention:	Drug: Ganciclovir
21	Recruiting		umab in Subjects With Active
		Uveitis Condition:	Uveitis
		Interventions:	Drug: adalimumab; Drug: pr ednisone; Drug: adalimuma
			b placebo
22	Recruiting	Clinical Study of TA-650 in Pa	•
		(BD) With Special Lesions	
		Conditions:	Behcet's Disease; Behcet S
			yndrome; Neuro-Behcet's D
			isease
		Intervention:	Drug: TA-650
23	Recruiting	Efficacy and Safety of Adalim	umab in Subjects With Inactive
		<u>Uveitis</u>	
		Condition:	Uveitis

		Interventions:	Drug: adalimumab; Drug: pr ednisone; Drug: adalimuma b placebo
24	Unknown [†]	Behcet's Disease	t for Treating Refractory Ocular
		Intervention:	Drug: flucinolone acetonide

93. Vision Disorders

Rank	Status	Study	
1	Completed	Efficacy and Safety of Ranibiz	cumab (Intravitreal
	Has Results	Injections) in Patients With Vi	
	published on	Diabetic Macular Edema	
	website	Condition:	Diabetic Macular Edema
		Interventions:	Drug: Ranibizumab; Proce
			dure: Laser photocoagulatio
			n; Drug: Sham ranibizuma
			b; Procedure: Sham laser
			photocoagulation
2	Completed	Impact of Maternal Vitamin A	or Beta-Carotene
	Has Results	Supplementation on Maternal	and Infant Mortality in
	Published in	Bangladesh	
	journals	Conditions:	Vitamin A Deficiency; Ma
			ternal Mortality; Infant M
			ortality
		Intervention:	Dietary Supplement:
			Vitamin A or Beta-Carotene
			Supplements
3	Completed	Effect of Intraoperative Dexamethasone Implant in Taut	
	no results	Posterior Hyaloid Removal in	Diabetic Macular Edema
	published yet	Conditions:	Diabetic Macular Edema;
			Vision Disorders
		Intervention:	Drug: Dexamethasone Drug
			delivery system (Ozurdex)
4	Completed	Efficacy and Safety of Ranibiz	umab in Patients With
	no results	Visual Impairment Due to Cho	
	published yet	Secondary to Pathologic Myo	
		Condition:	Pathological Myopia
		Interventions:	Drug: 0.5 mg ranibizumab
			driven by disease
			activity; Drug: 0.5 mg
			ranibizumab driven by
			stabilization
			criteria; Drug: verteporfin PDT
F	Completed		
5	Completed no results	Newborn Vitamin A (VA) Supp	nementation Pliot Project,
	published yet	Pakistan Condition	Vitamin A Deficiency
	published yet	Condition:	Vitamin A Deficiency

		Interventions:	Dietary Supplement: Vitami
			n A; Dietary Supplement: Placebo
6	Completed	An Efficacy Trial of Iron, Zinc	and Vitamin A Fortified Rice
	no results	in Children in Satun, Thailand	
	published yet	Conditions:	Vitamin A Deficiency; Iro
			n Deficiency; Zinc Defici ency
		Intervention:	Dietary Supplement: fortifie
			d extruded rice
7	Completed	Efficacy of Vitamin A in Fortifi	ed Extruded Rice in School
	no results	<u>Children</u>	
	published yet	Condition:	Vitamin A Deficiency
		Intervention:	Dietary Supplement: Triple
			fortified extruded tice (Fe,
			Zn and vitamin A)
8	Completed	Effect of Intravitreal Long Acti	ing Dexamethasone Implant,
	no results	Ozurdex in Patients With Diab	etic Macular Edema
	published yet	Conditions:	Diabetic Macular Edema;
			Macular Edema, Cystoid;
			Vision Disorders; Clinical ly Significant Macular Ede ma
		Intervention:	Drug: long acting intravitreal dexamethasone implant
9	Completed	The Extract of Green Tea on C	bese Women: a
	no results	Randomized Double Blindnes	s Clinical Trial
	published yet	Condition:	Obesity
		Intervention:	Drug: the extract of green tea
10	Completed	Dietary Vitamin A Requiremen	
	no results	the New Technology of Dietar	y Assessment
	published yet	Condition:	Vitamin A Deficiency
		Intervention:	
11	Completed	Vitamin A Bioavailability in La	ctating Women With
	no results	Marginal Vitamin A Status	

Interventions: Other: 0 mg retinol activity equivalents; Other: 12 m g of BC; Other: 10 mg RAE 12 Completed no results Condition: published yet Intervention: 13 Completed no results Retina Projection System Trials for Low Vision People no results Condition: published yet Intervention: 14 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh Condition: Intervention: 14 Terminated Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Condition: Drug: ranibizumab 16 Active, not recruiting Fificacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Impairment Due to Diabetic Macular Edema; Visual Impairment Impairment Due to Diabetic Macular Edema; Visual Impairment Impairment Due to Diabetic Macular Edema; Visual Impairment Intervention: Drug: ranibizumab 17 Recruiting Efficacy and Safety of Ranibizumab With o		published yet	Condition:	Vitamin A Deficiency
g of BC; Other: 6 mg of CX; Other: 1.0 mg RAE 12 Completed no results published yet Thickness of Retinal Layers in Amblyopia 13 Completed no results Condition: Amblyopia 14 Terminated Retina Projection System Trials for Low Vision People no results 14 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh Conditions: Infant Mortality; Vitamin A Deficiency 15 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion 16 Active, not recruiting An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema; Visual Impairment 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Retinal Vein Occlusion 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion			Interventions:	Other: 0 mg retinol activity
CX; Other: 1.0 mg RAE 12 Completed no results published yet Thickness of Retinal Layers in Amblyopia 13 Completed no results Condition: Amblyopia 14 Terminated Retina Projection System Trials for Low Vision People Condition: Vision, Low Intervention: 14 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh 15 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion 16 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion 17 Recruiting An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema; Visual Impairment 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion 18 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Linterventions: Drug: Ranibizumab; Pro cedure: Laser 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion				equivalents; Other: 12 m
12 Completed no results published yet Thickness of Retinal Layers in Amblyopia Intervention: Amblyopia Intervention: Other: Optical coherence t ornography 13 Completed no results published yet Retina Projection System Trials for Low Vision People Condition: Vision, Low Intervention: 14 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh Conditions: Infant Mortality; Vitamin A Deficiency Intervention: Drug: vitamin A suppleme ntation (50,000 IU) 15 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Intervention: Drug: ranibizumab 16 Active, not recruiting An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients Conditions: Diabetic Macular Edema; Visual Impairment 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: 18 Recruiting Efficacy and Safety of Ranibizumab With or Vithout Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: 18 Recruiting Efficacy and Safety of Ranibizumab Yith or Vithout Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion <th></th> <th></th> <th></th> <th>g of BC; Other: 6 mg of</th>				g of BC; Other: 6 mg of
no results published yet Condition: Intervention: Amblyopia 13 Completed no results published yet Retina Projection System Trials for Low Vision People Condition: Vision, Low 14 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh 14 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh 15 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion 16 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion 17 Recruiting An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema; Visual Impairment 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central. Retinal Vein Occlusion				CX; Other: 1.0 mg RAE
Published yetIntervention:Condition:Charlow point13Completed no results published yetRetina Projection System Trials for Low Vision People Condition:Vision, Low Vision, Low14TerminatedCommunity Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh Conditions:Infant Mortality; Vitamin A Deficiency Intervention:15Active, not recruitingEfficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Intervention:Drug: vitamin A suppleme ntation (50,000 IU)16Active, not recruitingAn Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema; Visual Impairment Usual ImpairmentIntervention: Drug: ranibizumab17RecruitingEfficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition:18RecruitingRanibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion	12	Completed	Thickness of Retinal Layers in	n Amblyopia
13 Completed no results published yet Retina Projection System Trials for Low Vision People Condition: Vision, Low Intervention: 14 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh Conditions: Infant Mortality; Vitamin A Deficiency Intervention: Drug: vitamin A suppleme ntation (50,000 IU) 15 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Intervention: Drug: ranibizumab 16 Active, not recruiting An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema; Visual Impairment 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Intervention: Drug: ranibizumab 18 Recruiting Efficacy and Safety of Manibizumab Difficacy and Safety of Manibizumab Difficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Norther Laser 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central, Retinal Vein Occlusion		no results	Condition:	Amblyopia
no results published yet Condition: Vision, Low 14 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh 14 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh 14 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh 14 Terminated Conditions: Infant Mortality; Vitamin A Deficiency 15 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Condition: Retinal Vein Occlusion 16 Active, not recruiting An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients 16 Active, not recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Conditions: 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: 18 Recruiting Ranibizumab Intravitreal Injecti		published yet	Intervention:	·
published yet Intervention: 14 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh 14 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh 14 Terminated Conditions: Infant Mortality; Vitamin A Deficiency 15 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion 16 Active, not recruiting Efficacy and Safety of Ranibizumab 16 Active, not recruiting An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients Conditions: 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: 17 Recruiting Efficacy and Safety of Ranibizumab; Pro cedure: Laser 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion	13	Completed	Retina Projection System Tria	Is for Low Vision People
14 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh 14 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh 14 Conditions: Infant Mortality; Vitamin A Deficiency 15 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients. 16 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients. 16 Active, not recruiting An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Condition: Branch Retinal Vein Occlusion 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Condition: Branch Retinal Vein Occlusion 17 Recruiting Efficacy and Safety of Ranibizumab; Pro cedure: Laser 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion		no results	Condition:	Vision, Low
10 Intervention: Intervention: Infant Mortality in Rural Bangladesh 11 Conditions: Infant Mortality; Vitamin A Deficiency 11 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients. 12 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients. 13 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients. 14 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients. 16 Active, not recruiting An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion		published yet	Intervention:	
to Reduce Infant Mortality in Rural BangladeshConditions:Infant Mortality; Vitamin A DeficiencyIntervention:Drug: vitamin A suppleme ntation (50,000 IU)15Active, not recruitingEfficacy and Safety of Ranibizumab in Japanese Patients. With Retinal Vein Occlusion16Active, not recruitingEfficacy and Safety of Ranibizumab16Active, not recruitingAn Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients Conditions:17RecruitingEfficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Sion17RecruitingEfficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlu sion18RecruitingRanibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion	14	Terminated	Community Trial of Newborn	Vitamin A Supplementation
A Deficiency Intervention: Drug: vitamin A suppleme ntation (50,000 IU) 15 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients. With Retinal Vein Occlusion Condition: Retinal Vein Occlusion 16 Active, not recruiting An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients Conditions: Diabetic Macular Edema in Patients Conditions: Diabetic Macular Edema; Visual Impairment Intervention: Drug: ranibizumab 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Interventions: Drug: Ranibizumab; Procedure: Laser 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion			to Reduce Infant Mortality in F	Rural Bangladesh
Intervention:Drug: vitamin A suppleme ntation (50,000 IU)15Active, not recruitingEfficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Condition:16Active, not recruitingAn Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients Conditions:16Active, not recruitingAn Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients Conditions:17RecruitingEfficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition:18RecruitingRanibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion			Conditions:	Infant Mortality; Vitamin
15 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients. With Retinal Vein Occlusion 16 Active, not recruiting An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients Conditions: Diabetic Macular Edema; Visual Impairment 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion				A Deficiency
15 Active, not recruiting Efficacy and Safety of Ranibizumab in Japanese Patients. With Retinal Vein Occlusion 16 Active, not recruiting Condition: An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients Conditions: 17 Recruiting Efficacy and Safety of Ranibizumab Intervention: 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion			Intervention:	Drug: vitamin A suppleme
recruitingWith Retinal Vein OcclusionCondition:Retinal Vein OcclusionIntervention:Drug: ranibizumab16Active, not recruitingAn Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients Conditions:16Active, not recruitingAn Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients Conditions:17RecruitingEfficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition:17RecruitingEfficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Sion18RecruitingRanibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion				ntation (50,000 IU)
Condition: Retinal Vein Occlusion Intervention: Drug: ranibizumab 16 Active, not recruiting An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients Conditions: Diabetic Macular Edema in Patients Conditions: Diabetic Macular Edema; Visual Impairment Intervention: Drug: ranibizumab 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Interventions: Drug: Ranibizumab; Pro cedure: Laser 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion	15	Active, not	Efficacy and Safety of Ranibiz	umab in Japanese Patients
Intervention:Drug: ranibizumab16Active, not recruitingAn Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients Conditions:16Active, not recruitingImpairment Due to Diabetic Macular Edema in Patients Conditions:17RecruitingEfficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition:17RecruitingEfficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Sion18RecruitingRanibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion		recruiting	With Retinal Vein Occlusion	
16 Active, not recruiting An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients Conditions: Diabetic Macular Edema; Visual Impairment 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlu sion 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion			Condition:	Retinal Vein Occlusion
recruiting Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients Conditions: Diabetic Macular Edema; Visual Impairment 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlu sion 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion			Intervention:	Drug: ranibizumab
Impairment Due to Diabetic Macular Edema in Patients Conditions: Diabetic Macular Edema; Visual Impairment17RecruitingEfficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlu sion18RecruitingRanibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion	16			
Conditions: Diabetic Macular Edema; Visual Impairment Intervention: Drug: ranibizumab 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlu sion Interventions: Drug: Ranibizumab; Procedure: Laser 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion		recruiting		
17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion 17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion 18 Recruiting Recruiting 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion				
Intervention:Drug: ranibizumab17RecruitingEfficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition:18RecruitingRanibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion			Conditions:	
17 Recruiting Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion 17 Condition: Branch Retinal Vein Occlusion 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion				·
in Comparison to Laser in Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Sion Interventions: Drug: Ranibizumab; Procedure: Laser 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion				•
Condition: Branch Retinal Vein Occlu sion Interventions: Drug: Ranibizumab; Pro cedure: Laser 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion	17	Recruiting		
18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion				
Interventions: Drug: Ranibizumab; Procedure: Laser 18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion			Condition:	
18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion			Interventioner	
18 Recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion			Interventions:	U
Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion	18	Recruiting	Ranihizumah Intravitreal Injec	
Retinal Vein Occlusion		Recruiting		
			Conditions:	Macular Edema; Central

			Retinal Vein Occlusion
		Intervention:	
		Intervention:	Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal
			injection
10	Deenviting	Efficiency of Newborn Vitemin /	•
19	Recruiting	Efficacy of Newborn Vitamin A	A Supplementation in
		Improving Immune Function	Mitamin A Dafisian au
		Condition:	Vitamin A Deficiency
		Interventions:	Dietary Supplement: retinyl
			palmitate; Dietary Suppl
			ement: Placebo
20	Recruiting	Intraoperative Dexamethason	
		Outcome of Cataract Surgery	With Diabetic Macular
		Edema	
		Conditions:	Macular Edema, Cystoid;
			Vision Diserdares Disheti
			Vision Disorders; Diabeti
			c Macular Edema; Cystoi d Macular Edema Followin
			g Cataract Surgery; Cata
			ract
		Interventions:	Drug: Dexamethasone
			Drug delivery system
			(Ozurdex); Procedure: C
			ataract surgery
21	Recruiting	Polycaprolactone / Tricalcium	
		Titanium Orbital Implant : Ran	
		Conditions:	Fractures; Enophthalmos;
			Diplopia
		Interventions:	Device: Polycaprolactone / T
			ri-Calcium Phosphate; De
			vice: Titanium Mesh
22	Unknown [†]	To Compare Visual Field Impa	
		Double Frequency Nd: YAG Pa	
		With PASCAL Panretinal Phot	_
		Conditions:	Macular Edema; Diabetic
			Retinopathy; Visual Field
			Loss
		Interventions:	Procedure: PASCAL laser;
			,

			Procedure: Conventional las
			er
23	Unknown [†]	RCT of an Intervention to Imp	rove the Health of
		Adolescents With Intellectual	<u>Disability</u>
		Conditions:	Vision Impairment; Heari
			ng Impairment; Obesity
		Intervention:	Behavioral: Health Interven
			tion Package

94. Vitreous Detachment	94.	Vitreous	Detachment
-------------------------	-----	----------	------------

Rank	Status	Study	
1	Completed	Vitrectomy for Optic Disc Pit Maculopathy	
	no results	Condition: Optic Disc Pit Maculopathy	
	published	Intervention: Procedure: vitrectomy without	
	yet	laser or gas tamponade	
1	Recruiting	Intravitreal Ranibizumab in Exudative Age-related Macular	
		Degeneration With Posterior Vitreomacular Adhesion	
		Condition: Neovascular Age-related Macular Degeneration	
		Intervention: Procedure: Intravitreal expansile gas and	
		ranibizumab injection	
1	Unknown †	A Safety and Efficacy Study of Vitreosolve® for	
		Non-Proliferative Diabetic Retinopathy Subjects	
		Condition: Diabetic Retinopathy	
		Intervention: Drug: Vitreosolve	

95. Vitreous Hemorrhage

Rank	Status	Study	
1	Completed	Intravitreal Bevacizumab Pret	reatment for Reducing
	no results	Preretinal Hemorrhage in Diat	petic Vitrectomy
	published	Condition:	Proliferative Diabetic Retinopa
	yet		thy
		Intervention:	
2	Completed	Bevacizumab and Long Acting	g Gas in Diabetic Vitrectomy
	no results	Condition:	Proliferative Diabetic Retinopa
	published		thy
	yet	Intervention:	Drug: Bevacizumab
3	Completed	Safety and Efficacy Study of V	/itrase for Clearance of
	no results	Severe Vitreous Hemorrhage	
	published	Conditions:	Vitreous Hemorrhage; Dia
	yet		betic Retinopathy
		Intervention:	Drug: Vitrase (ovine hyaluro
			nidase)
4	Completed	Pre- and Intra-operative Intrav	vitreal Bevacizumab Injection
	no results	in Diabetic Vitrectomy	
	published	Conditions:	Proliferative Diabetic Retino
	yet		pathy; Vitrectomy
		Intervention:	Drug: Bevacizumab
5	Recruiting	Intravitreal Bevacizumab for F	Proliferative Diabetic
		<u>Retinopathy</u>	
		Conditions:	Vitreous Hemorrhage; Prolif
			erative Diabetic Retinopathy
		Intervention:	Drug: intravitreal injection of b
			evacizumab
6	Unknown [†]	Efficacy and Safety of Intravit	
		in Eyes With Post Vitrectomy	Diabetic Vitreous
		<u>Hemorrhage</u>	
		Conditions:	Post Vitrectomy State; Re
			current Diabetic Vitreous He
		Interventions:	morrhage Procedure: Intravitreal triamc
		Interventions:	
			inolone injection; Procedur e: Air-fluid exchange
7	Unknown [†]	Intravitreal Long Acting Gas in	
'		Postoperative Vitreous Hemor	
L		· Soloporative vitreous riellio	mage in Brabelle Allectonly

Conditions:	Diabetes Mellitus; Diabetic
	Retinopathy; Vitreous He
	morrhage
Intervention:	Procedure: Intravitreal long
	acting gas

96. Xerophthalmia

Rank	Status	Study	
1	Completed	Trial to Compare the Efficacy of Systane Ultra and Refresh	
	Has Results	Drop in the Treatment of Dry Eye in Asian Eyes	
	published	Conditions:	Xerophthalmia; Blepharitis
	on website	Interventions:	Drug: Systane Ultra eyedrops;
			Drug: Refresh eye drops
2	Completed	Use of Autologous Serum Eye-drops as Tears in Patients	
	no results	With Recalcitrant Dry Eye	
	published	Condition:	Xerophthalmia
	yet	Intervention:	Drug: Autologous serum eyed
			rops